=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehaf191.pdf",
  "converted_date": "2026-01-31T14:48:46.453626",
  "file_size_bytes": 6984518,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehaf191.pdf"
}

=== СОДЕРЖАНИЕ ===

--- Страница 1 ---
ESC GUIDELINES
European Heart Journal (2025) 46, 4156–4225
https://doi.org/10.1093/eurheartj/ehaf191
2025 ESC Clinical Consensus Statement on
mental health and cardiovascular disease:
developed under the auspices of the ESC
Clinical Practice Guidelines Committee
Developed by the task force on mental health and cardiovascular
disease of the European Society of Cardiology (ESC)
Endorsed by the European Federation of Psychologists’ Associations
AISBL (EFPA), the European Psychiatric Association (EPA), and the
International Society of Behavioral Medicine (ISBM)
Authors/Task Force Members: Héctor Bueno *†, (Chairperson) (Spain),
Christi Deaton *†, (Chairperson) (United Kingdom), Marta Farrero ‡,
(Task Force Co-ordinator) (Spain), Faye Forsyth ‡, (Task Force Co-ordinator)
(United Kingdom), Frieder Braunschweig (Sweden), Sergio Buccheri (Sweden),
Simona Dragan (Romania), Sofie Gevaert (Belgium), Claes Held (Sweden),
Donata Kurpas (Poland), Karl-Heinz Ladwig (Germany), Christos D. Lionis
(Greece), Angela H.E.M. Maas (Netherlands), Caius Ovidiu Merșa (Romania),
Richard Mindham (United Kingdom), Susanne S. Pedersen (Denmark),
Martina Rojnic Kuzman 1 (Croatia), Sebastian Szmit (Poland), Rod S. Taylor
(United Kingdom), Izabella Uchmanowicz (Poland), Noa Vilchinsky 2 (Israel),
and ESC Scientific Document Group
* Corresponding authors: Héctor Bueno, Multidisciplinary Translational Cardiovascular Research Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, and
Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain, and Facultad de Medicina,
Universidad Complutense de Madrid, Madrid, Spain. Tel: +34 4531290, Extension 4110, E-mail: hbueno@cnic.es; and Christi Deaton, Public Health and Primary Care, University of
Cambridge School of Clinical Medicine, Cambridge, United Kingdom. Tel: +44 1223 330300, E-mail: cd531@cam.ac.uk
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the European Psychiatric Association (EPA)
2 Representing the European Health Psychology Society (EHPS)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Preventive Cardiology
(EAPC), European Heart Rhythm Association (EHRA), and Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council of Cardio-Oncology.
Working Groups: Cardiovascular Pharmacotherapy.
Patient Forum
© The European Society of Cardiology 2025. All rights reserved.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 2 ---
ESC Guidelines 4157
Document Reviewers: Konstantinos C. Koskinas, (CPG Review Co-ordinator) (Switzerland), Pascal Vranckx, (CPG
Review Co-ordinator) (Belgium), Marianna Adamo (Italy), Elena Arbelo (Spain), Folkert W. Asselbergs
(Netherlands), Giuseppe Boriani (Italy), Margarita Brida (Croatia), Noeleen Burke (Ireland), Robert A. Byrne
(Ireland), Ingrid de Laval (Sweden), Lidia Einsfeld (Brazil), Enrico Frigoli (Switzerland), Leonarda Galiuto (Italy),
Estelle Gandjbakhch (France), Sherry L. Grace (Canada), Johannes Grand (Denmark), Bettina Heidecker
(Germany), Mirjam Heldner (Switzerland), Charlotte Helmark (Denmark), Marwa Hemmat Gaber (Egypt),
Loreena Hill (United Kingdom), Lisa Hynes2(Ireland), Borja Ibanez (Spain), Stefan James (Sweden),
Alexander Kharlamov (Netherlands), Hanne Kindermans (Belgium), Lars Køber (Denmark), Ulf Landmesser
(Germany), Gregory Y.H. Lip (United Kingdom), Emma F. Magavern (United Kingdom), John William McEvoy
(Ireland), Paul McGreavy (United Kingdom), Borislava Mihaylova (United Kingdom), Inge Moelgaard (Denmark),
Manuela Abreu (Portugal), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Eva Prescott (Denmark),
Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Annett Salzwedel (Germany),
Anna Sannino (Germany), Eduard Shantsila (United Kingdom), Chantal Ski (United Kingdom), Andrew Steptoe2
(United Kingdom), Felix C. Tanner (Switzerland), Diogo Telles1(Portugal), Ilonca Vaartjes (Netherlands),
Berlinde von Kemp (Belgium), Christiaan Vrints (Belgium), and Katja Zeppenfeld (Netherlands)
All experts involved in the development of this Clinical Consensus Statement have submitted declarations of
interest which are reported in a supplementary document to the Clinical Consensus Statement. See the European
Heart Journal online or https://www.escardio.org/Guidelinesfor supplementary documents as well as evidence
tables.
Disclaimer: This European Society of Cardiology (ESC) Clinical Consensus Statement was developed under the auspices of the ESC
Clinical Practice Guidelines Committee and represents the views of the ESC and was produced after careful consideration of the scientific
and medical knowledge and the evidence available at the time of its publication. The ESC is not responsible in the event of any
contradiction, discrepancy and/or ambiguity between the ESC Guidelines and documents and any other official recommendations or
guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies.
Health professionals are encouraged to take the ESC Clinical Consensus Statement fully into account when exercising their clinical
judgement, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however,
the ESC Clinical Consensus Statement does not override, in any way whatsoever, the individual responsibility of health professionals to
make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and,
where appropriate and/or necessary, the patient’s caregiver. Nor does the ESC Clinical Consensus Statement exempt health
professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the
competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their
respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations
relating to drugs and medical devices prior to making any clinical decision and to check whether a more recent version of this document
exists. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions: The content of this ESC Clinical Consensus Statement has been published for personal and educational use only. No
commercial use is authorized. No part of the ESC Clinical Consensus Statement may be translated or reproduced in any form without
written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the
publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC. For permissions, please
e-mail: journals.permissions@oup.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Mental health • Cardiovascular disease • Cardiovascular risk • Mental health conditions • Mental health disorders •
Mental health screening • Stress • Depression • Anxiety • Post-traumatic stress disorder • Severe mental illness •
Psycho-cardio team • Stepped care • Psychological therapy • Psychotropic drugs • Stigma
Table of contents 3. Introduction ....................................................................................................... 4162
3.1. The relationship between mental and cardiovascular health
1. Preamble.............................................................................................................. 4160 and disease......................................................................................................... 4162
2. The scope of this consensus statement................................................. 4161 3.2. Enduring problems................................................................................. 4164
2.1. Methods employed in the consensus statement...................... 4161 3.3. Aims of the document......................................................................... 4165
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 3 ---
4158 E S C G u id e l in e s
3.4. The Psycho-Cardio team.................................................................... 4165 6.2. Identification and screening ............................................................... 4175
3.5. Section summary points and management consensus 6.2.1. Assessment of depression and anxiety ................................. 4176
statements from Section 3........................................................................... 4166 6.2.2. Suggested approach to screening people with
4. Impact of mental health on the risk of developing cardiovascular cardiovascular disease for psychological distress, depression,
disease........................................................................................................................ 4166 and anxiety..................................................................................................... 4177
4.1. Positive mental health states as predictors of better 6.2.3. Challenges in specific cardiovascular conditions ............... 4177
cardiovascular health ..................................................................................... 4166 6.2.4. Assessment of subjective well-being and quality of life.. 4178
4.2. Psychosocial stress................................................................................. 4166 6.3. Management of mental health conditions in people with
4.3. Work stress and unemployment .................................................... 4167 cardiovascular disease ................................................................................... 4178
4.4. Socioeconomic and subjective social status................................ 4168 6.3.1. Communication, education, and support for people with
4.5. Perceived discrimination ..................................................................... 4168 mental health conditions and cardiovascular disease .................. 4178
4.6. Mental stress through impaired social relationships............... 4168 6.3.2. Psychological interventions......................................................... 4179
4.6.1. Adverse childhood experiences ............................................... 4168 6.3.3. Psycho-education............................................................................ 4179
4.6.2. Partnership violence...................................................................... 4168 6.3.4. Social prescribing ............................................................................ 4180
4.6.3. Loneliness and social isolation................................................... 4168 6.3.5. Other psychological interventions .......................................... 4180
4.7. Mental health conditions and personality traits as risk factors 6.3.6. Interventions for people with post-traumatic stress
for cardiovascular disease............................................................................ 4168 disorder........................................................................................................... 4181
4.7.1. Depression ........................................................................................ 4168 6.3.7. Lifestyle interventions................................................................... 4181
4.7.2. Anxiety................................................................................................ 4168 6.3.8. Physical activity and exercise in people with
4.7.3. Post-traumatic stress disorder.................................................. 4169 cardiovascular disease and mental health conditions .................. 4181
4.8. Section summary points and management consensus 6.3.9. Diet and nutrition approaches in cardiovascular disease
statements from Section 4........................................................................... 4169 and mental health conditions................................................................. 4181
5. Mental health and mental health conditions in people with 6.3.10. Smoking cessation........................................................................ 4181
cardiovascular disease ......................................................................................... 4169 6.3.11. Stress management techniques.............................................. 4182
5.1. Impact of cardiovascular disease on mental health ................. 4169 6.3.12. Sleep hygiene ................................................................................. 4182
5.2. Specific mental health conditions in people with 6.4. Tools and resources to support lifestyle change ..................... 4182
cardiovascular disease: prevalence and prognostic impact ........... 4169 6.4.1. Digital health tools ......................................................................... 4182
5.2.1. Depressive symptoms and depression.................................. 4169 6.4.2. Motivational interviewing ............................................................ 4182
5.2.1.1. Prevalence of depressive symptoms and depression 6.4.3. Cardiac rehabilitation.................................................................... 4183
in people with cardiovascular disease........................................... 4170 6.5. Medical interventions............................................................................ 4183
5.2.1.2. Impact of depressive symptoms and depression on 6.5.1. Efficacy and safety of pharmacological treatment for
cardiovascular disease prognosis..................................................... 4170 mental health conditions in people with cardiovascular disease 4183
5.2.1.3. Impact of depressive symptoms/depression on self- 6.5.2. Use of specific medications in people with depression,
management and adherence ............................................................. 4171 anxiety, or post-traumatic stress disorders and cardiovascular
5.2.2. Anxiety................................................................................................ 4171 disease.............................................................................................................. 4183
5.2.2.1. Prevalence of anxiety in people with cardiovascular 6.5.3. Use of antidepressants................................................................. 4183
disease......................................................................................................... 4171 6.5.4. Use of anxiolytics, sedatives, and hypnotics........................ 4185
5.2.2.2. Impact of anxiety on cardiovascular disease 6.5.5. Pharmacological treatment for mental health conditions
prognosis ................................................................................................... 4171 in specific cardiovascular diseases........................................................ 4185
5.2.2.3. Impact of anxiety on self-management and 6.5.5.1. Ischaemic heart disease ....................................................... 4185
adherence.................................................................................................. 4171 6.5.5.2. Ventricular arrhythmias....................................................... 4185
5.2.3. Cardiac disease-induced post-traumatic stress disorder/ 6.5.5.3. Heart failure ............................................................................. 4185
symptoms....................................................................................................... 4171 6.5.5.4. Procedures (coronary artery bypass grafting,
5.2.3.1. Prevalence of post-traumatic stress disorder in percutaneous coronary intervention)........................................... 4186
cardiovascular disease .......................................................................... 4171 6.6. Organization of care ............................................................................. 4186
5.2.3.2. Impact of post-traumatic stress disorder on 6.7. Section summary points and management consensus
cardiovascular disease prognosis..................................................... 4171 statements from Section 6........................................................................... 4186
5.2.3.3. Impact of post-traumatic stress disorder on self- 7. Severe mental illness and cardiovascular disease............................... 4187
management and adherence to medical recommendations 4172 7.1. Cardiovascular risk in people with severe mental illness...... 4187
5.2.4. Loneliness and living conditions................................................ 4172 7.2. Prognosis in severe mental illness and cardiovascular disease 4187
5.2.5. Chronic stress.................................................................................. 4173 7.3. Increased cardiovascular disease risk in people with severe
5.3. Addressing the mental health needs of informal caregivers for mental illness..................................................................................................... 4188
people with cardiovascular disease ......................................................... 4173 7.3.1. Lifestyle and biological risk factors.......................................... 4188
5.4. Section summary points and management consensus 7.3.2. Medication-induced cardiovascular risk factors................. 4188
statements from Section 5........................................................................... 4174 7.3.3. Assessing cardiovascular disease risk ..................................... 4190
6. Identification, prevention, and management of mental health 7.4. Gaps and disparities in the management of cardiovascular
issues in people with cardiovascular disease............................................. 4174 disease in people with severe mental illness....................................... 4191
6.1. Awareness of needs in people with cardiovascular disease 4174 7.4.1. Autonomy, communication, and informed consent........ 4191
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 4 ---
ESC Guidelines 4159
7.5. Management of cardiovascular disease in people with severe 8.5.6. Psychological interventions......................................................... 4204
mental illness..................................................................................................... 4191 8.5.7. Lifestyle interventions in cardio-oncology ........................... 4205
7.5.1. Management of modifiable risk factors................................. 4191 8.5.8. Medical interventions (including pharmacological
7.5.2. Diet, physical activity, and body weight control................ 4191 therapies)........................................................................................................ 4206
7.5.3. Smoking cessation .......................................................................... 4192 8.6. Section summary points and management consensus
7.5.4. Pharmacological management................................................... 4192 statements from Section 8........................................................................... 4206
7.6. Management of cardiovascular conditions in people with 9. Key messages..................................................................................................... 4206
severe mental illness...................................................................................... 4192 10. Gaps in knowledge ....................................................................................... 4207
7.6.1. Rhythm disturbances..................................................................... 4192 10.1. Knowledge gaps in relation to prevention and screening.. 4207
7.6.1.1. QTc interval prolongation ................................................. 4194 10.2. Knowledge gaps in relation to clinical management............. 4207
7.6.1.2. Heart rate changes ................................................................ 4194 10.3. Knowledge gaps in relation to special populations............... 4207
7.6.2. Clozapine-induced myocarditis................................................. 4194 10.4. Knowledge gaps in relation to healthcare systems and
7.7. Interventions to improve the management of people with healthcare delivery.......................................................................................... 4207
severe mental illness and cardiovascular disease............................... 4196 11. Conclusions...................................................................................................... 4207
7.8. Section summary points and management consensus 12. Summary of mental health aspects in specific cardiovascular
statements from Section 7........................................................................... 4196 diseases...................................................................................................................... 4208
8. Mental health in specific populations and situations......................... 4197 13. Clinical cases and patient perspectives ................................................ 4208
8.1. Sex and gender differences in mental health and 14. Evidence tables ............................................................................................... 4208
cardiovascular disease ................................................................................... 4197 15. Data availability statement......................................................................... 4208
8.1.1. Cardiovascular disease and mental health conditions in 16. Author information...................................................................................... 4208
transgender individuals ............................................................................. 4198 17. Appendix........................................................................................................... 4208
8.1.2. Sex and gender differences in mental health in people 18. References........................................................................................................ 4209
with obstructive coronary artery disease......................................... 4198 List of tables
8.1.3. Sex and gender differences in mental health in ischaemia/
angina with non-obstructive coronary arteries and coronary Table 1 Prevalence of depression/depressive symptoms in people
vasomotor disorders ................................................................................. 4198 with cardiovascular disease............................................................................... 4170
8.1.4. Sex and gender differences in mental health in people Table 2 Prevalence of anxiety/anxiety symptoms in people with
with takotsubo syndrome....................................................................... 4198 cardiovascular disease ......................................................................................... 4172
8.1.5. Sex and gender differences in mental health in people Table 3 Prevalence of post-traumatic stress disorder/post-traumatic
with heart failure......................................................................................... 4198 stress symptoms in people with cardiovascular disease...................... 4173
Table 4 Psychometric properties of screening tools for anxiety and
8.1.6. Sex and gender differences in mental health in people
depression symptoms ......................................................................................... 4177
with arrhythmias ......................................................................................... 4199
Table 5 Timing and tools for screening anxiety and depression
8.1.7. Mental health conditions associated with peri-partum
symptoms................................................................................................................. 4177
cardiomyopathy........................................................................................... 4199
Table 6 Summary of the negative effect of different antipsychotics on
8.2. Mental and cardiovascular health in older adults ..................... 4199
cardiovascular risk factors................................................................................. 4190
8.3. Mental health and cardiovascular disease in people with frailty
Table 7 Management of psychotropic drugs with QT interval
and multimorbidity......................................................................................... 4200
prolongation properties..................................................................................... 4196
8.3.1. Mental health and frailty .............................................................. 4200
8.3.2. Mental health, cardiovascular disease, and
List of figures
multimorbidity.............................................................................................. 4200
8.3.3. Summary of evidence in older adults with cardiovascular
Figure 1 Concept of mental health within this consensus statement 4162
disease and mental disorders................................................................. 4200 Figure 2 Mental/cardiovascular health, disease interaction, and future
8.4. Mental health and cardiovascular disease in socioeconomically directions.................................................................................................................. 4163
deprived populations..................................................................................... 4201 Figure 3 The Psycho-Cardio team................................................................. 4164
8.4.1. Mental health and cardiovascular disease in migrants and Figure 4 The ACTIVE principles to improve mental health in
refugees........................................................................................................... 4202 cardiovascular care............................................................................................... 4165
8.4.2. Barriers to mental healthcare access ..................................... 4202 Figure 5 Sources of psychosocial stress as risk factors for
8.4.3. Stigma in healthcare provision .................................................. 4203 cardiovascular disease ......................................................................................... 4167
8.4.4. Community and policy interventions..................................... 4203 Figure 6 Suggestions for supporting informal caregivers of people
8.5. Mental health and cardiovascular disease in people with living with cardiovascular disease ................................................................... 4174
cancer (cardio-oncology)............................................................................. 4204 Figure 7 Visualization of an ‘on demand’ support system for people
8.5.1. Mental health in people with cancer and cardiovascular with cardiovascular disease to improve mental health................................ 4175
disease.............................................................................................................. 4204 Figure 8 Screening for mental health conditions in people with
cardiovascular disease ......................................................................................... 4176
8.5.2. Cancer survivors............................................................................. 4204
Figure 9 Stepped care model for assessment and management of
8.5.3. Advanced cancer disease............................................................. 4204
mental health conditions in people with cardiovascular disease...... 4179
8.5.4. Cancer therapy-related cardiovascular toxicity................. 4204
Figure 10 Pharmacological management of cardiovascular disease
8.5.5. Impact of cancer therapy on mental health........................ 4204
and depression, anxiety, or post-traumatic stress disorders............. 4184
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 5 ---
4160 E S C G u id e l in e s
Figure 11 Severe mental illnesses................................................................... 4188 IHD Ischaemic heart disease
Figure 12 Multifactorial aetiology of cardiovascular disease risk in INOCA Ischaemia with non-obstructive coronary
people with severe mental illness.................................................................. 4189 arteries
Figure 13 Management of people with cardiovascular disease and LDL Low-density lipoprotein
severe mental illness............................................................................................ 4193 MACE Major adverse cardiac events
Figure 14 Management of people with severe mental illness and MAOI Monoamine oxidase inhibitor
arrhythmias.............................................................................................................. 4195 mHealth Mobile health
Figure 15 Sex and gender differences in the psycho-cardio MI Myocardial infarction
interaction................................................................................................................ 4197 MINOCA Myocardial infarction with non-obstructive
Figure 16 Ageing, mental disorders, and cardiovascular disease ...... 4201 coronary arteries
Figure 17 Mechanisms through which socioeconomic deprivation MotInt Motivational interviewing
contributes to cardiovascular risk.................................................................. 4202 NYHA New York Heart Association
Figure 18 Mental health challenges in migrant populations................ 4203 OCEAN Omega-3 Supplementation for Co-Morbid
Figure 19 Management of mental health in people with cardiovascular Depression and Heart Failure Treatment
disease and cancer................................................................................................................. 4205 OHCA Out-of-hospital cardiac arrest
OR Odds ratio
Abbreviations and acronyms
PAH Pulmonary arterial hypertension
PCI Percutaneous coronary intervention
ACE Adverse childhood experience
PH Pulmonary hypertension
ACHD Adult congenital heart disease
PHQ Patient Health Questionnaire
ACS Acute coronary syndrome
PTSD Post-traumatic stress disorder
ACTIVE Acknowledge, Check, Tools, Implement,
PTSS Post-traumatic stress symptom
Venture, Evaluate
QoL Quality of life
AF Atrial fibrillation
RCT Randomized controlled trial
AMI Acute myocardial infarction
RR Risk ratio
CABG Coronary artery bypass graft
SCAD Spontaneous coronary artery dissection
CAD Coronary artery disease
SCD Sudden cardiac death
CBT Cognitive-behavioural therapy
SDM Shared decision-making
CDI-PTSD Cardiac disease-induced post-traumatic stress
SES Socioeconomic status
disorder
SMI Severe mental illness
CDI-SF Cardiac Distress Inventory-Short Form
SNRI Serotonin and norepinephrine reuptake
CHD Coronary heart disease
inhibitor
CI Confidence interval
SSRI Selective serotonin reuptake inhibitor
CODIACS-QoL Comparison of Depression Interventions After
SSS Subjective social status
Acute Coronary Syndrome: Quality of Life
SWB Subjective well-being
CV Cardiovascular
TCA Tricyclic antidepressant
CVD Cardiovascular disease
TTS Takotsubo syndrome
EAPC European Association of Preventive
VAD Ventricular assist device
Cardiology
WHO World Health Organization
EASD European Association for the Study of
Diabetes
ECG Electrocardiogram 1. Preamble
ECR Exercise-based cardiac rehabilitation
eHealth Information and communication technologies ESC Clinical Consensus Statements, developed under the auspices of
for health the ESC Clinical Practice Guidelines Committee, evaluate and summar-
EMDR Eye movement desensitization and ize available evidence with the aim of assisting health professionals in
reprocessing proposing the best diagnostic or therapeutic approach for an individual
ESC European Society of Cardiology patient with a given condition. ESC Clinical Consensus Statements are
GAD Generalized Anxiety Disorder intended for use by health professionals but do not override their indi-
HADS Hospital Anxiety and Depression Scale vidual responsibility to make appropriate and accurate decisions in con-
HDL High-density lipoprotein sideration of each patient’s health condition and in consultation with
HF Heart failure the patient or the patient’s caregiver where appropriate and/or neces-
HF-ACTION Heart Failure-A Controlled Trial Investigating sary. It is also the health professional’s responsibility to verify the
Outcomes of Exercise Training rules and regulations applicable in each country to drugs and devices
HR Hazard ratio at the time of prescription and to respect the ethical rules of their
HRQoL Health-related quality of life profession.
HTx Heart transplantation ESC Clinical Consensus Statements represent the official position of
ICD Implantable cardioverter-defibrillator the ESC on a given topic. ESC Policies and Procedures for formulating
IES Impact of Event Scale and issuing ESC Guidelines and documents developed under the
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 6 ---
ESC Guidelines 4161
auspices of the ESC Clinical Practice Guidelines Committee can be found (CVD) and vice versa. It also outlines how the negative impacts of this
on the ESC website (https://www.escardio.org/Guidelines/Clinical- reciprocal relationship can be prevented or minimized. Clinical cardio-
Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). vascular (CV) practice often overlooks the impact of mental health and
This Task Force was selected by the ESC to include professionals in- the importance of its inclusion in CV care; this needs to change.
volved with the medical care of patients with this pathology and to include Therefore, this consensus statement sets out to be broad and ambi-
patient representatives and methodologists. The selection procedure in- tious. The high burden of concomitant CVD and mental health condi-
cluded an open call for authors and aimed to include members from tions requires a new integrated approach to caring for people with
across the whole of the ESC region and from relevant ESC Subspecialty CVD. Cardiovascular health professionals need to develop collabora-
Communities. Consideration was given to diversity and inclusion. tions with mental health professionals to provide guidance for practice
Clinical consensus statement Task Forces perform a critical review and appropriate support for people with CVD and their caregivers.
and evaluation of the published literature on diagnostic and therapeutic Whilst challenging, healthcare professionals are encouraged to pursue
approaches including assessment of the risk–benefit ratio. Evidence ta- the implementation of the suggestions in this statement, regardless of
bles summarizing key information from relevant studies are generated their profession, clinical setting, or resources. Changes in the current
to facilitate the formulation of management consensus statements, to models of care, with structure and resource adjustments, may require
enhance their comprehension after publication, and to reinforce trans- both centre-specific and country-specific measures. Consequently, the
parency in the clinical consensus statement development process. The document adopts a global perspective and reviews the evidence
tables are published in their own section of the ESC Clinical Consensus on the association between mental and CV health, as well as tackling
Statement and reference specific recommendation tables. key aspects such as awareness, communication, screening, optimal
After an iterative process of deliberations, a modified Delphi process management, stigma, gaps in evidence, and needs for research. A com-
on all management consensus statements was conducted. The Task prehensive and inclusive perspective has also prompted the use of re-
Force members ranked their level of agreement or disagreement spectful language in healthcare.1People with lived experience of CVD
with each management consensus statement using the Likert ordinal and mental health conditions have been central in the creation of this
scale: strongly agree, agree, neither agree nor disagree, disagree, strong- document, and their perspectives underpin the importance of changing
ly disagree, recuse. Consensus of agreement was inferred if >75% of practice, and emphasize the need for implementation of the steps sug-
the respondents selected the options ‘strongly agree’ or ‘agree’. gested in this statement.
The writing and reviewing panels provided declaration of interest
forms for all relationships that might be perceived as real or potential
2.1. Methods employed in the consensus
sources of conflicts of interest. Their declarations of interest were re-
statement
viewed according to the ESC declaration of interest rules which can be
found on the ESC website (http://www.escardio.org/doi) and were This consensus document involved a multidisciplinary team of cardiol-
compiled in a report published in a supplementary document with ogists, nurses, general professionals, psychologists, psychiatrists, geria-
the Clinical Consensus Statement. Funding for the development of tricians, and people with experience of mental health and CV
ESC Clinical Consensus Statements is derived entirely from the ESC conditions. It was developed under the auspices of the ESC Clinical
with no involvement of the healthcare industry. Practice Guidelines Committee. The Task Force Chairs proposed the
The CPG Committee supervises and co-ordinates the preparation document structure; this was subsequently refined through group in-
of new clinical consensus statements and approves their publication. In add- put, with section leaders ensuring consistency, coherence, and clinical
ition to review by the CPG Committee, ESC Clinical Consensus Statements relevance. Literature reviews are comprehensively presented within
undergo multiple rounds of double-blind peer review on a dedicated online evidence tables. Relevant, clinically tangible information is summarized
review platform. The review is conducted by topic experts, including mem- within the text for the benefit of the clinical professional. Multiple meet-
bers from ESC National Cardiac Societies and from relevant ESC ings were held to discuss the available evidence and the relative strength
Subspecialty Communities. Guideline Task Forces consider all review com- of that evidence.
ments and are required to respond to all those classified as major. After ap- On the basis of the evidence reviews and discussion, the Task Force
propriate revisions, Task Force and the CPG Committee members identified that there is limited evidence to guide practice, despite the
approve the final document for publication in the European Heart Journal. clear and important multidirectional interaction between mental health
Unless otherwise stated, ESC Clinical Consensus Statement content and CVD. As a result of the dearth of research, the Task Force adopted
refers to sex, understood as the biological condition of being male or a modified Delphi process to generate main recommendations. The
female, defined by genes, hormones, and sexual organs. Off-label use modified Delphi process is a structured communication technique
of medication may be presented in this Guideline if a sufficient level that allows a group of experts to gather opinions on a given complex
of evidence shows that it can be considered medically appropriate or controversial topic, for which there is insufficient evidence or incom-
for a given condition. However, decisions on off-label use must be plete knowledge.2The modified Delphi questionnaire included manage-
made by the responsible health professional giving special consideration ment consensus statements. These statements summarize factors from
to ethical rules concerning healthcare, the specific situation of the pa- each section and typically consist of actions or practical suggestions that
tient, patient consent, and country-specific health regulations. healthcare professionals should endeavor to implement in their prac-
tice. As these are based on limited evidence, the Task Force members
ranked their level of agreement or disagreement with each manage-
2. The scope of this consensus
ment consensus statement using the Likert ordinal scale: strongly agree,
statement agree, neither agree nor disagree, disagree, strongly disagree, recuse.
Consensus of agreement was inferred if >75% of the respondents se-
This consensus statement provides readers with insights into the extent lected the options ‘strongly agree’ or ‘agree’. Consensus was reached
and magnitude of the impact of mental health on cardiovascular disease for all the proposed management consensus statements following the
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 7 ---
4162 E S C G u id e l in e s
first round of voting. A total of 34 management consensus statements mental health disturbances also lacks consistent definitions. Mental
are presented in this document. Section summary points represent im- health condition is a wide term that will be used in this document to
portant components of the section that a healthcare professional refer to psychosocial difficulties and other mental states associated
should be aware of. They were also reviewed and revised by the with distress, impairment in cognitive functioning, altered emotional re-
Task Force, to ensure that they reflected the key elements of each sec- sponses, altered behaviour, and risk of self-harm. Within mental health
tion. Section summary points and management consensus statements conditions, mental health disorders refer to mental health states char-
are presented at the end of each section. acterized by a clinically significant disturbance in an individual’s cogni-
tion, emotional regulation, or behaviour, usually associated with
distress or impairment in important areas of functioning.3Mental health
3. Introduction
disorders include severe mental illnesses (SMI) defined by a significantly
impaired level of psychosocial functioning (Figure 1).6In relation to the
3.1. The relationship between mental and
latter, we have drawn upon definitions and diagnostic criteria for men-
cardiovascular health and disease
tal health conditions that are specified in the International Classification
Mental health is an integral component of a person’s health. According of Diseases for Mortality and Morbidity Statistics, Eleventh Revision.7
to the World Health Organization (WHO), mental health is a state of Organic mental health disorders, such as cognitive impairment and de-
mental well-being that enables people to cope with the stresses of life, mentia, are outside the scope of this document.
realize their abilities, learn well and work well, and contribute to their This consensus statement will address mental health conditions
community.3Despite its importance, there is not a single agreed defin- across the spectrum of severity and type, as both people with symp-
ition for mental health.4 toms of suboptimal mental health identified through screening, and
Although mental health and mental illness are sometimes considered people with manifest mental health disorders, are at high CVD risk.
as dual continua, for the purpose of this document, mental health is an Core principles, across the spectrum of disease, are outlined. To illus-
overarching concept of a complex continuum spanning from optimal trate the impact and implementation of some of the key aspects of the
mental health with dominant features such as optimism, resilience, document, the narratives of people living with CVD and clinical cases
and well-being, to negative mental health states including severe mental have been incorporated into the online document ‘Clinical cases and
illness (Figure 1).5The nomenclature surrounding negative aspects and patient perspectives’.
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:27)(cid:23)(cid:22)(cid:29)(cid:26)(cid:25)(cid:24)(cid:21)(cid:23)(cid:26)(cid:25)(cid:29)(cid:21) (cid:20)(cid:23)(cid:22)(cid:29)(cid:26)(cid:25)(cid:24)(cid:28)(cid:25)(cid:25)(cid:22)(cid:23)(cid:19)(cid:19)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:24)(cid:25)(cid:30)(cid:27)(cid:26)(cid:28)(cid:25) Mental health (cid:18)(cid:30)(cid:17)(cid:30)(cid:16)(cid:30)(cid:24)(cid:15)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)
(cid:25)(cid:30)(cid:27)(cid:26)(cid:28)(cid:25) (cid:23)(cid:22)(cid:29)(cid:21)(cid:20)(cid:28)(cid:20)(cid:22)(cid:29)(cid:19) disorders (cid:20)(cid:26)(cid:26)(cid:29)(cid:30)(cid:19)(cid:19)(cid:24)
Figure 1 Concept of mental health within this consensus statement.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 8 ---
ESC Guidelines 4163
Mental health and mental health conditions interact with CV health • The concurrence of CVD and mental health conditions may interact,
(defined as the health of the heart and blood vessels)8and CVD in a worsening both mental health and CV prognosis.17–19
multidirectional way (Figure 2). For example: • People with mental health conditions are often the most disadvan-
taged, experiencing social and economic hardship as well as dealing
• Positive features of mental health at an individual and societal level are with stigma, stereotypes, and prejudice.20
associated with better CV health,9–11 while people with mental • People with mental health disorders, particularly SMI, are more
health conditions are more likely to be at greater risk of CVD.12 vulnerable, and are less likely to receive the same diagnostic
• Acute CV events or chronic CVD impact on mental health, worsen- and treatment efforts as persons without mental health condi-
ing pre-existing mental conditions or triggering new conditions.13–16 tions.21–26
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:26)(cid:23)(cid:26)(cid:28)(cid:27)(cid:30)(cid:27)(cid:25)(cid:25)
(cid:26)(cid:30)(cid:22)(cid:24)(cid:27)(cid:22)(cid:21)(cid:29)(cid:26)(cid:20)(cid:19)(cid:18)(cid:30)
(cid:127)(cid:19)(cid:25)(cid:129)
(cid:1)(cid:27)(cid:30)(cid:20)(cid:26)(cid:5) (cid:13)(cid:7)
(cid:15)(cid:27)(cid:26)(cid:5)(cid:20)(cid:15) (cid:15)(cid:27)(cid:26)(cid:5)(cid:20)(cid:15)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)
(cid:25)(cid:29)(cid:28)(cid:27)(cid:27)(cid:30)(cid:19)(cid:30)(cid:3) (cid:28)(cid:27)(cid:25)(cid:27)(cid:26)(cid:28)(cid:29)(cid:15)
(cid:1)(cid:27)(cid:30)(cid:20)(cid:26)(cid:5)(cid:24)(cid:15)(cid:27)(cid:26)(cid:5)(cid:20)(cid:15) (cid:13)(cid:26)(cid:28)(cid:22)(cid:19)(cid:18)(cid:4)(cid:26)(cid:25)(cid:29)(cid:21)(cid:5)(cid:26)(cid:28)
(cid:29)(cid:18)(cid:30)(cid:22)(cid:19)(cid:20)(cid:19)(cid:18)(cid:30)(cid:25) (cid:22)(cid:19)(cid:25)(cid:27)(cid:26)(cid:25)(cid:27)
(cid:127)(cid:19)(cid:25)(cid:129)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:27)(cid:26)(cid:25)(cid:24)(cid:25)(cid:23)(cid:22)(cid:26)(cid:21)(cid:24)(cid:26)(cid:20)(cid:21)(cid:25)(cid:27)(cid:19)(cid:25)(cid:23)(cid:26)(cid:18)(cid:21)(cid:22)(cid:17)(cid:21)(cid:16)(cid:22)(cid:26)(cid:19)(cid:27)(cid:26)(cid:19)(cid:15)(cid:19)(cid:14)(cid:13)(cid:24)(cid:19)(cid:27)(cid:20)(cid:21)(cid:18)(cid:15)(cid:23)(cid:20)(cid:24)(cid:26)(cid:16)(cid:27)
(cid:31)
(cid:30)
(cid:29)
(cid:28)
(cid:27)
(cid:26)
(cid:9)(cid:13)(cid:8)(cid:31)(cid:7)(cid:6) (cid:17)(cid:25)(cid:16)(cid:29)(cid:15)(cid:18)(cid:14)(cid:13)(cid:26)(cid:28)(cid:22)(cid:19)(cid:18) (cid:11)(cid:20)(cid:27)(cid:10)(cid:10)(cid:27)(cid:22)
(cid:10)(cid:28)(cid:19)(cid:30)(cid:29)(cid:19)(cid:10)(cid:5)(cid:27)(cid:25) (cid:20)(cid:27)(cid:26)(cid:12) (cid:29)(cid:26)(cid:28)(cid:27)(cid:24)(cid:26)(cid:10)(cid:10)(cid:28)(cid:18)(cid:26)(cid:29)(cid:15)
(cid:31)(cid:12)(cid:10)(cid:28)(cid:18)(cid:4)(cid:27)(cid:22)(cid:24)(cid:12)(cid:26)(cid:30)(cid:26)(cid:3)(cid:27)(cid:12)(cid:27)(cid:30)(cid:20)(cid:24)(cid:26)(cid:30)(cid:22)(cid:24)(cid:2)(cid:27)(cid:20)(cid:20)(cid:27)(cid:28)(cid:24)(cid:18)(cid:21)(cid:20)(cid:29)(cid:18)(cid:12)(cid:27)(cid:25)
Figure 2 M(cid:13)e(cid:27)n(cid:30)t(cid:20)a(cid:28)l/(cid:26)c(cid:5)a(cid:24)r(cid:19)(cid:5)d(cid:5)i(cid:21)o(cid:25)v(cid:20)a(cid:28)s(cid:26)cu(cid:20)(cid:19)la(cid:18)r(cid:30) h(cid:24)e(cid:4)a(cid:141)lt(cid:143)h(cid:24)(cid:8), (cid:144)d(cid:24)i(cid:13)se(cid:15)as(cid:26)e(cid:19) (cid:28)i(cid:24)n(cid:22)te(cid:27)r(cid:29)a(cid:19)c(cid:25)t(cid:19)i(cid:18)on(cid:30), (cid:24)a(cid:18)n(cid:30)d(cid:24) (cid:29)fu(cid:18)t(cid:12)ure(cid:2) d(cid:19)(cid:30)ir(cid:27)e(cid:22)ct(cid:24)i(cid:157)o(cid:3)ns(cid:21). (cid:28)C(cid:27)V(cid:25),(cid:24) (cid:18)ca(cid:30)r(cid:24)d(cid:31)i(cid:30)o(cid:20)v(cid:27)as(cid:28)c(cid:26)u(cid:29)la(cid:20)(cid:19)r(cid:18). A(cid:30)C(cid:24)(cid:2)T(cid:27)IV(cid:20)(cid:23)E, (cid:27)A(cid:27)c(cid:30)k(cid:24)n(cid:12)ow(cid:27)(cid:30)le(cid:20)d(cid:26)g(cid:5)e(cid:24), Check, (use validated)
Tools, Imple(cid:15)m(cid:27)e(cid:26)n(cid:5)(cid:20)t(cid:15), V(cid:24)(cid:26)e(cid:30)n(cid:22)tu(cid:24)r(cid:29)e(cid:26), (cid:28)E(cid:22)v(cid:19)a(cid:18)lu(cid:4)a(cid:26)t(cid:25)e(cid:29) ((cid:21)se(cid:5)(cid:26)e (cid:28)F(cid:24)(cid:22)igu(cid:19)(cid:25)re(cid:27) (cid:26)4(cid:25)).(cid:27) (cid:24)(cid:26)(cid:30)(cid:22)(cid:24)(cid:13)(cid:26)(cid:28)(cid:22)(cid:19)(cid:18)(cid:4)(cid:26)(cid:25)(cid:29)(cid:21)(cid:5)(cid:26)(cid:28)(cid:24)(cid:26)(cid:30)(cid:22)(cid:24)(cid:1)(cid:27)(cid:30)(cid:20)(cid:26)(cid:5)(cid:24) (cid:27)(cid:26)(cid:5)(cid:20)(cid:15)(cid:24)(cid:31)(cid:30)(cid:20)(cid:27)(cid:3)(cid:28)(cid:26)(cid:20)(cid:19)(cid:18)(cid:30)
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 9 ---
4164 E S C G u id e l in e s
3.2. Enduring problems • Little guidance about how to improve the care of people with SMI,
despite strong evidence that people with SMI and CVD have worse
Despite the strong association between mental health, CV health, and
CV prevention, acute and chronic care, and prognosis.21,24–26
CVD, and its clinical relevance, there are multiple problems (Figure 2)
• Limited awareness of the importance of family and caregivers and
including:
their needs, as both CVD and mental health conditions affect a per-
son’s wider social network.31–34
• Insufficient awareness among healthcare professionals of the preva-
lence of mental health conditions in the population and their impact
on increasing risk of developing CVD.27 Cardiovascular care is optimal when it is person-centred and seeks
• Limited appreciation among healthcare professionals of the incidence to improve overall health, not only CV but also mental health, as an in-
and prevalence of mental health conditions and mental disorders tegral component. This approach needs to be integrated into routine
among people with CVD and their impact on quality of life (QoL), practice as most current models of CV care do not consider mental
therapeutic adherence, and CVD prognosis.27 health as a primary goal. To achieve this, healthcare professionals
• Inadequate recognition of the stigma of SMI in society and in health- need more comprehensive information about mental health and how
care, and its consequences for people coping with SMI, their family, to deliver mental health sensitive, person-centred care. Furthermore,
and caregivers.28 the mental health challenges experienced by family members and care-
• Lack of systematic and appropriate screening, evaluation, communi- givers are often not recognized nor addressed.35Central to this state-
cation, and management of mental health, which are not integrated in ment is the recognition that CV care professionals need to develop
routine clinical CV practice.29 collaboration with mental health professionals in order to ensure opti-
• Little knowledge and ongoing research about how to improve CV mal care and outcomes. Access to mental health services may vary, but
health and prevent CVD in people with mental health conditions the multidisciplinary CV team needs to include a collaborating mental
and mental disorders.21–23,27 health professional, psychologist, or psychiatrist to provide guidance
• Limited evidence and ongoing research on the best ways to commu- for practice and appropriate support for people with CVD and their
nicate, promote, maintain, and improve mental health and resilience caregivers. In this consensus statement, we have called this the
in people with CVD and their family members.30 Psycho-Cardio team (Figure 3).
(cid:9)(cid:23)(cid:8)(cid:22)(cid:27)(cid:19)(cid:25)(cid:7)(cid:23)(cid:27)(cid:19)(cid:22)(cid:7)(cid:25)(cid:11)(cid:30)(cid:20)(cid:6)(cid:23)(cid:16)(cid:16)(cid:29)(cid:20)(cid:8)(cid:27)(cid:19)(cid:16)
(cid:10)(cid:12)(cid:30)(cid:16)(cid:23)(cid:16) (cid:15)(cid:27)(cid:30)(cid:14)(cid:29)(cid:20)(cid:13)(cid:27)(cid:16)(cid:24)(cid:12)(cid:19)(cid:27)(cid:30)
(cid:16)(cid:11)(cid:23)(cid:24)(cid:29)(cid:27)(cid:19)(cid:29)(cid:16)(cid:22)(cid:16)
(cid:5)(cid:22)(cid:7)(cid:23)(cid:30)(cid:25)(cid:27)(cid:19)(cid:19)(cid:29)(cid:23)(cid:14) (cid:21)(cid:20)(cid:24)(cid:29)(cid:27)(cid:19)(cid:25)(cid:18)(cid:20)(cid:30)(cid:17)(cid:23)(cid:30)(cid:16)
(cid:11)(cid:30)(cid:20)(cid:6)(cid:23)(cid:16)(cid:16)(cid:29)(cid:20)(cid:8)(cid:27)(cid:19)(cid:16)
(cid:4)(cid:8)(cid:22)(cid:23)(cid:3)(cid:30)(cid:27)(cid:22)(cid:23)(cid:14)(cid:25)(cid:24)(cid:27)(cid:30)(cid:23)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:26)(cid:25)(cid:24)(cid:27)(cid:30)(cid:23)(cid:25)(cid:22)(cid:23)(cid:27)(cid:28)
Figure 3 The Psycho-Cardio team.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 10 ---
ESC Guidelines 4165
3.3. Aims of the document the multidisciplinary primary care team, and psychosocial determinants
and potential social interventions discussed with social workers and
This document adopts a broad, summarizing approach, and provides
relevant professionals. All professionals should advocate for improved
key and consensus statements which collectively:
mental health and CV care; those with advocacy responsibilities within
• Critically review the evidence on the association between mental and the public health and policy domain should ensure changes recom-
CV health. mended here are priorities. A practical approach to change routine clin-
• Increase awareness of the clinical importance of the association be- ical CV care towards being more person-centred is to focus on
tween mental and CV health. awareness toward the person with CVD and caregivers’ mental health,
• Increase awareness and combat the stigma of mental health condi- CV prevention, and care of people with mental health conditions fol-
tions and mental health disorders. lowing the ACTIVE principles (Figure 4).
• Promote increased mental health screening and better management
for people with CVD and mental health conditions and support for
• First, acknowledge (A) the intricate relationship between mental
caregivers.
health, CV health, and CVD, their common and specific determi-
• Provide guidance on initial clinical, systemic, and organizational
nants, and the influence that mental health conditions may have on
changes needed, as well as signposting future directions.
prognosis and care equity. Particular attention is required to identify
• Identify gaps in evidence and research needed to improve the care for
and eliminate potential bias, disparities and stigma associated with
people with mental health conditions and CVD.
mental health conditions and disorders, particularly in those with SMI.
• Second, check (C) systematically for the presence of symptoms of
3.4. The Psycho-Cardio team
mental health conditions or mental health disorders at CV visits,
Multidisciplinary teams are needed to offer a holistic approach to health and check CV risk factors during mental health visits.
promotion and management in people with CVD and mental health • Third, use validated tools (T) to assess mental and CV health
conditions. In addition to CV and mental health professionals, the status among people with CVD, and use tools to inform and
Psycho-Cardio team should be augmented by allied professionals, as ap- educate about the importance of mental and CV health, and their
propriate.36Care continuity should be ensured via co-ordination with relationships.
(cid:31) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:24)(cid:31)(cid:30)(cid:29)(cid:28)(cid:31)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:31)(cid:22)(cid:28)(cid:30)(cid:21)(cid:28)(cid:28)(cid:25)(cid:31)(cid:20)(cid:28)(cid:25)(cid:30)(cid:19)(cid:27)(cid:31)(cid:19)(cid:25)(cid:18)(cid:31)(cid:17)(cid:19)(cid:16)(cid:18)(cid:26)(cid:15)(cid:14)(cid:19)(cid:23)(cid:17)(cid:13)(cid:27)(cid:19)(cid:16)(cid:31)(cid:29)(cid:28)(cid:19)(cid:27)(cid:30)(cid:29)(cid:31)(cid:19)(cid:25)(cid:18)
(cid:18)(cid:28)(cid:30)(cid:28)(cid:16)(cid:20)(cid:26)(cid:25)(cid:19)(cid:25)(cid:30)(cid:23)(cid:12)(cid:31)(cid:22)(cid:26)(cid:19)(cid:23)(cid:12)(cid:31)(cid:18)(cid:26)(cid:23)(cid:11)(cid:19)(cid:16)(cid:26)(cid:30)(cid:26)(cid:28)(cid:23)(cid:31)(cid:19)(cid:25)(cid:18)(cid:31)(cid:23)(cid:30)(cid:26)(cid:10)(cid:20)(cid:19)(cid:31)(cid:19)(cid:23)(cid:23)(cid:15)(cid:17)(cid:26)(cid:19)(cid:30)(cid:28)(cid:18)(cid:31)(cid:21)(cid:26)(cid:30)(cid:29)(cid:31)(cid:20)(cid:28)(cid:25)(cid:30)(cid:19)(cid:27)(cid:31)(cid:29)(cid:28)(cid:19)(cid:27)(cid:30)(cid:29)
(cid:30) (cid:19)(cid:18)(cid:24)(cid:30)(cid:29)(cid:31)(cid:6)(cid:15)(cid:16)(cid:31)(cid:23)(cid:7)(cid:20)(cid:11)(cid:30)(cid:15)(cid:20)(cid:23)(cid:31)(cid:15)(cid:16)(cid:31)(cid:20)(cid:28)(cid:25)(cid:30)(cid:19)(cid:27)(cid:31)(cid:29)(cid:28)(cid:19)(cid:27)(cid:30)(cid:29)(cid:31)(cid:17)(cid:15)(cid:25)(cid:18)(cid:26)(cid:30)(cid:26)(cid:15)(cid:25)(cid:23)(cid:31)(cid:19)(cid:30)(cid:31)(cid:17)(cid:19)(cid:16)(cid:18)(cid:26)(cid:15)(cid:14)(cid:19)(cid:23)(cid:17)(cid:13)(cid:27)(cid:19)(cid:16)(cid:31)(cid:14)(cid:26)(cid:23)(cid:26)(cid:30)(cid:23)
(cid:16)(cid:28)(cid:10)(cid:13)(cid:27)(cid:19)(cid:16)(cid:27)(cid:7)(cid:31)(cid:19)(cid:25)(cid:18)(cid:31)(cid:17)(cid:19)(cid:16)(cid:18)(cid:26)(cid:15)(cid:14)(cid:19)(cid:23)(cid:17)(cid:13)(cid:27)(cid:19)(cid:16)(cid:31)(cid:16)(cid:26)(cid:23)(cid:24)(cid:31)(cid:6)(cid:19)(cid:17)(cid:30)(cid:15)(cid:16)(cid:23)(cid:31)(cid:18)(cid:13)(cid:16)(cid:26)(cid:25)(cid:10)(cid:31)(cid:20)(cid:28)(cid:25)(cid:30)(cid:19)(cid:27)(cid:31)(cid:17)(cid:19)(cid:16)(cid:28)
(cid:29) (cid:21)(cid:27)(cid:27)(cid:25)(cid:20)(cid:9)(cid:31)(cid:8)(cid:23)(cid:28)(cid:31)(cid:14)(cid:19)(cid:27)(cid:26)(cid:18)(cid:19)(cid:30)(cid:28)(cid:18)(cid:31)(cid:30)(cid:15)(cid:15)(cid:27)(cid:23)(cid:31)(cid:30)(cid:15)(cid:31)(cid:23)(cid:17)(cid:16)(cid:28)(cid:28)(cid:25)(cid:31)(cid:19)(cid:25)(cid:18)(cid:31)(cid:18)(cid:26)(cid:19)(cid:10)(cid:25)(cid:15) (cid:23)(cid:28)(cid:31)(cid:20)(cid:28)(cid:25)(cid:30)(cid:19)(cid:27)(cid:31)(cid:29)(cid:28)(cid:19)(cid:27)(cid:30)(cid:29)(cid:31)(cid:23)(cid:7)(cid:20)(cid:11)(cid:30)(cid:15)(cid:20)(cid:23)
(cid:19)(cid:25)(cid:18)(cid:31)(cid:17)(cid:15)(cid:25)(cid:18)(cid:26)(cid:30)(cid:26)(cid:15)(cid:25)(cid:23)
(cid:28) (cid:17)(cid:16)(cid:15)(cid:25)(cid:24)(cid:16)(cid:24)(cid:28)(cid:14)(cid:31)(cid:11)(cid:28)(cid:16)(cid:23)(cid:15)(cid:25)(cid:5)(cid:17)(cid:28)(cid:25)(cid:30)(cid:16)(cid:28)(cid:18)(cid:31)(cid:20)(cid:19)(cid:25)(cid:19)(cid:10)(cid:28)(cid:20)(cid:28)(cid:25)(cid:30)(cid:31)(cid:13)(cid:23)(cid:26)(cid:25)(cid:10)(cid:31)(cid:23)(cid:29)(cid:19)(cid:16)(cid:28)(cid:18)(cid:31)(cid:18)(cid:28)(cid:17)(cid:26)(cid:23)(cid:26)(cid:15)(cid:25)(cid:5)(cid:20)(cid:19)(cid:24)(cid:26)(cid:25)(cid:10)(cid:31)(cid:19)(cid:25)(cid:18)
(cid:23)(cid:30)(cid:28)(cid:11)(cid:11)(cid:28)(cid:18)(cid:31)(cid:17)(cid:19)(cid:16)(cid:28)(cid:31)(cid:19)(cid:11)(cid:11)(cid:16)(cid:15)(cid:19)(cid:17)(cid:29)(cid:28)(cid:23)
(cid:27) (cid:13)(cid:24)(cid:28)(cid:14)(cid:12)(cid:11)(cid:24)(cid:31)(cid:30)(cid:15)(cid:31)(cid:17)(cid:29)(cid:19)(cid:25)(cid:10)(cid:28)(cid:31)(cid:17)(cid:19)(cid:16)(cid:18)(cid:26)(cid:15)(cid:14)(cid:19)(cid:23)(cid:17)(cid:13)(cid:27)(cid:19)(cid:16)(cid:31)(cid:17)(cid:19)(cid:16)(cid:28)(cid:31)(cid:22)(cid:7)(cid:31)(cid:26)(cid:20)(cid:11)(cid:27)(cid:28)(cid:20)(cid:28)(cid:25)(cid:30)(cid:26)(cid:25)(cid:10)(cid:31)(cid:30)(cid:29)(cid:28)(cid:31)(cid:23)(cid:30)(cid:16)(cid:13)(cid:17)(cid:30)(cid:13)(cid:16)(cid:19)(cid:27)(cid:31)(cid:19)(cid:25)(cid:18)(cid:31)(cid:6)(cid:13)(cid:25)(cid:17)(cid:30)(cid:26)(cid:15)(cid:25)(cid:19)(cid:27)(cid:31)
(cid:17)(cid:29)(cid:19)(cid:25)(cid:10)(cid:28)(cid:23)(cid:31)(cid:25)(cid:28)(cid:28)(cid:18)(cid:28)(cid:18)(cid:31)(cid:30)(cid:15)(cid:31)(cid:26)(cid:25)(cid:30)(cid:28)(cid:10)(cid:16)(cid:19)(cid:30)(cid:28)(cid:31)(cid:20)(cid:28)(cid:25)(cid:30)(cid:19)(cid:27)(cid:31)(cid:29)(cid:28)(cid:19)(cid:27)(cid:30)(cid:29)(cid:31)(cid:17)(cid:19)(cid:16)(cid:28)(cid:31)(cid:21)(cid:26)(cid:30)(cid:29)(cid:26)(cid:25)(cid:31)(cid:17)(cid:19)(cid:16)(cid:18)(cid:26)(cid:15)(cid:14)(cid:19)(cid:23)(cid:17)(cid:13)(cid:27)(cid:19)(cid:16)(cid:31)(cid:11)(cid:16)(cid:19)(cid:17)(cid:30)(cid:26)(cid:17)(cid:28)
(cid:26) (cid:10)(cid:9)(cid:8)(cid:25)(cid:12)(cid:8)(cid:14)(cid:24)(cid:31)(cid:25)(cid:28)(cid:28)(cid:18)(cid:23)(cid:31)(cid:6)(cid:15)(cid:16)(cid:31)(cid:28)(cid:18)(cid:13)(cid:17)(cid:19)(cid:30)(cid:26)(cid:15)(cid:25)(cid:19)(cid:27)(cid:31)(cid:23)(cid:13)(cid:11)(cid:11)(cid:15)(cid:16)(cid:30)(cid:31)(cid:19)(cid:25)(cid:18)(cid:31)(cid:17)(cid:29)(cid:19)(cid:25)(cid:10)(cid:28)(cid:23)(cid:31)(cid:26)(cid:25)(cid:31)(cid:20)(cid:19)(cid:25)(cid:19)(cid:10)(cid:28)(cid:20)(cid:28)(cid:25)(cid:30)(cid:31)(cid:19)(cid:25)(cid:18)
(cid:11)(cid:16)(cid:15)(cid:10)(cid:16)(cid:28)(cid:23)(cid:23)(cid:31)(cid:26)(cid:25)(cid:31)(cid:17)(cid:19)(cid:16)(cid:18)(cid:26)(cid:15)(cid:14)(cid:19)(cid:23)(cid:17)(cid:13)(cid:27)(cid:19)(cid:16)(cid:31)(cid:19)(cid:25)(cid:18)(cid:31)(cid:20)(cid:28)(cid:25)(cid:30)(cid:19)(cid:27)(cid:31)(cid:29)(cid:28)(cid:19)(cid:27)(cid:30)(cid:29)(cid:31)(cid:15)(cid:13)(cid:30)(cid:17)(cid:15)(cid:20)(cid:28)(cid:23)
Figure 4 The ACTIVE principles to improve mental health in cardiovascular care.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 11 ---
4166 E S C G u id e l in e s
• Fourth, implement (I) person-centred practices in CV care using 4. Impact of mental health on the
evidence-based, stepped care approaches. These should be individua-
risk of developing cardiovascular
lized to the person and their circumstances and recognize the im-
portance of caregivers and caregivers’ health status. disease
• Fifth, venture (V) to convince professionals, managers, and people liv-
ing with CVD, to obtain their collaboration, support, and resources This section focuses on the relationship between mental health and CV
to make the needed structural and functional changes to face this risk in individuals without known CVD. The aim is to elucidate for the
challenge. These will not occur spontaneously. Professionals and in- healthcare professional the aetiological impact of psychosocial stress
stitutions willing to improve CV and mental healthcare through col- factors on the onset of CVD. The evidence, which includes large
laborative, person-centred models, with compassionate support for population-based studies and meta-analyses that adjust or control for
families and caregivers will undoubtedly face several barriers when concurrent somatic risk factors, is robust. Such evidence underscores
implementing change. the independent impact of psychosocial risk factors on the prediction
• Sixth, evaluate (E) the current status of routine CV care in each set- of hard endpoints including all-cause mortality, and major adverse car-
ting and estimate the needs for organizational, educational, and clin- diac events (MACE).
ical support to implement the required changes. Progress in
4.1. Positive mental health states as
management and mental health outcomes will also have to be evalu-
ated for quality assurance and improvement purposes. predictors of better cardiovascular health
Subjective well-being (SWB) is an overarching term that covers dif-
ferent aspects of positive mental affect states.3 An individual with
3.5. Section summary points and
SWB is satisfied with life, has a sense of purpose, and possesses
management consensus statements from meaning in life.37Related features to positive affectivity encompass
Section 3 psychological well-being, high life satisfaction, joy, optimism, and
happiness.38Sexual health is also an important component of mental
well-being and can be impaired both as a cause or as a consequence
of mental and CV issues.39Positive trait-like dispositions like sense
SECTION SUMMARY POINTS of coherence, a person’s view of life, and capacity to respond to
stressful situations,40and other more psychobiological-driven per-
(i) Mental health and mental health conditions interact with CV health
sonality factors (i.e. emotional vitality, vigour, positive energy, and
and CVD in a multidirectional way.
resilience) are further linked concepts employed in population-
(ii) The coexistence of CVD and mental health conditions can create a
based studies.
mutual interaction that worsens both mental and CV health, Subjective well-being and related features have been advocated as
leading to poorer outcomes. protective states against premature mortality and morbidity, mainly fo-
(iii) Routine CV clinical practice lacks integrated, systematic and cusing on CVD conditions. Systematic review and meta-analytic evi-
appropriate screening, evaluation, communication, and dence have shown favourable effects on mortality.41,42 In the largest
management of mental health. meta-analysis, the survival impact of SWB was significant in both men
(iv) There is limited evidence on the best ways to communicate, and women, however, more protective in men.42Positive affect was as-
promote, maintain, and improve mental health and resilience in sociated with a lower risk of coronary heart disease (CHD),43and op-
people with CVD and their family members. timism with a lower incidence of heart failure (HF).44 Consecutive
(v) The evidence base to guide practice in relation to the screening and studies have demonstrated the importance of sexual well-being in over-
management of mental health conditions in people with CVD is all well-being in CVD.39Lastly, negative affect, a component of SWB,
limited. has also been shown to increase incident CVD events, even after con-
trolling for known confounders.45
MANAGEMENT CONSENSUS STATEMENTS
Mechanistically, SWB may have stress-buffering properties that di-
(i) Cardiovascular care is optimal if it is person-centred and seeks to
minish physiological hyper-responsiveness46or exert protective CV ef-
improve overall health, not only CV but also mental health, as an
fects via a more balanced physiology (i.e. autonomic regulation,
integral component.
enhanced neuroendocrine functioning, reduced inflammation).47
(ii) A multidisciplinary team including mental health professionals,
Alternatively, SWB may result in greater engagement in healthy beha-
psychologists, and/or psychiatrists (Psycho-Cardio team) is needed viours,48that in turn drive better social functioning, personal relation-
in CV care to provide guidance for practice and appropriate mental ships, and QoL.49
health assessment, support, and management to people with CVD
and their caregivers. 4.2. Psychosocial stress
(iii) Cardiovascular services should aspire to implement a Psycho-Cardio
Psychosocial stress arises when an individual perceives and responds to
team approach, tailored to the local population, context, and
a social demand (family issues, social isolation, financial pressures, and
resources.
work) that exceeds an individual’s adaptive capacity or regulatory
(iv) Implementing the ACTIVE principles is a practical approach to homeostatic range to cope.50,51 The same situation can be stressful
transform routine clinical CV care towards being more for one person but not for another, due to psychological appraisal pro-
person-centred, integrating mental healthcare into routine CV cesses that typically operate outside of conscious awareness.52In most
practice to improve care. cases, psychosocial stress results in an appropriate state of arousal
5202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 12 ---
ESC Guidelines 4167
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:21)(cid:23)(cid:27)(cid:24)(cid:20)(cid:19)(cid:18)(cid:22)(cid:24)(cid:22)(cid:19)(cid:17)(cid:29)(cid:26) (cid:9)(cid:20)(cid:27)(cid:25)(cid:24)(cid:23)(cid:22)(cid:21)(cid:23)(cid:8)(cid:7)(cid:6)(cid:23) (cid:3)(cid:22)(cid:16)(cid:25)(cid:13)(cid:16)(cid:17)(cid:29)(cid:26)(cid:23)(cid:17)(cid:13)(cid:16)(cid:25)(cid:15)(cid:2)(cid:25)(cid:13)(cid:16)(cid:17)(cid:22)(cid:13)(cid:24)(cid:23)(cid:23)
(cid:24)(cid:16)(cid:15)(cid:25)(cid:24)(cid:24)(cid:22)(cid:15)(cid:24) (cid:19)(cid:22)(cid:13)(cid:24)(cid:25)(cid:5)(cid:4)(cid:25)(cid:13)(cid:19)(cid:25)(cid:24) (cid:15)(cid:25)(cid:5)(cid:4)(cid:17)(cid:15)(cid:25)(cid:12)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:29)(cid:24)(cid:26)(cid:26) (cid:23)(cid:22)(cid:21)(cid:20)(cid:19)(cid:20)(cid:21)(cid:18)(cid:17)(cid:16)
(cid:14)(cid:13)(cid:19)(cid:15)(cid:25)(cid:29)(cid:24)(cid:25)(cid:12)(cid:23)(cid:15)(cid:17)(cid:24)(cid:11)(cid:23)(cid:22)(cid:21)(cid:10)
(cid:1)(cid:13)(cid:9)(cid:24)(cid:29)(cid:25)(cid:24)(cid:22)(cid:26)(cid:20)(cid:30)(cid:22)
(cid:23)(cid:14)(cid:9)(cid:17)(cid:20)(cid:29)(cid:24)(cid:21)(cid:27)(cid:26)(cid:30)(cid:11)(cid:20)(cid:17)(cid:16)(cid:27)(cid:29)(cid:24)(cid:16)(cid:17)(cid:25)(cid:20)(cid:30)(cid:22)(cid:26)
(cid:15)(cid:30)(cid:29)(cid:30)(cid:22)(cid:17)(cid:29)(cid:13)(cid:27)(cid:17)(cid:29)(cid:25)(cid:24)(cid:29)(cid:13)(cid:27)(cid:21)(cid:20)(cid:26)(cid:24)(cid:17)(cid:26)(cid:24)
(cid:15)(cid:24)(cid:29)(cid:24)(cid:10)(cid:29)(cid:30)(cid:19)(cid:17)(cid:26)(cid:11)(cid:18)(cid:16)(cid:17)(cid:29)(cid:27)(cid:21)(cid:20)(cid:26)(cid:24)(cid:17)(cid:26)(cid:24)
(cid:15)(cid:30)(cid:14)(cid:14)(cid:18)(cid:22)(cid:20)(cid:25)(cid:13)
(cid:12)(cid:24)(cid:29)(cid:20)(cid:9)(cid:8)(cid:24)(cid:29)(cid:17)(cid:16)(cid:27)(cid:19)(cid:17)(cid:26)(cid:11)(cid:18)(cid:16)(cid:17)(cid:29)(cid:27)(cid:21)(cid:20)(cid:26)(cid:24)(cid:17)(cid:26)(cid:24)
(cid:7)(cid:25)(cid:29)(cid:20)(cid:17)(cid:16)(cid:27)(cid:6)(cid:10)(cid:29)(cid:20)(cid:16)(cid:16)(cid:17)(cid:25)(cid:20)(cid:30)(cid:22)
(cid:2)(cid:30)(cid:11)(cid:20)(cid:30)(cid:24)(cid:11)(cid:30)(cid:22)(cid:30)(cid:14)(cid:20)(cid:11)(cid:27)(cid:26)(cid:25)(cid:29)(cid:24)(cid:26)(cid:26)
(cid:5)(cid:24)(cid:22)(cid:25)(cid:29)(cid:20)(cid:11)(cid:18)(cid:16)(cid:17)(cid:29)(cid:27)(cid:17)(cid:29)(cid:29)(cid:8)(cid:13)(cid:25)(cid:8)(cid:14)(cid:20)(cid:17)(cid:26)
(cid:4)(cid:13)(cid:30)(cid:11)(cid:17)(cid:29)(cid:21)(cid:20)(cid:17)(cid:16)(cid:27)(cid:20)(cid:22)(cid:3)(cid:17)(cid:29)(cid:11)(cid:25)(cid:20)(cid:30)(cid:22)
(cid:2)(cid:18)(cid:21)(cid:21)(cid:24)(cid:22)(cid:27)(cid:11)(cid:17)(cid:29)(cid:21)(cid:20)(cid:17)(cid:11)(cid:27)(cid:21)(cid:24)(cid:17)(cid:25)(cid:8)
(cid:127)(cid:30)(cid:22)(cid:24)(cid:16)(cid:20)(cid:22)(cid:24)(cid:26)(cid:26)(cid:129)(cid:26)(cid:30)(cid:11)(cid:20)(cid:17)(cid:16)(cid:27)(cid:20)(cid:26)(cid:30)(cid:16)(cid:17)(cid:25)(cid:20)(cid:30)(cid:22) (cid:1)(cid:24)(cid:17)(cid:29)(cid:25)(cid:27)(cid:3)(cid:17)(cid:20)(cid:16)(cid:18)(cid:29)(cid:24) (cid:12)(cid:30)(cid:16)(cid:20)(cid:11)(cid:13)
Figure 5 Sources of psychosocial stress as risk factors for cardiovascular disease. CVD, cardiovascular disease.
and hyper-mobilization53 that is contextually applicable.52 However, 4.3. Work stress and unemployment
clinically more important are long-term sustained stress conditions
Most individuals spend a major portion of their active lives in work envir-
(chronic stress) which cause exacerbated pathophysiological changes
onments, which can be a source of psychosocial stress. A large-scale
in the heart and vasculature. Various psychosocial risk factors are de-
meta-analysis demonstrated that work stress/job strain was significantly as-
scribed below and illustrated in Figure 5. sociated with a higher risk for CHD.58In equally large prospective cohort
Psychosocial factors as a whole are as potent risk factors as conven-
studies, job strain was associated with shorter chronic disease-free life ex-
tional risk factors, with an adjusted odds ratio (OR) of 2.51 [95% con- pectancy,59and loss of chronic disease-free life expectancy.60Workplace
fidence interval (CI) 2.15–2.93].54 Chronic psychological stress is
bullying at baseline increased risk of CHD or stroke by 59% and by 25%
associated with an increased risk of CVD.55People experiencing their
over more than 12 years of follow-up in those who reported physical vio-
first myocardial infarction (MI) reported higher prevalence of stress lence or threat of violence at work after adjustment for confounders.61
(work home, financial, major life events) in the 12 months prior to ad- Reduced life expectancy is likely driven through increased CVD risk
mission; the highest risk was for permanent stress at work (OR 2.14; factors. Strong evidence links work stress to increased risk of hyperten-
99% CI 1.73–2.64). The increased risk is consistent across regions, sion,62insomnia,63and negative affectivity.64Further, effects can be cu-
ethnic groups, men, and women.56 Stress can trigger CVD events mulative.65Maladaptive compensatory behaviour patterns (smoking,66
through: (i) changes in autonomic balance, (ii) alteration of neuroen- physical inactivity,67self-damaging alcohol consumption, and other un-
docrine axes, (iii) activation of inflammatory systems, and (iv) engage- healthy lifestyle patterns)68also drive work-related stress burdens that
ment in health-damaging behaviours like smoking and alcohol can result in CVD.69Unemployed persons have equally high prevalences
consumption.57The latter typically cluster significantly with stress ex- of unhealthy lifestyles, biological CV risk factors, and CVD.70–73Work
posure.57Management of psychosocial stress and promotion of men- stress is therefore an important mediator of CVD risk and outcome. If
tal well-being should therefore be integral parts of comprehensive CV people with CVD voice concern about work stress, they should be
healthcare and prevention. appropriately counselled as suggested in Section 5.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 13 ---
4168 E S C G u id e l in e s
4.4. Socioeconomic and subjective social relationships’.91Evidence from meta-analyses and population-based
status cohort studies have determined that both loneliness and social
isolation are associated with increased CVD risk.92,93 Healthcare
Low socioeconomic status (SES) is an independent risk factor for
professionals should be aware of the potential impact these experi-
CVD.74Subjective social status (SSS), which refers to the ‘individual’s
ences have on CVD risk. Social prescribing may be a potential inter-
perception of his or her own position in the social hierarchy’,75 is
vention to improve social isolation and loneliness as discussed in
also an important mediator of CVD risk. Risk appears to be mediated
Section 5.
through lifestyle pathways, however, it is increased via delayed or poor
CVD management.76Whilst healthcare professionals may be limited in
4.7. Mental health conditions and
their ability to address these factors, there remains a need to advocate
for social policies to address inequalities in SES for those with such a personality traits as risk factors for
remit. cardiovascular disease
4.7.1. Depression
4.5. Perceived discrimination
The WHO defines depressive disorder as a common mental condition
Lifetime discrimination (experiences of unfair treatment in various life
that involves a low mood or loss of pleasure or interest in activities for
domains) and everyday discrimination (frequency of day-to-day occur-
long periods of time.94 Common symptoms are feelings of sadness,
rences of perceived unfair treatment), and related features like social
emptiness, hopelessness, having trouble concentrating, losing interest
stigmatization, have been linked to CVD.77 Multiple studies have de-
in things that one used to enjoy, feeling worthless, guilt, and experien-
monstrated that lifetime discrimination increases CVD risk or all-cause
cing disrupted sleep.94Depressive mood is a normal reaction to severe
mortality even after adjustment for important confounders.77–80The
adverse life events and problems (i.e. divorce, job loss). Diagnostic cri-
strength of the evidence suggests that discrimination is important,
teria for depressive disorders are shown in Supplementary data online,
thus people describing discrimination in the clinical setting should be ap-
Table S1. The prevalence of depression is estimated to be 4.4% in the
propriately counselled in terms of prevention of health hazards.
general population (in total, 322 million globally) posing a significant
public health challenge.94Depression has been shown to be as strong
4.6. Mental stress through impaired social
a CV risk factor as traditional somatic risk factors.95,96Large observa-
relationships
tional and case-control studies demonstrate that depression is inde-
There are multiple avenues through which mental stress can drive CVD pendently associated with incident CVD, all-cause mortality, and
risk and prognosis. Important categories of mental stress are summar- combined CVD/mortality outcome, with hazard ratios (HRs) or ORs
ized below. ranging from 1.14 to 1.55.56,97Meta-analyses have shown depression
to confer increased risk for incident HF, new-onset and recurring atrial
4.6.1. Adverse childhood experiences fibrillation (AF), ventricular tachycardia/fibrillation, and sudden cardiac
Adverse childhood experiences (ACEs) are broadly defined as ‘child- death (SCD).98–101
hood events, varying in severity and often chronic, occurring in a child’s
family or social environment that cause harm or distress, thereby dis-
4.7.2. Anxiety
rupting the child’s physical or psychological health and development’.81
Anxiety is an emotion characterized by worrying that may be accom-
These events include physical, sexual, or emotional abuse, neglect, care-
panied by non-specific physical and psychological symptoms such as
giver mental illness, and domestic violence.81Several studies comparing
restlessness, fatigue, difficulty concentrating, irritability, muscle tension,
adults with and without ACEs exposure have shown higher incidence of
or sleep disturbances.102If it is intense and sudden, anxiety may present
CVD, type 2 diabetes mellitus, depression, and all-cause mortality.82–86
as a panic attack, with palpitations, shortness of breath, dizziness, chest
Healthcare professionals must be aware of the relationship between
pain, lightheadedness, or a dying sensation lasting several minutes.103
ACEs and CVD, and if described during clinical interview they should
Fear and anxiety are closely related phenomena, but differ in terms
raise awareness to the potential health ramifications and refer these in-
of their orientation in time. Anxiety is ‘future-oriented’ (i.e. perceived/
dividuals to the appropriate preventative services.
anticipated threats), whilst fear is a reaction to a perceived imminent
threat in the present.104
4.6.2. Partnership violence
Anxiety or fear-related disorders are characterized by excessive fear
Intimate partner violence is associated with a greater prevalence of and anxiety that cause distress or impairment in functioning. These dis-
mental health conditions,87and appears to be an additional stressor orders include generalized anxiety, panic disorder, agoraphobia, specific
that directly and indirectly impacts women’s CV health. However, phobia, social anxiety disorder, separation anxiety, selective mutism,
the findings across studies are inconsistent.88Although the evidence and other related disorders. Multiple studies and meta-analyses have
is more limited in males, experiences of intimate partner violence, shown that anxiety and anxiety disorders (together or individually)
whether as victim or perpetrator, have been linked to increased are associated with increased risk of CVD and/or CV mortality.105–109
CVD risk.89 The relationship between anxiety and arrhythmias or HF is less clear
with mixed findings.100,109–111Panic disorders and panic attacks have
4.6.3. Loneliness and social isolation also been associated with incident CVD events.112Overall, evidence
Loneliness is defined as a ‘subjective negative experience that results suggests that the link between anxiety or fear and CVD risk is suffi-
from inadequate meaningful connections, where “inadequate” refers cient that healthcare professionals should be aware of the relationship
to the discrepancy or unmet need between an individual’s preferred and consider early screening as clinically indicated. Diagnostic criteria
and actual experience’.90Social isolation whilst conceptually similar for anxiety and fear-related disorders can be found in Supplementary
is defined as ‘an objective “lack” or “absence” of social contact or data online, Table S2.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 14 ---
ESC Guidelines 4169
4.7.3. Post-traumatic stress disorder 5. Mental health and mental health
Post-traumatic stress disorder (PTSD) is a complex and debilitating conditions in people with
condition, often stemming from exposure to traumatic events that
shatter a person’s sense of safety and security.113Symptoms encom- cardiovascular disease
pass intrusive thoughts, flashbacks, nightmares, and heightened arousal,
all of which can severely impair an individual’s QoL.114Onset of PTSD The previous section focused on the analysis of CV risk associated with
mental health conditions in individuals without CVD. This section ad-
can occur at any time during the lifespan following exposure to a trau-
dresses the prevalence of mental health conditions among people
matic event.
with CVD, their impact on CV prognosis, self-management and adher-
Post-traumatic stress disorder is an important risk factor for
ence to medical recommendations, as well as the impact of CVD on the
CVD, both in terms of its development and progression. PTSD
mental health of family members or caregivers.
among Armed Forces veterans has been linked to a 25%–50%
higher risk of CVD, including HF, MI, and CVD mortality com-
pared with those without PTSD, even after adjustment for de- 5.1. Impact of cardiovascular disease on
pression and other factors.115–117 The mechanisms by which mental health
PTSD may increase CV risk are not fully understood. However,
Cardiovascular disease can induce significant mental health conditions.
it has been shown that PTSD elicits psychological, physiological,
The perceived characteristics of acute CV events, such as acute coronary
and behavioural responses that lead to increased risk.118
syndrome (ACS) or arrhythmia, coupled with the threat of death and
Autonomic imbalance (increased activity of the sympathetic ner-
helplessness,124,125may trigger intense negative emotional responses.126
vous system and decreased activity of the parasympathetic ner-
Even when diagnostic criteria for mental health disorders are not met,
vous system), damaged baroreflex function, and subsequent
people with CVD may experience existential concerns. These include
blood pressure dysregulation may also play a role.119 PTSD is
fear of recurrence, apprehension about death, emotional and work-
also associated with elevated markers of inflammation,120 and of-
related stress, anger, grief, and worries about the well-being of family
ten associated with unhealthy diet and lifestyle, obesity, sleep dis-
members.127,128The need for complex treatment regimens and lifestyle
turbance, decreased physical activity, medication non-adherence,
changes negatively impacts QoL and general well-being, and may be dif-
substance abuse, smoking, and alcohol abuse, all of which contrib-
ficult to initiate and maintain.129 Combined with the perceived loss of
ute to poor CV health.121–123 Definition and characteristics of
health and independence, these factors may contribute to an increased
PTSD can be found in Supplementary data online, Table S3.
risk of developing mental health conditions in people with CVD.
Symptoms and suggested key questions to identify depression,
In some instances, these reactions and symptoms might become
anxiety, or PTSD can be found in Supplementary data online,
severe enough to warrant a diagnosis of a mental health disorder,
Tables S4–S6.
such as depression, anxiety, and even cardiac disease-induced PTSD
(CDI-PTSD).13,125,126 The prevalence of mental health conditions in
4.8. Section summary points and people with CVD varies widely based on type of CVD, individual char-
management consensus statements acteristics, life contexts, and assessment tools. Most importantly, these
comorbid mental health conditions might impact self-management,
from Section 4
adherence to medication prescriptions, diet, physical activity, and smok-
ing cessation plans, overall outcomes, and even prognosis in people
with CVD.125,126 This association is particularly evident with stress
and depression, where 1 year healthcare costs for society are 33%
SECTION SUMMARY POINTS
higher compared with those with CVD.130Therefore, it is imperative
(i) Indicators of positive mental health, such as optimism, to inform and educate CV care professionals about the mental
happiness, and high life satisfaction are associated with lower health-related consequences of CVD.
CV risk.
(ii) Hazardous psychosocial factors (e.g. social isolation, financial 5.2. Specific mental health conditions in
pressures, and work) are associated with increased risk of
people with cardiovascular disease:
developing CVD.
prevalence and prognostic impact
(iii) Mental health conditions such as depression, anxiety, and PTSD are
associated with an increased risk of developing CVD. 5.2.1. Depressive symptoms and depression
(iv) Healthcare professionals have a responsibility to: It is important to differentiate depressive symptoms from depression as
• Be informed of these associations. the term ‘depression’ encompasses various meanings, spanning from
• Be alert to these risk factors during consultation. temporary feelings of low mood to severe clinical conditions that are dis-
• Inform, counsel, and refer individuals at risk as needed. abling, recurrent, and severe. Moreover, some individuals exhibit a per-
• Advocate for system changes as appropriate. sistently distressed personality with certain depressive traits. People
coping with CVD may experience any of these distinct clusters of symp-
MANAGEMENT CONSENSUS STATEMENTS
toms, however, the most prevalent type of depression observed follow-
(i) Management of psychosocial stress and promotion of mental
ing ACS is an ‘adjustment disorder with depressed mood’.131 People
well-being are essential components of integrated CV
meeting the criteria for major depressive disorder are at elevated risk
prevention.
for subsequent events and often experience significantly diminished
(ii) Screening for depression, anxiety, and PTSD is advised to be
QoL. Consequently, these individuals require focused efforts for identi-
integrated into CV risk assessment. fication, precise diagnosis, and dedicated management.132
5202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 15 ---
4170 E S C G u id e l in e s
Table 1 Prevalence of depression/depressive symptoms in people with cardiovascular disease
CVD Prevalence data
ACS/Post-MI Depressive symptoms were reported by 31% of individuals following MI.136
The prevalence of depression at the time of hospitalization was 40% in women under 60 years, compared with 22% in
men of the same age group. Among those over 60 years, the prevalence was 21% in women and 15% in men.137
In 8580 people with ACS from 22 European countries who were ≥6 months post-hospitalization,a depressive
symptoms were more frequent in women (32.3%) than men (21.2%), with moderate/severe depression in 12.7% of
women and 7.4% of men.138
Chronic HF Clinically significant depression affected 21.5% of people with HF, ranging from 33.6% via questionnaires to 19.3% via
interviews, and 11% in NYHA class I to 42% in NYHA class IV.15
Depression was more common in women with chronic HF (32.7% vs 26.1%), with rates of 11%–67% in women and
7%–63% in men, and increased with higher NYHA functional class.15
Advanced HF and Depression affects 25%–35% of individuals after HTx.139–141
post-transplantation Depression was reported in 35% of individuals pre-transplant and 26.3% post-transplant.140
Depression occurs in 15%–39% of people with ventricular assist devices, often exceeding clinical cut-offs, particularly in
older people.114,142
People experiencing HTx had less depression than those with mechanical assist devices.143
AF 38% of people with AF met Beck Depression Inventory criteria for significant depression.144
ICD Random-effects meta-analyses showed clinically relevant depression in 15.4% (95% CI 11.9%–18.9%) of people with an
ICD at all timepoints post-insertion.145
The 2 year incidence of new-onset depression after ICD implantation was 11.3% in a national ICD registry.146
Depressive symptoms affected 20% of people with ICDs (12% mild, 6% moderate, 2% severe). Moderate to severe
depression was more common in secondary prophylactic indications and in people experiencing ≥5 ICD shocks.147
People with ICDs and pacemakers had similarly increased levels of depression.148
ACHD Individuals with ACHD have higher depression rates than the general population, with a weighted prevalence of 24% vs 15%.149
People with ACHD had a low and comparable suicide risk to the reference cohort.150
PH/PAH In 2161 people with PH, the reported pooled prevalence of depression was 28% (95% CI 20.5–36.8).134
Smaller studies report depression prevalence in people with PAH ranging from 9% to 70%, linked to disease
severity.151–155
ACHD, adult congenital heart disease; AF, atrial fibrillation; CI, confidence interval; CVD, cardiovascular disease; HF, heart failure; HTx, heart transplantation; ICD, implantable
cardioverter-defibrillator; MI, myocardial infarction; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.
aThis study included: (i) coronary artery bypass graft surgery (including emergency procedures for acute MI), (ii) percutaneous coronary intervention (including emergency procedures for
acute MI), (iii) acute MI (ST-elevation and non-ST-elevation MI), and (iv) acute myocardial ischaemia without infarction (troponin-negative).
5.2.1.1. Prevalence of depressive symptoms and depression in depression on CV or all-cause mortality after MI,156more recent stud-
people with cardiovascular disease ies suggest otherwise. For example, post-MI depression, though attenu-
Depression is one of the most common mental health conditions in ated by severity, independently predicts a 22% higher all-cause
people with CVD. The global prevalence of depression among people mortality and 13% more CV events per standard deviation increase
with CVD, as measured by various self-report questionnaires, is esti- in depression z-score.157Depression has been associated with an in-
mated to be 18%.14 It is more common among women and in older creased risk of non-fatal CV events, as well as all-cause mortality after
ages, yet healthy and physically functioning older adults are at lower ACS.17Even 10 years after percutaneous coronary intervention (PCI)
risk of depression compared with young adults.14,133,134 Depression (∼50% elective), depression was associated with an increased risk for
is associated with several negative lifestyle factors, such as smoking, al- all-cause mortality.158Depression is also a marker of poor prognosis
cohol intake, physical inactivity, and unhealthy diet, as well as other in people with HF, where both depressive symptoms and depressive
CVD risk factors including diabetes and hypertension.135These poten-
disorders have been prospectively linked to frequent hospitalizations,
tially modifiable risk factors are all associated with coronary artery dis- recurrent CV events, and mortality.18The prospective associations be-
ease (CAD), MI, HF, stroke, and mortality.54Table 1presents examples
tween elevated depressive symptoms or a depressive disorder and HF
of studies demonstrating how rates of depression vary based on the
was associated with a two-fold increased risk of death or CV events.15
condition, diagnostic methods, and population demographics.
Depression at the start of exercise-based cardiac rehabilitation (ECR)
was significantly associated with lower improvement in exercise capacity
5.2.1.2. Impact of depressive symptoms and depression on and QoL during rehabilitation.129 Depression and previous suicide at-
cardiovascular disease prognosis tempts detected before or after heart transplantation (HTx) may impact
Depression is a known risk factor for poor prognosis among people long-term HTx outcomes (rejection, cardiac allograft vasculopathy, and
with CVD. While one study did not find a significant impact of death),159probably related to increased non-adherence to medications.160
5202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 16 ---
ESC Guidelines 4171
Depression is also related to increased adverse events in people with increase the risk for rehospitalization and mortality in people with
ventricular assist devices (VAD),161,162and is a factor for negative out- HF.185–187Among people with an implantable cardioverter-defibrillator
comes among people coping with AF. In a meta-analysis consisting of (ICD), anxiety was a strong predictor of mortality with an OR of 4.17 in
seven cohort studies with 1070 AF people who underwent catheter ab- a cross-sectional national survey in Denmark.188
lation, depression before the procedure was independently associated
with an increased risk of AF recurrence after ablation.163Further, symp- 5.2.2.3. Impact of anxiety on self-management and adherence
toms of depression were the strongest independent predictor of future
Interestingly, anxiety, as opposed to depression, may encourage people
QoL post-ablation.144
to be adherent (e.g. to their medication regimen) and can have a posi-
tive impact on clinical outcome in people with CVD.189,190However,
5.2.1.3. Impact of depressive symptoms/depression on anxiety disorders are mostly linked with unhealthy lifestyle, poor adher-
self-management and adherence ence to lifestyle modification, and lower participation in ECR.138One
One possible path by which depression is associated with adverse out- possible explanation of this trend is people with anxiety have a ten-
comes among people with CVD is limited engagement in self-care prac- dency to avoid reminders of the illness.191
tices and lack of adherence, as depression is associated with challenges in
self-management of CV medication, healthy lifestyle, ECR, and self- 5.2.3. Cardiac disease-induced post-traumatic stress
care.129,164–166Kronish et al. reported that people with persistent de- disorder/symptoms
pression were only half as likely to enrol in an ECR programme com- 5.2.3.1. Prevalence of post-traumatic stress disorder in
pared with those without persistent depression.167 People with
cardiovascular disease
persistent depression also showed lower rates of adherence to smoking
Cardiac disease-induced PTSD, or post-traumatic stress symptoms
cessation, taking medications, and exercising. A recent daily diary study
(PTSS) defined as post-traumatic symptoms to full disorder emerging
demonstrated that on days when people attending ECR experienced ele-
from an acute CV event or intervention, has a heterogeneous incidence
vated depression symptoms, they engaged in less physical activity and
among different types of CVD. Table 3 presents examples of studies
more sedentary behaviour.168In a cohort study of individuals who under-
demonstrating how rates of PTSD and PTSS vary based on the condi-
went PCI (n = 124 443), participants with depression were 10% to 20%
tion, diagnostic methods, and population demographics.
less likely to attain optimal adherence to Guideline-recommended med-
ications compared with those without depression.169Finally, a systematic
5.2.3.2. Impact of post-traumatic stress disorder on cardiovascular
review of quantitative studies indicated that even mild to moderate levels
of depression were significantly associated with medication adherence in disease prognosis
people with HF.170 Cardiac disease-induced PTSS are linked to numerous adverse physical
and emotional outcomes, including increased overall psychopathology
and heightened mortality risk. However, due to the predominantly
5.2.2. Anxiety
cross-sectional or retrospective nature of existing studies, distinguish-
5.2.2.1. Prevalence of anxiety in people with cardiovascular disease
ing the effects of CDI-PTSS from those of the triggering event remains
Systematic reviews and meta-analyses have found prevalence of anx-
challenging. Nevertheless, the association between CDI-PTSS and ele-
iety among people with CVD to range from 28.9% to 32.9%.16,171
vated rates of mortality and CV events underscores the need for fur-
Higher rates are found using questionnaires (34.8% to 9%) compared
ther research.13
with clinical diagnostic interviews (17%). The highest rates of anxiety
Studies examining the implications of CDI-PTSS on subsequent
disorder based on diagnostic interviews were reported in people with
MACE or all-cause mortality yielded mixed results. The severity of in-
undifferentiated chest pain or palpitations (19%). Anxiety tended to
trusion symptoms (intrusive thoughts or images related to the traumat-
be more prevalent among females compared with males (43% vs
ic event, nightmares, and flashbacks) measured 1 month after a first MI
29.5%).171 As with depression, prevalence of anxiety varies by CV
predicted recurrent MACE/all-cause mortality 42 months later.198
condition, method of diagnosis, and population demographics. People scoring >11 on the intrusions dimension of the Impact of
Table 2presents examples of studies demonstrating how rates of anx- Event Scale (IES)199 had a three times higher risk of developing
iety vary based on the condition, diagnostic methods, and population
MACE and all-cause mortality than did those classified as low on this
demographics.
symptom cluster.198Similarly, dissociative symptoms during hospitaliza-
tion predict 15 year all-cause mortality among people with MI,200and
5.2.2.2. Impact of anxiety on cardiovascular disease prognosis people with above-threshold PTSD-related symptoms at 6 months
A meta-analysis estimating the effect of anxiety on CV outcomes in post-event had a 42%–50% prevalence of experiencing other serious
more than 30 000 people with CAD found that the impact depends CV events during the next 6 months compared with a 26%–32% preva-
on the timing, with no effect of anxiety in the first 2 months after lence of the same among people without PTSS.201Other studies found
ACS but with a negative effect on outcome in people with stable that PTSD measured 4 to 6 weeks post-MI was not predictive of MACE
CAD.19 Generalized anxiety disorder, present in 5.5% of people 3 9 months later.202
months after acute MI (AMI), was associated with a two-fold increased Cardiac disease-induced PTSS predict non-fatal CVD-related hospital
risk of adverse outcomes (CV events and all-cause mortality) during a readmissions 1 to 4 years after a previous index MI.203Increasing levels of
10 year follow-up period.184There is little effect of anxiety symptoms CDI-PTSS, measured by the IES and PTSD Symptom Scale,204are asso-
alone on outcome in HF although comorbid anxiety and depression ciated with CV readmissions.205Further, people with IES-reported PTSS
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 17 ---
4172 E S C G u id e l in e s
Table 2 Prevalence of anxiety/anxiety symptoms in people with cardiovascular disease
CVD Prevalence data
ACS/Post-MI In an international cohort of people with CABG, PCI, post-MI, and ACS ≥6 months post-hospitalization, anxiety prevalence
ranged from 12% to 42% in men and 22% to 64% in women, with moderate to severe anxietya in 11% of men and 23% of
women.138
At 3 months post-MI, 10% reported high anxiety, dropping to reference population levelsb at 3–18 months.172
In people diagnosed with SCAD, 41% had mild anxiety and 16% moderate to severe anxiety by questionnaire. Higher anxiety
scores were more common in women, younger individuals, those with lower resilience, and those closer to the event.173
Chronic HF Up to 72% of people with HF experience anxiety, with pooled estimates of 56% for symptoms, 29% for clinically significant
anxiety, and 13.1% for anxiety disorders. Prevalence was higher in studies with more female participants.174
People with HF face a higher risk of anxiety, with 23% experiencing symptoms and 32% having both anxiety and
depression.175
Advanced HF and The pooled prevalence of anxiety among people experiencing HTx was 11% (95% CI 3.8%–28.5%).176
post-transplantation
AF People with AF exhibited a 28% prevalence of anxiety at baseline, comparable to controls, with symptoms persisting in 37%
after 6 months.144
Among people undergoing cardioversion or ablation, 30% reported clinically significant anxiety.177
ICD Among OHCA survivors, anxiety was reported in 36% of women vs 20% of men, with higher rates in younger women
(<55 years) than older women (43% vs 28%).178
At 18 months post-OHCA, 32% showed anxiety symptoms.179
A large-scale registry reported 20% anxiety among people experiencing OHCA.180
Random-effects meta-analysis found clinically relevant anxiety in 23% (95% CI 18.3%–27.0%) of people with an ICD at all
timepoints post-insertion.145
New-onset anxiety incidence was 15% at 24 months post-ICD implantation, with higher rates in women and the secondary
prevention setting.146,181
People with ICDs and pacemakers exhibited similarly elevated anxiety levels.148
ACHD A review found anxiety symptoms to be common both immediately after CV events or surgery and during follow-up.182
Anxiety prevalence was higher in people with ACHD (13%) compared with a historical cohort of people with non-Hodgkin
lymphoma and German reference values (6%).183
PH/PAH A total of 24 studies with 2161 people with PH reported a pooled prevalence of 37% for anxiety (95% CI 28.7–46.4).134
Smaller studies reported anxiety prevalence in people with PAH ranging from 9% to 58%, linked to disease severity.151–154
Anxiety incidence was higher in people with PAH living in urban areas and in non-smokers or non-drinkers compared with
their counterparts.154
ACHD, adult congenital heart disease; ACS, acute coronary syndrome; AF, atrial fibrillation; CABG, coronary artery bypass graft; CI, confidence interval; CV, cardiovascular; CVD,
cardiovascular disease; HADS, Hospital Anxiety and Depression Scale; HF, heart failure; ICD, implantable cardioverter-defibrillator; MI, myocardial infarction; OHCA, out-of-hospital
cardiac arrest; PAH, pulmonary arterial hypertension; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; SCAD, spontaneous coronary artery dissection.
aHADS anxiety score ≥8.
bNorwegian population.
are more than twice as likely as those without PTSS to be readmitted 5.2.4. Loneliness and living conditions
during the year following their MI.206However, other studies showed In a cross-sectional study of hospitalized people with various types of
that PTSD measured by the Post-traumatic Diagnostic Scale may not CVD, loneliness measured at discharge was associated with significantly
be associated with frequency of CVD-related hospital readmissions.207 worse outcomes in men and women.211 Moreover, loneliness pre-
dicted all-cause mortality risk, which was almost three-fold among wo-
men and two-fold among men. Living alone predicted CV event risk in
5.2.3.3. Impact of post-traumatic stress disorder on men only (HR 1.39; 95% CI 1.05–1.85).211In a prospective randomized
self-management and adherence to medical recommendations controlled trial (RCT) in people with stable CHD, living alone was re-
Evidence on CDI-PTSD and non-adherence is mixed, with some studies lated to a higher risk of CV death and the primary composite endpoint
showing positive associations and others not.201,206,208–210 However, of non-fatal MI or non-fatal stroke. Being married, as compared with
stronger evidence links CDI-PTSD to non-adherence to medication being widowed, was associated with a lower risk of CV death and
and physical activity. the primary composite endpoint.212
5202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 18 ---
ESC Guidelines 4173
Table 3 Prevalence of post-traumatic stress disorder/post-traumatic stress symptoms in people with cardiovascular
disease
CVD Prevalence data
ACS/Post-MI Clinically significant PTSD 12%, and PTSS prevalence 0%–26% depending on type of measurement.13,192
PTSD occurs in 7%–20% of people post-CABG.13
PTSD prevalence among people with SCAD ranged from 28% to 35%.173,193
Advanced HF and PTSD occurs in 11%–19% of people post-HTx.13
post-transplantation
ICD 12%–38% prevalence of PTSD in survivors of cardiac arrest.13,145,178
Experiencing ≥1 appropriate ICD shocks was an independent risk factor for PTSD
(OR 6.0; 95% CI 1.45–24.63; P < 0.013).194
A single study found higher PTSD prevalence in people with ICD who experienced electric storms compared with
those who did not.195
ACHD 1%–30% prevalence of PTSD in people with ACHD, varying by measurement and geographical region.196,197
Women and people with multiple medical encounters lacking psychosocial intervention are more likely to have
PTSD.196
ACHD, adult congenital heart disease; ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CI, confidence interval; CVD, cardiovascular disease; HF, heart failure; HTx, heart
transplantation; ICD, implantable cardioverter-defibrillator; MI, myocardial infarction; OR, odds ratio; PTSD, post-traumatic stress disorder; PTSS, post-traumatic stress symptom; SCAD,
spontaneous coronary artery dissection.
5.2.5. Chronic stress The caregiving efforts of informal caregivers can exert a significant toll
Chronic stress, defined as the experience of physical and emotional im- on themselves.31,35Providing emotional and tangible support to a person
balance determined by life events and conditions, was found in 58% of coping with CVD may lead to caregiver emotional and/or physical strain.
people with CVD based on a systematic review (five studies, n = 533).16 Some studies have identified mental health risks, such as increased levels
A large observational study (n = 3572) reported that perceived stress of anxiety, depression, or CDI-PTSD among caregivers in the context of
was significantly higher in women vs men at baseline and 1 month after CVD.31–33,220A recent review221suggested that low to moderate levels
MI.213Perceived chronic stress was associated with worse recovery in of distress were common among family caregivers of people with CAD
overall QoL and mental status among people with MI.213 (prevalence ranging from 6% to 67% of caregivers). Family caregivers of
Recent studies have focused on the concept of CV distress, defined people with HF cope with significantly higher physical and psychological
as ‘a persistent negative emotional state rather than a transient state; involv- health risks compared with non-caregivers.222In the context of a VAD
ing multiple psychosocial domains; that challenges a person’s capacity to implantation, spouses have been found to have higher anxiety rates com-
cope with living with their heart condition, the treatment of the condition, pared with the person with the VAD,223as well as lower mental QoL as a
and the resultant changes to daily living; and challenges the person’s sense consequence of VAD-related disturbances in sexual activity.224
of self and future orientation’.214This study, using the Cardiac Distress Despite ample literature documenting the adverse effects of caregiv-
Inventory-Short Form (CDI-SF), found significantly higher scores on ing, the person with CVD is seen as the sole focal point of attention and
the CDI-SF among younger people and women.214 People with HF exclusive recipient of care, thus overlooking the needs of the informal
and elevated stress levels may undergo a more challenging disease tra- caregiver.34A shift in healthcare systems from focusing solely on indivi-
jectory, characterized by a diminished QoL and heightened susceptibil- duals to adopting a holistic approach that includes the individual and
ity to adverse events.215Indeed, people with HF reporting high stress their families, is needed. Family caregivers are essential collaborators,
levels had a higher likelihood of adverse events during the study as they often ensure people can build change into their lives and adhere
period.216 to their treatment plans. Educating and supporting informal caregivers
represents not only a mechanism for improving long-term outcomes,
5.3. Addressing the mental health needs of but also a means of reducing healthcare costs through the avoidance
of repeat engagements with the health system.225,226Most importantly,
informal caregivers for people with
caring for informal caregivers not only benefits the person living with
cardiovascular disease
CVD and reduces medical costs, but also reflects a holistic approach
Following the initial diagnosis, people may be asked to implement sub- to CV practice. By supporting informal caregivers, a compassionate
stantial lifestyle changes to reduce CV risk, prevent further disease pro- and sustainable healthcare system of CVD management is fostered,
gression, and enhance QoL.217Coping with CVD and embracing new which is essential for the long-term success. Different Psycho-Cardio
habits can prove challenging, and for adults, the primary source of sup- team members engage with informal caregivers at varying levels.
port often comes from their informal caregivers, primarily their part- Every team member should remain mindful of the challenges faced by
ners.218,219 Partners are usually the most available and accessible those who care for a person living with CVD. Figure 6outlines specific
persons for support, physically during hospitalizations and medical vis- actions the Psycho-Cardio team members can take to assess and alle-
its, at home, and emotionally.220 viate caregiver distress.
5202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 19 ---
4174 E S C G u id e l in e s
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:25)(cid:27)(cid:21)(cid:20)(cid:19)(cid:18)(cid:21)(cid:27)(cid:17)(cid:23)(cid:26)(cid:16)(cid:17)(cid:15)(cid:23)(cid:14)(cid:21)(cid:23)(cid:13)(cid:21)(cid:25)(cid:27)(cid:12)(cid:23)(cid:25)(cid:17)(cid:23)(cid:15)(cid:13)(cid:21)(cid:11)(cid:23)(cid:25)(cid:27)(cid:21)(cid:23)(cid:25)(cid:30)(cid:23)(cid:19)(cid:30)(cid:18)(cid:25)(cid:24)(cid:16)(cid:25)(cid:14)(cid:24)(cid:21)(cid:23)(cid:17)(cid:28)(cid:16)(cid:27)(cid:22)(cid:21)(cid:23)(cid:28)(cid:29)(cid:23)
(cid:21)(cid:23)(cid:26)(cid:22)(cid:30)(cid:20)
(cid:19)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:15)(cid:19)(cid:28)(cid:30)(cid:23)(cid:25)(cid:30)(cid:12)(cid:23)(cid:28)(cid:29)(cid:15)(cid:21)(cid:30)(cid:23)(cid:21)(cid:10)(cid:9)(cid:21)(cid:27)(cid:19)(cid:21)(cid:30)(cid:22)(cid:21)(cid:23)(cid:26)(cid:16)(cid:22)(cid:13)(cid:23)(cid:12)(cid:19)(cid:17)(cid:15)(cid:27)(cid:21)(cid:17)(cid:17)
(cid:8)(cid:25)(cid:27)(cid:21)(cid:20)(cid:19)(cid:18)(cid:21)(cid:27)(cid:17)(cid:23)(cid:17)(cid:13)(cid:28)(cid:16)(cid:24)(cid:12)(cid:23)(cid:14)(cid:21)(cid:23)(cid:27)(cid:21)(cid:25)(cid:17)(cid:17)(cid:16)(cid:27)(cid:21)(cid:12)(cid:23)(cid:15)(cid:13)(cid:25)(cid:15)(cid:23)(cid:15)(cid:13)(cid:21)(cid:11)(cid:23)(cid:25)(cid:27)(cid:21)(cid:23)(cid:30)(cid:28)(cid:15)(cid:23)(cid:25)(cid:24)(cid:28)(cid:30)(cid:21)(cid:23)(cid:25)(cid:30)(cid:12)(cid:23)(cid:15)(cid:13)(cid:25)(cid:15)(cid:23)(cid:15)(cid:13)(cid:21)(cid:19)(cid:27)
(cid:31)(cid:30)(cid:27)(cid:26)(cid:26)(cid:25)(cid:28)(cid:30)
(cid:21)(cid:26)(cid:28)(cid:15)(cid:19)(cid:28)(cid:30)(cid:25)(cid:24)(cid:23)(cid:27)(cid:21)(cid:17)(cid:9)(cid:28)(cid:30)(cid:17)(cid:21)(cid:17)(cid:23)(cid:25)(cid:27)(cid:21)(cid:23)(cid:14)(cid:28)(cid:15)(cid:13)(cid:23)(cid:18)(cid:25)(cid:24)(cid:19)(cid:12)(cid:23)(cid:25)(cid:30)(cid:12)(cid:23)(cid:19)(cid:26)(cid:9)(cid:28)(cid:27)(cid:15)(cid:25)(cid:30)(cid:15)
(cid:8)(cid:25)(cid:27)(cid:21)(cid:20)(cid:19)(cid:18)(cid:21)(cid:27)(cid:17)(cid:23)(cid:30)(cid:21)(cid:21)(cid:12)(cid:23)(cid:25)(cid:17)(cid:17)(cid:19)(cid:17)(cid:15)(cid:25)(cid:30)(cid:22)(cid:21)(cid:23)(cid:15)(cid:28)(cid:23)(cid:25)(cid:22)(cid:7)(cid:16)(cid:19)(cid:27)(cid:21)(cid:23)(cid:30)(cid:21)(cid:6)(cid:23)(cid:5)(cid:30)(cid:28)(cid:6)(cid:24)(cid:21)(cid:12)(cid:20)(cid:21)(cid:4)(cid:23)(cid:28)(cid:27)(cid:20)(cid:25)(cid:30)(cid:19)(cid:3)(cid:21)(cid:23)(cid:19)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:15)(cid:19)(cid:28)(cid:30)(cid:4)(cid:23)
(cid:24)(cid:26)(cid:26)(cid:23)(cid:26)(cid:22)
(cid:29)(cid:28)(cid:24)(cid:24)(cid:28)(cid:6)(cid:23)(cid:26)(cid:25)(cid:30)(cid:25)(cid:20)(cid:21)(cid:26)(cid:21)(cid:30)(cid:15)(cid:23)(cid:19)(cid:30)(cid:17)(cid:15)(cid:27)(cid:16)(cid:22)(cid:15)(cid:19)(cid:28)(cid:30)(cid:17)(cid:4)(cid:23)(cid:25)(cid:30)(cid:12)(cid:23)(cid:19)(cid:26)(cid:9)(cid:24)(cid:21)(cid:26)(cid:21)(cid:30)(cid:15)(cid:23)(cid:24)(cid:19)(cid:29)(cid:21)(cid:17)(cid:15)(cid:11)(cid:24)(cid:21)(cid:23)(cid:22)(cid:13)(cid:25)(cid:30)(cid:20)(cid:21)(cid:17)
(cid:8)(cid:25)(cid:27)(cid:21)(cid:20)(cid:19)(cid:18)(cid:21)(cid:27)(cid:17)(cid:23)(cid:17)(cid:13)(cid:28)(cid:16)(cid:24)(cid:12)(cid:23)(cid:14)(cid:21)(cid:23)(cid:21)(cid:30)(cid:22)(cid:28)(cid:16)(cid:27)(cid:25)(cid:20)(cid:21)(cid:12)(cid:23)(cid:15)(cid:28)(cid:23)(cid:25)(cid:22)(cid:22)(cid:21)(cid:17)(cid:17)(cid:23)(cid:27)(cid:21)(cid:24)(cid:21)(cid:18)(cid:25)(cid:30)(cid:15)(cid:23)(cid:26)(cid:21)(cid:12)(cid:19)(cid:22)(cid:25)(cid:24)(cid:23)(cid:25)(cid:30)(cid:12)(cid:23)(cid:17)(cid:28)(cid:22)(cid:19)(cid:25)(cid:24)
(cid:19)(cid:20)(cid:18)(cid:17)(cid:25)(cid:28)(cid:27)(cid:16)(cid:30)
(cid:17)(cid:16)(cid:9)(cid:9)(cid:28)(cid:27)(cid:15)(cid:4)(cid:23)(cid:14)(cid:28)(cid:15)(cid:13)(cid:23)(cid:29)(cid:28)(cid:27)(cid:23)(cid:15)(cid:13)(cid:21)(cid:23)(cid:9)(cid:25)(cid:15)(cid:19)(cid:21)(cid:30)(cid:15)(cid:23)(cid:25)(cid:30)(cid:12)(cid:23)(cid:29)(cid:28)(cid:27)(cid:23)(cid:15)(cid:13)(cid:21)(cid:26)(cid:17)(cid:21)(cid:24)(cid:18)(cid:21)(cid:17)
(cid:8)(cid:25)(cid:27)(cid:21)(cid:20)(cid:19)(cid:18)(cid:21)(cid:27)(cid:17)(cid:23)(cid:17)(cid:13)(cid:28)(cid:16)(cid:24)(cid:12)(cid:23)(cid:14)(cid:21)(cid:23)(cid:27)(cid:21)(cid:29)(cid:21)(cid:27)(cid:27)(cid:21)(cid:12)(cid:23)(cid:15)(cid:28)(cid:23)(cid:27)(cid:21)(cid:24)(cid:21)(cid:18)(cid:25)(cid:30)(cid:15)(cid:23)(cid:17)(cid:21)(cid:27)(cid:18)(cid:19)(cid:22)(cid:21)(cid:17)(cid:23)(cid:15)(cid:28)(cid:23)(cid:17)(cid:16)(cid:9)(cid:9)(cid:28)(cid:27)(cid:15)(cid:23)(cid:15)(cid:13)(cid:21)(cid:19)(cid:27)(cid:23)(cid:13)(cid:21)(cid:25)(cid:24)(cid:15)(cid:13)
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)
(cid:25)(cid:30)(cid:12)(cid:23)(cid:17)(cid:28)(cid:22)(cid:19)(cid:25)(cid:24)(cid:23)(cid:30)(cid:21)(cid:21)(cid:12)(cid:17)
Figure 6 Suggestions for supporting informal caregivers of people living with cardiovascular disease.
5.4. Section summary points and 6. Identification, prevention, and
management consensus statements from management of mental health
Section 5
issues in people with cardiovascular
disease
SECTION SUMMARY POINTS 6.1. Awareness of needs in people with
(i) There is a multidirectional association between CVD and mental cardiovascular disease
health conditions such as depression, anxiety, and PTSD, increasing Depression and anxiety can easily be overlooked in the routine care of
each other’s risk. people with CVD and/or considered ‘normal’ reactions to the clinical
(ii) Mental health conditions in people with CVD, such as depression, can and prognostic burden of their disease. Given the high prevalence of
negatively affect self-management, including adherence to medication mental health conditions among people with CVD, and their impact
and lifestyle changes, and are associated with worse outcomes. on outcomes and adherence, the possibility of evaluating mental health
(iii) The effects of anxiety and PTSD on adherence and CV outcomes are status at some point during professional encounters can be considered
less clear and might be time-dependent. a worthy strategy to improve health. People with CVD with potential
(iv) Caregivers play an essential role in supporting their family members symptoms of mental health conditions should undergo formal screen-
who cope with CVD to incorporate lasting lifestyle changes and to ing and, at least, a low threshold for formal screening of mental health
symptoms should be applied in people with CVD.
adhere to treatment plans: assessing and supporting caregivers
The recent manuscript ‘How your patient is really feeling: the emotional
well-being benefits both parties.
hinterland of a cardiac diagnosis’, written by individuals with CVD, illumi-
MANAGEMENT CONSENSUS STATEMENTS
nates their experience.30In this piece, people coping with CVD high-
(i) It is reasonable to assess depression, anxiety, and PTSD in people
light challenges faced when diagnosed, gaps in care, and unmet
with established CVD as they are highly prevalent and impact needs.30Priorities, such as the need for an on demand, accessible, tai-
outcomes, and refer promptly to a professional when needed.
lored, and long-term multidisciplinary support network, are outlined.
(ii) Chronic stress and loneliness are associated with negative outcomes
Suggestions for establishing the best possible person-centred support
in people with CVD and should prompt referral if identified during system and components for long-term support are outlined in
clinical assessment. Figure 7. Additional experiences of people coping with CVD, presented
(iii) Incorporating informal caregiver well-being assessment and support in the associated ‘Clinical cases and patient perspectives’ text, further
is advisable in the holistic approach of mental and CV health. highlight the importance of integrating mental health assessment within
CVD care.
5202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 20 ---
ESC Guidelines 4175
(cid:31)(cid:30)(cid:29)(cid:28)(cid:29)(cid:27)(cid:26)(cid:30)(cid:25)
(cid:26)(cid:24)(cid:24)(cid:23)(cid:24)(cid:24)(cid:22)(cid:23)(cid:28)(cid:21)
(cid:3)(cid:23)(cid:28)(cid:21)(cid:26)(cid:30)(cid:25)(cid:2)(cid:23)(cid:26)(cid:30)(cid:21)(cid:2)
(cid:20)(cid:19)(cid:18)(cid:27)(cid:26)(cid:21)(cid:29)(cid:17)(cid:28)
(cid:24)(cid:18)(cid:13)(cid:13)(cid:17)(cid:15)(cid:21)
(cid:11)(cid:26)(cid:21)(cid:29)(cid:23)(cid:28)(cid:21)(cid:10)(cid:25)(cid:9)(cid:26)(cid:22)(cid:29)(cid:30)(cid:14)
(cid:26)(cid:28)(cid:19)(cid:25)(cid:27)(cid:26)(cid:15)(cid:23)(cid:8)(cid:29)(cid:12)(cid:23)(cid:15)(cid:24)
(cid:31)
(cid:3)(cid:23)(cid:19)(cid:29)(cid:27)(cid:26)(cid:21)(cid:29)(cid:17)(cid:28) (cid:16)(cid:23)(cid:27)(cid:17)(cid:28)(cid:19)(cid:26)(cid:15)(cid:14)
(cid:21)(cid:29)(cid:21)(cid:15)(cid:26)(cid:21)(cid:29)(cid:17)(cid:28) (cid:13)(cid:15)(cid:23)(cid:12)(cid:23)(cid:28)(cid:21)(cid:29)(cid:17)(cid:28)
(cid:16)(cid:17)(cid:27)(cid:29)(cid:26)(cid:30)(cid:25)(cid:27)(cid:26)(cid:15)(cid:23)
(cid:24)(cid:18)(cid:13)(cid:13)(cid:17)(cid:15)(cid:21)
(cid:7)(cid:23)(cid:26)(cid:22)
(cid:19)(cid:29)(cid:24)(cid:27)(cid:18)(cid:24)(cid:24)(cid:29)(cid:17)(cid:28)(cid:31)(cid:26)(cid:28)(cid:19)
(cid:24)(cid:14)(cid:24)(cid:21)(cid:23)(cid:22)
(cid:27)(cid:17)(cid:17)(cid:15)(cid:19)(cid:29)(cid:28)(cid:26)(cid:21)(cid:29)(cid:17)(cid:28)
(cid:6)(cid:23)(cid:9)(cid:23)(cid:15)(cid:15)(cid:26)(cid:30)(cid:25)(cid:26)(cid:28)(cid:19)(cid:25)(cid:9)(cid:17)(cid:30)(cid:30)(cid:17)(cid:5)(cid:4)(cid:18)(cid:13)
Figure 7 Visualization of an ‘on demand’ support system for people with cardiovascular disease to improve mental health. Cardiovascular disease support
team on standby. People with cardiovascular disease, family members and caregivers access the relevant healthcare or allied professional, or other resources
appropriate to their immediate need, the process is cyclical, allowing for repeat access as needed. Adapted from Mindham et al. with permission30.
6.2. Identification and screening To ensure that people are being screened and treated for potential
mental health conditions in addition to their underlying CVD, consider-
Taking a clinical history is an opportunity for the evaluation of potential
ation needs to be given to: (i) who will screen, (ii) when screening
symptoms and any history of mental health conditions. Conversations
during the clinical course are further opportunities to identify previous- should be performed, (iii) which screening tools should be used, and
ly unrecognized symptoms, the appearance of new difficulties, manifes- (iv) how often screening should occur (Figure 8). Given that resources
tations of mental health conditions, or the need for help. These may may vary across countries, hospitals, and specialized and general prac-
indicate a requirement for more education relating to their condition(s) tices, a one-size-fits-all approach is unlikely to work. Collaboration with
or support from social care services, which is not unusual in people with mental health professionals (the Psycho-Cardio team) can support de-
CVD.227 veloping a protocol for screening and guiding referrals based on severity
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 21 ---
4176 E S C G u id e l in e s
(cid:9)(cid:15)(cid:29)(cid:29)(cid:15)(cid:8)(cid:27)(cid:22)(cid:7)(cid:18)(cid:22)(cid:12)(cid:8)(cid:18)(cid:13)(cid:6)(cid:5)(cid:18)(cid:26)(cid:27)(cid:21)(cid:7)(cid:22)(cid:15)(cid:25)(cid:27)(cid:25)(cid:4)(cid:12)(cid:3)(cid:12)(cid:22)(cid:28)(cid:2)
(cid:23)(cid:12)(cid:20)(cid:27)(cid:15)(cid:26)(cid:27)(cid:24)(cid:21)(cid:29)(cid:29)(cid:19)(cid:18)(cid:21)(cid:22)(cid:26)(cid:18)(cid:8)(cid:16)(cid:12)(cid:22)(cid:18)(cid:24)(cid:29)(cid:27)(cid:22)(cid:27)(cid:24)(cid:21)(cid:29)(cid:29)(cid:19)(cid:18)(cid:27)(cid:22)(cid:26)(cid:27)(cid:24)(cid:21)(cid:28)(cid:12)(cid:26)
(cid:1)(cid:24)(cid:20)(cid:12)(cid:12)(cid:22)(cid:18)(cid:26)(cid:30)(cid:20)(cid:27)(cid:22)(cid:7)(cid:18)(cid:24)(cid:29)(cid:27)(cid:22)(cid:27)(cid:24)(cid:21)(cid:29)(cid:18) (cid:141)(cid:143)(cid:18)(cid:144)(cid:20)(cid:25)(cid:28)(cid:18)(cid:24)(cid:16)(cid:12)(cid:24)(cid:157)(cid:18)(cid:23)(cid:15)(cid:25)(cid:27)(cid:28)(cid:27)(cid:3)(cid:12)(cid:2)(cid:18)
(cid:12)(cid:22)(cid:24)(cid:15)(cid:30)(cid:22)(cid:28)(cid:12)(cid:20)(cid:25) (cid:143)(cid:15)(cid:20)(cid:11)(cid:21)(cid:29)(cid:18)(cid:25)(cid:24)(cid:20)(cid:12)(cid:12)(cid:22)(cid:27)(cid:22)(cid:7)(cid:18)(cid:8)(cid:27)(cid:28)(cid:16)(cid:18)
(cid:31)(cid:30)(cid:28)(cid:27)
(cid:1)(cid:28)(cid:21)(cid:20)(cid:28)(cid:18)(cid:8)(cid:27)(cid:28)(cid:16)(cid:18)(cid:127)(cid:14)(cid:27)(cid:28)(cid:12)(cid:11)(cid:18) (cid:5)(cid:14)€(cid:2)(cid:18)(cid:17)‚ƒ(cid:14)„(cid:18)(cid:15)(cid:20)(cid:18)(cid:15)(cid:28)(cid:16)(cid:12)(cid:20)(cid:18)
(cid:129)(cid:30)(cid:12)(cid:25)(cid:28)(cid:27)(cid:15)(cid:22)(cid:22)(cid:21)(cid:27)(cid:20)(cid:12) (cid:3)(cid:21)(cid:29)(cid:27)(cid:26)(cid:21)(cid:28)(cid:12)(cid:26)(cid:18)(cid:28)(cid:15)(cid:15)(cid:29)
(cid:26)(cid:29)(cid:25)
(cid:31)(cid:30)(cid:29)
(cid:13)(cid:15)(cid:22)(cid:25)(cid:30)(cid:29)(cid:28)(cid:18)(cid:17)(cid:25)(cid:19)(cid:24)(cid:16)(cid:15)(cid:14)(cid:13)(cid:21)(cid:20)(cid:26)(cid:27)(cid:15)(cid:18)(cid:28)(cid:12)(cid:21)(cid:11) (cid:5)(cid:27)(cid:25)(cid:24)(cid:30)(cid:25)(cid:25)(cid:18)(cid:20)(cid:12)(cid:25)(cid:30)(cid:29)(cid:28)(cid:25)(cid:18)(cid:21)(cid:22)(cid:26)(cid:18)(cid:24)(cid:21)(cid:20)(cid:12)(cid:18)
(cid:143)(cid:15)(cid:20)(cid:18)(cid:23)(cid:21)(cid:28)(cid:27)(cid:12)(cid:22)(cid:28)(cid:18)(cid:20)(cid:12)(cid:143)(cid:12)(cid:20)(cid:20)(cid:21)(cid:29)(cid:18)(cid:21)(cid:22)(cid:26)(cid:18) (cid:23)(cid:29)(cid:21)(cid:22)(cid:18)(cid:8)(cid:27)(cid:28)(cid:16)(cid:18)(cid:23)(cid:21)(cid:28)(cid:27)(cid:12)(cid:22)(cid:28)(cid:2)(cid:18)(cid:143)(cid:21)(cid:11)(cid:27)(cid:29)(cid:19)(cid:2)(cid:18)
(cid:25)(cid:30)(cid:23)(cid:23)(cid:15)(cid:20)(cid:28) (cid:24)(cid:21)(cid:20)(cid:12)(cid:7)(cid:27)(cid:3)(cid:12)(cid:20)
(cid:13)(cid:15)(cid:22)(cid:25)(cid:27)(cid:26)(cid:12)(cid:20)(cid:18)(cid:23)(cid:21)(cid:28)(cid:27)(cid:12)(cid:22)(cid:28)(cid:4)(cid:24)(cid:21)(cid:20)(cid:12)(cid:7)(cid:27)(cid:3)(cid:12)(cid:20)(cid:18)
(cid:23)(cid:20)(cid:12)(cid:143)(cid:12)(cid:20)(cid:12)(cid:22)(cid:24)(cid:12)(cid:25)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:27)(cid:25)(cid:24)(cid:27)(cid:23)(cid:29)(cid:27)(cid:22)(cid:21)(cid:20)(cid:19)(cid:18)(cid:17)(cid:25)(cid:19)(cid:24)(cid:16)(cid:15)(cid:14)(cid:13)(cid:21)(cid:20)(cid:26)(cid:27)(cid:15)
(cid:28)(cid:12)(cid:21)(cid:11)(cid:18)(cid:11)(cid:12)(cid:11)(cid:10)(cid:12)(cid:20)(cid:25)
Figure 8 Screening for mental health conditions in people with cardiovascular disease. CVD, cardiovascular disease; GAD, Generalized Anxiety
Disorder; PHQ, Patient Health Questionnaire.
of mental health conditions and local situation. Ideally, screening for Whooley questions are a two-item screening tool for the identification
anxiety and depression should be conducted following a new diagnosis of depression that has shown high sensitivity and moderate specifi-
of CVD or acute CV event, at least once during follow-up and period- city,229making this measure a useful initial screening tool for depres-
ically (e.g. annually or when clinically indicated). Brief two-item screen- sion:32,230–233
ing measures ensure that the time needed for initial screening is limited The Whooley questions229
(see Section 5.2.1). (i) During the past month, have you often been bothered by feeling
down, depressed, or hopeless?
• When should the screening be done? Following a new diagnosis of CVD
(ii) During the past month, have you often been bothered by little
or acute CV event, periodically, at least once during follow-up, or
interest or pleasure in doing things?
when clinically indicated.
‘Yes’ to one (or both) questions = positive test (requires further
• How should screening be done? Via use of any valid and reliable short
evaluation).
screening tool, appropriate to the setting and context.
‘No’ to both questions = negative test (not depressed).
• Who should screen? Any member of the Psycho-Cardio multidisciplin-
ary team who are appropriately qualified to do so. The two-item and seven-item GAD questionnaires, and the
two-item and nine-item PHQ tools for depression are widely used
Of note, screening by itself does not help people with CVD but in- with good sensitivity and specificity in people with CVD.234–237 The
cludes responsibility to address and provide appropriate referral and GAD and PHQ have been translated into many languages and their
treatment options. Further, it is important to acknowledge that screen- use does not require a license agreement. Their psychometric proper-
ing has been linked to psychological harms (worry and anxiety) that re- ties are shown in Table 4.
main underexplored in the context of CVD.228A proposal for the who, Although it can be a challenging task to choose a screening tool, gen-
when, and how of screening for mental health conditions in people with eric questionnaires are widely used. It is key to find a screening tool that
CVD is illustrated in Figure 8. is valid and reliable for people with CVD. The Hospital Anxiety and
Depression Scale (HADS) is widely used, including in people with
6.2.1. Assessment of depression and anxiety CVD in the inpatient and outpatient setting. However, use of the
Two-item screening tools, which only take a few minutes to answer, are HADS requires a license fee. The joint ESC societies statement on
the simplest way to assess depression and anxiety. We highlight three patient-reported outcome measures, referred to in Section 5.1.1,239
measures, the Whooley questions, the Patient Health Questionnaire also notes the Cardiac Anxiety Questionnaire, Cardiac Depression
(PHQ)-2, and the Generalized Anxiety Disorder (GAD)-2. Positive Scale, and Cardiac Distress Inventory can be considered as possible
screens indicate the need for a longer screening measure. The measures.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 22 ---
ESC Guidelines 4177
Table 4 Psychometric properties of screening tools for anxiety and depression symptoms
Psychometric property Whooley questionsa GAD-2b PHQ-2b
≥2 points
Sensitivity 95% (95% CI 88–97) 91% 97%
Specificity 65% (95% CI 56–74) 37% 48%
CI, confidence interval; GAD, Generalized Anxiety Disorder; PHQ, Patient Health Questionnaire.
aValidated in an unrestricted population, i.e. not specifically CVD.232
bValidated in an Australian population.238
Table 5 Timing and tools for screening anxiety and depression symptoms
Timing of screening Measurement
Anxiety symptoms Depressive symptoms
(1) Following a new diagnosis of CVD, a CV event or procedure.
May be during hospitalization.
(2) At follow-up (e.g. annually) to determine change from GAD-2 followed by GAD-7 if positive PHQ-2 followed by PHQ-9 if positive
baseline or previous measurement
(3) Anytime based on clinical judgement
CV, cardiovascular; CVD, cardiovascular disease; GAD, Generalized Anxiety Disorder; PHQ, Patient Health Questionnaire.
Mental health conditions can evolve over time and may be episodic. 6.2.2. Suggested approach to screening people with
Therefore, professionals involved in the long-term management of peo- cardiovascular disease for psychological distress,
ple with CVD need to be aware of their mental well-being, and its depression, and anxiety
changes so, ideally, its assessment should be seamlessly integrated
There are two ways in which people can be assessed: (i) by means of a
into routine care (Table 5). Supplementary data online, Tables S4–S6
clinical diagnostic interview, or (ii) screening by a questionnaire that can
offer examples of targeted questions that might be helpful to address
identify symptom levels but not deliver a diagnosis.
specific aspects of depression, anxiety, and PTSD during clinical
In clinical practice the diagnostic interview may be lengthy, requires
encounters.
specific expertise, and thus is likely untenable to perform as a routine
The intensity of symptoms may also change over time. A recent
practice in most clinical settings. However, given that elevated scores
study of people without distress at the time of ICD implant found
on a screening questionnaire as well as a diagnosis of depression or anx-
that 14.5% developed new-onset anxiety and 11.3% new-onset de-
iety increases the risk of morbidity, mortality, and poor QoL, question-
pression during 24 months of follow-up.146One cue that might be
naires are a reasonable starting point. High scores on a screening
helpful is to monitor scores at the time of first screening (e.g.
instrument should lead to referral to a mental health professional for
when being implanted with the ICD), as people with a high score
assessment and/or diagnosis. Questionnaires also provide the means
at that time are more likely to also have an increased score at
for monitoring changes in symptoms over time. As noted previously,
follow-up.240
there are several options with respect to questionnaires to choose
The value of routine screening is still debated, therefore robust
from and it is important to know the reliability, validity, and appropriate
mandates have been avoided. The Comparison of Depression
usage of the instruments.
Interventions After Acute Coronary Syndrome: Quality of Life
(CODIACS-QoL) RCT is one of few studies where screening for
depression within 2–12 months post-ACS with or without providing 6.2.3. Challenges in specific cardiovascular conditions
depression treatment, did not alter quality-adjusted life years, In people with HF, depression and anxiety can easily be overlooked in
depression-free days, or led to harm.235Nonetheless, European and routine care due to overlapping symptoms, such as fatigue, apathy, lack
American Guidelines recommend assessment and screening for de- of energy, and sleep disorders. Thus, there is a risk that both people
pression and anxiety (usually during hospitalization), although do with HF and healthcare professionals may misinterpret the situation.
not specify how often.132,241–244 Therefore, the optimal timing of Depression and anxiety can also be considered ‘normal’ reactions to
screening within different CV conditions is not established. This the clinical and prognostic burden of HF. Although routine screening
Task Force considers it prudent to screen people after a new diagno- for mental health conditions using validated questionnaires and tools is
sis of CVD or a CV event, then periodically (e.g. annually and at least advised during hospitalization and follow-up,29,241 it is still not clear
once during follow-up), and when clinical judgement indicates that it is when and where to screen people with HF. The diagnosis of mental
needed (Table 5). Screening can be conducted during hospitalization if health conditions can also be affected by the continuous fluctuations of
time permits. HF symptoms that can interfere with mood and psychology.241,245,246
5202CSE©
5202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 23 ---
4178 E S C G u id e l in e s
Psychosocial assessment is an essential component of the evaluation and those with a diagnosis of anxiety disorder, depression, or PTSD,
of candidates for VAD, mainly aimed at identifying targets for treatment should be considered potential candidates for receiving treatment.
and improvement before the procedure, but also identifying potential Although evidence is sparse that people with CVD screened for anxiety
contraindication in some candidates (e.g. uncontrolled psychiatric con- and depression and treated afterwards have a better prognosis,235there
ditions, consistent non-adherence, active substance abuse). A consen- are a few promising studies. A retrospective cohort study of people
sus document on psychosocial assessment in advanced HF,247 with depression who received psychotherapies via primary care services
endorsed by multiple societies, defined the main domains to evaluate as: (n = 636 955), reported that intervention-driven improvements in
depression symptoms were associated with a lower risk of any-cause
• Risk factors for poor post-HTx or VAD outcomes.
new-onset CVD (HR 0.88; 95% CI 0.86–0.89). Subanalyses suggested
• Capacity to engage in decision-making.
the association was greater in those <60 years of age.253In recognition
• Personal and environmental resources.
of the different levels of stress, anxiety, depression, and PTSD experi-
• Capacity to operate VAD.
enced, and therefore the different needs with respect to treatment, a
stepped care approach (Figure 9) would be one way forward.254–257
Two scores have been used for psychosocial assessment in HTx:
Stepped care takes into account people’s preferences and can be adapted
the Psychosocial Assessment of Candidates for Transplantation
to symptom severity and resources available, and does not mean that all
(PACT) and the Stanford Integrated Psychosocial Assessment for
earlier steps need to be done before accessing higher level support.
Transplantation (SIPAT). Both have shown good predictive capacity to
identify people at risk of post-HTx non-adherence and psychosocial
complications,248,249 although their impact on clinical outcomes is un- 6.3.1. Communication, education, and support for
clear. These tools have not been validated in the VAD population. people with mental health conditions and
Quality of life and mental health assessment are needed in people
cardiovascular disease
with pulmonary hypertension (PH) due to the high reported preva-
Effective communication is a cornerstone of healthcare delivery, foster-
lence of depression and anxiety (see Section 5, Tables 1and 2), but there
ing person-centred care, and addressing the complex interplay between
is lack of evidence on the ideal timing or specific method. The HADS
mental and physical health.258Proportional stress, anxiety, or fear may
may be a useful tool, since it was able to rule out anxiety and depression
be normal reactions after a diagnosis of CVD, acute CV events, CV pro-
disorder with a negative predictive value of 90% in a PH population.250
cedures or interventions, or their complications. Empathy and active lis-
tening are essential to understanding the potential difficulties and
6.2.4. Assessment of subjective well-being and quality worries the person with CVD and their family members may face. It
of life is important to recognize that challenges may not only be due to the
The WHO-5 questionnaire, available in 30 languages,251,252can be used physical consequences of CVD or its therapy. Rather, healthcare pro-
to assess SWB and does not require a license fee. A percentage score fessionals must appreciate the full spectrum of mental and emotional
<50 (or a raw score <13) has been suggested as a cut-off for poor men- consequences, as well as the impacts this may have on lifestyle, profes-
tal well-being and as an indication for further assessment for the pos- sional, family, social, or economic factors as presented in the associated
sible presence of a mental health condition (e.g. depressive disorder). ‘Clinical cases and patient perspectives’ document. Healthcare profes-
Patient-reported measures such as QoL are seen as essential in clin- sionals should ensure that people receive support for both physical and
ical practice as well as in clinical trials as ways to assess symptoms, mental health needs, preventing or attenuating unwanted psychological
function, well-being, perspectives, and undisclosed problems. Several or emotional reactions, and potentially improving therapeutic adher-
disease-specific QoL instruments are available, valid in specific con- ence and clinical outcomes.259
ditions such as HF, ischaemic heart disease (IHD), AF, congenital Open dialogue with people with CVD, family, and caregivers,
heart disease, and PH. Generic measures such as the Short-Form 12 adapted to their age, cultural level, beliefs, and preferences, is essen-
or 36 or EuroQol 5-Dimension (EQ-5D) questionnaire are often used tial.260Answering questions, solving doubts and clarifying uncertainties
as well. Most QoL instruments include items related to mental health is a key aspect of therapeutic relationships and may help prevent mis-
status as well as physical health, which can alert a healthcare profes- understandings and irrational fears.261While in ECR programmes there
sional to a need for screening for mental health conditions. These in- is more time and opportunity for communication, this may be challen-
struments are being incorporated into electronic medical records in ging to deliver in acute or critical care and in outpatient care, where
some systems, but implementation of regular QoL assessment is hin- time pressure is constant. In these settings, time for high-quality com-
dered by limited integration into clinical practice and interpretation of munication should be facilitated.
scores. However, electronic medical records and automated systems Multiple individual, professional, condition-specific, and organization-
should in future simplify assessment of well-being, QoL, and mental al factors including health literacy, mental health issues, and time pres-
health conditions at regular intervals. A full list of these measures can sures, impact the quality of communication. The impact of mental
be found in a recent ESC statement on ‘Placing patient-reported out- health on communication may be particularly strong in people with
comes at the centre of CV clinical practice’.239 SMI. Shared decision-making (SDM), in which the person coping with
CVD and professionals discuss evidence and options for treatment,
6.3. Management of mental health and people are supported to make informed decisions, is dependent
on good communication. A systematic review and meta-analysis of in-
conditions in people with cardiovascular
terventions to increase SDM in CVD found that the interventions re-
disease
duced decisional conflict and increased knowledge across a wide
Given the negative impact of poorer mental health on adherence to range of CVD conditions and formats.262
medication and lifestyle, QoL, prognosis, and costs, people with an in- Compassion in CVD care is an important element in communication
creased symptom score on anxiety and/or depression questionnaires and understanding. More information on compassionate care can be
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 24 ---
ESC Guidelines 4179
(cid:10)(cid:19)(cid:24)(cid:29)(cid:19) (cid:13)(cid:18)(cid:18)(cid:24)(cid:12)(cid:11)(cid:10)(cid:24) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:24)(cid:23)(cid:28)(cid:29)(cid:22)(cid:24)(cid:17)(cid:16)(cid:25)(cid:28)(cid:29)(cid:28)(cid:21)(cid:27) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:24)(cid:23)(cid:28)(cid:29)(cid:22)(cid:24)(cid:25)(cid:27)(cid:21)(cid:27)(cid:20)(cid:27)
(cid:12)(cid:26)(cid:14)(cid:24)(cid:27)(cid:30)(cid:14)(cid:25) (cid:17)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25) (cid:28)(cid:26)(cid:28)(cid:29)(cid:28)(cid:30)(cid:18)(cid:24)(cid:25)(cid:15)(cid:20)(cid:27)(cid:27)(cid:26)(cid:28)(cid:26)(cid:14) (cid:19)(cid:27)(cid:26)(cid:29)(cid:30)(cid:18)(cid:24)(cid:28)(cid:18)(cid:18)(cid:26)(cid:27)(cid:25)(cid:25)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:30)(cid:23)(cid:22)(cid:21)(cid:25)(cid:20)(cid:29)(cid:19)(cid:18)(cid:17)(cid:16)(cid:26)(cid:28)(cid:15)(cid:24)(cid:18)(cid:22)(cid:14)(cid:27)(cid:26)(cid:13)(cid:22)(cid:24)(cid:30)(cid:12)(cid:11)(cid:14)
(cid:9)(cid:24)(cid:8)(cid:27)(cid:25)(cid:14)(cid:20)(cid:7)(cid:27)(cid:22)(cid:13)(cid:27)(cid:26)(cid:25)(cid:11)(cid:28)(cid:27)(cid:25)(cid:22)(cid:26)(cid:30)(cid:15)(cid:22)(cid:12)(cid:25)(cid:20)(cid:29)(cid:19)(cid:18)(cid:17)(cid:27)(cid:15)(cid:11)(cid:29)(cid:26)(cid:14)(cid:24)(cid:18)(cid:30)
(cid:9)(cid:27)(cid:26)(cid:29)(cid:30)(cid:18)(cid:24)(cid:22)(cid:27)(cid:30)(cid:18)(cid:29)(cid:22)(cid:24)(cid:30)(cid:25)(cid:25)(cid:27)(cid:25)(cid:25)(cid:19)(cid:27)(cid:26)(cid:29) (cid:144)(cid:27)(cid:141)(cid:27)(cid:20)(cid:20)(cid:30)(cid:18)(cid:24)(cid:141)(cid:16)(cid:20) (cid:31)(cid:22)(cid:30)(cid:20)(cid:19)(cid:30)(cid:15)(cid:16)(cid:18)(cid:16)(cid:14)(cid:28)(cid:15)(cid:30)(cid:18)(cid:24)(cid:30)(cid:26)(cid:143)
(cid:10)(cid:19)(cid:26)(cid:14) (cid:8)(cid:7)(cid:28)(cid:29)(cid:27)(cid:19)(cid:24)(cid:19)(cid:27)(cid:30)(cid:25)(cid:6)(cid:20)(cid:27)(cid:24)(cid:31)(cid:5)(cid:4)(cid:7)(cid:8)(cid:3)(cid:24)(cid:2)(cid:13)(cid:10)(cid:7)(cid:8)(cid:3) (cid:143)(cid:28)(cid:30)(cid:14)(cid:26)(cid:16)(cid:25)(cid:29)(cid:28)(cid:15)(cid:24)(cid:30)(cid:25)(cid:25)(cid:27)(cid:25)(cid:25)(cid:19)(cid:27)(cid:26)(cid:29) (cid:26)(cid:16)(cid:26)(cid:7)(cid:17)(cid:22)(cid:30)(cid:20)(cid:19)(cid:30)(cid:15)(cid:16)(cid:18)(cid:16)(cid:14)(cid:28)(cid:15)(cid:30)(cid:18)
(cid:16)(cid:20)(cid:24)(cid:1)(cid:22)(cid:16)(cid:16)(cid:18)(cid:27)(cid:127)(cid:24)(cid:129)(cid:6)(cid:27)(cid:25)(cid:29)(cid:28)(cid:16)(cid:26)(cid:25) (cid:30)(cid:26)(cid:143)(cid:24)(cid:16)(cid:17)(cid:29)(cid:28)(cid:19)(cid:30)(cid:18)(cid:24)(cid:29)(cid:20)(cid:27)(cid:30)(cid:29)(cid:19)(cid:27)(cid:26)(cid:29) (cid:29)(cid:20)(cid:27)(cid:30)(cid:29)(cid:19)(cid:27)(cid:26)(cid:29)
(cid:31)(cid:20)(cid:28)(cid:19)(cid:30)(cid:20)(cid:127)(cid:24)(cid:15)(cid:30)(cid:20)(cid:27)(cid:24)(cid:16)(cid:20) (cid:31)(cid:25)(cid:127)(cid:15)(cid:22)(cid:16)(cid:7)(cid:12)(cid:30)(cid:20)(cid:143)(cid:28)(cid:16)(cid:24)(cid:29)(cid:27)(cid:30)(cid:19)(cid:24)(cid:16)(cid:20) (cid:31)(cid:25)(cid:127)(cid:15)(cid:22)(cid:16)(cid:7)(cid:12)(cid:30)(cid:20)(cid:143)(cid:28)(cid:16)(cid:24)(cid:29)(cid:27)(cid:30)(cid:19)(cid:24)(cid:16)(cid:20)
(cid:10)(cid:19)(cid:18)
(cid:12)(cid:11)(cid:24)(cid:15)(cid:30)(cid:20)(cid:27)(cid:24)(cid:29)(cid:27)(cid:30)(cid:19) (cid:19)(cid:27)(cid:26)(cid:29)(cid:30)(cid:18)(cid:24)(cid:22)(cid:27)(cid:30)(cid:18)(cid:29)(cid:22)(cid:24)(cid:17)(cid:20)(cid:16)(cid:141)(cid:27)(cid:25)(cid:25)(cid:28)(cid:16)(cid:26)(cid:30)(cid:18) (cid:19)(cid:27)(cid:26)(cid:29)(cid:30)(cid:18)(cid:24)(cid:22)(cid:27)(cid:30)(cid:18)(cid:29)(cid:22)(cid:24)(cid:17)(cid:20)(cid:16)(cid:141)(cid:27)(cid:25)(cid:25)(cid:28)(cid:16)(cid:26)(cid:30)(cid:18)
(cid:13)(cid:141)(cid:29)(cid:27)(cid:20)(cid:24)(cid:26)(cid:27)(cid:23)(cid:24)(cid:143)(cid:28)(cid:30)(cid:14)(cid:26)(cid:16)(cid:25)(cid:28)(cid:25) (cid:13)(cid:29)(cid:24)(cid:29)(cid:28)(cid:19)(cid:27)(cid:24)(cid:16)(cid:141)(cid:24)(cid:143)(cid:27)(cid:29)(cid:27)(cid:15)(cid:29)(cid:28)(cid:16)(cid:26)(cid:3) (cid:13)(cid:29)(cid:24)(cid:29)(cid:28)(cid:19)(cid:27)(cid:24)(cid:16)(cid:141)(cid:24)(cid:143)(cid:28)(cid:30)(cid:14)(cid:26)(cid:16)(cid:25)(cid:28)(cid:25)(cid:3)
(cid:10)(cid:19)(cid:27)(cid:30)
(cid:16)(cid:20)(cid:24)(cid:27)(cid:21)(cid:27)(cid:26)(cid:29)(cid:24)(cid:30)(cid:26)(cid:143)(cid:24)(cid:17)(cid:27)(cid:20)(cid:28)(cid:16)(cid:143)(cid:28)(cid:15)(cid:30)(cid:18)(cid:18)(cid:127) (cid:30)(cid:25)(cid:24)(cid:17)(cid:27)(cid:20)(cid:24)(cid:15)(cid:18)(cid:28)(cid:26)(cid:28)(cid:15)(cid:30)(cid:18)(cid:24)(cid:26)(cid:27)(cid:27)(cid:143) (cid:30)(cid:25)(cid:24)(cid:17)(cid:27)(cid:20)(cid:24)(cid:15)(cid:18)(cid:28)(cid:26)(cid:28)(cid:15)(cid:30)(cid:18)(cid:24)(cid:26)(cid:27)(cid:27)(cid:143)
(cid:157)(cid:28)(cid:14)(cid:6)(cid:20)(cid:27)(cid:24) (cid:21)
Figure 9 Stepped care model for assessment and management of mental health conditions in people with cardiovascular disease. CV, cardiovascular;
CVD, cardiovascular disease; GAD, Generalized Anxiety Disorder; PHQ, Patient Health Questionnaire. Adapted from Pedersen et al with
permission.254
found in supplementary data online, and Table S7. Caregivers and family its treatment adherence and effectiveness.264 It is considered an im-
involvement can improve mental well-being and CV outcomes; a para- portant component of treatment in both medical and mental health
digm shift in the organization of care may be needed to include the per- conditions.265 A psycho-educational approach is already embedded
son’s social environment into treatment. More information can be within multiple CV care settings, including ECR and secondary preven-
found in the supplementary data online. tion programmes. It includes education on the underlying disease and
current risk factors and suggestions for lifestyle modifications. Based
on the results of a recent synthesis of RCTs (n = 8748 people
6.3.2. Psychological interventions
post-MI or revascularization), a psycho-educational approach should in-
A broad range of strategies, from cognitive-behavioural therapy (CBT),
tegrate several modes of delivery and preferably last for at least 3
psycho-education, and mindfulness-based techniques to lifestyle modi-
months.266The effects of psycho-educational interventions on depres-
fication programmes and support groups, including internet-based in-
sion and anxiety symptoms when combined in meta-analysis are large
terventions and mobile health (mHealth) solutions, have been
based on accepted thresholds.267
proposed as psychological therapeutic options for people with CVD.263
For people with arrhythmias and/or ICD for primary or secondary
prevention, there are physical symptoms, such as sleep disturbance, fa-
6.3.3. Psycho-education tigue, and also psychological fears (fear of shocks, worry about the fu-
Psycho-education is an intervention with structured knowledge trans- ture, and fear of ICD dysfunction) affecting QoL. Psycho-education
fer about an illness and its treatment, integrating emotional and motiv- improved the physical component summary of QoL but had no effect
ational aspects to enable people to cope with the illness and to improve on mental component summary scores.268 In people with AF,
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 25 ---
4180 E S C G u id e l in e s
reductions in serious adverse events [risk ratio (RR) 0.78; 95% CI 0.63– 6.3.5. Other psychological interventions
0.97], anxiety, depression, and health-related QoL (HRQoL) were ob- A Cochrane systematic review and meta-analysis of RCTs of psycho-
served with psycho-education, although the incidence of AF episodes logical interventions for CHD including relaxation, cognitive techni-
was not affected.269 ques, emotional support and/or client-led discussion, and adjunct
pharmacology, reported a reduction in CV mortality (from 7.3% to
5.5%) with psychological interventions compared with usual care con-
6.3.4. Social prescribing trols.281No between-group differences were observed for the rates
Social prescribing is a transformative healthcare approach that connects of total mortality, non-fatal MI, or revascularization procedures.
people with non-medical resources to enhance their holistic well-being. Psychological interventions were found to achieve small to moderate
The core idea behind social prescribing is to provide people with per- improvements in depressive symptoms, anxiety, and stress compared
sonalized interventions that extend beyond traditional medical pre- with controls, although there remains some uncertainty in these
scriptions, encompassing a spectrum of community-based activities estimates.281
and resources.270,271The aim is to address diverse aspects of mental Cognitive-behavioural therapy is a psychological intervention that fo-
health, such as social isolation, loneliness, stress, and anxiety, by facilitat- cuses on changing patterns of unhelpful thinking and behaviour.282Two
ing access to supportive community activities. Social prescribing le- recent systematic reviews and meta-analyses assessing the efficacy of
verages a variety of activities, ranging from arts workshops, music CBT-based interventions in RCTs in people with CAD showed that
therapy, and group dance sessions to support networks, to enhance CBT-based interventions can reduce CV events, MI, and angina dur-
mental well-being and cultivate a sense of belonging and purpose. ation and intensity at the end of follow-up. Findings varied by trials,
Engagement in community activities, such as group dance, hiking, with no effect on other clinical outcomes,283but improving significantly
and cooking classes, combats feelings of isolation and fosters meaningful psychological outcomes, such as depressive symptoms, anxiety, depres-
social interactions, thereby bolstering mental well-being.272,273 sion, stress, and increasing vital satisfaction at the end of follow-up.284
These community connections act as protective factors against stress A recent study assessing the effect of CBT has shown efficacy in im-
and isolation, potentially enhancing mental health support for people proving AF-specific QoL for people with symptomatic paroxysmal AF.
with CVD. This can lead to reductions in depressive symptoms, im- AF-CBT led to large improvements, reducing healthcare-related con-
provements in QoL, and better adherence to CV treatment plans.270 sumption by 56%, although the AF burden remained unchanged.285A
A systematic review of 17 studies involving 13 social prescribing inter- further RCT testing a CBT intervention in young people with CAD
ventions with a total of 5036 participants found statistically significant showed improvement in the total HADS score after 3 months, with dif-
improvements in mental health, general well-being, and QoL in 16 ferences maintained after 6 months. The intervention group also had
of the studies.274Despite these promising findings, more research fo- greater adherence to ECR and more improvement in HRQoL at 6
cusing specifically on people with CVD is necessary to draw reliable months. A significant reduction in CVD-related admissions at 12
conclusions. months was also observed.286
Interventions involving social professionals were found to be more Recently, a multicentre study in which 250 people with AMI were
effective for reducing anxiety and depression, while those involving randomized after PCI to either control or cognitive-behavioural stress
health professionals had a greater impact on improving blood pressure management detected that the latter improves anxiety, depression,
and encouraging physical activity.275Participating in arts, including visual and QoL but does not affect MACE.287 However, another trial of
art therapy and music therapy, has shown positive effects on mood and 362 people who had experienced a CVD event randomized to usual
emotional regulation.276Music, in particular, can be a powerful tool in care or usual care plus CBT, found that CBT decreased the risk of re-
reducing stress and enhancing mood in people with CVD. Activities current events including MI.288Cognitive-based or external support
such as gardening, green exercise, and nature walks have been effective coping mechanisms seem to attenuate the mental impact of PH, de-
in reducing systolic and diastolic blood pressure and have demonstrated creasing anxiety or depression rates.289 This suggests a potential
moderate to large effects on depression and anxiety scores.275,277 benefit for early identification and psychological intervention. In
These interventions also increase daily step counts, though the overall fact, psychosocial support has a Class I recommendation in the cur-
impact on physical activity time is still being evaluated. rent ESC/European Respiratory Society (ERS) Guidelines for the diag-
Technology plays a pivotal role in facilitating social prescribing. nosis and treatment of pulmonary hypertension,290and is endorsed in
Mobile apps and online platforms can recommend suitable social pre- the 2024 ESC Guidelines for the management of chronic coronary
scriptions based on personal profiles and mental health assessments, syndromes.242
serving as valuable resources for people to explore options, engage Cognitive-behavioural therapy is safe and has shown to have benefi-
in virtual support groups, and track their progress.278 Real-time data cial effects in improving mental symptoms, in particular depression, and
collection through these platforms allows healthcare professionals to QoL in people with CVD and HF, and it could be a valid option due to
monitor engagement and outcomes more effectively.279Integrating so- the lack of potential side effects or drug interactions. However, a small
cial prescribing into standard care pathways, fostering community part- qualitative study found that some people reported side effects, includ-
nerships, and leveraging technology ensures efficient and personalized ing discomfort with treatment and worsening of symptoms.287,289,291
recommendations. This approach aligns with modern healthcare para- Exposure therapy can be helpful for people with CVD, who due to
digms, emphasizing holistic well-being and personalized interventions, their disease stop doing the things that they used to enjoy due to fear of
particularly for people with CVD dealing with mental health concerns, another CV event, which may lead to depression. An example is a per-
although more research is needed.280There is growing evidence sup- son who experiences an out-of-hospital cardiac arrest (OHCA) while
porting the use of social prescribing in the management of CVD. cycling. Often this will cause anxiety and fear of taking up cycling again,
Healthcare professionals should be aware of local social prescribing in- as cycling is associated with OHCA. However, exposure therapy,
terventions and availability in their environment and refer when where the therapist exposes the person gradually and in a safe way
appropriate. to situations and activities that they fear, is often helpful.292
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 26 ---
ESC Guidelines 4181
Similarly, behavioural activation uses behaviours to influence emo- combined with antidepressants and psychotherapy, significantly re-
tional state as engaging in activities that increase social connections duced depressive symptoms at 8 weeks. The study suggested that while
and feelings of well-being can decrease depression. A pragmatic RCT antidepressants remained effective at 26 weeks, the addition of exercise
in 416 people with HF and comorbid depression compared the effect- could enhance overall treatment efficacy.307
iveness of antidepressant medication vs behavioural activation psycho- For people with HF, the Heart Failure-A Controlled Trial
therapy. Both groups experienced equal benefits with close to a 50% Investigating Outcomes of Exercise Training (HF-ACTION) demon-
reduction in depressive symptoms at 3, 6, and 12 months.293People re- strated that exercise training led to a modest but significant decline in
ceiving behavioural activation psychotherapy had significantly better depression symptoms at both 3 and 12 months, as evidenced by im-
physical HRQoL and HF-specific HRQoL. Although there is limited evi- provements in the Beck Depression Inventory score in the exercise
dence within CVD, some people have reported that philosophical group. The study emphasized that while exercise is beneficial, the
counselling (Supplementary data online, Table S8) can be a complemen- type and duration should be tailored to functional capacity, with consid-
tary approach to other therapeutic strategies. erations for independent or supervised exercise programmes.308,309
In summary, exercise is a critical component of managing CVD in
6.3.6. Interventions for people with post-traumatic adults, particularly for those with HF and CAD. Its benefits include im-
stress disorder provements in both physical and mental health, which are crucial for en-
hancing the overall QoL in people with CVD.
Limited evidence on the prevention and management of CDI-PTSD is
available. A comparison of eye movement desensitization and repro-
cessing (EMDR) with imaginal exposure in 42 people with PTSD in- 6.3.9. Diet and nutrition approaches in cardiovascular
duced by life-threatening CV events, including surgery, MI, and disease and mental health conditions
cardiac arrest, showed EMDR significantly reduced CDI-PTSD symp- Dietary interventions and nutritional strategies hold promise for im-
toms at 4 weeks and 6 months.294Fifty-one people with PTSD symp- proving both CVD310and mental health outcomes in individuals with
toms due to a CV event randomized to imaginal exposure or control CVD. However, the current evidence specifically addressing mental
group reported improved PTSD symptoms compared with the control health improvements through dietary changes in this population is lim-
group, although this difference was not statistically significant due to the ited, highlighting the need for more robust and targeted research to es-
small sample size. This initial study in the field of exposure psychothera- tablish clear recommendations.
pies provides promising evidence for the safety of using this technique Several dietary patterns have been explored for their potential men-
in people with CVD.295 tal health benefits in people with CVD. The Mediterranean diet, rich in
In a more recent RCT designed to determine if trauma-focused fruits, vegetables, whole grains, and healthy fats, has been associated
counselling within 48 h of hospital admission could prevent the devel- with lower rates of depression and cognitive decline in the general
opment of PTSS, 190 people with ACS experiencing distress were as- population, but data specific to people with CVD are still emer-
signed to either trauma-focused counselling (one session) or a general ging.311,312Some studies suggest that the anti-inflammatory properties
stress management active control group. Results showed fewer bene- of this diet could be beneficial, yet conclusive evidence in CVD popula-
ficial effects for the trauma-focused counselling group compared with tions is lacking.313,314
the control group.296 Fasting interventions, including intermittent fasting and calorie re-
striction, have also been examined for potential to improve mental
6.3.7. Lifestyle interventions health. While some studies report encouraging results, such as im-
Adopting a holistic approach that includes lifestyle changes can effect- provements in mood and cognitive function, these findings are prelim-
ively improve mental health, CV well-being, risk factors, and CV out- inary. The evidence is not yet strong enough to endorse one fasting
comes.297–302 Examples of lifestyle changes include regular physical method over another, particularly for individuals with psychiatric
activity, a balanced diet, stress management techniques (such as mind-
conditions.314,315
fulness and yoga), adequate sleep, and positive coping strategies.303,304 The Omega-3 Supplementation for Co-Morbid Depression and
Heart Failure Treatment (OCEAN) trial reported that supplementa-
6.3.8. Physical activity and exercise in people with tion with eicosapentaenoic acid and docosahexaenoic acid in people
with HF (n = 108) led to positive changes in cognitive depressive symp-
cardiovascular disease and mental health conditions
toms and social functioning. However, the small sample size and the use
Physical activity encompasses a wide range of bodily movements that
of soft endpoints suggest that these findings should be interpreted with
increase energy expenditure, including everyday tasks such as walking,
caution, and larger, more definitive trials are needed.316
household chores, and active commuting. Exercise is a more structured
While dietary approaches and nutritional interventions are appealing
and purposeful form of physical activity designed to enhance or main-
for their potential dual benefits on CV and mental health in people with
tain physical fitness. The benefits of exercise in people with CVD ex-
CVD, current evidence is insufficient to advise on diet interventions.
tend beyond improving physical health; it also significantly enhances
More rigorous studies are needed to determine the most effective diet-
psychological well-being, including reassurance in those who are con-
ary strategies for improving mental health outcomes in this population.
cerned for potential recurrences of their event or worsening of their
disease. Exercise induces the release of endorphins and other neuroac-
tive substances, contributing to mood improvement and stress reduc- 6.3.10. Smoking cessation
tion.305These effects are particularly beneficial for people with CVD, Tobacco cessation offers significant CV health benefits, particularly for
who often face psychological challenges in addition to their physical individuals with mental health conditions, including those with SMI.
health issues.306 In people with CAD and depression, exercise has However, addressing tobacco use in this population is challenging due
been shown to be an effective component of treatment. A network to the complex interplay between addiction and mental health issues.
meta-analysis (33 RCTs, n = 7240) demonstrated that exercise, when Sustained tobacco abstinence over 52 weeks can significantly reduce
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 27 ---
4182 E S C G u id e l in e s
the 10 year CV risk in people with SMI.317Despite these CV benefits, A study demonstrated that progressive muscle relaxation could reduce
individuals often face significant challenges post-cessation, such as not- anxiety and improve heart rate variability in individuals with CVD.327
able weight gain, which can contribute to high rates of obesity, diabetes,
and hypertension.318The addictive nature of tobacco use, especially in 6.3.12. Sleep hygiene
individuals with mental health conditions, necessitates treating tobacco
Sleep quality is integral to both CV health and mental well-being, particu-
use as an addiction and addressing it with comprehensive strategies.
larly in individuals with CVD. Poor sleep quality and insufficient sleep dur-
Addressing tobacco cessation in individuals with mental health con- ation are linked to various adverse CV outcomes, including mortality,329
ditions requires a tailored approach. The Five A’s model (Ask, Advise, atherosclerosis,330 hypertension, impaired glucose metabolism, and in-
Assess, Assist, Arrange) is a structured method commonly used to en-
creased inflammatory markers, and associated with an elevated risk of
courage and support tobacco cessation. However, it should be adapted
mental health conditions such as depression and anxiety, which can fur-
to meet the unique needs of those with mental health conditions. For ther complicate the management of CVD.331–333 It is important for
instance, healthcare professionals should be particularly attentive when
healthcare professionals to routinely inquire about sleep quality during
assessing a person’s readiness to quit, considering his or her mental clinical evaluations, given the significant impact of sleep on both CV
health status, and providing additional support and resources that ad-
and mental health. Interventions that improve sleep quality such as sleep
dress both their tobacco use and mental health needs.
hygiene measures and CBT for insomnia have been shown to improve
Cognitive therapies, when combined with medication, have been mental health conditions.331Healthcare professionals should encourage
shown to improve tobacco abstinence rates in adults, including those people to adopt specific sleep hygiene practices, such as maintaining a
with mental health conditions. A review of 21 RCTs found that cogni-
consistent sleep schedule, avoiding stimulants like caffeine or nicotine
tive therapies combined with medication or nicotine replacement ther-
close to bedtime, limiting screen exposure in the evening, and creating
apy are more effective than medication alone, although the quality of a restful sleep environment with minimal noise and light.331While wear-
evidence varied.319 While tobacco cessation is crucial for improving
ables like smartwatches offer insights into sleep patterns, their diagnostic
CV and overall health in people with mental health conditions, it re-
accuracy remains limited, and they should be complemented by validated
quires a nuanced and supportive approach that considers the complex-
clinical assessments and evidence-based interventions.
ities of addiction in this population.
6.4. Tools and resources to support
6.3.11. Stress management techniques
lifestyle change
Mindfulness,320meditation,321and progressive muscle relaxation322–324
6.4.1. Digital health tools
are stress management techniques that have shown promise in foster-
Among the many new mobile apps released every day for monitoring
ing cognitive resilience, emotional regulation, and relaxation. However,
personal health data, only a minority have been scientifically validated
their specific effects on people with CVD need careful consideration
and evidence-based discussion.325–327 on healthcare behavioural and clinical outcomes in the CV field. A sys-
tematic review encompassing 39 studies of wearable devices in multiple
Mindfulness involves focused attention on the present moment,
CVDs found potential benefits mainly in lifestyle aspects like physical ac-
fostering cognitive resilience against stressors and aiding emotional regu-
lation.320A study of mindfulness on people with CVD showed improve- tivity and smoking cessation. However, the same review highlighted
ments in psychological well-being and CV markers.325Mindfulness-based safety, reliability, and regulation concerns.334 A systematic review and
meta-analysis of mobile phone and mHealth interventions in people
interventions for adults aged 19 to 40 years in developed countries, in-
who had experienced a coronary event (20 studies, n = 4535) reported
cluding mindfulness-based stress reduction programmes, mindfulness-
benefits in exercise capacity, physical activity, reductions in all-cause and
based cognitive therapy programmes, and the Learning 2 BREATHE
CV readmissions, and improved physical and mental QoL.335 A
(Body, Reflections/thoughts, Emotions, Attention, Tenderness, Habits,
meta-analysis evaluating the efficacy of a digital health intervention in peo-
Empowerment) programme, generally improve well-being and can be ef-
fectively implemented in a virtual format.325 ple with CVD showed that telemonitoring reduced depression in people
with HF and CAD, and device-based psychological education and training Meditation focuses on controlled breathing or visualization, trigger-
had a significant positive effect in reducing depression in people with ing the parasympathetic nervous system to induce relaxation and re-
duce stress hormones.321 A meta-analysis indicated that distress CAD or ICD. Although the use of information and communication tech-
nologies for health (eHealth) in daily practice is promising, there are still
management, when combined with ECR, offers limited additional ef-
several barriers, including reimbursement challenges, digital literacy is-
fects, suggesting that meditation should be integrated cautiously with
existing ECR programmes.328A further study showed that meditation sues, and unequal access to digital technology (digital divide) in low-
income countries or in remote areas as well as in the elderly.336
can reduce stress and improve CV health outcomes in people with
CVD.326Meditation and mindfulness, especially evidence-based forms
like mindfulness-based stress reduction, can support people with 6.4.2. Motivational interviewing
CVD and their caregivers to reduce anxiety, depression, and pain. Motivational interviewing (MotInt) is a person-centred counselling style
These practices have shown structural and functional brain changes, for addressing the common problem of ambivalence about healthy life-
translate well across different populations, and offer a low-cost, bene- style changes. It can be an effective counselling approach that bolsters
ficial method to complement treatment during this crisis.326 motivation by resolving ambivalence. Motivational interviewing has
Progressive muscle relaxation involves sequentially tensing and re- shown efficacy in helping to make healthy behavioural changes and con-
leasing muscle groups to promote physical and mental relaxation, coun- trol CV risk factors with some evidence that shows an effect on the
tering stress-induced physiological manifestations such as elevated management of depression.337 More information about MotInt can
heart rate, increased blood pressure, and muscle tension.322–324 be found in the supplementary data online.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 28 ---
ESC Guidelines 4183
6.4.3. Cardiac rehabilitation results. A systematic review and meta-analysis of 10 RCTs of anti-
Cardiac rehabilitation is a comprehensive multicomponent programme depressant treatment following ACS found no general improvement
of secondary prevention aiming to reduce CVD risk and optimize in all-cause mortality and recurrent MI while the risk of repeat hospital-
health and well-being. A key component of most cardiac rehabilitation ization was significantly reduced. However, in people with a concomi-
programmes is structured exercise (ECR) along with other compo- tant diagnosis of depression, antidepressants decreased the odds of
nents such as assessment, education, psychosocial support, informa- recurrent MI.352A Cochrane review examining trials on psychological
tion, behavioural interventions, and risk factor management.338,339 treatments and antidepressant drugs in adults with CAD and comorbid
Meta-analyses have shown that ECR is effective in improving mortality, depression concluded that pharmacological interventions may have a
morbidity, and HRQoL outcomes across multiple CV conditions,340–344 large effect on end-of-treatment depression symptoms, while effects
but few meta-analyses provide evidence of improvement in measures on mortality or CV endpoints were deemed uncertain.353
of mental health.343–345These have found only weak evidence and small Studies on the safety of antidepressant medication in HF have yielded
effects of ECR on depression and anxiety symptoms in people with conflicting results. One meta-analysis indicated that the use of antide-
CVD, even when psychological interventions were added.328,344–346 pressants in people with HF is associated with an increased risk of all-
These results may be surprising given that psychosocial management cause death regardless of whether they have clinical depression or the
is one of the core components of comprehensive ECR,347and exercise type of antidepressants used.354In contrast, a recent meta-analysis re-
has been shown to have beneficial effects on the risk for and symptoms viewing studies of people with depression and known HF in both out-
of depression and anxiety. Possible explanations include lack of sys- patient and hospital settings indicated that selective serotonin reuptake
tematic measurement of mental health outcomes, lack of recruitment inhibitors (SSRIs) seem to be a safe treatment option.355This analysis,
of people with mental health conditions, and reluctance of people with however, was limited by the variety of study designs and mixed results
mental health conditions to attend ECR or participate in studies. for different antidepressants.
Screening for depression and anxiety in ECR is advocated,348but has Given the inconsistency of findings across studies on the effective-
been found to be inconsistently implemented with variation across ness of pharmacological treatment for mental health conditions in peo-
conditions and services.349A position statement from the European ple with CVD, there is a clear need for larger and robust RCTs.
Association of Preventive Cardiology (EAPC)348 advises screening Concerns about drug safety, CV side effects, and interactions between
for mental health conditions and referral to a psychologist or psych- psychiatric medications and CVD treatments complicate this manage-
iatrist when needed. ment and need to be clarified in future research.
Exercise-based cardiac rehabilitation has the potential to benefit
people with mild to moderate symptoms of depression, anxiety, 6.5.2. Use of specific medications in people with
and stress, but studies and evaluation are essential. One recent depression, anxiety, or post-traumatic stress
RCT trained ECR staff to deliver metacognitive therapy to people with disorders and cardiovascular disease
CVD (n = 332) and demonstrated significant small to moderate improve-
In the treatment of depression, anxiety, and PTSD, antidepressants are
ment in depression and anxiety scores compared with ECR alone.350
the first-line pharmacological treatment, while additional medications
Suggestions for ensuring mental health benefit from ECR include:
including anxiolytics, sedatives, and hypnotics, may be used in the short
• Screening for mental health conditions by ECR staff at the start and term. Other drugs, such as mood stabilizers and antipsychotics, may
end of programme. also be used, depending on the severity of symptoms. A brief descrip-
• Improving the implementation of screening through Guidelines com- tion of the most common medications used for the treatment of mental
bined with local/national initiatives to support screening.351 health conditions is given in Supplementary data online, Table S9.
• Determining optimal interventions in ECR to improve symptoms of Figure 10provides an algorithm for the pharmacological treatment of
mental health conditions, including who should deliver these. depression, anxiety, and PTSD in CVD.
• Collaborating with mental health experts to ensure psychosocial
support in ECR is robust and that referrals can be made when 6.5.3. Use of antidepressants
appropriate.
• The use of antidepressants in CVD populations requires careful se-
• Evaluating mental health symptoms as an outcome in ECR. The EAPC
lection of medications, dosage adjustments, and close monitoring
advocates a goal of improvement of depression and anxiety symptom
due to potential side effects and clinically relevant drug interactions.
scores by 10% on valid measures.348 In general, newer antidepressants are considered safe and asso-
ciated with few serious long-term side effects in people with
6.5. Medical interventions CVD.356–358However, CVD side effects may occur and are typically
exerted through noradrenergic activation resulting from the use of
Medical interventions including pharmacotherapy may be needed for
serotonin and norepinephrine reuptake inhibitors (SNRIs), nor-
people with CVD with diagnosed mental health conditions and for peo-
epinephrine reuptake inhibitors, noradrenergic and specific seroto-
ple with severe symptoms of depression, anxiety, or PTSD. Careful as-
nergic antidepressants, that can cause orthostatic hypotension or
sessment of the risks and benefits and open dialogue as recommended
hypertension.359
in Section 6.3will facilitate decision-making.
• Weight gain (e.g. through mirtazapine use) may worsen CV risk.
• QTc prolongation can increase the risk of polymorphic ventricular
6.5.1. Efficacy and safety of pharmacological
arrhythmias, which has been associated with some tricyclic antide-
treatment for mental health conditions in people pressants (TCAs), SSRIs, and other antidepressants and bupropion,
with cardiovascular disease although the evidence is inconsistent.360 A large population study
Studies evaluating the effectiveness of pharmacological treatment for did not find an increased risk of arrhythmias for citalopram.361A net-
mental health conditions in CV populations have shown inconsistent work meta-analysis demonstrated a low risk of ventricular
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 29 ---
4184 E S C G u id e l in e s
People with depression, anxiety or post-traumatic stress disorders
Screening
Moderate or severe according to
In remission or with mild symptoms
ICD-11 criteria
Already on psychotropic therapy? Psychiatric consultation
Offer psychological
Continuing medication New
support or
or re-assessment. psychotropic/antidepressant
counselling
Consider switching medication.
medication if associated Choice based on:
with:
• Severity of • Possible CV
• Weight • QTc
psychiatric side effects
gain prolongation
symptoms • Lifetime
• Diabetes • Dyslipidaemia
• Treatment CVD risk
benefit • Comorbidities
• Possible • Patient
medication preferences
interactions
Special considerations
• Introduce SSRIs, SNRIs, or newer antidepressants
(excluding esketamine) for up to 4 weeks.
• Gradual discontinuation of benzodiazepines is recommended
if used >1 month.
• Avoid antidepressants in HF, except in severe depression
where risks of untreated depression outweigh HF risks.
All:
Assess and manage CVD risk factors (including medication if needed)
Behavioural interventions to support healthy lifestyles
Figure 10 Pharmacological management of cardiovascular disease and depression, anxiety, or post-traumatic stress disorders. CV, cardiovascular;
CVD, cardiovascular disease; HF, heart failure; ICD, International Classification of Diseases; SNRI, serotonin and norepinephrine reuptake inhibitor;
SSRI, selective serotonin reuptake inhibitor.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 30 ---
ESC Guidelines 4185
arrhythmia and SCD among people using antidepressants like SNRIs, include assessment for suitability to switch to a safer alternative like
SSRIs, and especially TCAs.362 Some antidepressants (mirtazapine, SSRIs for anxiety, or CBT for insomnia. Further, these drugs are over-
venlafaxine, trazodone) were not found to prolong the QTc interval used and overprescribed worldwide in the general population and es-
in healthy volunteers.363–365 pecially among the elderly and people with mental health
• Reduction of heart rate variability has been associated with TCA conditions.377Benzodiazepine prescription, especially long-term or dai-
use.366,367 ly use, has been linked to an increased risk of all-cause mortality.378,379
• Temporary increase in blood pressure immediately after administra- These findings may be partly explained by residual confounding.380
tion has been described with esketamine, which is indicated for Some studies also suggested that benzodiazepines may elevate the
treatment-resistant depression, however, it is not associated with risk of CV events and mortality, particularly in older adults.381
long-term development of hypertension.368
6.5.5. Pharmacological treatment for mental health
Importantly, several pharmacokinetic and pharmacodynamic interac- conditions in specific cardiovascular diseases
tions between antidepressants and CV drugs may affect the efficacy 6.5.5.1. Ischaemic heart disease
and safety of treatment. Therefore, therapeutic drug monitoring, de-
Pharmacological treatment for IHD in people with mental health condi-
fined as the measurement and interpretation of drug concentrations
tions aims to reduce the symptoms of mental health conditions, improve
in blood to optimize pharmacotherapy, is proposed in special clinical
CV outcomes, and reduce modifiable CV risk factors. In general, it is pref-
scenarios. It is particularly useful in cases of non-response at thera- erable to avoid benzodiazepines routinely for managing AMI,382and to be
peutic doses, uncertain drug adherence, suboptimal tolerability, or
cautious about adding medications given the potential for interactions
pharmacokinetic drug–drug interactions. In people with mental health
and possible side effects. In people who smoke, bupropion or varenicline
disorders, therapeutic drug monitoring has additional applications
can be used as they are effective and safe in reducing smoking in the short
ranging from strongly recommended to potentially useful including term.383,384If a person with depression is being treated with mirtazapine,
use in children and adolescents, pregnant women, elderly people, in-
switching to other antidepressant drugs with less propensity to induce
dividuals with intellectual disabilities, people with substance abuse dis- weight gain may be considered, in consultation with psychiatrists.356
orders, forensic psychiatric conditions, or people with known or
suspected pharmacokinetic abnormalities.369
6.5.5.2. Ventricular arrhythmias
Many antidepressants and CV drugs are metabolized by cytochrome
In people with ventricular arrhythmias, it is necessary to evaluate the
P450 (CYP) enzymes leading to potential interactions, which are dose
link between arrhythmias and the use of reported antidepressants. In
dependent and can be exaggerated by smoking (Supplementary data
the context of clinical suspicion, it is preferable to switch to drugs
online, Table S10). Smoking is a potent inducer of CYP1A2 enzymes
with less propensity to cause ventricular arrhythmias. Several antide-
with maximal increase by 10 or more cigarettes per day and decrease
of CYP1A2 activity within 3 days after smoking cessation.370,371 pressants have shown a potential to change ventricular repolarization:
Potential risks for interactions between antidepressants and CV drugs (i) Citalopram/escitalopram possibly increase the risk of QTc pro-
include beta-blockers and calcium channel blockers. For example, SSRIs longation in dosages over 20 mg compared with placebo.
inhibit the enzyme activity phase of the CYP pathway by blocking the (ii) TCAs are associated with increased risk of QTc prolongation com-
active site of certain CYP isoenzymes, thereby reducing the metabolism pared with newer antidepressants.
of other drugs. This may lead, for example, to increased plasma levels of
metoprolol with a risk of bradycardia or hypotension. Furthermore, For more information on QTc prolongation associated with psycho-
amiodarone inhibits CYP2C9, CYP2D6, and CYP3A4, leading to po- tropic drugs see Section 7.6.1.
tential interactions with both SSRIs and TCAs, requiring careful moni-
toring for side effects.369
6.5.5.3. Heart failure
Notably, SSRIs and SNRIs can increase bleeding risk.372 However,
In people with HF, the efficacy of antidepressant and/or antipsychotic drugs
there is little evidence that SSRIs increase the risk of clinically relevant is not well established.385Therefore, careful assessment of risks and ben-
bleedings or mortality.373Further, SSRI interactions via the CYP isoen-
efits should be performed by a multidisciplinary Psycho-Cardio team be-
zyme system can potentially increase the effects of warfarin and thus,
fore initiation. Indeed, despite mental health conditions increasing the
the risk of major bleeding requiring close monitoring and management
risk for adverse outcomes and mortality in people with HF, the indiscrim-
of risk factors for bleeding in people treated with both SSRI and vitamin
inate use of antidepressants may increase the risk of CV side effects and
K antagonists like warfarin.374Although studies suggest that direct oral
drug interactions, especially among the elderly or frail. This is well summar-
anticoagulants have lower potential for pharmacokinetic interactions
ized in a position paper endorsed by the EAPC.386In addition, the use of
with SSRIs, caution is also required with concomitant use of SSRI and
antidepressants has been associated with an increased risk for all-cause and
direct oral anticoagulants, which showed a similarly increased risk
CV mortality, irrespective of the presence of clinical depression.354,387
of major bleeding as vitamin K antagonists.375,376Potential interactions
If antidepressants are needed:
between antidepressants and drugs for SMI are summarized in
Supplementary data online, Table S9. • SSRIs are considered the safer class of antidepressants to use in HF as
they are associated with fewer adverse CV side effects (less likely to
cause orthostatic hypotension or tachycardia, little effect on intraven-
6.5.4. Use of anxiolytics, sedatives, and hypnotics tricular conduction).388However, SSRIs can cause QTc prolongation,
Anxiolytics, sedatives, and hypnotics may be used to manage symptoms especially citalopram and escitalopram (but also sertraline and fluoxet-
like anxiety and insomnia, which are common in the CVD population. ine), can increase the bleeding risk in elderly people receiving antiplate-
However, potential benefits need to be balanced against risks, especially let or anticoagulant medications through their inhibition of platelet
with long-term or high-dose use. If used, clinical evaluation should aggregation/activation, and enhance gastric acid secretion.372,389,390
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 31 ---
4186 E S C G u id e l in e s
• Due to their minimal inhibition of CYP enzymes, sertraline, citalo- collaborative care of people with CVD and other conditions has been
pram, and escitalopram have a lower risk of drug interactions com- shown to improve CV risk factors, cardiometabolic disease control, gen-
pared with fluvoxamine, fluoxetine, and paroxetine. eral function, and symptoms of depression.399–402A systematic review
• Monoamine oxidase inhibitors and TCAs should be avoided for the and meta-analysis of collaborative care in primary or community health-
treatment of depression in HF as they may cause orthostatic hypo- care settings (79 trials) reported significantly greater improvements in
tension, worsening HF, and ventricular arrhythmias.391 depression and anxiety in the short and long term, along with increased
• Venlafaxine and duloxetine should be used with caution in people medication use, mental health components of QoL measure (SF-12,
with HF due to the small and contradictory evidence.392 SF-36), and satisfaction.403However, an RCT of a collaborative care pro-
gramme for people with HF and depression did not show significant im-
The use of antidepressants in people with HF should be restricted to provements in clinical outcomes compared with enhanced usual care.404
those with severe depression, where the risk of untreated depression An integrated adult congenital heart disease (ACHD) psychology service
outweighs the risk of taking antidepressants. The use of specific drugs has been shown to reduce psychological distress, however, few people
for the treatment of HF can also be associated with the development received full psychological assessment.405 A recent position paper ad-
of depression/anxiety: diuretics and nitrate esters are associated with dresses the main mental health concerns in congenital heart disease
a higher risk of depression in people with HF,393 while no increased and advocates the generation of models for the integration of mental
risk of depression has been reported for beta-blockers (especially for health professionals in paediatric and ACHD teams.406
the hydrophilic form since they do not significantly cross the blood/ Although often delivered in primary care, collaborative care models
brain barrier), statins, angiotensin-converting enzyme inhibitors, angio- have also been evaluated in rehabilitation facilities,407,408and acute care
tensin receptor blockers, aspirin, aldosterone antagonists, and sodium– hospitals.409Collaborative care has been tested in mental health clinics
glucose co-transporter-2 inhibitors.393,394 and was found to improve physical health compared with usual care
with no differences in overall QoL. Half of the effects on functioning
were mediated through the effects of collaborative care on depression
6.5.5.4. Procedures (coronary artery bypass grafting, percutaneous
severity in people with bipolar depression.410,411
coronary intervention)
Collaborative care is usually delivered by nurses supported by a
In general, the use of benzodiazepines is not indicated for PCI or cor-
multidisciplinary team. Further study of novel applications of collabora-
onary artery bypass grafting, but this consideration is based upon low-
tive care and related interventions is warranted due to the potential of
quality evidence.395,396No specific recommendations are available for
these programmes to improve management of CVD and mental health
the use of psychotropic drugs.395 conditions and enable CV practices to deliver holistic care.398In par-
ticular, new models of integrated care with multidisciplinary teams
6.6. Organization of care (Psycho-Cardio team) and experts in improving mental health are
Healthcare is frequently fragmented by specialties, hindering efforts to needed in clinical CV care. The composition and function of these
provide holistic care that addresses physical and mental health condi- teams should be dynamic and flexible, adapted to the needs of people
tions. New care models have sought to integrate physical healthcare with CVD, their caregivers, clinical scenarios, and available resources.
into mental healthcare settings, and mental healthcare into settings fo-
cused on physical conditions.397 Novel integrated programmes using
remote delivery of mental health interventions and promoting psycho- 6.7. Section summary points and
logical well-being have garnered growing interest in the literature.398
management consensus statements from
Several RCTs have explored the effectiveness of collaborative care
models in managing various health conditions. Co-ordinated or Section 6
SECTION SUMMARY POINTS
(i) Ideally, assessment of mental health status should be performed routinely within CVD clinical practice and implemented when the context of local capacity
and capability allows.
(ii) Depression and anxiety can easily be overlooked in the routine care of people with CVD and/or considered ‘normal’ reactions to individual clinical/
prognostic burden of disease.
(iii) Clinical history can be used to identify mental health symptoms. If there is clinical suspicion, formal screening with validated tools is advised.
(iv) Psycho-Cardio teams are needed to structure pathways for:
• Screening.
• Referral.
• Treatment of people with CVD and suspected or established mental health conditions.
(v) Medical interventions including pharmacotherapy may be needed for people with CVD who are diagnosed with mental health conditions, especially for
severe symptoms of depression, anxiety, or PTSD.
(vi) In some people with CVD, combination therapy of psychological interventions plus medication may be useful.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 32 ---
ESC Guidelines 4187
MANAGEMENT CONSENSUS STATEMENTS
(i) Screening of mental health with validated screening tools is advised after a new diagnosis or CV event, at least once during follow-up and anytime based on
clinical judgement of need.
(ii) Initial simple screening with a two-item measure (i.e. Whooley questions, PHQ-2, GAD-2) can be incorporated into routine practice.
(iii) A low threshold for mental health screening in people with CVD is advised, considering the high prevalence of mental health conditions in people with CVD
and its impact on outcomes.
(iv) Following an abnormal result in the initial screening, a longer validated screening instrument should be used to determine if condition severity is low,
moderate, or high.
(v) Psycho-Cardio teams must define who is responsible for the assessment of mental health conditions and how and when it will be done, tailoring it to the
specific context and resources.
(vi) Each Psycho-Cardio team may choose a particular screening tool after careful assessment of its validity, reliability, and applicability to their population, but
standardized screening tools are preferred for mental health assessment.
(vii) People scoring high on a screening questionnaire need referral for diagnostic assessment and appropriate treatment by a mental health professional.
(viii) Applying a stepped care approach to manage mental health conditions in people with CVD is reasonable based on preferences, severity of symptoms and
condition, and resources available.
(ix) Developing and evaluating tailored intervention programmes aimed at alleviating distress of people coping with CVD and caregivers may be useful.
(x) Lifestyle measures and psycho-education are useful for all people with CVD while psychological therapies may be helpful for people experiencing
depression and/or anxiety.
(xi) Cardiac rehabilitation is an opportunity to screen people for depression and anxiety and can contribute to improve mental health after CV events or be an
opportunity to identify and manage mental health conditions.
(xii) Avoiding benzodiazepines as first-line therapy in the management of anxiety and depression is advised.
(xiii) Anxiolytics, sedatives, and hypnotics are overused and overprescribed in the general population, especially among the elderly and people with mental
health conditions, so careful selection of indications is advisable.
(xiv) Antidepressant use is advised for those with moderate to severe anxiety disorders and depression under the guidance of qualified mental health
professionals.
(xv) The use of antidepressants in HF is only advisable in severe depression symptoms where the risk of untreated depression outweighs the risk of taking
antidepressants.
(xvi) In people with ventricular arrhythmias, antidepressants associated with an increased propensity to prolong QTc (such as TCAs and possibly citalopram/
escitalopram in dosages over 20 mg), may be switched to newer antidepressants with better safety profiles.
(xvii) Given the frequent interactions between antidepressants and CV drugs affecting their efficacy and safety, therapeutic drug monitoring is advisable to
optimize pharmacotherapy and minimize potential side effects and clinically relevant drug interactions.
7. Severe mental illness and incidence compared with controls in longitudinal studies.12 People
with schizophrenia have significantly higher rates of SCD, exceeding
cardiovascular disease
population rates by 11-fold.416 There is some evidence to suggest
young adults with SMI may be at particular risk of increased CV 7.1. Cardiovascular risk in people with
events.417,418
severe mental illness
Severe mental illnesses are diseases defined by a significantly impaired
7.2. Prognosis in severe mental illness and
level of psychosocial functioning and usually comprise disorders such
cardiovascular disease as schizophrenia, bipolar disorder, and severe recurrent major
depressive disorder6(Figure 11). Definitions and characteristics of SMI ac- The co-occurrence of SMI and CVD increases all-cause mortality risk
cording to ICD (International Classification of Diseases)-11 criteria,7can and worsens CV prognosis. Observational studies suggest that, among
be found in Supplementary data online, Table S11. people with SMI, the risk for CHD and CV mortality is up to 2.5 times
Individuals with schizophrenia and bipolar disorder have been higher in people with schizophrenia and bipolar disorder compared
found to live approximately 14.5 and 8–12 years less than their coun- with controls, with larger effects in younger people.419 According to
terparts without SMI, respectively.412,413All-cause mortality in people Danish national registry data, while trends in MI mortality rates declined
with SMI is more than 2.5 times higher compared with the general over 1 and 5 years of follow-up, people with schizophrenia did not ex-
population,414and the standardized mortality gap may be increasing perience the same decline in mortality rate following MI in long-term
over time.415 Cardiovascular disease plays a major role in cause- follow-up.420People with SMI present clinically with HF 7 years earlier
specific mortality among people with SMI,26and SMI increases the in- than the general population, and men with SMI and HF have excess
cidence and prevalence of CVD. People with schizophrenia are at mortality compared with men with HF without SMI. ICD implantation,
two- to three-fold higher risk of having CVD, particularly younger in- cardiac resynchronization therapy, VAD implantation, and HTx
dividuals.12In a large-scale meta-analysis (3 211 768 people with SMI; are used at a similar rate in people with HF with reduced ejection frac-
113 383 368 controls), the pooled prevalence of CVD was 9.9% and tion and SMI as those without SMI, but people with SMI experienced
the cumulative incidence of CVD was 3.6% in people with SMI (me- poorer prognosis following cardiac resynchronization therapy, VAD,
dian follow-up 8.4 years), a significantly higher adjusted risk of CVD and HTx.421
5202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 33 ---
4188 E S C G u id e l in e s
(cid:13)(cid:21)(cid:19)(cid:12)(cid:25)(cid:25)(cid:21)(cid:16)(cid:14)(cid:24)(cid:11)(cid:26)(cid:10)(cid:28)(cid:25)
(cid:23)(cid:21)(cid:29)(cid:25)(cid:21)(cid:22)(cid:22)(cid:30)(cid:28)(cid:16)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:30)(cid:27)(cid:27)(cid:26)(cid:25)(cid:30)(cid:24)(cid:23)(cid:22)(cid:22)(cid:21)
(cid:20)(cid:22)(cid:19)(cid:18)(cid:26)(cid:17)(cid:26)(cid:25)(cid:30)(cid:24)(cid:27)(cid:16)(cid:23)(cid:29)(cid:17)(cid:22)(cid:23)(cid:27)(cid:15)(cid:24)(cid:14)(cid:17)(cid:17)(cid:30)(cid:18)(cid:17)(cid:26)(cid:22)(cid:18)(cid:24)(cid:14)(cid:18)(cid:21)
(cid:23)(cid:30)(cid:23)(cid:22)(cid:28)(cid:16)(cid:24)(cid:21)(cid:30)(cid:13)(cid:12)(cid:26)(cid:17)(cid:27)
(cid:31)(cid:30)(cid:11)(cid:10)(cid:27)(cid:26)(cid:22)(cid:18)(cid:27)(cid:15)(cid:24)(cid:9)(cid:14)(cid:11)(cid:11)(cid:10)(cid:12)(cid:26)(cid:18)(cid:14)(cid:17)(cid:26)(cid:22)(cid:18)(cid:27)
(cid:7)(cid:27)(cid:16)(cid:12)(cid:9)(cid:22)(cid:23)(cid:22)(cid:17)(cid:22)(cid:28)(cid:24)(cid:28)(cid:30)(cid:27)(cid:17)(cid:11)(cid:30)(cid:27)(cid:27)(cid:18)(cid:30)(cid:27)(cid:27)(cid:24)(cid:22)(cid:28)(cid:24)(cid:26)(cid:23)(cid:29)(cid:14)(cid:26)(cid:28)(cid:23)(cid:30)(cid:18)(cid:17)
(cid:8)(cid:10)(cid:26)(cid:12)(cid:26)(cid:21)(cid:14)(cid:11)(cid:26)(cid:17)(cid:16)
(cid:21)(cid:26)(cid:22)(cid:21)(cid:23)(cid:24)(cid:27)(cid:21)(cid:8)(cid:21)(cid:27)(cid:24)(cid:28)(cid:7)(cid:24)(cid:7)(cid:12)
(cid:16)
(cid:19)(cid:14)(cid:30)
(cid:25) (cid:28)
(cid:21)(cid:19) (cid:16)(cid:30)
(cid:9) (cid:16) (cid:6)
(cid:20)(cid:19)(cid:18)(cid:30)(cid:17)(cid:28)(cid:29)(cid:18)(cid:25)(cid:21)(cid:16)(cid:30)(cid:26)(cid:24)(cid:26)(cid:16)(cid:23)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:30)(cid:22)(cid:28)(cid:25)(cid:23)(cid:21)(cid:25)(cid:22)
(cid:29)(cid:22)(cid:15)(cid:19)(cid:18)(cid:28)(cid:14)(cid:30)(cid:19)(cid:24)(cid:23)(cid:30)(cid:22)(cid:28)(cid:25)(cid:23)(cid:21)(cid:25)(cid:22)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:30)(cid:27)(cid:27)(cid:26)(cid:25)(cid:30)(cid:24)(cid:23)(cid:22)(cid:22)(cid:21)(cid:15)(cid:24)(cid:11)(cid:22)(cid:27)(cid:27)(cid:24)(cid:22)(cid:5)(cid:24)(cid:29)(cid:11)(cid:30)(cid:14)(cid:27)(cid:10)(cid:28)(cid:30) (cid:6)(cid:11)(cid:30)(cid:25)(cid:14)(cid:17)(cid:30)(cid:21)(cid:24)(cid:22)(cid:28)(cid:24)(cid:21)(cid:30)(cid:29)(cid:28)(cid:30)(cid:27)(cid:27)(cid:26)(cid:25)(cid:30)(cid:24)(cid:23)(cid:22)(cid:22)(cid:21)
(cid:20)(cid:22)(cid:19)(cid:18)(cid:26)(cid:17)(cid:26)(cid:25)(cid:30)(cid:24)(cid:27)(cid:16)(cid:23)(cid:29)(cid:17)(cid:22)(cid:23)(cid:27)(cid:24)(cid:5)(cid:28)(cid:22)(cid:23)(cid:24)(cid:23)(cid:10)(cid:11)(cid:17)(cid:26)(cid:29)(cid:11)(cid:30) (cid:20)(cid:22)(cid:19)(cid:18)(cid:26)(cid:17)(cid:26)(cid:25)(cid:30)(cid:24)(cid:27)(cid:16)(cid:23)(cid:29)(cid:17)(cid:22)(cid:23)(cid:27)(cid:15)(cid:24)(cid:14)(cid:17)(cid:17)(cid:30)(cid:18)(cid:17)(cid:26)(cid:22)(cid:18)
(cid:21)(cid:22)(cid:23)(cid:14)(cid:26)(cid:18)(cid:27) (cid:14)(cid:18)(cid:21)(cid:24)(cid:23)(cid:30)(cid:23)(cid:22)(cid:28)(cid:16)(cid:24)(cid:21)(cid:30)(cid:13)(cid:12)(cid:26)(cid:17)(cid:27)
(cid:31)(cid:30)(cid:11)(cid:10)(cid:27)(cid:26)(cid:22)(cid:18)(cid:27)(cid:15)(cid:24)(cid:9)(cid:14)(cid:11)(cid:11)(cid:10)(cid:12)(cid:26)(cid:18)(cid:14)(cid:17)(cid:26)(cid:22)(cid:18)(cid:27) (cid:31)(cid:30)(cid:11)(cid:10)(cid:27)(cid:26)(cid:22)(cid:18)(cid:27)(cid:15)(cid:24)(cid:9)(cid:14)(cid:11)(cid:11)(cid:10)(cid:12)(cid:26)(cid:18)(cid:14)(cid:17)(cid:26)(cid:22)(cid:18)(cid:27)
(cid:7)(cid:27)(cid:16)(cid:12)(cid:9)(cid:22)(cid:23)(cid:22)(cid:17)(cid:22)(cid:28)(cid:24)(cid:28)(cid:30)(cid:27)(cid:17)(cid:11)(cid:30)(cid:27)(cid:27)(cid:18)(cid:30)(cid:27)(cid:27) (cid:7)(cid:27)(cid:16)(cid:12)(cid:9)(cid:22)(cid:23)(cid:22)(cid:17)(cid:22)(cid:28)(cid:24)(cid:28)(cid:30)(cid:27)(cid:17)(cid:11)(cid:30)(cid:27)(cid:27)(cid:18)(cid:30)(cid:27)(cid:27)(cid:24)(cid:22)(cid:28)
(cid:26)(cid:23)(cid:29)(cid:14)(cid:26)(cid:28)(cid:23)(cid:30)(cid:18)(cid:17)
(cid:4)(cid:30)(cid:19)(cid:14)(cid:17)(cid:26)(cid:25)(cid:30)(cid:24)(cid:27)(cid:16)(cid:23)(cid:29)(cid:17)(cid:22)(cid:23)(cid:27)
(cid:8)(cid:10)(cid:26)(cid:12)(cid:26)(cid:21)(cid:14)(cid:11)(cid:26)(cid:17)(cid:16)
(cid:8)(cid:10)(cid:26)(cid:12)(cid:26)(cid:21)(cid:14)(cid:11)(cid:26)(cid:17)(cid:16)
Figure 11 Severe mental illnesses.
7.3. Increased cardiovascular disease risk general population,426 and metabolic syndrome and diabetes were
in people with severe mental illness also found to be more prevalent in people with schizophrenia and bi-
polar disorder.426–429Hypertension was found to be more prevalent
The aetiology of CVD in people with SMI is multifactorial, involving gen- in people with bipolar disorders, but not schizophrenia.430 Finally,
etic/biological, disease-specific and treatment-specific effects, lifestyle
people with schizophrenia had five times higher odds of smoking
factors, and treatment disparities, which are mutually inter- than the general population,431up to 65% of people with schizophre-
twined.422,423A summary of these factors is given in Figure 12, and de- nia are smokers,432,433and they have higher rates of alcohol addic-
scribed in the text below. tion.434 People with SMI have not shown the same reduction of
modifiable risk factors and resulting decrease in CVD mortality rates
7.3.1. Lifestyle and biological risk factors as the general population.419
Risk factors including hypertension, diabetes mellitus, dyslipidaemia,
obesity, and smoking, contribute to a significantly higher CV risk in
people with SMI.424,425Genetic/biological, disease-specific factors in- 7.3.2. Medication-induced cardiovascular risk factors
clude common genetic vulnerability for schizophrenia and diabetes, Disease-specific and medication-induced factors include side effects to
the effects of psychopathology such as negative and depressive symp- medications, obesity, diabetes, hypertriglyceridaemia, and hypercholes-
toms leading to sedentary lifestyle.424 Schizophrenia is associated terolaemia.427,435–438The effect of medication is not straightforward, as
with more than a three-fold risk of obesity compared with the metabolic-induced side effects may not be independent predictors for
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 34 ---
ESC Guidelines 4189
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:26)(cid:23)(cid:22)(cid:26)(cid:27)(cid:28)(cid:21)(cid:20)(cid:19)(cid:28)(cid:24)(cid:18)(cid:22)(cid:17)
(cid:10)‚ƒ(cid:23)„(cid:28)(cid:26)(cid:26)(cid:23)(cid:14)(cid:27)(cid:30)(cid:27)(cid:8)(cid:28)(cid:16)(cid:23)„(cid:22)(cid:25)(cid:29)(cid:23)(cid:15)(cid:20)(cid:24)(cid:11)(cid:29)(cid:18)(cid:25)(cid:12)(cid:18)(cid:15)(cid:22)(cid:11)(cid:23)(cid:16)(cid:12)(cid:9)(cid:8)(cid:20)(cid:23)
(cid:25)(cid:29)(cid:27)(cid:25)(cid:23)(cid:22)(cid:14)(cid:15)(cid:12)(cid:18)(cid:1)(cid:28)(cid:23)(cid:14)(cid:28)(cid:30)(cid:25)(cid:27)(cid:26)(cid:23)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:29)(cid:23)(cid:27)(cid:30)(cid:16)(cid:23)(cid:27)(cid:16)(cid:29)(cid:28)(cid:12)(cid:28)(cid:30)(cid:11)(cid:28)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:18)(cid:16)(cid:25)(cid:24)(cid:26)(cid:23)(cid:22)(cid:26)(cid:27)(cid:28)(cid:21)(cid:20)(cid:19)(cid:28)(cid:24)(cid:18)(cid:22)(cid:17) (cid:25)(cid:18)(cid:23)(cid:27)(cid:26)(cid:26)(cid:23)(cid:25)(cid:29)(cid:28)(cid:12)(cid:27)(cid:15)(cid:22)(cid:28)(cid:20)(cid:27)
(cid:143)(cid:15)(cid:25)(cid:22)(cid:14)(cid:22)(cid:144)(cid:27)(cid:25)(cid:22)(cid:18)(cid:30)(cid:23)(cid:18)(cid:21)(cid:23)(cid:15)(cid:29)(cid:27)(cid:12)(cid:14)(cid:27)(cid:11)(cid:18)(cid:26)(cid:18)(cid:8)(cid:22)(cid:11)(cid:27)(cid:26)(cid:23)(cid:25)(cid:12)(cid:28)(cid:27)(cid:25)(cid:14)(cid:28)(cid:30)(cid:25)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:29)(cid:24)(cid:23)(cid:26)(cid:22)(cid:21)(cid:28)(cid:20)(cid:25)(cid:24)(cid:26)(cid:28)(cid:20)(cid:19)(cid:23)(cid:18)(cid:17)(cid:28)(cid:20)(cid:22)(cid:25)(cid:24)(cid:19)(cid:23)(cid:16)(cid:24)(cid:20)(cid:26)(cid:22)(cid:15)(cid:22)(cid:16)(cid:27)(cid:28)(cid:14)(cid:22)(cid:27)(cid:19) (cid:27)(cid:30)(cid:16)(cid:23)(cid:14)(cid:27)(cid:30)(cid:27)(cid:8)(cid:28)(cid:14)(cid:28)(cid:30)(cid:25)(cid:23)(cid:18)(cid:21)(cid:23)(cid:14)(cid:28)(cid:25)(cid:27)(cid:17)(cid:18)(cid:26)(cid:22)(cid:11)(cid:23)(cid:20)(cid:22)(cid:16)(cid:28)(cid:23)(cid:28)(cid:157)(cid:28)(cid:11)(cid:25)(cid:20)
(cid:16)(cid:22)(cid:27)(cid:17)(cid:28)(cid:25)(cid:28)(cid:20)
(cid:28)(cid:8)(cid:9)(cid:26)(cid:27)(cid:12)(cid:23)(cid:27)(cid:20)(cid:20)(cid:28)(cid:20)(cid:20)(cid:14)(cid:28)(cid:30)(cid:25)(cid:23)(cid:27)(cid:30)(cid:16)(cid:23)(cid:14)(cid:27)(cid:30)(cid:27)(cid:8)(cid:28)(cid:14)(cid:28)(cid:30)(cid:25)
(cid:10)(cid:18)(cid:14)(cid:28)(cid:23)(cid:15)(cid:20)(cid:24)(cid:11)(cid:29)(cid:18)(cid:25)(cid:12)(cid:18)(cid:15)(cid:22)(cid:11)(cid:23)(cid:16)(cid:12)(cid:9)(cid:8)(cid:20)(cid:23)(cid:14)(cid:27)(cid:24)(cid:23)(cid:22)(cid:30)(cid:11)(cid:12)(cid:28)(cid:27)(cid:20)(cid:28)(cid:23)(cid:7)(cid:6) (cid:18)(cid:21)(cid:23)(cid:7)(cid:6)(cid:23)(cid:12)(cid:22)(cid:20)(cid:5)(cid:23)(cid:21)(cid:27)(cid:11)(cid:25)(cid:18)(cid:12)(cid:20)
(cid:12)(cid:22)(cid:20)(cid:5)(cid:23)(cid:21)(cid:27)(cid:11)(cid:25)(cid:18)(cid:12)(cid:20)(cid:23)(cid:4)(cid:16)(cid:22)(cid:27)(cid:17)(cid:28)(cid:25)(cid:28)(cid:20)(cid:19)(cid:23)(cid:18)(cid:17)(cid:28)(cid:20)(cid:22)(cid:25)(cid:24)(cid:19)(cid:23)(cid:16)(cid:24)(cid:20)(cid:26)(cid:22)(cid:15)(cid:22)(cid:16)(cid:27)(cid:28)(cid:14)(cid:22)(cid:27)(cid:3)
(cid:7)(cid:18)(cid:26)(cid:26)(cid:27)(cid:17)(cid:18)(cid:12)(cid:27)(cid:25)(cid:22)(cid:1)(cid:28)(cid:23)(cid:11)(cid:27)(cid:12)(cid:28)(cid:23)(cid:21)(cid:12)(cid:18)(cid:14)(cid:23)(cid:7)(cid:6)(cid:19)(cid:23)(cid:14)(cid:28)(cid:30)(cid:25)(cid:27)(cid:26)(cid:23)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:29)
(cid:2)(cid:28)(cid:20)(cid:20)(cid:23)(cid:26)(cid:22)(cid:5)(cid:28)(cid:26)(cid:24)(cid:23)(cid:25)(cid:18)(cid:23)(cid:12)(cid:28)(cid:11)(cid:28)(cid:22)(cid:1)(cid:28)(cid:23)(cid:7)(cid:6)(cid:23)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:29)(cid:23)(cid:11)(cid:27)(cid:12)(cid:28)(cid:23)(cid:27)(cid:30)(cid:16) (cid:27)(cid:30)(cid:16)(cid:23)(cid:15)(cid:12)(cid:22)(cid:14)(cid:27)(cid:12)(cid:24)(cid:23)(cid:11)(cid:27)(cid:12)(cid:28)(cid:23)(cid:15)(cid:12)(cid:18)(cid:21)(cid:28)(cid:20)(cid:20)(cid:22)(cid:18)(cid:30)(cid:27)(cid:26)(cid:20)
(cid:12)(cid:22)(cid:20)(cid:5)(cid:23)(cid:27)(cid:20)(cid:20)(cid:28)(cid:20)(cid:20)(cid:14)(cid:28)(cid:30)(cid:25)
(cid:16)(cid:28)€(cid:9)(cid:27)(cid:25)(cid:28)(cid:23)(cid:28)(cid:16)(cid:9)(cid:11)(cid:27)(cid:25)(cid:22)(cid:18)(cid:30)(cid:23)(cid:27)(cid:30)(cid:16)(cid:23)(cid:20)(cid:9)(cid:15)(cid:15)(cid:18)(cid:12)(cid:25)(cid:23)(cid:17)(cid:24)
(cid:2)(cid:27)(cid:11)(cid:5)(cid:23)(cid:18)(cid:21)(cid:23)(cid:14)(cid:9)(cid:26)(cid:25)(cid:22)(cid:16)(cid:22)(cid:20)(cid:11)(cid:22)(cid:15)(cid:26)(cid:22)(cid:30)(cid:27)(cid:12)(cid:24)(cid:23)(cid:11)(cid:18)(cid:26)(cid:26)(cid:27)(cid:17)(cid:18)(cid:12)(cid:27)(cid:25)(cid:22)(cid:18)(cid:30) (cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:29)(cid:11)(cid:27)(cid:12)(cid:28)(cid:23)(cid:15)(cid:12)(cid:18)(cid:21)(cid:28)(cid:20)(cid:20)(cid:22)(cid:18)(cid:30)(cid:27)(cid:26)(cid:20)
(cid:2)(cid:28)(cid:20)(cid:20)(cid:23)(cid:26)(cid:22)(cid:5)(cid:28)(cid:26)(cid:24)(cid:23)(cid:25)(cid:18)(cid:23)(cid:12)(cid:28)(cid:11)(cid:28)(cid:22)(cid:1)(cid:28)(cid:23)(cid:28)(cid:1)(cid:22)(cid:16)(cid:28)(cid:30)(cid:11)(cid:28)(cid:127)(cid:17)(cid:27)(cid:20)(cid:28)(cid:16)(cid:23)(cid:11)(cid:27)(cid:12)(cid:28)(cid:129)
(cid:12)(cid:28)(cid:11)(cid:18)(cid:14)(cid:14)(cid:28)(cid:30)(cid:16)(cid:28)(cid:16)(cid:23)(cid:22)(cid:30)(cid:25)(cid:28)(cid:12)(cid:1)(cid:28)(cid:30)(cid:25)(cid:22)(cid:18)(cid:30)(cid:20)(cid:23)(cid:21)(cid:18)(cid:12)(cid:23)(cid:7)(cid:6)(cid:141)(cid:19)
(cid:16)(cid:22)(cid:27)(cid:17)(cid:28)(cid:25)(cid:28)(cid:20)(cid:19)(cid:23)(cid:18)(cid:17)(cid:28)(cid:20)(cid:22)(cid:25)(cid:24)(cid:19)(cid:23)(cid:16)(cid:24)(cid:20)(cid:26)(cid:22)(cid:15)(cid:22)(cid:16)(cid:27)(cid:28)(cid:14)(cid:22)(cid:27)
(cid:13)(cid:18)(cid:18)(cid:12)(cid:26)(cid:24)(cid:23)(cid:11)(cid:18)(cid:30)(cid:25)(cid:12)(cid:18)(cid:26)(cid:26)(cid:28)(cid:16)(cid:23)(cid:14)(cid:28)(cid:30)(cid:25)(cid:27)(cid:26)(cid:23)(cid:22)(cid:26)(cid:26)(cid:30)(cid:28)(cid:20)(cid:20)
(cid:21)(cid:20)(cid:19)(cid:28)(cid:24)(cid:18)(cid:22)(cid:17)
Figure 12 Multifactorial aetiology of cardiovascular disease risk in people with severe mental illness. CV, cardiovascular; CVD, cardiovascular disease;
SMI, severe mental illness. aChoose psychotropic drugs less likely to cause obesity and metabolic risk.
CVD in persons with SMI.438,439A summary of data on CV risk asso- non-use (long-acting injectable olanzapine and oral flupentixol) and
ciated with antipsychotic use is highlighted below: the use of clozapine reduced all-cause mortality by 61% and CV death
risk by 45% compared with non-use of antipsychotics.442Findings were
possibly explained by improved adherence to antipsychotics of people
• Current reports do not show that antipsychotics are associated
with SMI, as this has been associated with decreased discontinuation
with increased risk of MI or stroke in people with schizophrenia
and bipolar disorder compared with placebo,440despite previous risk of antidiabetics, statins, antihypertensives, and beta-blockers in
meta-analyses.12,441 people with schizophrenia.443The use of medication appears not to
influence the cardiorespiratory fitness level of people with SMI receiv-
• The use of long-acting antipsychotic medication and second-
ing treatment.444
generation antipsychotics were found protective against all-cause
mortality compared with no antipsychotic use. The largest effects
were seen for second-generation long-acting injectable antipsycho- Antipsychotics vary in their propensity to induce modifiable CVD
tics, clozapine, any long-acting injectable antipsychotics, and any risk factors. Most second-generation antipsychotics with wide receptor
second-generation antipsychotics.26 In a Finnish nationwide data- activity profiles (serotonin 5-HT , histamine H1, muscarinic M3), such
2A
base study (median follow-up 14.1 years), CV mortality was significant- as olanzapine, clozapine, and quetiapine, are associated with increased
ly lower among patients with schizophrenia on any antipsychotic risk of weight gain and consequent metabolic syndrome, weight gain-
treatment compared with non-use. Several antipsychotics were asso- related diabetes, and hypertriglyceridaemia.437 According to a
ciated with a significantly reduced CV death risk compared with meta-analysis of RCTs, olanzapine, clozapine, zotepine, sertindole,
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 35 ---
4190 E S C G u id e l in e s
Table 6 Summary of the negative effect of different antipsychotics on cardiovascular risk factors
Drug Weight gain Hyperglycaemia LDL cholesterol HDL cholesterol Total cholesterol Triglycerides
Haloperidol 0 ++ ND ND ++ ++
Ziprasidone 0 + 0 0 + +
Aripiprazole + ++ + + ++ +
Lurasidone + 0 + + + +
Cariprazine + ++ 0 + 0 +
Fluphenazine + ND ND ND ND ND
Amisulpride + 0 ND +++ ++ ++
Brexpiprazole + + ++ 0 ++ 0
Flupentixol + ND ND ND ND ND
Asenapine ++ 0 ND ND ND ND
Risperidone ++ + ++ ++ ++ +
Paliperidone ++ + ++ ++ ++ +
Quetiapine ++ + +++ ++ +++ ++
Iloperidone ++ ++ ND ND + ++
Sertindole +++ + ND ND ++ +
Zotepine +++ +++ ND ND ND +++
Clozapine +++ +++ ND ND +++ +++
Olanzapine +++ ++ +++ +++ +++ +++
HDL, high-density lipoprotein; LDL, low-density lipoprotein; +, strength of effect; ND, no data.
iloperidone, and quetiapine were found to be associated with worse Diabetes (EASD), and the ESC have made recommendations for
metabolic profiles (weight gain, glucose increase, hypertriglyceridaemia, screening.449 We highlight the following as particularly important for
hypercholesterolaemia, and decrease of high-density lipoprotein chol- people with SMI and CVD:
esterol) in short-term use.435Zotepine, olanzapine, sertindole, caripra-
zine, iloperidone, quetiapine, clozapine, and risperidone have been • Routine screening for CVD risk factors should be performed by psy-
associated with the greatest weight gain (up to 3 kg), but nearly half chiatrists and general practitioners at all stages of the disorder, re-
of antipsychotics caused significantly more weight gain than pla- gardless of age, with initial risk assessment carried out during the
cebo.445,446A summary of effects of antipsychotics on CVD modifiable first visit and before the prescription of antipsychotics. Baseline risk
risk factors is presented in Table 6. assessment includes:
⚬ Personal and family history of CVD or diabetes or related disease.
⚬ Lifestyle patterns: smoking and alcohol consumption, healthy diet,
7.3.3. Assessing cardiovascular disease risk physical activity.
Widely used tools for CV risk assessment in the general population usu- ⚬ Weight, height, waist circumference, calculation of body mass
ally underestimate the risk of CVD in the population with SMI.447 index.
Significant differences in risk prediction screening tools such as metabolic ⚬ Fasting blood glucose and lipids (total cholesterol, low-density
syndrome concept, Systematic Coronary Risk Evaluation (SCORE) mod- lipoprotein cholesterol, high-density lipoprotein cholesterol,
el and two PRedIction and Management of cardiovascular Risk in triglycerides).
peOple with SEvere mental illnesses (PRIMROSE) models, carry the ⚬ Blood pressure, heart rate.
risk of significant disparities in treatment initiation in people with • All individuals with SMI taking antipsychotics should be actively mon-
SMI.447 Moreover, these models generally underestimate CV risk in itored for modifiable risk factors at baseline, after 12 weeks, and at
adolescents with SMI.447,448 Finally, there is no consensus of which least annually thereafter.
healthcare professionals should screen and monitor for CVD in SMI. • People who have CV risk factors should be monitored at the start of
While screening is usually in the domain of primary care, persons a new treatment and re-assessed 6 and 12 weeks after initiation of a
with SMI have overall low use of health services, therefore, new antipsychotic drug, and periodically, depending on the presence
mental health professionals may need to take the lead for screening,21 of risk factors.449In people with diabetes, monitoring should include
diagnostics,22,23and treatment.21,24–26 glycated haemoglobin every 12 weeks.
Several practice Guidelines for the screening and monitoring of CV • After initiation of antipsychotics known to induce CV side effects [e.g.
risk in people with schizophrenia are proposed but have been scarcely prolongation of QTc interval or tachycardia (see Section 7.6.1)], elec-
implemented. Position statements by the European Psychiatric trocardiogram (ECG) is advised at baseline, after 1 week, and after 6
Association, supported by the European Association for the Study of and 12 weeks, and annually thereafter.
5202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 36 ---
ESC Guidelines 4191
7.4. Gaps and disparities in the to participate in the treatment processes due to the nature of SMI lead-
management of cardiovascular disease in ing to unintentional non-adherence. In severe active psychosis, the indi-
vidual may not be able to communicate CV symptoms or may not be
people with severe mental illness
able to tolerate invasive investigations and/or therapies because of psy-
The presence of SMI in itself does not explain the lifespan chiatric symptoms.
inequalities observed.450Multiple factors have been identified including Many people with SMI may become suitable for an invasive strategy and
systemic barriers to prevention,310 screening,21 diagnosis,22,23 and be clinically assessed for CV interventions. This may require an advocating
treatment.21,24–26Collectively, these lead to large healthcare disparities and assertive approach by the management team, and close collaboration
for people with SMI. Key studies confirm these inequalities persist in with liaising mental health professionals and general practitioners. The
CVD.451–454 To overcome these barriers healthcare professionals management of CAD in people with SMI should be discussed by the
need to be aware of, and address, system-level problems including stig- Psycho-Cardio team (Figure 3), with input from a psychiatrist. Many defi-
ma, stereotypes, prejudice, and diagnostic overshadowing (defined as ciencies in the management of CAD in people with SMI occur for obvious
the misattribution of physical symptoms to pre-existing psychological and at times insurmountable reasons. Consensus and collaboration
illnesses).455
among people with SMI, families, general practitioners/family physicians,
CV specialists, and mental health professionals is essential for good prac-
7.4.1. Autonomy, communication, and informed tice. General practitioners play a particularly relevant role in reviewing and
optimizing the physical and mental health of people with SMI and CVD, consent
being responsible for the integral process of care and co-ordinating
Communication between the CV team and people with SMI and CVD
care by the different specialists involved.
should follow similar principles as for people with CVD without SMI
In the care of SMI, flexible assertive community treatment models
outlined in Section 6.3. For people with SMI, this may require a move
usually ensure better availability of health services for persons with
away from the established ‘best interest’ approach (healthcare profes-
SMI and prominent psychiatric symptoms, but there is a lack of studies
sionals know what is best), to a ‘will and preference’ approach which
analysing the effects of these models in people with CVD.457,458
prioritizes goals and values.456This shift is particularly critical for people
Interactive telemedicine (therapy delivered via video conferencing)
with SMI and CVD, who may experience heightened stigma or bias that
was found comparable to in-person delivery in effectiveness, accept-
can lead to paternalistic treatment. Respecting their will and preference
ability, and cost in people with various mental health and substance
not only affirms their human right to self-determination and dignity, but
abuse issues.459
also allows them greater control over their care, promoting a sense of
ownership in managing their health. The Psycho-Cardio team should
7.5. Management of cardiovascular disease
develop a more proactive and person-centred approach in caring for
persons with SMI including: in people with severe mental illness
• Educating the people about their illness, warning signs, treatment, and 7.5.1. Management of modifiable risk factors
management plan. Management of modifiable risk factors in people with SMI follow the
• Including people with SMI and family/caregivers in the management same principles as in people without SMI, such as education, behaviour-
plan using SDM. al counselling, lifestyle interventions, and peer and family support inter-
• Engaging people with SMI to participate in their care actively by in- ventions. Increased efficacy of interventions directed to improve CV
cluding them in all forms of treatment (lifestyle modification pro- risk in people with SMI is associated with:
grammes, smoking cessation).
• High intensity and high co-ordination.
• Encouraging people with SMI to check up regularly for CVD risks and
• Inclusion of both behavioural and pharmacological management, fol-
CV symptoms.
lowing a multimorbidity approach.
• Monitoring adherence to medication.
• Reassuring and signposting to practical information or resources. Few studies, however, have evaluated interventions addressing one
• Asking if there is someone the person with SMI would like you to
or more CVD risk factors in people with SMI.
contact.
People with SMI are presumed to have capacity to consent to treat- 7.5.2. Diet, physical activity, and body weight control
ment unless there is reason to believe this is not the case. In those rare The diet of people with schizophrenia is often unhealthy, characterized
situations, a decision-making capacity assessment may be required, and as being poor in fibre and fruit, and rich in saturated fats with a high cal-
this should be undertaken by the professionals involved in delivering the oric intake.460People with SMI are generally less physically active than
physical health intervention being proposed. Depending on jurisdiction, the general population, performing significantly lower volumes of mod-
people with SMI may have appointed a decision-maker themselves or erate to vigorous activity per day according to a meta-analysis of 69
may have an advanced healthcare directive, so it is important to be studies.424 Currently available studies in people with SMI indicate a
aware of these issues and determine a person’s capacity to consent beneficial effect of exercise and diet on CV risk, with interventions in-
to treatment before proceeding. creasing weekly activity compared with no intervention.461Significant
If the person with SMI already has a legal guardian, they have the legal improvements in fitness, psychiatric symptoms, and overall functioning
authority to sign medical informed consent, but different acts may be were found in participants who attended 50% of physical activity ses-
applied in different countries. People with SMI may have reduced ability sions.462 The European Psychiatric Association (EPA) suggests that
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 37 ---
4192 E S C G u id e l in e s
physical activity should be regularly offered to people with SMI as a low and frequently anxiolytics or sedatives. The same is true for severe re-
risk and accessible way of improving health.463 current depression, where antipsychotics are added to antidepressants.
In general, weight loss should be advised to people with SMI who CYP450 pharmacokinetic profiles of psychotropic medications can be
have a body mass index ≥25 kg/m2 or a waist circumference ≥88 cm found in Supplementary data online, Table S10.
in women or ≥102 cm in men.449The effectiveness of behavioural or While pharmacologic treatment in SMI is associated with decreased
integrative interventions to improve CV risk in people with SMI has risk of CVD compared with no treatment, a rational pharmacotherapy
had mixed results.422Two of four studies reported a decrease in CV is needed as some medications are associated with CV risks. As dis-
risk in the integrated care intervention group compared with control cussed in Section 7.6these include the development of CV side effects
groups, however, two studies reported no difference.464–467 via receptor blockade of muscarinic receptors and adrenergic recep-
Glucose and lipid-related laboratory results were mainly reported as tors and worsening modifiable CV risk factors.475
secondary outcome assessments in studies of weight management in- Rational pharmacotherapy for persons with SMI takes a multifactor-
terventions. Metformin is the currently accepted first-line treatment ial approach as outlined in the principles below:
of antipsychotic-associated weight gain, although not all people bene-
• Use of monotherapy whenever possible.
fit.468In 2020, the ESC in collaboration with the EASD updated their
• Use of medication with lower propensity to induce or worsen CV risk.
treatment algorithms to recommend the use of glucagon-like peptide-1
• Addition of medication to prevent CV risk factors (e.g. metformin or
receptor agonists and sodium–glucose co-transporter-2 inhibitors as
glucagon-like peptide-1 receptor agonists to prevent weight gain).
alternate therapy options to metformin based on CV and renal co-
• Consideration of possible drug interactions and monitoring for CV
morbidities independent of glycaemic control. However, there are still
side effects upon initiation of a new drug.
no data to support their use for antipsychotic-associated weight gain
• Ensuring adequate adherence to psychiatric medication.
and diabetes.469 In a meta-analysis of 33 RCTs (3473 people with
SMI), weight control was improved with behavioural interventions
People with SMI respond to the same strategies to increase adher-
compared with control, metformin, anticonvulsive medications topira-
ence as those without SMI, including simplifying medication regimens
mate and zonisamide, and adjunctive or antipsychotic switching to ari-
and use of behavioural interventions. Text message reminders, phone
piprazole (meta-analysis not possible). Evidence was insufficient for all
calls, electronic pill counters, and training family members can improve
other interventions and for effects on glucose and lipid control.470
medication adherence in SMI populations.422
7.5.3. Smoking cessation
7.6. Management of cardiovascular
Smoking cessation strategies for persons with SMI are similar to the gen-
conditions in people with severe mental
eral population as summarized previously (Section 6.3.10), including ap-
illness
propriate pharmacological therapy in combination with behavioural
therapy. Brief behavioural interventions (motivational enhancement, per- Managing CVD in people with SMI requires good communication and
sonalized feedback) have increased rates of pursuing nicotine collaboration between mental health and CV specialists. Several factors
dependence treatment compared with psycho-education in people that may help improve CVD management and secondary prevention in
with schizophrenia.471 Studies have confirmed the safety and efficacy those with CV conditions are listed below and summarized in Figure 13.
of first-line smoking cessation pharmacotherapies, including varenicline,
• Raise awareness of specialists and primary care professionals regard-
bupropion, nicotine replacement therapy, and nicotine patch monother-
ing the importance of controlling CV risk factors.
apy in individuals with and without schizophrenia or schizoaffective dis-
• Promote adherence to psychotropic drugs; long-acting injectables
orders.384,472–474 Although studies do not indicate a serious safety
may help.
signal with varenicline or bupropion, there is a general risk of deterio-
• Decrease the number of psychotropic drugs if possible.
rated mental health in association with smoking cessation due to nicotine
• Switch to drugs with less propensity to induce metabolic syndrome, abstinence. People with previous mental health issues should be well in-
in consultation with psychiatrists and evaluation of relapse risk.476 formed and followed up carefully during smoking cessation interventions.
• Reinforce lifestyle modifications and prescribe CV prevention medi-
Maintenance of pharmacotherapeutic and behavioural treatment has
cations as needed.
been reported to significantly reduce relapse rates among smokers with
• Addition of varenicline/bupropion or other forms of nicotine re-
schizophrenia.471Smoking cessation has a double benefit effect as it also
placement therapy combined with smoking cessation programmes
potentially enables the need for a lower dose of antipsychotic treatment.
in case of smoking.
Specifically, smoking can influence the efficacy of multiple medications used
in the treatment of SMI through CYP1A2 induction, reducing plasma levels
of some drugs (Supplementary data online, Table S10). Therefore, smoking 7.6.1. Rhythm disturbances
cessation may lead to increased plasma levels of these drugs (e.g. clozapine) People with SMI are at increased risk of developing supraventricular and
and thus doses of medications may need to be reduced when someone ventricular arrhythmias, which may eventually lead to SCD. This in-
stops smoking, in consultation with psychiatrist. creased arrhythmia risk is multifactorial, including distress resulting
from the SMI, high prevalence of risk factors and unhealthy lifestyles,
CV comorbidities commonly observed in SMI, and side effects of psy-
7.5.4. Pharmacological management
chotropic medications. Furthermore, autonomic dysfunction, chronic
Psychiatric medication in people with SMI is prescribed long term with a
inflammation, and oxidative stress are common in SMI and have been
variety of psychotropic medications, depending largely on the state of
associated with an increased arrhythmia risk.423
the disease and comorbidities. People with schizophrenia, other psych-
otic disorders, and bipolar disorders are treated with antipsychotics, • Pre-existing arrhythmias or their development after the initiation of
sometimes in combination with antidepressants, mood stabilizers, treatment can pose significant challenges to the medical management
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 38 ---
ESC Guidelines 4193
Assess individual’s mental health and cardiovascular risk
SMI in remission or with mild New or unremitted SMI
symptoms (moderate/severe)
Psychiatric consultation and
Is individual adherent to psychiatric
introduction or change to
and CVD treatment?
psychotropic medication
• Assess treatment • Assess CV side effects • Choose medication with less
of psychotropic propensity to cause metabolic
• Support adherence
medication syndrome if possible
with behavioural
interventionsa • Consider change in • Monotherapy if possibleb
medication if
• Consider • Long-acting injectables may
CV effects
long-acting improve adherence
injectables • Check for medication
interactions
• Initiate therapeutic
drug monitoring
if required
Use a person-centred multidisciplinary approach with shared decision-making
and collaboration among members of Psycho-Cardio team
• Monitor ECG post initiation of new antipsychotics at week 1 and 6
• Assess risk factors, drug side effects and interactions at week 6 and 12, then annually
• Monitor adherence to CVD and antipsychotic therapy
• Psycho-education, behavioural counselling to improve CV risk factors and adherence
• CVD medications as indicated, consider change in medication if CV side effectsc
Figure 13 Management of people with cardiovascular disease and severe mental illness. CV, cardiovascular; CVD, cardiovascular disease; ECG, elec-
trocardiogram; GLP-1 RA, glucagon-like peptide-1 receptor agonist; SGLT-2i, sodium–glucose co-transporter-2 inhibitor; SMI, severe mental illness.
aVarenicline or bupropion can be used to support smoking cessation behavioural interventions. bMonotherapy for SMI if possible; antipsychotics
with lower propensity to worsen CVD risk (psychiatrist to advise). → choice based on severity of symptoms, risk of relapse, medication interactions,
comorbidities, and person-centred/shared decision-making preferences. cGLP-1 RA and SGLT-2i for diabetes; Metformin first line for antipsychotic
associated weight gain.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 39 ---
4194 E S C G u id e l in e s
of SMI. The risk of SCD is significantly increased in people with SMI • The inherent risk of QT prolongation associated with specific drugs is
with estimates suggesting a two- to four-fold higher risk compared provided on the CredibleMeds website.486
with the general population.298 Several medications prescribed to • QT prolongation may also be the effect of other reversible causes
persons with SMI have potential pro-arrhythmic side effects and such as hypokalaemia, hypothyroidism, or bradycardia.
may cause or exacerbate atrial and ventricular tachycardia. Caution • Sinus tachycardia is common in SMI, heart rate correction of the QT
and careful monitoring are needed when prescribing potentially interval with the Fridericia formula is optimal, rather than Bazett’s
pro-arrhythmic drugs in people with known heart disease, with formula which overestimates QT at higher heart rates.487
the following considerations: quetiapine, olanzapine, risperidone, ilo- • The measurement of QT intervals can be complicated by abnormal
peridone, ziprasidone, amisulpride, and sertindole increase the risk of T-wave morphology requiring expert consultation for correct
QTc prolongation compared with placebo.477 interpretation.477,483
• Iloperidone, chlorpromazine, loxapine, risperidone, quetiapine, and pa-
7.6.1.2. Heart rate changes
liperidone increase the risk of tachycardia compared with placebo.478
Both tachycardia and bradycardia are side effects of antipsychotic medi-
• Low-potency first-generation antipsychotics and multi-acting cation.478Sinus tachycardia has been reported with most antipsychotic
receptor-targeted second-generation antipsychotic treatment (spe-
medications, including first- and second-generation therapies. It is most
cifically clozapine, chlorpromazine, olanzapine, quetiapine, and risper-
common with clozapine (17%–33%),488but has usually a transient and
idone) are associated with an increased risk of AF especially in those
benign course. However, possible medical causes of sinus tachycardia
with hypertension, diabetes, or CAD although evidence is limited.479
should be excluded. In those with symptoms, rate control with cardio-
• Lithium may induce electrocardiographic changes and arrhythmias
selective beta-blockers, calcium channel blockers, or ivabradine may be
such as T-wave inversions, sinus bradycardia, sinoatrial block, PR pro-
used. Persistent heart rates above 130 beats per minute (b.p.m) may in
longation, incomplete bundle branch block, QTc prolongation, in-
rare cases cause a tachycardiomyopathy, which is usually reversible by
creased QT dispersion, the Brugada electrocardiographic pattern,
improved rate control.
and ventricular tachyarrhythmias.480
Bradycardia is a rare side effect of antipsychotics, with incidence not
significantly higher compared with controls.478 Bradycardia warrants
The risk of AF appears not to be generally increased among people
careful clinical attention in people at risk, e.g. in those with pre-existing
with SMI after adjustment for sex and age, although this may reflect un-
conduction disturbances or symptoms like dizziness or syncope.
derdiagnosis of AF and misinterpretation of palpitation symp-
Lithium has a unique mechanism of action and a narrow therapeutic
toms.423,479,481 In a study from Korea, young adults (20–39 years)
window. Common side effects include sinus node dysfunction, bradycar-
diagnosed with mental disorder had a higher risk of incident AF (ad-
dia, conduction delays (e.g. atrioventricular block, bundle branch block)
justed HR 1.53, 95% CI 1.44–1.62).482
but also precordial T-wave changes including Brugada pattern, and QT
prolongation. Prolonged use and high blood levels increase the complica-
7.6.1.1. QTc interval prolongation tion risk making maintenance of optimal lithium serum levels essential.480
QTc intervals can be prolonged in association with several antipsychot- Since lithium concentration is affected by sodium, conditions like dehy-
ic drugs such as sertindole, amisulpride, ziprasidone, iloperidone, risper- dration or renal failure must be managed carefully. However, with appro-
idone, olanzapine, and quetiapine.477This effect may be more common priate monitoring, lithium does not pose a significant CV risk.478,480
in women than men due to differences in pharmacokinetic profiles.483 In summary, in people with SMI and arrhythmias, it is necessary to
A prolongation of the QTc interval increases the risk of torsades de evaluate the link between arrhythmias and antipsychotics. If clinically
pointes tachycardias and SCD. Therefore, a 12-lead ECG should be re- suspected, switching to other drugs with less propensity to cause
corded before and after initiation of antipsychotic drugs and further changes in heart rhythm may be appropriate, however, this must be ba-
ECG controls performed on a yearly basis during long-term follow-up. lanced against the risk of SMI relapse. Clozapine, as the only medication
Prolonged QTc in response to antipsychotic medication may indicate indicated in people with treatment-resistant schizophrenia, is often
acquired long QT syndrome and/or reveal an underlying genetic predis- hard to switch due to a high risk of relapse. A decision algorithm is given
position. Diagnosis and management of long QT syndrome in SMI in Figure 14and additional information is provided in Table 7.
should follow general Guidelines.484
• Acquired long QT syndrome is usually defined by a QTc of >500 ms 7.6.2. Clozapine-induced myocarditis
or a drug-induced change from baseline >60–70 ms.485 Although clozapine has been associated with an increased risk of develop-
• In people with QTc intervals >500 ms, suspected causal drugs should ing myocarditis and cardiomyopathy, reviews and meta-analyses show that
be stopped and switched to alternative medication with lower event rates and death rates are low. Results are limited by inconsistency in
QT-prolonging properties and be evaluated by a cardiologist for the diagnostic criteria for myocarditis and cardiomyopathy.489The odds of
underlying genetic conditions. clozapine-induced myocarditis increased with concurrent sodium valpro-
• In cases of intermediate QTc prolongation (e.g. ≥470 ms in men; ate use, and possibly increasing age and higher clozapine dose.490
≥480 ms in women), dose reduction or switching to a different If clozapine-induced myocarditis or cardiomyopathy is suspected,
antipsychotic may be considered and repeated ECGs should be treatment should be discontinued promptly and referred urgently to
documented. Individualized risk-benefit assessments are useful, con- a cardiologist for diagnostic evaluation.491People who have persistent
sidering the presence of additional risk factors for QT prolongation, tachycardia at rest, especially during the first 2 months of treatment,
symptoms, and the QT-prolonging potential of the prescribed should be closely observed for other signs or symptoms of myocarditis
medication. or cardiomyopathy (palpitations, arrhythmias, symptoms mimicking MI,
• Given that QT-prolonging effects are dose dependent, always aim for chest pain, and other unexplained symptoms of HF). However, special-
the lowest effective dose. Interactions with other QT-prolonging ist advice and link with psychiatrists is needed to prevent inappropriate
drugs like amiodarone, sotalol, or erythromycin should be avoided. discontinuation of clozapine.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 40 ---
ESC Guidelines 4195
People with SMI and symptoms People with SMI and established
indicative of arrhythmia arrhythmia diagnosis
Diagnostic work-upa
Indicated for treatment with psychotropic drug?
General advice
• As for all people with SMI and CVD • Arrhythmia treatment according
follow management and guidance to ESC Guidelines
from Psycho-Cardio teamb • Check for other pro-arrhythmic
risk factorsc
Monitor for QT prolongation
• In case of QT prolongation: consider avoiding or switching medicationd
• If drug with QT prolonging properties is chosen see relevant tablee
Management of specific arrhythmias
Sinus PSVT Atrial VPB, VT Bradycardia
tachycardia fibrillation
• Exclude other • Management • Thromboembolic • Re-evaluate • Avoid other drugs
medical causesf according to prophylaxis if potential drug causing
(incl myocarditis) ESC Guidelines needed side effects bradycardia
• If asymptomatic: • Consider • Choose • Consider • For management
wait for ablation rhythm or rate avoiding in people taking
normalization as first-line control according or switching Lithiumh
• If symptomatic treatment for to ESC Guidelines medication • Manage according
or persistent AVNRT and • Caution with • Risk assessment to ESC Guidelines
HR >130 bpm: AVRT specific by cardiologist
beta-blocker, psychotropic
alternatively drugsg
verapamil
or ivabradine
If persistent symptomatic arrhythmia
• Address modifiable CV risk factors which may also increase the risk
of arrhythmias
• Follow-up by cardiologist
• Ensure person-centred management approach
• Check for anxiety, depression, and symptom preoccupation related
to arrhythmia
• Promote interventions to enhance arrhythmia coping skills
Figure 14 Management of people with severe mental illness and arrhythmias. AVNRT, atrioventricular nodal reentry tachycardia; AVRT, atrioven-
tricular reentry tachycardia via accessory pathway; bpm, beats per minute; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram;
ESC, European Society of Cardiology; HR, heart rate; PSVT, paroxysmal supraventricular tachycardia; SMI, severe mental illness; VPB, ventricular pre-
mature beat; VT, ventricular tachycardia. aHistory, symptoms, status, 12-lead ECG, Holter-ECG and/or event recorder, echocardiography, blood test
and other evaluation if appropriate. bSee Figure 13. cSuch as hypertension, heart failure, ischaemic heart disease, electrolyte imbalance, history of ar-
rhythmia, or syncope, family history of sudden cardiac death. dSpecial caution with quetiapine, olanzapine, risperidone, iloperidone, amisulpride, ser-
tindole. eSee Table 7. fSuch as anaemia, hyperthyroidism, infection/sepsis, pain. gSpecial caution with clozapine, chlorpromazine, olanzapine,
quetiapine, risperidone. hSee Section 7.6.1.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 41 ---
4196 E S C G u id e l in e s
Table 7 Management of psychotropic drugs with QT interval prolongation properties
Action Supporting information
Assess symptoms Typically, asymptomatic
In case of torsades de pointes: palpitations, dizziness, syncope, cardiac arrest.
Diagnostic • 12-lead ECG providing QTc at baseline and after 1, 6, and 12 weeks after initiating drug
work-up • ECG more often in case of QT prolongation
• Use Fridericia formula for heart rate correction if there is tachycardia
• Check electrolytes: potassium, calcium, magnesium
• Ambulatory ECG monitoring in people with symptoms
• Exclude possible inherited long QT syndrome.
Management Special caution with: sertindole, amisulpride, ziprasidone, iloperidone, risperidone, olanzapine, and quetiapine
• Always aim for the lowest effective dose
• Check for other QT-prolonging drugs
• Check for drug interactions
• Always special caution when new medication is started
• Consult https://www.crediblemeds.org/for specific information on QT-prolonging drug effects
• Correct electrolyte imbalances
• Address other reversible QT-prolonging factors (e.g. bradycardia, hypothyroidism, starvation/eating disorders, alcohol and substance
abuse, myocardial ischaemia)
Note other non-reversible potentially QT-prolonging factors: heart failure, ventricular hypertrophy, recent conversion from atrial
fibrillation, impaired hepatic/renal function, female sex, age over 65 years
If QTc is prolonged (>470 ms) at baseline, treatment initiation is generally not recommended and should be carefully considered based
on individualized risk-benefit assessment (Psycho-Cardio team)a.
Special Stop treatment with antipsychotic drug (and any other potentially QT-prolonging medication) if:
precautions • QTc >500 msb
• Increase in QTc >60–70 ms from baselinec.
ECG, electrocardiogram; QTc, corrected QT interval.
aQTc prolongation (>470 ms) during treatment warrants repeated ECG documentation and thorough evaluation of symptoms and additional risk factors for QT prolongation. Dose
reduction or switching to a different antipsychotic drug may be considered in selected cases after individualized risk-benefit assessment (Psycho-Cardio team).
bRequest urgent consultation with Psycho-Cardio team/cardiologist.
cRequest urgent consultation with Psycho-Cardio team/cardiologist, repeat ECG.
7.7. Interventions to improve the
management of people with severe mental before the prescription of antipsychotics and, afterwards, periodically
in all stages of illness. illness and cardiovascular disease
(iii) Management of CVD in people with SMI aims to reduce modifiable
Existing programmes of prevention, early detection, and treatment of
CV risk factors, including weight gain, diabetes, hypertension,
CVD have not consistently and significantly improved the CV risk profile dyslipidaemia, smoking, unhealthy diet, and sedentary lifestyle
in people with schizophrenia and other SMI conditions.492Poor motiv- habits.
ation, lack of insight and cognitive impairment, and limited participation (iv) CVD management in people with SMI benefits from optimizing SMI
in decision-making by persons with SMI may be contributing to non-
pharmacotherapy: (i) preferring monotherapy, (ii) using
adherence to prevention, diagnostic, and treatment programmes.
medications less likely to induce weight gain or other CV risks, (iii)
Cardiovascular disease prevention and treatment programmes need to
monitoring for possible drug interactions and side effects, and (iv)
work with mental health experts to provide CVD screening and care
ensuring medication adherence.
that is accessible and appropriate for people with SMI.
(v) Efforts to alleviate the impact of psychosocial and stress-related
7.8. Section summary points and factors are needed in people with SMI.
MANAGEMENT CONSENSUS STATEMENTS
management consensus statements from
(i) Addressing stigma and managing CVD in people with SMI in
Section 7
accordance with CV Guidelines and best clinical practice is a
responsibility of all healthcare professionals.
(ii) CV care for people with SMI can be improved by following a holistic
SECTION SUMMARY POINTS
person-centred approach, involving close collaboration between the
(i) The presence of SMI increases CV risk, especially in younger people. Psycho-Cardio team with psychiatrists, general practitioners, and
(ii) Regular CV risk assessment is essential in people with SMI regardless sometimes other specialists to proactively facilitate the engagement of
of age, to prevent the development or progression of CVD, ideally people with SMI in such programmes.
Continued
5202CSE©
5202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 42 ---
ESC Guidelines 4197
8. Mental health in specific • Risk ratio for psychosocial factors is higher in women with CVD com-
pared with men with CVD (RR 25.7 vs 21.7, respectively).56,496
populations and situations
• The association between depression or anxiety and CVD risk is
stronger in young and middle-aged women compared with men.94,497
8.1. Sex and gender differences in mental
• Women experience a greater impact from chronic self-perceived
health and cardiovascular disease
stress and marital stress, whilst men are more affected by job-related
Biological (‘sex’) and sociocultural (‘gender’) aspects may explain differ- stress.498
ences or disparities between women and men in incidence, prevalence,
However, this has to be interpreted in the context of the following
presentation, diagnosis, management, and response to treatment in CV
factors: (i) prevailing social norms may lead to underreporting of mental
and mental health conditions (Figure 15). Sex reflects biological factors
stress in men,499,500 and (ii) men may have better perceived health
like genetics, anatomy, physiology, and hormones, while gender involves
and less anxiety than women, despite reporting more health risk
socially constructed norms shaping roles, relationships, and power dy-
behaviours.501
namics. Gender interacts with sex, affecting traits that define women,
Sex differences in stress response have been seen in animal and hu-
men, and intersex individuals. Pregnancy and menopause are clear ex-
man models.502,503Although pre-clinical studies in rodents and neuro-
amples of the differential influence of sex and gender in CV and mental
biological studies in the past have predominantly been done in males,
well-being. Multiple studies and analyses have shown that:
evidence of sex differences in neurobiological alterations in people
• Depression and anxiety are twice as prevalent in women, have increased with depression and anxiety is mounting.504–507These are associated
more in women over the past two decades compared with men, and with genetic differences, inflammation, platelet activation, sympathetic
are important risk factors for ACS and CV mortality.94,493–495 function, and hormone-related receptor signalling pathways.
(cid:31)(cid:30)(cid:29) (cid:31)(cid:30)(cid:29)(cid:28)(cid:29)(cid:27)(cid:30)(cid:26)(cid:25)(cid:28)(cid:24)(cid:23)(cid:22)(cid:21)(cid:22)(cid:20)(cid:19)(cid:30)(cid:18)(cid:25)(cid:18)(cid:21)(cid:17)(cid:16)(cid:24)(cid:27)(cid:22)(cid:18)(cid:22)(cid:17)(cid:15)(cid:24)(cid:14)(cid:29)(cid:20)(cid:19)(cid:29)(cid:18)(cid:22)(cid:17)(cid:13)(cid:13)(cid:13)
(cid:7)(cid:30)(cid:12)(cid:14)(cid:30)(cid:15) (cid:29)(cid:26)(cid:30)(cid:29)(cid:26)(cid:10)(cid:28)(cid:21)(cid:10)(cid:20)(cid:25)(cid:28)(cid:24)(cid:26)(cid:29)(cid:18)(cid:26)(cid:22)(cid:7)(cid:21)(cid:17)(cid:15)(cid:24)(cid:20)(cid:29)(cid:28)(cid:22)(cid:17)(cid:13)(cid:13)(cid:13)
(cid:12)(cid:22)(cid:18)(cid:21)(cid:25)(cid:28)(cid:24)(cid:25)(cid:18)(cid:23)(cid:24)(cid:26)(cid:25)(cid:20)(cid:23)(cid:30)(cid:29)(cid:11)(cid:25)(cid:17)(cid:26)(cid:10)(cid:28)(cid:25)(cid:20)(cid:24)(cid:14)(cid:22)(cid:25)(cid:28)(cid:21)(cid:14)
(cid:9)(cid:29)(cid:8)(cid:22)(cid:20)(cid:24)(cid:7)(cid:20)(cid:22)(cid:11)(cid:25)(cid:28)(cid:22)(cid:18)(cid:26)(cid:22)(cid:24)(cid:29)(cid:6) (cid:1)(cid:30)(cid:27)(cid:14)(cid:22)(cid:20)(cid:24)(cid:7)(cid:20)(cid:22)(cid:11)(cid:25)(cid:28)(cid:22)(cid:18)(cid:26)(cid:22)(cid:24)(cid:29)(cid:6) (cid:1)(cid:30)(cid:27)(cid:14)(cid:22)(cid:17)(cid:21)(cid:24)(cid:20)(cid:30)(cid:17)(cid:143)(cid:24)(cid:6)(cid:29)(cid:20)(cid:24)(cid:23)(cid:30)(cid:17)(cid:26)(cid:20)(cid:30)(cid:19)(cid:30)(cid:18)(cid:25)(cid:21)(cid:30)(cid:29)(cid:18)(cid:15)
(cid:23)(cid:22)(cid:7)(cid:20)(cid:22)(cid:17)(cid:17)(cid:30)(cid:29)(cid:18)(cid:24)(cid:25)(cid:18)(cid:23)(cid:24)(cid:25)(cid:18)(cid:5)(cid:30)(cid:22)(cid:21)(cid:4) (cid:23)(cid:22)(cid:7)(cid:20)(cid:22)(cid:17)(cid:17)(cid:30)(cid:29)(cid:18)(cid:24)(cid:25)(cid:18)(cid:23)(cid:24)(cid:25)(cid:18)(cid:5)(cid:30)(cid:22)(cid:21)(cid:4) (cid:19)(cid:22)(cid:18)(cid:21)(cid:25)(cid:28)(cid:24)(cid:14)(cid:22)(cid:25)(cid:28)(cid:21)(cid:14)(cid:24)(cid:26)(cid:29)(cid:18)(cid:23)(cid:30)(cid:21)(cid:30)(cid:29)(cid:18)(cid:17)
(cid:3)(cid:10)(cid:21)(cid:24)(cid:10)(cid:18)(cid:23)(cid:22)(cid:20)(cid:2)(cid:20)(cid:22)(cid:7)(cid:29)(cid:20)(cid:21)(cid:22)(cid:23) (cid:127)~(cid:129)(cid:5)(cid:141) (cid:25)(cid:18)(cid:23)(cid:24)(cid:17)(cid:10)(cid:30)(cid:26)(cid:30)(cid:23)(cid:22)
ˆ(cid:18)(cid:26)(cid:20)(cid:22)(cid:25)(cid:17)(cid:22)(cid:23)(cid:24)(cid:157) €‚(cid:24)(cid:20)(cid:30)(cid:17)(cid:143)(cid:24) (cid:144)(cid:18)(cid:23)(cid:29)(cid:27)(cid:22)(cid:18)(cid:29)(cid:10)(cid:17)(cid:24)(cid:29)(cid:22)(cid:17)(cid:21)(cid:20)(cid:29)(cid:27)(cid:22)(cid:18)(cid:17)(cid:24) (cid:29)(cid:26)(cid:30)(cid:25)(cid:28)(cid:24)(cid:23)(cid:30)(cid:17)(cid:30)(cid:18)(cid:21)(cid:22)(cid:27)(cid:20)(cid:25)(cid:21)(cid:30)(cid:29)(cid:18)(cid:24)(cid:25)(cid:18)(cid:23)(cid:24)
(cid:1)(cid:22)(cid:25)(cid:28)(cid:21)(cid:14)(cid:24)(cid:20)(cid:30)(cid:17)(cid:143)(cid:24)(cid:3)(cid:22)(cid:14)(cid:25)(cid:11)(cid:30)(cid:29)(cid:10)(cid:20)(cid:17) (cid:7)(cid:20)(cid:29)(cid:21)(cid:22)(cid:26)(cid:21)(cid:24)(cid:6)(cid:20)(cid:29)(cid:19)(cid:24)(cid:157) €‚ (cid:19)(cid:25)(cid:20)(cid:27)(cid:30)(cid:18)(cid:25)(cid:28)(cid:30)ƒ(cid:25)(cid:21)(cid:30)(cid:29)(cid:18)
(cid:31)(cid:22)(cid:21)(cid:21)(cid:22)(cid:20)(cid:24)(cid:7)(cid:22)(cid:20)(cid:26)(cid:22)(cid:30)(cid:11)(cid:22)(cid:23)(cid:24)(cid:19)(cid:22)(cid:18)(cid:21)(cid:25)(cid:28)(cid:24)(cid:14)(cid:22)(cid:25)(cid:28)(cid:21)(cid:14) (cid:22)(cid:28)(cid:6)(cid:2)(cid:7)(cid:22)(cid:20)(cid:26)(cid:22)(cid:30)(cid:11)(cid:22)(cid:23)(cid:24)(cid:17)(cid:21)(cid:20)(cid:22)(cid:17)(cid:17) (cid:157)(cid:23)(cid:23)(cid:30)(cid:26)(cid:21)(cid:30)(cid:11)(cid:22)(cid:24)(cid:3)(cid:22)(cid:14)(cid:25)(cid:11)(cid:30)(cid:29)(cid:10)(cid:20)(cid:17)
‰(cid:29)(cid:3)(cid:24)(cid:17)(cid:21)(cid:20)(cid:22)(cid:17)(cid:17) (cid:12)(cid:25)(cid:20)(cid:30)(cid:21)(cid:25)(cid:28)(cid:24)(cid:17)(cid:21)(cid:20)(cid:22)(cid:17)(cid:17) (cid:1)(cid:4)(cid:7)(cid:22)(cid:20)(cid:26)(cid:29)(cid:25)(cid:27)(cid:10)(cid:28)(cid:25)(cid:3)(cid:28)(cid:22)(cid:24)(cid:22)„(cid:22)(cid:26)(cid:21)(cid:24)(cid:29)(cid:6)(cid:24)
(cid:144)(cid:20)(cid:22)(cid:26)(cid:21)(cid:30)(cid:28)(cid:22)(cid:24)(cid:23)(cid:4)(cid:17)(cid:6)(cid:10)(cid:18)(cid:26)(cid:21)(cid:30)(cid:29)(cid:18)(cid:16) ˆ(cid:18)(cid:21)(cid:30)(cid:19)(cid:25)(cid:21)(cid:22)(cid:24)(cid:7)(cid:25)(cid:20)(cid:21)(cid:18)(cid:22)(cid:20)(cid:24)(cid:11)(cid:30)(cid:29)(cid:28)(cid:22)(cid:18)(cid:26)(cid:22) (cid:22)(cid:5)(cid:29)(cid:27)(cid:22)(cid:18)(cid:29)(cid:10)(cid:17)(cid:24)(cid:17)(cid:22)(cid:5)(cid:24)(cid:14)(cid:29)(cid:20)(cid:19)(cid:29)(cid:18)(cid:22)(cid:17)
(cid:19)(cid:25)(cid:20)(cid:143)(cid:22)(cid:20)(cid:24)(cid:29)(cid:6)(cid:24) €‚ (cid:22)(cid:5)(cid:10)(cid:25)(cid:28)(cid:24)(cid:25)(cid:3)(cid:10)(cid:17)(cid:22) …†‡(cid:24)(cid:30)(cid:18)(cid:26)(cid:20)(cid:22)(cid:25)(cid:17)(cid:22)(cid:23)(cid:24) €(cid:24)(cid:20)(cid:30)(cid:17)(cid:143)
(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:21)(cid:20)(cid:24)(cid:19)(cid:18)(cid:17)(cid:16)(cid:15)(cid:24)(cid:25)(cid:30)(cid:29)(cid:24)(cid:14)(cid:22)(cid:13)(cid:30)(cid:15)(cid:30)(cid:12)(cid:11)(cid:30)(cid:25)(cid:24)(cid:22)(cid:12)(cid:24)(cid:22)(cid:12)(cid:11)(cid:22)(cid:14)(cid:30)(cid:12)(cid:11)(cid:30)
(cid:18)(cid:12)(cid:14)(cid:24)(cid:22)(cid:19)(cid:10)(cid:16)(cid:15)(cid:21)(cid:18)(cid:12)(cid:21)(cid:24)(cid:22)(cid:19)(cid:10)(cid:18)(cid:11)(cid:21)(cid:24)(cid:16)(cid:9)(cid:24)(cid:19)(cid:30)(cid:12)(cid:21)(cid:18)(cid:8)(cid:24)(cid:20)(cid:30)(cid:18)(cid:8)(cid:21)(cid:20)(cid:24)(cid:11)(cid:16)(cid:12)(cid:14)(cid:22)(cid:21)(cid:22)(cid:16)(cid:12)(cid:25)
Œ(cid:29)(cid:19)(cid:22)(cid:18)(cid:24)ŽŽ(cid:24)(cid:19)(cid:22)(cid:18)(cid:16)
(cid:127)(cid:12)(cid:141)ˆ‘’ (cid:157)“(cid:157)‘’ (cid:157)
(cid:7)(cid:29)(cid:18)(cid:21)(cid:25)(cid:18)(cid:22)(cid:29)(cid:10)(cid:17)(cid:24)(cid:26)(cid:29)(cid:20)(cid:29)(cid:18)(cid:25)(cid:20)(cid:4)(cid:24)(cid:25)(cid:20)(cid:21)(cid:22)(cid:20)(cid:4)(cid:24)(cid:23)(cid:30)(cid:17)(cid:17)(cid:22)(cid:26)(cid:21)(cid:30)(cid:29)(cid:18)
”(cid:25)(cid:143)(cid:29)(cid:21)(cid:17)(cid:10)(cid:3)(cid:29)(cid:24)(cid:17)(cid:4)(cid:18)(cid:23)(cid:20)(cid:29)(cid:19)(cid:22)
Š(cid:22)(cid:20)(cid:30)(cid:7)(cid:25)(cid:20)(cid:21)(cid:10)(cid:19)(cid:24)(cid:26)(cid:25)(cid:20)(cid:23)(cid:30)(cid:29)(cid:19)(cid:4)(cid:29)(cid:7)(cid:25)(cid:21)(cid:14)(cid:4)
(cid:26)(cid:22)(cid:13)(cid:30)(cid:15)(cid:30)(cid:12)(cid:11)(cid:30)(cid:25)(cid:24)(cid:22)(cid:12)(cid:24)(cid:19)(cid:30)(cid:12)(cid:21)(cid:18)(cid:8)(cid:24)(cid:20)(cid:30)(cid:18)(cid:8)(cid:21)(cid:20)(cid:24)(cid:11)(cid:16)(cid:12)(cid:14)(cid:22)(cid:21)(cid:22)(cid:16)(cid:12)(cid:25)(cid:24)(cid:22)(cid:12)(cid:24)(cid:23)(cid:16)(cid:19)(cid:30)(cid:12)(cid:24)(cid:23)(cid:22)(cid:21)(cid:20)(cid:24)(cid:28)(cid:27)(cid:26)
(cid:21)(cid:20)(cid:22)(cid:17)(cid:17)(cid:2)(cid:23)(cid:22)(cid:7)(cid:20)(cid:22)(cid:17)(cid:17)(cid:30)(cid:29)(cid:18)(cid:24)(cid:7)(cid:29)(cid:17)(cid:21)(cid:24)(cid:12)ˆ
Š(cid:22)(cid:20)(cid:26)(cid:22)(cid:30)(cid:11)(cid:22)(cid:23)(cid:24)(cid:17)(cid:21)(cid:20)(cid:22)(cid:17)(cid:17)(cid:24)(cid:25)(cid:18)(cid:23)(cid:24)(cid:1)‹(cid:24)(cid:25)(cid:23)(cid:19)(cid:30)(cid:17)(cid:17)(cid:30)(cid:29)(cid:18)(cid:17)
(cid:157)(cid:18)(cid:5)(cid:30)(cid:22)(cid:21)(cid:4)(cid:24)(cid:25)(cid:18)(cid:23)(cid:24)(cid:23)(cid:22)(cid:7)(cid:20)(cid:22)(cid:17)(cid:17)(cid:30)(cid:29)(cid:18)(cid:24)(cid:8)(cid:30)(cid:21)(cid:14)(cid:24)(cid:157)‹
(cid:157)(cid:18)(cid:5)(cid:30)(cid:22)(cid:21)(cid:4)(cid:24)(cid:30)(cid:18)(cid:24)(cid:26)(cid:25)(cid:20)(cid:23)(cid:30)(cid:25)(cid:26)(cid:24)(cid:25)(cid:20)(cid:20)(cid:22)(cid:17)(cid:21)(cid:24)(cid:17)(cid:10)(cid:20)(cid:11)(cid:30)(cid:11)(cid:29)(cid:20)(cid:17)
Figure 15 Sex and gender differences in the psycho-cardio interaction. AF, atrial fibrillation; ANOCA, angina with non-obstructive coronary arteries;
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular disease; HF, heart failure; MI, myocardial infarction;
(M)INOCA, (myocardial infarction) ischaemia with non-obstructive coronary arteries.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 43 ---
4198 E S C G u id e l in e s
Some SES factors like educational level and sex-specific life events obstructive coronary arteries (INOCA/ANOCA).56Mental stress trig-
(i.e. pregnancy, sexual abuse, intimate partner violence), have a different gers endothelial dysfunction and inflammation.528–531 While some
impact on the stress response in women and men. Women have a high- studies associate anxiety with INOCA/ANOCA, others found no link
er inflammatory response to stress compared with men, which is asso- between depression or general anxiety and these conditions.532,533
ciated with future adverse CV outcomes in people with IHD.508The Mental stress-induced ischaemia, more prevalent in women than
association between menopause transition and depression remains men, correlates with adverse CV outcomes.534,535This may be asso-
contentious, although severe vasomotor symptoms are recognized as ciated with worse long-term prognosis, particularly in women.536,537
a contributing factor associated with depression.509,510 Hormonal The influence of mental stress on INOCA/ANOCA contributes to
changes during menopause transition frequently induce mood distur- their underdiagnosis and undertreatment in women.538
bances, adversely impacting QoL and work performance.511,512 Young women with a history of ACS have a two-fold higher likeli-
During peri-menopause but not in post-menopause, temporary hor- hood of developing mental stress-induced myocardial ischaemia com-
mone therapy may alleviate these symptoms.511,512 pared with men.535 Chronic mental stress is a significant trigger for
In men, erectile dysfunction has not only been shown to be a conse- spontaneous coronary artery dissection (SCAD), which is nine times
quence of CVD, it is also a risk marker for future CVD.513 A recent more common in women.539–541 Emotional stressors are reported
meta-analysis demonstrated that sexual dysfunction is also a predictor twice as frequently prior to SCAD-ACS as by other ACS cohorts.542,543
of future CVD in women.514 Since most people experiencing SCAD are relatively young (40–60
years), rehabilitation should prioritize stress management, addressing
8.1.1. Cardiovascular disease and mental health work-life balance, and other present stressors. Psychological counsel-
conditions in transgender individuals ling may be needed in selected people.
Transgender individuals show a significantly higher risk for mental
health conditions, including suicidality, social disintegration, and margin- 8.1.4. Sex and gender differences in mental health in
alization, compared with non-transgender individuals.515High rates of people with takotsubo syndrome
discrimination and low levels of social support predispose to addictive Acute stress-induced takotsubo syndrome (TTS) occurs eight–nine times
behaviours in transgender persons,516but insufficient data are available more frequently in women than in men, likely due to different coping
to differentiate between transgender subgroups. Gender-affirming strategies for stress.544 Women over 55 years of age are five times
therapy, including sex hormones, aligns individuals with their gender more likely to develop TTS compared with younger women, as risk is
identity, enhancing QoL.517 The psychosocial benefits of hormone linked to increased sympathetic tone after menopause.545,546While phys-
therapy with an improved body image may result in healthier lifestyle ical stressors more often affect men, women are more likely to experience
choices. Evidence in the ageing transgender population suggests that an emotional trigger.547,548These different triggers suggest two categories
both transgender men and women face a 40% higher risk of CVD com- of TTS:549primary TTS, affecting women after emotional stress with lim-
pared with cisgender peers of the same birth sex.518–521The hypercoa- ited left ventricular dysfunction, and TTS triggered by physical stress,
gulable effect of exogenous sex hormones, alongside the increase in which causes more severe left ventricular dysfunction and a worse prog-
traditional CVD risk factors, may mediate this elevated risk. nosis. The latter seems to affect women and men equally. A direct connec-
tion between the brain and the heart associated with autonomic functions
8.1.2. Sex and gender differences in mental health in and regulation of the limbic system has been identified.550Mental health
people with obstructive coronary artery disease conditions are common in people with TTS, indicating that combined psy-
The impact of a life event like a diagnosis of CVD on mental stress af- chotherapy and ECR could improve mental health and reduce negative
fects all genders. However, long-term population studies evaluating thinking more effectively than ECR alone.350People with pre-admission
their influence according to sex and gender are scarce. Negative stress psychiatric disorders are at a higher risk of recurrent TTS.551 The use
leads more often to adverse lifestyle behaviours and substance use in of SSRIs may help prevent recurrence in selected individuals.551
men, whereas sociocultural inequalities, household problems, and
ACEs more often negatively affect women with CVD.522 Countries 8.1.5. Sex and gender differences in mental health in
with the highest levels of gender equity have reported some of the people with heart failure
greatest reductions in 40 year CVD mortality rates.496,523
Women are underrepresented in most HF trials, leading to a lack of
The negative impact of depression on obstructive CAD in women is sex- and gender-specific data on the impact of mental health conditions.
relatively more severe in younger women (<55 years) than at older
HF prevalence varies between the sexes: men typically present with HF
ages.510,524Moreover, feminine gender roles, lower educational level,
with reduced ejection fraction following ACS, while women more often
and distress-related psychological factors such as anxiety are important
experience HF with preserved ejection fraction due to hypertension,
determinants of outcomes after ACS in both sexes.525Meta-analyses of obesity, and ageing.552Sexual dimorphism is also evident in the expres-
negative psychological factors on obstructive CAD found no significant
sion of hereditary cardiomyopathies and risk factors like breast cancer,
differences among men and women.106,526In clinical practice, however,
and the potential treatment-induced cardiomyopathy. Additionally,
sex and gender differences in heart–brain interactions importantly con-
there are sex-specific disorders such as peri-partum cardiomyopathy.
tribute to different manifestations of stable and unstable IHD.507,527
Psychological stress has received limited attention as a potential dis-
ease modifier in HF. As HF with preserved ejection fraction often re-
8.1.3. Sex and gender differences in mental health in
mains undiagnosed, this contributes additional stress on the affected
ischaemia/angina with non-obstructive coronary predominantly female population. However, qualitative studies support
arteries and coronary vasomotor disorders the assertion of non-diagnosis burden.553,554The progressive course of
Psychological risk factors, including depression and anxiety are preva- HF, with increasing functional limitations, further increases stress in
lent among women with myocardial ischaemia or angina with non- both males and females.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 44 ---
ESC Guidelines 4199
Higher psychological stress and anxiety worsen HF out- specific mental health disorders like late-life depression are set to in-
comes.215,216,555,556Women with HF, former smokers, those with low- crease,573which has implications for CVD management. A recent sys-
er income, and people with obesity report higher perceived stress, as tematic review and meta-analysis of 61 prospective cohort studies
do people with New York Heart Association (NYHA) class II HF, com- (198 589 older adults) found that late-life depression is associated
pared with asymptomatic NYHA class I HF.215,557Social determinants with increased risk of CV mortality (RR 1.31, 95% CI 1.20–1.43).574
of health influence HF prevalence, with the highest rates of HF and re- Whilst there is reasonable population-level data on individual condi-
lated readmissions observed in the most economically disadvantaged tions, the rates of mental health disorders within older adults with any
communities with more representation of women and individuals type CVD and vice versa are not well known. Using HF as an exemplar,
from ethnically diverse backgrounds.558 which is mostly a disease of older adults, it would seem that the global
co-occurrence of CVD with mental disorders like depression is signifi-
8.1.6. Sex and gender differences in mental health in cant. One of the largest meta-analyses to date (149 studies, n = 305
people with arrhythmias 407, mean age 65.2 ± 7.1 years) determined that the prevalence of
any severity depression in HF was 41.9%, and severe depression was In people with AF, anxiety levels are significantly higher in women com-
28.1%.575In older adults with AF, a meta-analysis of 26 studies deter-
pared with men, potentially due to older age, living alone (e.g. divorced/
widowed), or comorbid conditions.559 Chronic AF increases anxiety, mined the rate of depression as 40.3% and anxiety as 33.6%.576Such
results suggest that the rates of depression may be significantly higher
depression, and affects QoL in both genders, but the effect is more pro-
nounced in women.560 Depression is more common in women with in older adults with co-existing CVD, compared with the previously de-
chronic AF,561and affects the subjective burden of symptoms, suggest- scribed population norms for older adults (19.2% depression, 16.5%
anxiety).572
ing that addressing psychological comorbidities may improve symptom
Non-pharmacological therapies: given that suboptimal mental
management and HRQoL. Anxiety is an important trigger for AF recur-
rence after cardioversion and ablation therapy.562 and CV health are common in older adults, it is necessary to develop
interventions that work synergistically to improve outcomes in both
Women report higher levels of anxiety (general and ICD-related),
conditions. Unfortunately, very few interventions have been trialled
and higher levels of body image concerns than men when having an
ICD.563 They also express worries about damaging the ICD during and thus clinical practice evidence is limited. One narrative review of in-
tegrated physical-mental healthcare services for older people living with
breast cancer screening, which in addition may compromise the quality
of mammography images.564 mental health diagnoses (9 studies, n = 1728) determined that such in-
terventions improved a range of health outcomes, however, studies
In a prospective observational study of OHCA survivors, females re-
were not large nor robust.577 The majority of RCTs included in the
ported significantly higher symptoms of anxiety and PTSD compared
Cochrane systematic review and meta-analysis of psychological inter-
with men, with younger women showing the highest symptom severity.
No sex differences were observed for depression.178In a cohort of 249 ventions discussed in Section 6, included older adults with comorbid
people with ICD,565most had relatively low distress scores at baseline CVD and mental disorders based on sample age (14 of 21 trials included
(mean anxiety 4.23 ± 4.47; mean depression 5.60 ± 4.73). However, adults ≥60 years, age range 56 to 71 years). This review suggests that
multicomponent psychological interventions such as CBT, MotInt,
those who received a shock showed a worsening of PTSD symptom se-
and mindfulness can improve anxiety and depression in this population,
verity scores at 3 months (11%), 6 months (7%), and 12 months (7%).
however, it did not improve MACE.263 A Cochrane review of social
network or social support interventions, both of which are postulated
8.1.7. Mental health conditions associated with
to be useful in CVD and mental health conditions, reported that in pre-
peri-partum cardiomyopathy
dominantly older patients with CVD (median age 62.5 years) and co-
Peri-partum cardiomyopathy is a serious condition with significant con-
morbidity (including concurrent anxiety and depression), there were
sequences for both mother and child, causing substantial psychological
no effects on CVD and psychological well-being outcomes.578
and social stress. Mental health conditions, including peri-natal psychi-
Pharmacological therapy: managing pharmacological treatments
atric illness such as major depression, panic disorder, and PTSD, can
in elderly patients with both mental health disorders and CVD requires
worsen prognosis. Screening, diagnosis, and multidisciplinary manage-
careful consideration of dose adjustments and potential drug interac-
ment of peri-partum cardiomyopathy-associated mental conditions
tions due to age-related changes in pharmacokinetics and pharmaco-
are described in a recent dedicated ESC Heart Failure Association sci-
dynamics. Ageing affects drug absorption, distribution, metabolism,
entific statement.566
and excretion. Reduced hepatic and renal function can alter drug clear-
ance, necessitating dose adjustments. For instance, lower doses of ben-
8.2. Mental and cardiovascular health in
zodiazepines, antidepressants, and antipsychotics are often required due
older adults to increased sensitivity and risk of adverse effects.579Individualized care,
Countries across the globe are experiencing an exponential rise in the considering the patient’s overall health status, comorbidities, and
proportion of older persons (often defined as aged 60 years or more) in personal health goals is needed. Selecting safer drug alternatives,
their population, such that the WHO predicts the number of people adjusting doses, and vigilant monitoring for adverse effects and interac-
aged 80 years or older will triple between 2020 and 2050.567With age- tions while balancing efficacy and safety is advisable. Guidance on poten-
ing populations comes a growing burden of chronic condition manage- tial toxicity and interactions per drug class is further discussed in Section 6.
ment due in part to ‘inflammageing’, whereby chronically raised blood A summary focusing specifically on the elderly population follows.
inflammatory markers increase the risk of morbidity, disability, frailty, SSRIs and SNRIs are generally the preferred antidepressants due to
and early mortality.568,569According to the Global Burden of Disease their favourable side effect profiles. ECG monitoring may be needed,
programme, both CVD and mental health disorders are on the especially when combined with other QT-prolonging drugs such as
rise.570,571In older adults, the prevalence of depression (19.2%), anxiety antiarrhythmics. The combination of antipsychotics and antiarrhythmic
(16.5%), and stress (13.9%) are already relatively high.572 However, drugs or other QT-prolonging agents requires careful monitoring.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 45 ---
4200 E S C G u id e l in e s
Additionally, antipsychotics metabolized by the CYP system can interact societal level, multimorbidity is associated with significant healthcare
with CV drugs like beta-blockers and statins, necessitating dose adjust- use,595and related utilization costs.596At the individual level, it results
ments.580,581Lithium can cause arrhythmias, so it requires regular mon- in loss of agency and isolation,597,598which in turn can lead to vulner-
itoring of serum levels and renal function. It can interact with diuretics ability, frailty, and a need for social care.599When interrogated by dis-
and angiotensin-converting enzyme inhibitors, increasing the risk of lith- ease or disease clusters in population studies,600 and systematic
ium toxicity.582Benzodiazepines can cause sedation and respiratory de- review,601 people with multimorbidity appear to have a high burden
pression, especially when combined with other central nervous system of concurrent CVD and mental health disorders like depression.
depressants.579,582,583 However, there is no consensus across multimorbidity cluster studies
Polypharmacy is highly prevalent in elderly patients, increasing the and results are dependent upon the measure and/or threshold used
risk of drug interactions. For example, combining central nervous sys- to define multimorbidity.602
tem depressants with CV drugs can lead to additive effects, such as in- The growing burden of multimorbidity and its complexity necessi-
creased sedation or hypotension. Regular medication reviews and tates collaborative management. Given that CVD and mental health dis-
deprescribing where appropriate are essential to minimize these orders are frequently highlighted as important contributors to
risks.584 Specific interactions with CV drugs need to be specially as- multimorbidity, it is reasonable that clinicians working in these fields
sessed. For example, antipsychotics can increase the risk of QT pro- can and should drive improvements in care. Degenerative neurological
longation, arrhythmias, or hypotension when combined with diseases should be considered as part of the multimorbidity assessment,
beta-blockers or antiarrhythmics.580,583 Antipsychotics can increase but this particular aspect is out of the scope of this document. Within
the risk of myalgia, myopathy, or creatine kinase elevation in combin- the secondary care setting, the evidence presented in Section 6.6is rele-
ation with statins.580 vant to the management of multimorbidity, and the implementation of
the Psycho-Cardio team would likely drive improvements in care and
8.3. Mental health and cardiovascular outcomes. However, there is an absence of empirical research con-
disease in people with frailty and ducted in the secondary care setting and trials of bespoke multimorbid-
ity management models are urgently needed. Within the primary care
multimorbidity
setting, there have been mixed results in RCTs of integrated care mod-
8.3.1. Mental health and frailty els. The largest trial to date (3D: Dimensions of health, Depression, and
Frailty is a state of diminished physiologic reserve and increased vulner- Drugs) which was conducted on older adults (mean age 71 years) failed
ability to adverse health outcomes.585It is a potentially reversible dy- to meet its primary or secondary endpoints.603A Cochrane review and
namic state fluctuating over time in response to stressors and meta-analysis of interventions designed to improve outcomes in pa-
interventions. Its incidence increases with age and overlaps with multi- tients with multimorbidity in the primary care or community setting
morbidity.585,586 Cardiovascular disease and frailty arise from similar (18 RCTs) reported that there was evidence that such interventions
causal mechanisms, and each increases the risk of the other condi- improved mental health outcomes, but there was no or very little im-
tion.569 Frailty has been found to affect 40%–80% of people with pact on clinical, functional, and healthcare use outcomes.604Overall, the
HF,587 and to have a pooled prevalence of 19% among individuals evidence suggests these interventions are effective for improving men-
with IHD.588The substantial prevalence of frailty among older adults tal health outcomes, however, further research is required to identify
with CVD and associated risks for adverse events such as falls necessi- interventions that have dual effects (i.e. improve mental health and
tate increased awareness and evaluation by clinicians.589 CVD outcomes).
Most brief screening tools used clinically to assess frailty focus on bio-
medical domains, rather than including a more holistic approach.
Comprehensive geriatric assessments are advised in older adults to as- 8.3.3. Summary of evidence in older adults with
sess multiple domains including psychological and socio-environmental cardiovascular disease and mental disorders
contributors to frailty.585Depression, anxiety, and frailty are associated
The older adult is at increased risk for the associated conditions of
with each other as seen in both observational and Mendelian random-
CVD, mental health conditions, multimorbidity, and frailty. These
ization studies, with a bidirectional relationship found between depres- conditions along with polypharmacy increase the complexity of
sion and frailty.590,591 An analysis of 444 094 participants (median
management and require expertise from the Psycho-Cardio team.
follow-up 7.8 years) determined that frailty resulted in over three times
Comprehensive geriatric assessment can highlight important issues
the risk for depression and twice the risk for anxiety in adjusted
and ensure that psychosocial domains are identified and addressed.
analyses.592
The evidence for non-pharmacological interventions and integrated
care models in older adults with CVD and mental disorders is het-
8.3.2. Mental health, cardiovascular disease, and erogeneous. However, based on the current evidence these inter-
multimorbidity ventions appear to be effective in improving mental health
Multimorbidity is defined as the presence of two or more chronic con- outcomes, although they are less likely to significantly improve
ditions in one person.593It is estimated to affect ∼40% of the world’s CVD outcomes. A summary of the core issues in the management
population,594and incidence is predicted to rise in parallel with gains of older adults with CVD, multimorbidity, and polypharmacy is pre-
in life expectancy and trends in global population ageing.595 At the sented in Figure 16.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 46 ---
ESC Guidelines 4201
(cid:1)(cid:25)(cid:26)(cid:22)(cid:25)(cid:19)(cid:9)(cid:28)(cid:25)(cid:13)(cid:19)(cid:21)(cid:24)(cid:9)(cid:30)(cid:22)(cid:19)(cid:29)(cid:24)(cid:17)(cid:30)(cid:17)(cid:6)(cid:19)(cid:18)(cid:22)(cid:24)(cid:15)(cid:22)(cid:30)(cid:17)(cid:17)(cid:19)(cid:17)(cid:21)(cid:24)(cid:9)(cid:21)(cid:10)(cid:19)
(cid:26)(cid:23)(cid:29)(cid:19)(cid:12)(cid:24)(cid:23)(cid:28)(cid:25)(cid:24)(cid:22)(cid:19)(cid:12)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:28)(cid:24)(cid:23)(cid:19)(cid:29)(cid:24)(cid:17)(cid:26)(cid:15)(cid:30)(cid:19)(cid:26)(cid:23)(cid:29)(cid:19)(cid:17)(cid:28)(cid:29)(cid:30)(cid:19)
(cid:30)(cid:3)(cid:30)(cid:27)(cid:25)(cid:17)(cid:127)(cid:19)(cid:8)(cid:7)(cid:19)(cid:18)(cid:17)(cid:10)(cid:27)(cid:13)(cid:24)(cid:25)(cid:22)(cid:24)(cid:18)(cid:28)(cid:27)(cid:19)(cid:29)(cid:22)(cid:4)(cid:15)(cid:17)(cid:19)(cid:26)(cid:22)(cid:30)(cid:19)(cid:23)(cid:30)(cid:30)(cid:29)(cid:30)(cid:29)(cid:6)(cid:19)
(cid:25)(cid:26)(cid:11)(cid:30)(cid:19)(cid:26)(cid:23)(cid:19)(cid:28)(cid:23)(cid:29)(cid:28)(cid:5)(cid:28)(cid:29)(cid:4)(cid:26)(cid:21)(cid:28)(cid:20)(cid:30)(cid:29)(cid:19)(cid:26)(cid:18)(cid:18)(cid:22)(cid:24)(cid:26)(cid:27)(cid:13)
(cid:14)(cid:13)(cid:26)(cid:22)(cid:12)(cid:26)(cid:27)(cid:24)(cid:11)(cid:28)(cid:23)(cid:30)(cid:25)(cid:28)(cid:27)
(cid:26)(cid:23)(cid:29)
(cid:18)(cid:13)(cid:26)(cid:22)(cid:12)(cid:26)(cid:27)(cid:24)(cid:29)(cid:10)(cid:23)(cid:26)(cid:12)(cid:28)(cid:27)
(cid:27)(cid:13)(cid:26)(cid:23)(cid:15)(cid:30)(cid:17)(cid:19)(cid:26)(cid:17)(cid:17)(cid:24)(cid:27)(cid:28)(cid:26)(cid:25)(cid:30)(cid:29)
(cid:9)(cid:28)(cid:25)(cid:13)(cid:19)(cid:26)(cid:15)(cid:30)(cid:28)(cid:23)(cid:15)
(cid:31)(cid:4)(cid:21)(cid:25)(cid:28)(cid:129)(cid:27)(cid:24)(cid:12)(cid:18)(cid:24)(cid:23)(cid:30)(cid:23)(cid:25)(cid:19)
(cid:18)(cid:17)(cid:10)(cid:27)(cid:13)(cid:24)(cid:21)(cid:24)(cid:15)(cid:28)(cid:27)(cid:26)(cid:21)(cid:19) (cid:8)(cid:23)(cid:27)(cid:22)(cid:30)(cid:26)(cid:17)(cid:30)(cid:29)(cid:19)(cid:22)(cid:28)(cid:17)(cid:11) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:28)(cid:24)(cid:23)
(cid:8)(cid:23)(cid:27)(cid:22)(cid:30)(cid:26)(cid:17)(cid:30)(cid:19)(cid:28)(cid:23)(cid:19)
(cid:28)(cid:23)(cid:25)(cid:30)(cid:22)(cid:5)(cid:30)(cid:23)(cid:25)(cid:28)(cid:24)(cid:23)(cid:17)(cid:19)(cid:27)(cid:26)(cid:23)(cid:19) (cid:24)(cid:7)(cid:19)(cid:18)(cid:24)(cid:21)(cid:10)(cid:18)(cid:13)(cid:26)(cid:22)(cid:12)(cid:26)(cid:27)(cid:10)(cid:6) (cid:22)(cid:26)(cid:25)(cid:28)(cid:24)(cid:23)(cid:26)(cid:21)(cid:28)(cid:20)(cid:26)(cid:25)(cid:28)(cid:24)(cid:23)(cid:19)(cid:26)(cid:23)(cid:29)
(cid:15)(cid:21)(cid:24)(cid:16)(cid:26)(cid:21)(cid:19)(cid:16)(cid:4)(cid:22)(cid:29)(cid:30)(cid:23)(cid:19)
(cid:28)(cid:12)(cid:18)(cid:22)(cid:24)(cid:5)(cid:30)(cid:19)(cid:29)(cid:30)(cid:18)(cid:22)(cid:30)(cid:17)(cid:17)(cid:28)(cid:24)(cid:23)(cid:19) (cid:27)(cid:21)(cid:28)(cid:23)(cid:28)(cid:27)(cid:26)(cid:21)(cid:21)(cid:10) (cid:29)(cid:30)(cid:18)(cid:22)(cid:30)(cid:17)(cid:27)(cid:22)(cid:28)(cid:16)(cid:28)(cid:23)(cid:15)
(cid:24)(cid:7)(cid:19)(cid:2)(cid:143)(cid:144)(cid:6)(cid:19)(cid:12)(cid:30)(cid:23)(cid:25)(cid:26)(cid:21)(cid:19)
(cid:26)(cid:23)(cid:29)(cid:19)(cid:26)(cid:23)(cid:141)(cid:28)(cid:30)(cid:25)(cid:10) (cid:22)(cid:30)(cid:21)(cid:30)(cid:5)(cid:26)(cid:23)(cid:25)(cid:19)(cid:29)(cid:22)(cid:4)(cid:15)
(cid:13)(cid:30)(cid:26)(cid:21)(cid:25)(cid:13)(cid:19)
(cid:28)(cid:23)(cid:25)(cid:30)(cid:22)(cid:26)(cid:27)(cid:25)(cid:28)(cid:24)(cid:23)(cid:17)(cid:19)(cid:26)(cid:23)(cid:29)
(cid:27)(cid:24)(cid:23)(cid:29)(cid:28)(cid:25)(cid:28)(cid:24)(cid:23)(cid:17)(cid:19)(cid:24)(cid:22)(cid:19)
(cid:17)(cid:28)(cid:29)(cid:30)(cid:19)(cid:30)(cid:3)(cid:30)(cid:27)(cid:25)(cid:17)
(cid:16)(cid:24)(cid:25)(cid:13)
(cid:157)(cid:22)(cid:26)(cid:28)(cid:21)(cid:25)(cid:10)(cid:19)(cid:28)(cid:17)(cid:19)(cid:18)(cid:22)(cid:30)(cid:5)(cid:26)(cid:21)(cid:30)(cid:23)(cid:25)(cid:19) (cid:28)(cid:17)(cid:30)(cid:19)(cid:28)(cid:23)(cid:19)
(cid:28)(cid:23)(cid:19)(cid:2)(cid:143)(cid:144)(cid:19)(cid:26)(cid:23)(cid:29)(cid:19) (cid:12)(cid:4)(cid:21)(cid:25)(cid:28)(cid:12)(cid:24)(cid:22)(cid:16)(cid:28)(cid:29)(cid:28)(cid:25)(cid:10)(cid:19)
(cid:28)(cid:23)(cid:27)(cid:22)(cid:30)(cid:26)(cid:17)(cid:30)(cid:17)(cid:19)(cid:22)(cid:28)(cid:17)(cid:11)(cid:19)(cid:24)(cid:7)(cid:19) (cid:26)(cid:23)(cid:29)(cid:19)(cid:28)(cid:23)(cid:27)(cid:22)(cid:30)(cid:26)(cid:17)(cid:28)(cid:23)(cid:15)(cid:19)
(cid:29)(cid:30)(cid:18)(cid:22)(cid:30)(cid:17)(cid:17)(cid:28)(cid:24)(cid:23)(cid:19)(cid:26)(cid:23)(cid:29)(cid:19) (cid:27)(cid:24)(cid:12)(cid:18)(cid:21)(cid:30)(cid:141)(cid:28)(cid:25)(cid:10)
(cid:26)(cid:23)(cid:141)(cid:28)(cid:30)(cid:25)(cid:10)
(cid:31)(cid:4)(cid:21)(cid:25)(cid:28)(cid:129)(cid:29)(cid:24)(cid:12)(cid:26)(cid:28)(cid:23)(cid:19)(cid:15)(cid:30)(cid:22)(cid:28)(cid:26)(cid:25)(cid:22)(cid:28)(cid:27)(cid:19) (cid:2)(cid:24)(cid:21)(cid:21)(cid:26)(cid:16)(cid:24)(cid:22)(cid:26)(cid:25)(cid:28)(cid:5)(cid:30)(cid:19)(cid:12)(cid:26)(cid:23)(cid:26)(cid:15)(cid:30)(cid:12)(cid:30)(cid:23)(cid:25)(cid:19)
(cid:26)(cid:17)(cid:17)(cid:30)(cid:17)(cid:17)(cid:12)(cid:30)(cid:23)(cid:25)(cid:19)(cid:25)(cid:24)(cid:19)(cid:30)(cid:23)(cid:17)(cid:4)(cid:22)(cid:30)(cid:19) (cid:28)(cid:12)(cid:18)(cid:22)(cid:24)(cid:5)(cid:30)(cid:17)(cid:19)(cid:12)(cid:30)(cid:23)(cid:25)(cid:26)(cid:21)(cid:19)(cid:13)(cid:30)(cid:26)(cid:21)(cid:25)(cid:13)(cid:19)
(cid:13)(cid:24)(cid:21)(cid:28)(cid:17)(cid:25)(cid:28)(cid:27)(cid:19)(cid:26)(cid:18)(cid:18)(cid:22)(cid:24)(cid:26)(cid:27)(cid:13) (cid:24)(cid:4)(cid:25)(cid:27)(cid:24)(cid:12)(cid:30)(cid:17)
Figure 16 Ageing, mental disorders, and cardiovascular disease. CVD, cardiovascular disease.
8.4. Mental health and cardiovascular where structural inequalities amplify the impact of socioeconomic
disease in socioeconomically deprived deprivation on health outcomes.607,609 Socioeconomic deprivation
status seems to be an important covariate in CV risk estimation mod-
populations
els while risk scores that exclude socioeconomic deprivation under-
Individuals facing economic difficulties often experience increased and overestimate risk in the most and least deprived individuals,
stress, reduced access to healthcare, and limited opportunities for respectively.606
social engagement.605 The role of psychosocial stress, its determi- Mental health conditions following CVD events are more common in
nants, and impact on mental health and CV risk have been presented individuals with lower SES. Mental health service utilization following an
in Section 4. Psychological stressors linked to socioeconomic depriv- MI is more frequent among men and women living in areas with high
ation can exacerbate the risk and progression of CV condi- ethnic concentration and material deprivation.610Several factors have
tions.606,607Concerns about financial or housing stability and other been postulated as potential mechanisms linking lower SES and higher
basic needs may amplify hormone stress responses, potentially accel- risk of mental health conditions and CVD (Figure 17).
erating CVD progression while increasing the vulnerability to mental Health inequities are also more frequent among populations such as
health conditions like depression and anxiety.608 Lower SES often the homeless, individuals with substance use disorders, sex workers,
correlates with unhealthy lifestyle behaviours, further exacerbating and imprisoned individuals with the impact of exclusion being greater
CVD risk. Research has consistently demonstrated that CVD and in females than in males.611 While addressing socioeconomic depriv-
HF are significantly more prevalent among individuals with low SES, ation is beyond the scope of practice, it is reasonable for healthcare
with disparities more pronounced in marginalized communities, professionals to:
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 47 ---
4202 E S C G u id e l in e s
(cid:24)(cid:23)(cid:22)(cid:21)(cid:22)(cid:20)(cid:27)(cid:23)
(cid:31)(cid:30)(cid:29)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:30)(cid:24)(cid:23)(cid:27)(cid:22)(cid:21)(cid:26)(cid:21)(cid:20)(cid:19)(cid:26)(cid:18)(cid:27)(cid:17)(cid:23)(cid:26)(cid:25)(cid:19)(cid:18)(cid:19)(cid:23)(cid:28)(cid:16)
(cid:15)(cid:30)(cid:24)(cid:17)(cid:19)(cid:21)(cid:14)(cid:16)(cid:27)(cid:25)(cid:26)(cid:17)(cid:19)(cid:20)(cid:27)(cid:21)(cid:13)(cid:13)(cid:12)(cid:17)
(cid:11)(cid:13)(cid:12)(cid:24)(cid:20)(cid:13)(cid:12)(cid:27)(cid:26)(cid:20)(cid:20)(cid:13)(cid:17)(cid:17)(cid:27)(cid:23)(cid:30)(cid:27)(cid:15)(cid:13)(cid:26)(cid:18)(cid:23)(cid:15)(cid:20)(cid:26)(cid:29)(cid:13)
(cid:26)(cid:21)(cid:12)(cid:27)(cid:17)(cid:24)(cid:10)(cid:10)(cid:30)(cid:29)(cid:23)
(cid:24)(cid:21)(cid:19)(cid:27)(cid:28)(cid:22)(cid:21)(cid:20)(cid:18)(cid:21)(cid:17)(cid:16)(cid:15)
(cid:129)(cid:17)(cid:17)(cid:13)(cid:17)(cid:17)
(cid:9)(cid:30)(cid:29)(cid:13)(cid:27)(cid:26)(cid:19)(cid:29)(cid:27)(cid:26)(cid:21)(cid:12)(cid:27)(cid:21)(cid:30)(cid:19)(cid:17)(cid:13)(cid:27)(cid:10)(cid:30)(cid:18)(cid:18)(cid:24)(cid:23)(cid:19)(cid:30)(cid:21)
(cid:11)(cid:13)(cid:17)(cid:10)(cid:30)(cid:21)(cid:12)
(cid:8)(cid:13)(cid:17)(cid:17)(cid:27)(cid:26)(cid:20)(cid:20)(cid:13)(cid:17)(cid:17)(cid:27)(cid:23)(cid:30)(cid:27)(cid:14)(cid:29)(cid:13)(cid:13)(cid:21)(cid:27)(cid:17)(cid:10)(cid:26)(cid:20)(cid:13)(cid:17)
(cid:11)(cid:13)(cid:7)(cid:13)(cid:29)
(cid:26)(cid:21)(cid:12)(cid:27)(cid:17)(cid:26)(cid:7)(cid:13)(cid:27)(cid:10)(cid:18)(cid:26)(cid:20)(cid:13)(cid:17)
(cid:129)(cid:12)(cid:2)(cid:30)(cid:20)(cid:26)(cid:23)(cid:13)
(cid:8)(cid:30)(cid:6)(cid:13)(cid:29)(cid:27)(cid:26)(cid:20)(cid:20)(cid:13)(cid:17)(cid:17)(cid:27)(cid:23)(cid:30)(cid:27)(cid:15)(cid:13)(cid:26)(cid:18)(cid:23)(cid:15)(cid:28)(cid:27)(cid:7)(cid:30)(cid:30)(cid:12)(cid:17)(cid:16)
(cid:5)(cid:30)(cid:29)(cid:13)(cid:27)(cid:7)(cid:26)(cid:17)(cid:23)(cid:4)(cid:7)(cid:30)(cid:30)(cid:12)(cid:27)(cid:30)(cid:24)(cid:23)(cid:18)(cid:13)(cid:23)(cid:17)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)
(cid:14)(cid:22)(cid:23)(cid:27)(cid:22)(cid:13)(cid:18)(cid:12)(cid:11)(cid:23)(cid:16)(cid:17)(cid:27)(cid:22)(cid:21)(cid:16)(cid:15)
(cid:3)(cid:30)(cid:30)(cid:29)(cid:27)(cid:15)(cid:13)(cid:26)(cid:18)(cid:23)(cid:15)(cid:27)(cid:18)(cid:19)(cid:23)(cid:13)(cid:29)(cid:26)(cid:20)(cid:28)
(cid:8)(cid:30)(cid:6)(cid:13)(cid:29)(cid:27)(cid:10)(cid:13)(cid:29)(cid:20)(cid:13)(cid:19)(cid:2)(cid:13)(cid:12)(cid:27)(cid:29)(cid:19)(cid:17)(cid:1)
(cid:127)(cid:21)(cid:15)(cid:13)(cid:26)(cid:18)(cid:23)(cid:15)(cid:28)(cid:27)(cid:25)(cid:13)(cid:15)(cid:26)(cid:2)(cid:19)(cid:30)(cid:24)(cid:29)(cid:17)
Figure 17 Mechanisms through which socioeconomic deprivation contributes to cardiovascular risk. CV, cardiovascular.
• Recognize that people facing socioeconomic deprivation may have in- Mental health challenges in migrant populations are illustrated in
creased risk of CVD and mental health conditions and may struggle Figure 18.
to make healthy lifestyle changes. Healthcare professionals can support migrant groups with CVD and
• Tailor lifestyle advice and behaviour change strategies to the specific mental health conditions by:
challenges of individuals living in deprived areas.
• Adopting culturally sensitive approaches.
• Support policies and governmental action that ensure equitable ac-
• Collaborating with community stakeholders.
cess to physical and mental healthcare, healthy food, exercise, and
• Tailoring community-based strategies to different ethnic groups.
safe places for walking.
• Advocate for efforts to reduce environmental pollution.
8.4.2. Barriers to mental healthcare access
8.4.1. Mental health and cardiovascular disease in Socioeconomic deprivation creates significant barriers to accessing
migrants and refugees both mental healthcare and CV care for individuals with CVD, worsen-
Minority populations are often subject to discrimination, socioeconom- ing the challenges faced by this vulnerable group. Financial constraints,
ic disadvantage, and inequity of access to optimal clinical care.612,613 lack of insurance coverage, and transportation difficulties are major ob-
Migrants and refugees, as vulnerable groups, are at increased risk stacles, with stigma surrounding mental health further exacerbating the
of mental health conditions and disorders, often with greater preva- problem. Despite high rates of depression and anxiety in this popula-
lence of CV risk factors and socioeconomic deprivation.614Migrants tion, the utilization of mental health services remains low due to these
in particular experience higher rates of CVD morbidity and mortality barriers.606,618–624
than host populations.615 War refugees are also at higher risk for Comprehensive strategies are needed to overcome these barriers
CVD and mental health conditions, especially PTSD, though they pre- and ensure equitable access to healthcare, including subsidizing mental
sent lower risk of suicide.613Additionally, migrants and refugees often health services, expanding insurance coverage, integrating mental
encounter language and cultural barriers, making engagement with healthcare into primary care settings, and investing in telehealth. High
community leaders essential for improving communication in cross- costs of therapy, medication, and other interventions can be prohibi-
cultural consultations in healthcare.616 While stakeholders’ involve- tive, deterring people with CVD from seeking needed care, with the fi-
ment can reduce healthcare barriers, structural factors may limit nancial burden of CVD care further limiting resources for mental health
the scope and sustainability of these improvements in practice.617 support.619
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 48 ---
ESC Guidelines 4203
(cid:12)(cid:16)(cid:16)(cid:20)(cid:24)(cid:30)(cid:23)(cid:23)(cid:26)(cid:13)(cid:13)(cid:24)(cid:30)(cid:29)(cid:19)
(cid:27)(cid:13)(cid:26)(cid:24)(cid:16)(cid:11)(cid:24)(cid:10)(cid:26)(cid:30)(cid:22)(cid:21)(cid:10)(cid:23)(cid:30)(cid:20)(cid:26)
(cid:13)(cid:26)(cid:20)(cid:18)(cid:17)(cid:23)(cid:26)(cid:13)
(cid:9)(cid:17)(cid:28)(cid:10)(cid:24) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:28)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:22)(cid:21)(cid:27)(cid:20)(cid:30)(cid:22)
(cid:14)(cid:27)(cid:20)(cid:19)(cid:26)(cid:29)(cid:24)(cid:16)(cid:11)(cid:24)(cid:15)(cid:26)(cid:29)(cid:21)(cid:30)(cid:22)(cid:24) (cid:30)(cid:29)(cid:19)(cid:24)(cid:26)(cid:29)(cid:18)(cid:17)(cid:20)(cid:16)(cid:29)(cid:15)(cid:26)(cid:29)(cid:21)(cid:30)(cid:22)
(cid:24)(cid:10)(cid:26)(cid:30)(cid:22)(cid:21)(cid:10)(cid:24)(cid:23)(cid:16)(cid:29)(cid:19)(cid:17)(cid:21)(cid:17)(cid:16)(cid:29)(cid:13) (cid:14)(cid:30)(cid:20)(cid:20)(cid:17)(cid:26)(cid:20)(cid:13)
(cid:9)(cid:17)(cid:28)(cid:10)(cid:24)(cid:8)(cid:20)(cid:26)(cid:18)(cid:30)(cid:22)(cid:26)(cid:29)(cid:23)(cid:26)
(cid:9)(cid:17)(cid:28)(cid:10)(cid:24)(cid:8)(cid:20)(cid:26)(cid:18)(cid:30)(cid:22)(cid:26)(cid:29)(cid:23)(cid:26)
(cid:16)(cid:11)(cid:24)(cid:23)(cid:10)(cid:20)(cid:16)(cid:29)(cid:17)(cid:23)(cid:24)(cid:8)(cid:10)(cid:7)(cid:13)(cid:17)(cid:23)(cid:30)(cid:22)
(cid:16)(cid:11)(cid:24)(cid:23)(cid:10)(cid:20)(cid:16)(cid:29)(cid:17)(cid:23)(cid:24)(cid:13)(cid:21)(cid:20)(cid:26)(cid:13)(cid:13)
(cid:23)(cid:16)(cid:29)(cid:19)(cid:17)(cid:21)(cid:17)(cid:16)(cid:29)(cid:13)
(cid:9)(cid:17)(cid:28)(cid:10)(cid:24)(cid:8)(cid:20)(cid:26)(cid:18)(cid:30)(cid:22)(cid:26)(cid:29)(cid:23)(cid:26)
(cid:16)(cid:11)(cid:24)(cid:27)(cid:29)(cid:21)(cid:20)(cid:26)(cid:30)(cid:21)(cid:26)(cid:19)
(cid:23)(cid:16)(cid:15)(cid:15)(cid:27)(cid:29)(cid:17)(cid:23)(cid:30)(cid:14)(cid:22)(cid:26)
(cid:19)(cid:17)(cid:13)(cid:26)(cid:30)(cid:13)(cid:26)(cid:13)
Figure 18 Mental health challenges in migrant populations.
Additionally, the lack of comprehensive health insurance coverage is a Stigma affects all populations across different socioeconomic strata,
significant issue, with many socioeconomically disadvantaged individuals contributing to mental health disparities. Effective interventions to re-
unable to afford out-of-pocket mental health services. This further per- duce stigma include social contact with individuals with mental health
petuates disparities in access to necessary mental healthcare.620 disorders and personal relationships, such as with friends or family
Addressing these challenges through enhanced service provision and members. Educational interventions, especially for general healthcare
support is essential for improving mental health outcomes in people professionals with little or no formal mental health training, have shown
with CVD from socioeconomically deprived backgrounds. promise in decreasing stigma.626 However, there is a significant re-
search gap regarding effective interventions to prevent and combat
structural and interpersonal stigma. Enhancing education to include
8.4.3. Stigma in healthcare provision
training on mental health and stigma for healthcare professionals could
Mental health-related stigma is a major barrier to accessing healthcare, op-
be crucial in addressing these issues.
erating at three interconnected levels: structural, interpersonal, and intra-
personal.625Structural discrimination is reflected in the disparity between
physical and mental healthcare provision, resulting in limited and poor- 8.4.4. Community and policy interventions
quality mental health services.626Interpersonal stigma involves problems Community-level and policy interventions are essential to reduce the
of knowledge (ignorance), attitudes (prejudice), and behaviour (discrimin- adverse impact of socioeconomic deprivation on mental health in indi-
ation). Intrapersonal mental health stigma, or self-stigma, reduces help- viduals with and without CVD.607,628,629 Initiatives addressing dispar-
seeking behaviour and further contributes to health disparities.627 ities include:
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 49 ---
4204 E S C G u id e l in e s
• Ensuring access to quality health education for socioeconomically 8.5.3. Advanced cancer disease
disadvantaged individuals to improve mental and CV outcomes. Awareness of cancer progression can lead to depression, which may be
• Creating job opportunities and implementing affordable housing in- worsened by cancer treatment-related toxicity.655Cancer progression,
itiatives and ensuring equitable access to healthcare services to ad- fatigue, and therapy-related toxicity (haematological, endocrinological,
dress mental health needs, neurological and particularly, cardiological) contribute to feelings of dis-
• Improving access to healthy foods and safe spaces for physical activity couragement and depression.656 One in four people with advanced
to reduce CVD risk. cancer, HF, chronic obstructive pulmonary disease, and/or human im-
• Ensuring equitable access to healthcare services to address mental munodeficiency virus/acquired immunodeficiency syndrome may ex-
and CV health needs. perience mental health issues, including depression, alcohol abuse,
• Integrating successful interventions into broader health systems and PTSD, or anxiety disorders.657 Such conditions often coexist and
social policies to enhance mental and CV health support.630–637 may be observed in cardio-oncology.
8.5. Mental health and cardiovascular 8.5.4. Cancer therapy-related cardiovascular
toxicity
disease in people with cancer
People with pre-existing CVD are more sensitive to cancer therapy-related
(cardio-oncology)
CV toxicity including CV dysfunction; however, stressors like anxiety can
8.5.1. Mental health in people with cancer and be an additional trigger.658 People with breast cancer who experienced
cardiovascular disease cancer therapy-related CV dysfunction reported significant declines in
Chronic stress may contribute to cancer development.638Cancer diag- physical, social, and psychosocial well-being, including overwhelming fatigue,
nosis and treatment initiation may cause or intensify psychological dis- mental burden of anxiety (fear of death, depression, stress, poor sleep qual-
tress,639 leading to an increased risk of major CV events (HF, ity), and social challenges (lack of understanding and acceptance).659Heart
ischaemic stroke, ACS, AF), with the highest incidence appearing 6–12 failure in breast cancer survivors is particularly linked to serious mental
months after cancer diagnosis.640–642People with a new diagnosis of can- well-being deficits, especially in the early stages.660This underscores the
cer experience significant stress and anxiety associated with an uncertain need for multidisciplinary cardio-oncological care models.659
prognosis, which may even trigger suicidal ideations. In prostate cancer,
the risk of CV death was increased during the first month after diagnosis 8.5.5. Impact of cancer therapy on mental health
(∼two-fold) and highest in people with metastatic cancer (∼three-
People in the cardio-oncology setting may experience neurotoxicity, in-
fold).642New CV symptoms (e.g. venous thrombosis, pulmonary embol-
cluding chemotherapy-induced cognitive dysfunction (‘chemobrain’),
ism, stroke, MI, TTS, arrhythmia) may appear with cancer,643suggesting
particularly with cardiotoxic therapies, which correlates with increased
common underlying factors, such as chronic inflammation and thrombo- fatigue and psychological distress.661 Potentially cardiotoxic cancer
embolic disorders. However, the importance of stress may be crucial.
treatments with possible cognitive impairment include: chemotherapy
Takotsubo syndrome in people living with cancer is a notable ex-
(doxorubicin, paclitaxel, methotrexate, fluorouracil), hormone therap-
ample of a role of stress and anxiety in cardio-oncology.644–647Three
ies (aromatase inhibitors, anti-oestrogen, androgen deprivation ther-
of the most important independent prognostic predictors of mortality
apy), targeted therapies (antiangiogenic therapy), and immunotherapy
in people with TTS include cancer history (HR 2.004; P = .004), physical (anti-CTLA-4, anti-PDL-1).662
stress as a trigger (HR 1.882; P = .012), and history of depression (HR
Androgen deprivation therapy, a primary treatment for prostate can-
1.622; P = .009).648 Takotsubo syndrome in people with prior in-
cer, is associated with a higher risk of depression and psychiatric outpatient
trathoracic malignancies and radiation therapy carries a higher risk of visits.663 Endocrine therapy for breast cancer may cause mood disor-
cardiogenic shock, cardiac arrest, arrhythmia, stroke, respiratory fail- ders,664 sleep problems,665 cognitive decline,666 fear of cancer recur-
ure, and all-cause mortality.649 rence,667 emotional distress, and concern about appearance.668 Severe
People with cancer and concomitant CVD may fear that their CVD will
fear of cancer recurrence was associated with a higher risk of depression
delay or prevent optimal cancer treatment. Cardio-oncology programmes and lower QoL in breast cancer survivors.669
aim to prevent such issues by ensuring proper CV management allowing
Chemotherapy-induced peripheral neuropathy significantly decreases
optimal oncology therapy and providing a supportive network throughout
QoL and impacts on mental health. Older (cisplatin and vinca alkaloids)
the treatment phase.650 Psychologists, as an integral part of the
and newer (taxanes, oxaliplatin) anticancer agents can be responsible for
cardio-oncology team, are essential to help people to cope with the psy-
these neurological side effects. Oncology expert documents recommend
chological consequences of the disease and treatment. Physiotherapists antidepressants (e.g. venlafaxine, duloxetine),670but these should be cho-
and dietitians also play vital roles in empowerment and reassurance.
sen following consideration of CVD risk (e.g. HF or arrhythmias/QTc pro-
longation). Radiation, while essential in many cancer treatments, can
8.5.2. Cancer survivors induce CV toxicity671 and significant mental health issues.672 The
After radical anticancer treatment, where a good long-term prognosis Ontario Cancer Registry showed mental health conditions (anxiety, de-
is expected, stress may be related to the fear of cancer recurrence,651 pression, and low well-being) were associated with higher comorbidity
or depression related to the complications of cancer or its treat- burden during radiation.673
ment.652Among childhood cancer survivors, stress/distress was asso-
ciated with new-onset dysrhythmia (RR 2.87), perceived stress with 8.5.6. Psychological interventions
hypertension (RR 1.42), PTSS and anxiety with dyslipidaemia (RR One of the roles of cardio-oncology is to minimize the barriers to onco-
1.72 and 1.54, respectively).653 A significant relationship between se- logical treatment related to a person’s CVD. Providing simultaneous
vere psychological distress and CVD in cancer survivors was observed cardiology care can improve the psychological well-being of people
(OR 2.95), especially in younger females.654 dealing with both cancer and CVD. Cardio-oncologists should identify
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 50 ---
ESC Guidelines 4205
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:24)(cid:23)(cid:28)(cid:29)(cid:22)(cid:24)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:24)(cid:23)(cid:28)(cid:29)(cid:22)(cid:24)(cid:21)(cid:20)(cid:19)(cid:24)(cid:30)(cid:26)(cid:18) (cid:14)(cid:30)(cid:26)(cid:14)(cid:27)(cid:13)(cid:143)(cid:13)(cid:27)(cid:127)(cid:30)(cid:29)(cid:27)(cid:18)(cid:24)(cid:21)(cid:20)(cid:19)(cid:24)
(cid:18)(cid:28)(cid:30)(cid:17)(cid:26)(cid:16)(cid:25)(cid:28)(cid:25)(cid:24)(cid:16)(cid:15)(cid:24)(cid:14)(cid:30)(cid:26)(cid:14)(cid:27)(cid:13) (cid:16)(cid:13)(cid:24)(cid:14)(cid:30)(cid:26)(cid:14)(cid:27)(cid:13)
(cid:29)(cid:13)(cid:27)(cid:30)(cid:29)(cid:8)(cid:27)(cid:26)(cid:29)(cid:143)(cid:13)(cid:27)(cid:127)(cid:30)(cid:29)(cid:27)(cid:18)(cid:24)(cid:21)(cid:20)(cid:19)
(cid:31)(cid:25)(cid:10)(cid:17)(cid:22)(cid:14)(cid:13)(cid:21)(cid:30)(cid:16)(cid:18)(cid:28)(cid:14)(cid:24)(cid:29)(cid:27)(cid:30)(cid:8)
(cid:4)(cid:26)(cid:29)(cid:27)(cid:13)(cid:11)(cid:27)(cid:26)(cid:29)(cid:28)(cid:16)(cid:26)(cid:25)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:24)(cid:23)(cid:28)(cid:29)(cid:22)
(cid:3)(cid:14)(cid:13)(cid:27)(cid:27)(cid:26)(cid:24)(cid:30)(cid:26)(cid:18)
(cid:21)(cid:20)(cid:19)(cid:24)(cid:30)(cid:26)(cid:18)(cid:24)(cid:17)(cid:30)(cid:26)(cid:17)(cid:27)(cid:16)
(cid:18)(cid:28)(cid:30)(cid:17)(cid:26)(cid:16)(cid:25)(cid:27)
(cid:15)(cid:17)(cid:30)(cid:16)(cid:18)(cid:28)(cid:14)(cid:13)(cid:14)(cid:26)(cid:17)(cid:14)(cid:12)(cid:14)(cid:11)(cid:10)(cid:9)
(cid:31)(cid:13)(cid:27)(cid:11)(cid:27)(cid:26)(cid:29) (cid:1)(cid:28)(cid:15)(cid:27)(cid:25)(cid:29)(cid:9)(cid:127)(cid:27)(cid:24)(cid:28)(cid:26)(cid:29)(cid:27)(cid:13)(cid:11)(cid:27)(cid:26)(cid:29)(cid:28)(cid:16)(cid:26)(cid:25)
(cid:5)(cid:27)(cid:26)(cid:29)(cid:30)(cid:12)(cid:24)(cid:22)(cid:27)(cid:30)(cid:12)(cid:29)(cid:22)
(cid:18)(cid:28)(cid:25)(cid:14)(cid:16)(cid:18)(cid:27)(cid:16)(cid:25)(cid:4)
(cid:25)(cid:10)(cid:8)(cid:3)(cid:29)(cid:14)(cid:8)(cid:25)
(cid:3)(cid:29)(cid:13)(cid:27)(cid:25)(cid:25)(cid:129)(cid:30)(cid:26)(cid:141)(cid:28)(cid:27)(cid:29)(cid:9)(cid:129)
(cid:18)(cid:27)(cid:6)(cid:13)(cid:27)(cid:25)(cid:25)(cid:28)(cid:16)(cid:26)(cid:129)(cid:31)(cid:2)(cid:3)(cid:19)
(cid:3)(cid:5)(cid:6)(cid:6)(cid:16)(cid:13)(cid:29) (cid:31)(cid:25)(cid:9)(cid:14)(cid:22)(cid:16)(cid:127)(cid:16)(cid:17)(cid:28)(cid:14)(cid:30)(cid:127)(cid:24)(cid:29)(cid:22)(cid:27)(cid:13)(cid:30)(cid:6)(cid:28)(cid:27)(cid:25)
(cid:7)(cid:14)(cid:16)(cid:25)(cid:27)(cid:26)(cid:28)(cid:26)(cid:11)(cid:24)(cid:14)(cid:6)
(cid:8)(cid:27)(cid:26)(cid:29)(cid:30)(cid:12)(cid:24)(cid:22)(cid:27)(cid:30)(cid:12)(cid:29)(cid:22)
(cid:12)(cid:14)(cid:29)(cid:28)(cid:11)(cid:27)(cid:24)(cid:14)(cid:30)(cid:26)(cid:14)(cid:27)(cid:13) (cid:21)(cid:30)(cid:26)(cid:14)(cid:27)(cid:13)(cid:24)(cid:25)(cid:5)(cid:13)(cid:11)(cid:28)(cid:11)(cid:16)(cid:13)(cid:25)
(cid:10)(cid:26)(cid:14)(cid:27)(cid:13)(cid:29)(cid:30)(cid:28)(cid:26)(cid:29)(cid:9)(cid:24)(cid:16)(cid:26)
(cid:7)(cid:27)(cid:30)(cid:13)(cid:24)(cid:16)(cid:15)(cid:24)(cid:6)(cid:13)(cid:16)(cid:17)(cid:26)(cid:16)(cid:25)(cid:28)(cid:25)
(cid:14)(cid:30)(cid:26)(cid:14)(cid:27)(cid:13)(cid:24)(cid:29)(cid:13)(cid:27)(cid:30)(cid:29)(cid:8)(cid:27)(cid:26)(cid:29) (cid:2)(cid:13)(cid:27)(cid:30)(cid:29) (cid:31)(cid:22)(cid:30)(cid:13)(cid:8)(cid:30)(cid:14)(cid:16)(cid:127)(cid:16)(cid:17)(cid:28)(cid:14)(cid:30)(cid:127)(cid:24)(cid:29)(cid:13)(cid:27)(cid:30)(cid:29)(cid:8)(cid:27)(cid:26)(cid:29)
(cid:144)(cid:157)(cid:27)(cid:14)(cid:29)(cid:28)(cid:11)(cid:27)(cid:26)(cid:27)(cid:25)(cid:25) (cid:21)(cid:30)(cid:26)(cid:14)(cid:27)(cid:13)(cid:24)(cid:13)(cid:27)(cid:14)(cid:5)(cid:13)(cid:13)(cid:27)(cid:26)(cid:14)(cid:27)
(cid:21)(cid:16)(cid:8)(cid:6)(cid:127)(cid:28)(cid:14)(cid:30)(cid:29)(cid:28)(cid:16)(cid:26)(cid:25) (cid:1)(cid:30)(cid:29)(cid:27)(cid:24)(cid:29)(cid:16)(cid:141)(cid:28)(cid:14)(cid:28)(cid:29)(cid:9)
Figure 19 Management of mental health in people with cardiovascular disease and cancer. CVD, cardiovascular disease; PTSD, post-traumatic stress disorder.
psychosocial distress, including depression, anxiety, anger, social oncological treatment or potential cancer relapse/progression, which
isolation, marital/family distress, sexual dysfunction, and substance may coexist.675The benefits in cardio-oncology include recommending
abuse. People in the cardio-oncology setting may benefit from multi- physical activity:
disciplinary team discussions, involving CV specialists, oncologists, and
mental health professionals. Alternatively, they should be referred to
• Cancer survivors with CVD: an exercise-based programme can im-
mental health specialists, who can collaborate with the primary
prove cardiorespiratory fitness and survival;676ECR can improve de-
cardio-oncology team to support comprehensive care.674
pression scores in breast cancer survivors.677
• In people with advanced or metastatic cancer,678 exercise interven-
8.5.7. Lifestyle interventions in cardio-oncology tions can lower mortality, and improve psychosocial function and
A comprehensive approach is necessary in cardio-oncology, as both CV sleep quality.679
health and mental health should be monitored during and after cancer • Women with breast cancer receiving potentially cardiotoxic therap-
therapy. The essence of a cardio-oncology clinic resides in the availabil- ies may improve their mental health by a comprehensive CV risk re-
ity of a doctor to address symptoms related to CV toxicity from duction programme.680
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 51 ---
4206 E S C G u id e l in e s
8.5.8. Medical interventions (including MANAGEMENT CONSENSUS STATEMENTS
pharmacological therapies)
(i) Psycho-Cardio teams may need to tailor their intervention to the
There are no specific recommendations or evidence for the efficacy of specificities of the target population, with special attention to sex
psychiatric drugs in cardio-oncology. However, data from general car- differences, age, frailty, and SES.
diology and oncology can be extrapolated and implemented with care- (ii) The appropriateness of antidepressants, drug interactions and side
ful consideration of specific requirements of people with cancer and effects in the multimorbid, elderly, and frail need careful evaluation
CVD.
by a multidisciplinary team.
The frequency of ventricular arrhythmias increases in people with
(iii) Migrants and refugees may benefit from directed proactive
advanced cancer,681 with the risk compounded by coexisting heart
programmes to assess their CV and mental health due to the high
disease.682 Psychiatric drugs (antipsychotics, antidepressants), CV
prevalence of conditions and their potential difficulties to access the
drugs (especially antiarrhythmics), and oncological drugs may interact,
healthcare system.
leading to QTc prolongation, and increased bleeding risk.683
Therefore, it is important to avoid significant drug–drug interactions
to minimize side effects and prevent reduced effectiveness of cancer
treatments due to altered plasma concentrations.680,683 There are 9. Key messages
potential positive indirect effects on mental health resulting from
CV therapies: (i) The interplay between mental and CV health should be known
and acknowledged in order to provide a holistic and integrated
• Treating cancer therapy-related CV dysfunction and cancer-related care.
anaemia may decrease shortness of breath, easing anxiety and (ii) Healthcare professionals should aspire to implement an inte-
distress.684
grated Psycho-Cardio team approach that is tailored to the local
• Treatment of tachycardia/tachyarrhythmia or autonomic dysfunction needs.
due to radiotherapy, chemotherapy, or cancer, may improve psycho- (iii) The ACTIVE principles (Acknowledge, Check, Tools, Implement,
logical symptoms.685–687 Venture, Evaluate) can be used as a practical approach to imple-
ment integrated mental healthcare into CV practice.
On the other hand, reducing anxiety and stress may lower blood (iv) Screening for mental health conditions (mainly anxiety, depres-
pressure and help control hypertension in people living with cancer. sion, and PTSD) and psychosocial risk factors could help improve
A summary of the major management steps of mental health in CV risk assessment in healthy individuals.
cardio-oncology and the main management approaches is shown in (v) Screening for mental health conditions in people with CVD is im-
Figure 19. portant since these are highly prevalent and associated with
worse outcomes.
(vi) Initial screening may be performed with a two-item measure,
8.6. Section summary points and
followed by longer validated tools if it raises mental health
management consensus statements from concerns.
Section 8 (vii) A stepped care approach for mental health in CVD is advisable:
intensity of mental care should be tailored to individual need.
(viii) There is low to moderate certainty evidence that psychological in-
terventions have an effect on depression, anxiety, and QoL in
SECTION SUMMARY POINTS people with CVD. The evidence is weaker or non-existent for a
reduction in MACE and mortality.
(i) Depression, anxiety, and chronic stress show higher prevalence in
(ix) Pharmacological treatment with anxiolytics or antidepressants in
women compared with men and are associated with increased
people with CVD and mental health conditions should be balanced
CVD risk. against risks, considering drug–drug interactions and side effects.
(ii) Women with CVD exhibit higher rates of mental health conditions,
(x) Caregivers of people with CVD, who play a key role in well-being
which are associated with worse outcomes, particularly depression. and treatment adherence, often face mental health challenges
(iii) Sex differences in the multidirectional relationship between CV and themselves, highlighting the need for strategies to assess and sup-
mental health suggest a role of biological and sociocultural port their mental health.
components (gender). (xi) People with SMI have a worse CV outcome. Efforts should be
(iv) Evaluation of mental health and frailty in elderly people with CVD is made to reduce stigma and provide optimal Guideline-directed
of utmost importance, CV care, with special attention to treatment adherence and clin-
(v) Socioeconomically deprived populations show higher rates of CVD ically relevant drug–drug interactions.
and mental disorders and require special attention. (xii) Specific characteristics (sex, gender, age, frailty, SES, comorbid-
(vi) Cancer, CVD, and mental disorders exhibit significant three-way ities, co-medications) should be carefully assessed as they are
relationships with shared risk factors. modifiers of the interaction between CVD and mental health
and may merit individualized approaches.
Continued
5202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 52 ---
ESC Guidelines 4207
10. Gaps in knowledge • Randomized controlled trials of interventions for elderly people with
comorbid CVD and mental health conditions are needed.
There are substantial gaps in the knowledge of the multidirectional re- • The efficacy of multidisciplinary approaches in improving outcomes
lationship between mental health, CV health, and CVD, and its mechan- for people with multimorbidity requires further research.
isms. Further, optimal strategies to identify, prevent, and manage
mental health conditions in people with CVD are lacking. These gaps 10.4. Knowledge gaps in relation to
not only include finding effective interventions to prevent and manage
healthcare systems and healthcare delivery
mental health conditions and ways to implement them, but also ways to
change the system to provide integrative healthcare including mental • Development and testing of integrated or collaborative care models
and physical health. A summary of the main gaps across the broad do- for people with coexisting CV and mental health conditions is
mains covered in this document are outlined below. needed.
• Care pathways to streamline the management of people with
CVD and mental health conditions need to be developed and
10.1. Knowledge gaps in relation to evaluated.
• Evaluation of community-level and policy interventions to address
prevention and screening
socioeconomic disparities impacting CV and mental health is
essential.
• There is a lack of evidence-based, cost-effective, and tailored inter-
ventions to improve psychosocial factors, mental health conditions,
and mental well-being as preventive measures for CVD. 11. Conclusions
• Determination of optimal screening protocols, including timing, fre-
quency, and methods, for mental health conditions in people with This document provides a comprehensive review of the evidence of the
CVD, and how these might vary by condition have not been established. critical interplay between mental and CV health and disease, emphasiz-
• Screening-based treatment algorithms are not defined. ing the need to integrate mental health assessment and management
• Data on the cost-effectiveness of interventions to identify, prevent, into routine CV care. However, the consistency of definitions, mechan-
or treat mental health conditions in people with CVD are lacking. isms of interactions, and optimal ways to investigate, prevent, or treat
the negative impact of mental health on CVD and vice versa need fur-
ther research.
10.2. Knowledge gaps in relation to clinical
Social and clinical efforts are needed to fight the stigma of mental
management health conditions in the population and in healthcare systems to reduce
its impact on CV care. This is particularly urgent for people with SMI, in
• Feasibility, effectiveness, and sustainability of long-term non- whom an extra effort is needed to reduce the major gaps in CV preven-
pharmacological interventions, such as physical activity, psychother- tion, acute and chronic CV care. Awareness campaigns and educational
apy, and social prescribing need to be established. programmes for CV care professionals, people with CVD, their care-
• Evaluation of specific psychological interventions and their delivery givers and decision-makers will be needed.
methods, including digital health solutions, is needed. Integrated CV care models with a holistic view of health need to be
• Effective behavioural strategies for achieving behaviour change and co-developed in hospital and outpatient CV care units, integrating and co-
improving CV risk profiles among people with mental disorders, in- ordinating with mental health professionals, primary care and social care.
cluding SMI, need to be developed and tested. These should be co-designed together with people with lived experience
• Understanding of the role of trauma-specific prevention or treat- of CVD and their caregivers, and adapted to the local conditions and
ments for CVD-related PTSD is lacking. availability, individual characteristics and needs. Comprehensive ECR pro-
• Research into the mental health impact of caregiving for people with grammes are good examples of care integration. Educational modules
CVD, prevention of its negative consequences, and integration of in- and specific training programmes designed by medical and nursing staff
terventions into routine CV care is needed. and allied health professionals, particularly mental health professionals,
• Pharmacological research is needed to: are warranted. Reimbursement models for the new models of care
⚬ Demonstrate the safety and efficacy of antidepressants and anti- need to be addressed and implemented by local authorities.
psychotics in people with HF and their effects on CV clinical Future research is needed to increase the knowledge of the multi-
outcomes. lateral interactions between mental health and CV health and obtain
⚬ Explore the role of pharmacogenomics in stratifying treatment to solid evidence for the prevention and management of the negative
minimize CV adverse effects and enhance psychiatric treatment consequences of these interactions. This should include prospective
efficacy. longitudinal studies in the population, in people with different CVDs,
⚬ Investigate the efficacy of psychiatric drugs in cardio-oncology. and in people with mental health conditions, including those with
SMI. There is an urgent need for RCTs, with larger and more diverse
samples of individuals and types of CVD that test the effectiveness
10.3. Knowledge gaps in relation to special
and safety of medical and non-medical interventions. These trials
populations should include psychological, pharmacological, social, and other types
of interventions to prevent or reduce negative mental and CV
• Cardiovascular risk scores for people with SMI need to be recalibrated. outcomes.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 53 ---
4208 E S C G u id e l in e s
12. Summary of mental health of Psychiatry and Psychological Medicine, Zagreb School of Medicine,
Zagreb, Croatia, and European Psychiatric Association, Strasbourg,
aspects in specific cardiovascular
France; Sebastian Szmit, Department of Cardio-Oncology, Centre
diseases of Postgraduate Medical Education, Warsaw, Poland, and
Department of Cancer Diagnostics and Cardio-Oncology, Maria
Summary information for the CVDs discussed in this consensus state- Sklodowska-Curie National Research Institute of Oncology, Warsaw,
ment is provided in Supplementary data online, Tables S12–S17. Poland; Rod S. Taylor, MRC/cso Social and Public Health Sciences
Unit & Robertson Centre for Biostatistics, University of Glasgow,
13. Clinical cases and patient Glasgow, United Kingdom; Izabella Uchmanowicz, Department
of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical
perspectives
University, Wroclaw, Poland, and Centre for Cardiovascular Health,
Edinburgh Napier University, United Kingdom; and Noa Vilchinsky,
Clinical cases and patient perspectivesare available at European Heart
Department of Psychology, Bar-Ilan University, Ramat-Gan, Israel.
Journal online.
14. Evidence tables
17. Appendix
Evidence tablesare available at European Heart Journal online.
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac
15. Data availability statement Societies.
Document Reviewers: Konstantinos C. Koskinas (CPG Review
Supplementary dataare available at European Heart Journal online. Co-ordinator) (Switzerland), Pascal Vranckx (CPG Review
Co-ordinator) (Belgium), Marianna Adamo (Italy), Elena Arbelo
16. Author information (Spain), Folkert W. Asselbergs (Netherlands), Giuseppe Boriani
(Italy), Margarita Brida (Croatia), Noeleen Burke (Ireland), Robert
Author/Task Force Member Affiliations: Frieder A. Byrne (Ireland), Ingrid de Laval (Sweden), Lidia Einsfeld (Brazil),
Braunschweig, Heart and Lung Diseases Unit, Department of Enrico Frigoli (Switzerland), Leonarda Galiuto (Italy), Estelle
Medicine (H7), Karolinska Institutet, Stockholm, Sweden, and Gandjbakhch (France), Sherry L. Grace (Canada), Johannes Grand
Department of Cardiology, Heart and Vascular Center, Karolinska (Denmark), Bettina Heidecker (Germany), Mirjam Heldner
University Hospital, Stockholm, Sweden; Sergio Buccheri, (Switzerland), Charlotte Helmark (Denmark), Marwa Hemmat Gaber
Department of Medical Sciences, Cardiology and Uppsala Clinical (Egypt), Loreena Hill (United Kingdom), Lisa Hynes (Ireland), Borja
Research Center, Uppsala University, Uppsala, Sweden; Simona Ibanez (Spain), Stefan James (Sweden), Alexander Kharlamov
Dragan, Cardiology, Victor Babes University of Medicine and (Netherlands), Hanne Kindermans (Belgium), Lars Køber (Denmark),
Pharmacy, Timisoara, Romania, and Clinic of Cardiac Rehabilitation, Ulf Landmesser (Germany), Gregory Y.H. Lip (United Kingdom),
Institute of Cardiovascular Diseases, Timisoara, Romania; Marta Emma F. Magavern (United Kingdom), John William McEvoy (Ireland),
Farrero, Heart Failure Unit, Cardiology, Hospital Clinic Barcelona, Paul McGreavy (United Kingdom), Borislava Mihaylova (United
Barcelona, Spain; Faye Forsyth, Department of Public Health and Kingdom), Inge Moelgaard (Denmark), Manuela Abreu (Portugal),
Primary Care, University of Cambridge, Cambridge, United Kingdom, Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Eva
and Department of Public Health and Primary Care, KU Leuven, Prescott (Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca
Leuven, Belgium; Sofie Gevaert, Cardiology, Ghent University (Italy), Xavier Rossello (Spain), Annett Salzwedel (Germany), Anna
Hospital, Gent, Belgium; Claes Held, Uppsala Clinical Research Sannino (Germany), Eduard Shantsila (United Kingdom), Chantal Ski
Center, Uppsala University, Uppsala, Sweden, and Department of (United Kingdom), Andrew Steptoe (United Kingdom), Felix
Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; C. Tanner (Switzerland), Diogo Telles (Portugal), Ilonca Vaartjes
Donata Kurpas, Division of Research Methodology, Department (Netherlands), Berlinde von Kemp (Belgium), Christiaan Vrints
of Nursing, Wroclaw Medical University, Wroclaw, Poland; (Belgium), and Katja Zeppenfeld (Netherlands).
Karl-Heinz Ladwig, Department of Psychosomatic Medicine and ESC National Cardiac Societies actively involved in the review
Psychotherapy, Klinikum rechts der Isar, Technische Universität process of the 2025 ESC Consensus Statement on Mental Health and
München, Munich, Germany, and German Center for Cardiovascular Cardiovascular Disease:
Research (DZHK), Partnersite Munich Heart Alliance, Munich, Algeria: Algerian Society of Cardiology, Mohammed El Amine
Germany; Christos D. Lionis, Laboratory of Health and Society, Bouzid; Azerbaijan: Azerbaijan Society of Cardiology, Emin Karimli;
School of Medicine, University of Crete, Greece, Heraklion, Crete, Belgium: Belgian Society of Cardiology, Michel De Pauw; Bosnia
Greece, and University of Limassol, Cyprus; Angela H.E.M. Maas, and Herzegovina: Association of Cardiologists of Bosnia and
Cardiology, Radboud University Medical Center, Nijmegen, Herzegovina, Lamija Ferhatbegović; Bulgaria: Bulgarian Society of
Netherlands; Caius Ovidiu Merșa, ESC Patient Forum, Sophia Cardiology, Kiril Karamfiloff; Croatia: Croatian Cardiac Society,
Antipolis, France; Richard Mindham, ESC Patient Forum, Sophia Valentina Rickovic; Cyprus: Cyprus Society of Cardiology, Joseph
Antipolis, France; Susanne S. Pedersen, Department of Moutiris; Denmark: Danish Society of Cardiology, Ann Dorthe
Psychology, University of Southern Denmark, Odense, Denmark, and Zwisler; Egypt: Egyptian Society of Cardiology, Ahmed Elghalid;
Department of Cardiology, Odense, Denmark; Martina Rojnic Estonia: Estonian Society of Cardiology, Alar Irs; France: French
Kuzman, Department of Psychiatry and Psychological Medicine, Society of Cardiology, Jean Jacques Monsuez; Georgia: Georgian
Zagreb University Hospital Centre, Zagreb, Croatia, and Department Society of Cardiology, Rusudan Agladze; Germany: German
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 54 ---
ESC Guidelines 4209
Cardiac Society, Christoph Herrmann-Lingen; Greece: Hellenic 6.Peck MC, Scheffler RM. An analysis of the definitions of mental illness used in state
Society of Cardiology, Athanasios Dritsas; Hungary: Hungarian parity laws. Psychiatr Serv 2002;53:1089–95. https://doi.org/10.1176/appi.ps.53.9.
1089
Society of Cardiology, Endre Zima; Iceland: Icelandic Society of
7.World Health Organization. International Classification of Diseases, Eleventh Revision
Cardiology, Hróbjartur Karlsson; Israel: Israel Heart Society, Inbar (ICD-11) 2022. https://icd.who.int/(5 February 2024, date last accessed).
Nardi Agmon; Italy: Italian Federation of Cardiology, Anna Vittoria 8.National Association of Chronic Disease Directors. Cardiovascular Health. https://
Mattioli; Kazakhstan: Association of Cardiologists of Kazakhstan, chronicdisease.org/page/cardiovascularhealth/(20 June 2024, date last accessed).
9.Boehm JK, Kubzansky LD. The heart’s content: the association between positive psy-
Meiramgul Tundybayeva; Kosovo (Republic of): Kosovo Society
chological well-being and cardiovascular health. Psychol Bull 2012;138:655–91. https://
of Cardiology, Shpend Elezi; Kyrgyzstan: Kyrgyz Society of
doi.org/10.1037/a0027448
Cardiology, Erkin Mirrakhimov; Latvia: Latvian Society of 10.Rozanski A. Behavioral cardiology: current advances and future directions. J Am Coll
Cardiology, Iveta Mintale; Lithuania: Lithuanian Society of Cardiol 2014;64:100–10. https://doi.org/10.1016/j.jacc.2014.03.047
11.Kubzansky LD, Huffman JC, Boehm JK, Hernandez R, Kim ES, Koga HK, et al. Positive
Cardiology, Tomas Lapinskas; Luxembourg: Luxembourg Society
psychological well-being and cardiovascular disease: JACC health promotion series. J
of Cardiology, Cristiana-Astra Banu; Moldova (Republic of):
Am Coll Cardiol 2018;72:1382–96. https://doi.org/10.1016/j.jacc.2018.07.042
Moldavian Society of Cardiology, Valeriu Revenco; Morocco: 12.Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al.
Moroccan Society of Cardiology, Iliyasse Asfalou; Netherlands: Prevalence, incidence and mortality from cardiovascular disease in patients with
Netherlands Society of Cardiology, Petra Kuijpers; North pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 pa-
tients and 113,383,368 controls. World Psychiatry 2017;16:163–80. https://doi.org/10.
Macedonia: National Society of Cardiology of North Macedonia,
1002/wps.20420
Jorgo Kostov; Norway: Norwegian Society of Cardiology, Eva Rice; 13.Vilchinsky N, Ginzburg K, Fait K, Foa EB. Cardiac-disease-induced PTSD (CDI-PTSD):
Poland: Polish Cardiac Society, Anna Mierzynska; Portugal: a systematic review. Clin Psychol Rev 2017;55:92–106. https://doi.org/10.1016/j.cpr.
Portuguese Society of Cardiology, Manuela Abreu; Romania: 2017.04.009
14.Rafiei S, Raoofi S, Baghaei A, Masoumi M, Doustmehraban M, Nejatifar Z, et al.
Romanian Society of Cardiology, Florin Mitu; San Marino: San
Depression prevalence in cardiovascular disease: global systematic review and
Marino Society of Cardiology, Luca Bertelli; Serbia: Cardiology meta-analysis. BMJ Support Palliat Care 2023;13:281–9. https://doi.org/10.1136/
Society of Serbia, Dusica Lecic Tosevski; Slovakia: Slovak Society of spcare-2022-003884
Cardiology, Zuzana Katreniakova; Slovenia: Slovenian Society of 15.Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a
meta-analytic review of prevalence, intervention effects, and associations with clinical
Cardiology, Zlatko Fras; Spain: Spanish Society of Cardiology,
outcomes. J Am Coll Cardiol 2006;48:1527–37. https://doi.org/10.1016/j.jacc.2006.06.055
Raquel Campuzano; Sweden: Swedish Society of Cardiology, Joanna
16.Karami N, Kazeminia M, Karami A, Salimi Y, Ziapour A, Janjani P. Global prevalence of
Hlebowicz; Switzerland: Swiss Society of Cardiology, Matthias depression, anxiety, and stress in cardiac patients: a systematic review and meta-analysis.
Hermann; Türkiye: Turkish Society of Cardiology, Baris Gungor; J Affect Disord 2023;324:175–89. https://doi.org/10.1016/j.jad.2022.12.055
17.Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N,
Ukraine: Ukrainian Association of Cardiology, Yuriy Sirenko; and
et al. Depression as a risk factor for poor prognosis among patients with acute coron-
Uzbekistan: Association of Cardiologists of Uzbekistan, Nargiza
ary syndrome: systematic review and recommendations: a scientific statement from
Makhkamova. the American Heart Association. Circulation 2014;129:1350–69. https://doi.org/10.
ESC Clinical Practice Guidelines (CPG) Committee: 1161/CIR.0000000000000019
Ulf Landmesser (Chairperson) (Germany), Stefan James 18.Sokoreli I, de Vries JJ, Riistama JM, Pauws SC, Steyerberg EW, Tesanovic A, et al.
Depression as an independent prognostic factor for all-cause mortality after a hospital
(Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman
admission for worsening heart failure. Int J Cardiol 2016;220:202–7. https://doi.org/10.
Aktaa (United Kingdom), Folkert W. Asselbergs (Netherlands), 1016/j.ijcard.2016.06.068
Colin Baigent (United Kingdom), Michael A. Borger (Germany), 19.Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association be-
Giuseppe Boriani (Italy), Margarita Brida (Croatia), Robert tween anxiety and mortality in patients with coronary artery disease: a meta-analysis. Am
Heart J 2015;170:1105–15. https://doi.org/10.1016/j.ahj.2015.09.013
A. Byrne (Ireland), Estelle Gandjbakhch (France), Bettina Heidecker
20.Morgan AJ, Reavley NJ, Ross A, Too LS, Jorm AF. Interventions to reduce stigma to-
(Germany), Anja Hennemuth (Germany), Borja Ibanez (Spain), wards people with severe mental illness: systematic review and meta-analysis. J
Peter Jüni (United Kingdom), Gregory Y.H. Lip (United Kingdom), Psychiatr Res 2018;103:120–33. https://doi.org/10.1016/j.jpsychires.2018.05.017
John William McEvoy (Ireland), Borislava Mihaylova (United 21.Heiberg IH, Jacobsen BK, Balteskard L, Bramness JG, Naess Ø, Ystrom E, et al.
Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with
Kingdom), Inge Moelgaard (Denmark), Lis Neubeck (United
severe mental illness. Acta Psychiatr Scand 2019;139:558–71. https://doi.org/10.1111/
Kingdom), Eva Prescott (Denmark), Bianca Rocca (Italy), Xavier acps.13017
Rossello (Spain), Anna Sannino (Germany), Felix C. Tanner 22.Marchand WE. Occurrence of painless myocardial infarction in psychotic patients. N
(Switzerland), Wojtek Wojakowski (Poland), and Katja Zeppenfeld Engl J Med 1955;253:51–5. https://doi.org/10.1056/NEJM195507142530202
23.Stubbs B, Thompson T, Acaster S, Vancampfort D, Gaughran F, Correll CU.
(Netherlands).
Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experi-
mental pain induction studies. Pain 2015;156:2121–31. https://doi.org/10.1097/j.pain.
18. References 0000000000000304
24.De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, et al. Physical
illness in patients with severe mental disorders. II. Barriers to care, monitoring and treat-
1.Cox C, Fritz Z. Presenting complaint: use of language that disempowers patients. BMJ
ment guidelines, plus recommendations at the system and individual level. World
2022;377:e066720. https://doi.org/10.1136/bmj-2021-066720
Psychiatry 2011;10:138–51. https://doi.org/10.1002/j.2051-5545.2011.tb00036.x
2.Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its
25.Mitchell AJ, Lord O. Do deficits in cardiac care influence high mortality rates in schizo-
appropriateness. World J Methodol 2021;11:116–29. https://doi.org/10.5662/wjm.v11.
phrenia? A systematic review and pooled analysis. J Psychopharmacol 2010;24:69–80.
i4.116
3.World Health Organization. Comprehensive Mental Health Action Plan 2013–2030. https://doi.org/10.1177/1359786810382056
2013. https://www.who.int/publications/i/item/9789240031029 (5 February 2024, 26.Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al.
date last accessed). Mortality in people with schizophrenia: a systematic review and meta-analysis of rela-
4.Manwell LA, Barbic SP, Roberts K, Durisko Z, Lee C, Ware E, et al. What is mental tive risk and aggravating or attenuating factors. World Psychiatry 2022;21:248–71.
health? Evidence towards a new definition from a mixed methods multidisciplinary https://doi.org/10.1002/wps.20994
international survey. BMJ Open 2015;5:e007079. https://doi.org/10.1136/bmjopen- 27.Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, et al. No health without men-
2014-007079 tal health. Lancet 2007;370:859–77. https://doi.org/10.1016/S0140-6736(07)61238-0
5.Chowdhury M. What is the Mental Health Continuum Model? 2019. https:// 28.Raj CT. The effectiveness of mental health disorder stigma-reducing interventions in
positivepsychology.com/mental-health-continuum-model/ (8 October 2024, date the healthcare setting: an integrative review. Arch Psychiatr Nurs 2022;39:73–83.
last accessed). https://doi.org/10.1016/j.apnu.2022.03.005
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 55 ---
4210 E S C G u id e l in e s
29.Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and man- 51.Kivimäki M, Bartolomucci A, Kawachi I. The multiple roles of life stress in metabolic
agement of depression in patients with cardiovascular disease: JACC state-of-the-art disorders. Nat Rev Endocrinol 2023;19:10–27. https://doi.org/10.1038/s41574-022-
review. J Am Coll Cardiol 2019;73:1827–45. https://doi.org/10.1016/j.jacc.2019.01.041 00746-8
30.Mindham R, Van Heetvelde M, Pedersen SS. How your patient is really feeling: the 52.Ginty AT, Kraynak TE, Fisher JP, Gianaros PJ. Cardiovascular and autonomic reactivity
emotional hinterland of a cardiac diagnosis. Eur Heart J 2024;45:748–50. https://doi. to psychological stress: neurophysiological substrates and links to cardiovascular dis-
org/10.1093/eurheartj/ehad840 ease. Auton Neurosci 2017;207:2–9. https://doi.org/10.1016/j.autneu.2017.03.003
31.George-Levi S, Vilchinsky N, Rafaeli E, Liberman G, Khaskiaa A, Mosseri M, et al. 53.Segerstrom SC, Miller GE. Psychological stress and the human immune system: a
Caregiving styles and anxiety among couples: coping versus not coping with cardiac ill- meta-analytic study of 30 years of inquiry. Psychol Bull 2004;130:601–30. https://doi.
ness. Anxiety Stress Coping 2017;30:107–20. https://doi.org/10.1080/10615806.2016. org/10.1037/0033-2909.130.4.601
1206530 54.Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially
32.Fait K, Vilchinsky N, Dekel R, Levi N, Hod H, Matetzky S. Cardiac disease-induced post- modifiable risk factors associated with myocardial infarction in 52 countries (the
traumatic stress symptoms (CDI-PTSS) among patients’ partners. Stress Health 2017; INTERHEART study): case-control study. Lancet 2004;364:937–52. https://doi.org/
33:169–76. https://doi.org/10.1002/smi.2686 10.1016/S0140-6736(04)17018-9
33.van Wijnen HG, Rasquin SM, van Heugten CM, Verbunt JA, Moulaert VR. The impact 55.Dar T, Radfar A, Abohashem S, Pitman RK, Tawakol A, Osborne MT. Psychosocial
of cardiac arrest on the long-term wellbeing and caregiver burden of family caregivers: stress and cardiovascular disease. Curr Treat Options Cardiovasc Med 2019;21:23.
a prospective cohort study. Clin Rehabil 2017;31:1267–75. https://doi.org/10.1177/ https://doi.org/10.1007/s11936-019-0724-5
0269215516686155 56.Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al.
34.Vilchinsky N. Unrecognized, undiagnosed, and untreated: cardiac-disease-induced Association of psychosocial risk factors with risk of acute myocardial infarction in
PTSD among patients’ partners. Front Psychol 2017;8:1265. https://doi.org/10.3389/ 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-
fpsyg.2017.01265 control study. Lancet 2004;364:953–62. https://doi.org/10.1016/S0140-6736(04)17019-0
35.Revenson TA, Griva K, Luszczynska A, Morrison V, Panagopoulou E, Vilchinsky N, et al. 57.Peterson PN. JAHA spotlight on psychosocial factors and cardiovascular disease. J Am
Caregiving in the Illness Context. Hampshire, England: Spinger, 2016, 1–156. Heart Assoc 2020;9:e017112. https://doi.org/10.1161/JAHA.120.017112
36.Back M. A New Task Force for Allied Professionals in the European Society of Cardiology 58.Kivimäki M, Nyberg ST, Batty GD, Fransson EI, Heikkilä K, Alfredsson L, et al. Job strain as
(ESC). 2020. https://www.escardio.org/Sub-specialty-communities/Association-of- a risk factor for coronary heart disease: a collaborative meta-analysis of individual partici-
pant data. Lancet 2012;380:1491–7. https://doi.org/10.1016/S0140-6736(12)60994-5
Cardiovascular-Nursing-&-Allied-Professions/News/celebrating-allied-health-
59.Magnusson Hanson LL, Westerlund H, Chungkham HS, Vahtera J, Rod NH,
professionals-day#:∼:text=An%20ESC%20transversal%20Task%20Force,in%
Alexanderson K, et al. Job strain and loss of healthy life years between ages 50 and
20cardiovascular%20disease%20management%20both (8 October 2024, date last
75 by sex and occupational position: analyses of 64 934 individuals from four prospect-
accessed).
ive cohort studies. Occup Environ Med 2018;75:486–93. https://doi.org/10.1136/
37.Solanes A, Albajes-Eizagirre A, Fullana MA, Fortea L, Fusar-Poli P, Torrent C, et al. Can
oemed-2017-104644
we increase the subjective well-being of the general population? An umbrella review of
60.Sørensen JK, Framke E, Pedersen J, Alexanderson K, Bonde JP, Farrants K, et al. Work
the evidence. Rev Psiquiatr Salud Ment (Engl Ed) 2021;14:50–64. https://doi.org/10.
stress and loss of years lived without chronic disease: an 18-year follow-up of 1.5 mil-
1016/j.rpsm.2020.08.002
lion employees in Denmark. Eur J Epidemiol 2022;37:389–400. https://doi.org/10.1007/
38.Levine GN, Cohen BE, Commodore-Mensah Y, Fleury J, Huffman JC, Khalid U, et al.
s10654-022-00852-x
Psychological health, well-being, and the mind-heart-body connection: a scientific
61.Xu T, Magnusson Hanson LL, Lange T, Starkopf L, Westerlund H, Madsen IEH, et al.
statement from the American Heart Association. Circulation 2021;143:e763–83.
Workplace bullying and workplace violence as risk factors for cardiovascular disease: a
https://doi.org/10.1161/CIR.0000000000000947
multi-cohort study. Eur Heart J 2019;40:1124–34. https://doi.org/10.1093/eurheartj/
39.Levine GN, Steinke EE, Bakaeen FG, Bozkurt B, Cheitlin MD, Conti JB, et al. Sexual activity
ehy683
and cardiovascular disease: a scientific statement from the American Heart Association.
62.Landsbergis PA, Dobson M, Koutsouras G, Schnall P. Job strain and ambulatory blood
Circulation 2012;125:1058–72. https://doi.org/10.1161/CIR.0b013e3182447787
pressure: a meta-analysis and systematic review. Am J Public Health 2013;103:e61–71.
40.Mc Gee SL, Höltge J, Maercker A, Thoma MV. Sense of coherence and stress-related
https://doi.org/10.2105/AJPH.2012.301153
resilience: investigating the mediating and moderating mechanisms in the development
63.Yang B, Wang Y, Cui F, Huang T, Sheng P, Shi T, et al. Association between insomnia
of resilience following stress or adversity. Front Psychiatry 2018;9:378. https://doi.org/
and job stress: a meta-analysis. Sleep Breath 2018;22:1221–31. https://doi.org/10.1007/
10.3389/fpsyt.2018.00378
s11325-018-1682-y
41.Chida Y, Steptoe A. Positive psychological well-being and mortality: a quantitative re-
64.Rugulies R, Aust B, Madsen IE. Effort-reward imbalance at work and risk of depressive
view of prospective observational studies. Psychosom Med 2008;70:741–56. https://doi.
disorders. A systematic review and meta-analysis of prospective cohort studies. Scand J
org/10.1097/PSY.0b013e31818105ba
Work Environ Health 2017;43:294–306. https://doi.org/10.5271/sjweh.3632
42.Martín-María N, Miret M, Caballero FF, Rico-Uribe LA, Steptoe A, Chatterji S, et al. 65.Li J, Atasoy S, Fang X, Angerer P, Ladwig KH. Combined effect of work stress and im-
The impact of subjective well-being on mortality: a meta-analysis of longitudinal studies paired sleep on coronary and cardiovascular mortality in hypertensive workers: the
in the general population. Psychosom Med 2017;79:565–75. https://doi.org/10.1097/ MONICA/KORA cohort study. Eur J Prev Cardiol 2021;28:220–6. https://doi.org/10.
PSY.0000000000000444 1177/2047487319839183
43.Davidson KW, Mostofsky E, Whang W. Don’t worry, be happy: positive affect and re- 66.Heikkilä K, Nyberg ST, Fransson EI, Alfredsson L, De Bacquer D, Bjorner JB, et al. Job
duced 10-year incident coronary heart disease: the Canadian Nova Scotia Health strain and tobacco smoking: an individual-participant data meta-analysis of 166,130
Survey. Eur Heart J 2010;31:1065–70. https://doi.org/10.1093/eurheartj/ehp603 adults in 15 European studies. PLoS One 2012;7:e35463. https://doi.org/10.1371/
44.Kim ES, Smith J, Kubzansky LD. Prospective study of the association between disposi- journal.pone.0035463
tional optimism and incident heart failure. Circ Heart Fail 2014;7:394–400. https://doi. 67.Fransson EI, Heikkilä K, Nyberg ST, Zins M, Westerlund H, Westerholm P, et al. Job
org/10.1161/CIRCHEARTFAILURE.113.000644 strain as a risk factor for leisure-time physical inactivity: an individual-participant
45.Shimbo D, Cohen MT, McGoldrick M, Ensari I, Diaz KM, Fu J, et al. Translational re- meta-analysis of up to 170,000 men and women: the IPD-Work Consortium. Am J
search of the acute effects of negative emotions on vascular endothelial health: findings Epidemiol 2012;176:1078–89. https://doi.org/10.1093/aje/kws336
from a randomized controlled study. J Am Heart Assoc 2024;13:e032698. https://doi. 68.Heikkilä K, Nyberg ST, Fransson EI, Alfredsson L, De Bacquer D, Bjorner JB, et al. Job
org/10.1161/JAHA.123.032698 strain and alcohol intake: a collaborative meta-analysis of individual-participant data
46.Rozanski A, Kubzansky LD. Psychologic functioning and physical health: a paradigm of from 140,000 men and women. PLoS One 2012;7:e40101. https://doi.org/10.1371/
flexibility. Psychosom Med 2005;67:S47–53. https://doi.org/10.1097/01.psy.0000164253. journal.pone.0040101
69550.49 69.Heikkilä K, Fransson EI, Nyberg ST, Zins M, Westerlund H, Westerholm P, et al. Job
47.Steptoe A, Wardle J, Marmot M. Positive affect and health-related neuroendocrine, strain and health-related lifestyle: findings from an individual-participant meta-analysis
cardiovascular, and inflammatory processes. Proc Natl Acad Sci USA 2005;102: of 118,000 working adults. Am J Public Health 2013;103:2090–7. https://doi.org/10.
6508–12. https://doi.org/10.1073/pnas.0409174102 2105/AJPH.2012.301090
48.Boehm JK, Chen Y, Koga H, Mathur MB, Vie LL, Kubzansky LD. Is optimism associated 70.Kaspersen SL, Pape K, Ose SO, Gunnell D, Bjørngaard JH. Unemployment and initi-
with healthier cardiovascular-related behavior? Meta-analyses of 3 health behaviors. ation of psychotropic medication: a case-crossover study of 2 348 552 Norwegian em-
Circ Res 2018;122:1119–34. https://doi.org/10.1161/CIRCRESAHA.117.310828 ployees. Occup Environ Med 2016;73:719–26. https://doi.org/10.1136/oemed-2016-
49.Lurz J, Ladwig KH. Mind and body interventions in cardiology: the importance of the 103578
brain-heart connection. Herz 2022;47:103–9. https://doi.org/10.1007/s00059-022- 71.Sanchez Rico M, Plessz M, Airagnes G, Ribet C, Hoertel N, Goldberg M, et al.
05104-y Cardiovascular burden and unemployment: a retrospective study in a large population-
50.Lazarus RS. Some principles of psychological stress and their relation to dentistry. J based French cohort. PLoS One 2023;18:e0288747. https://doi.org/10.1371/journal.
Dent Res 1966;45:1620–6. https://doi.org/10.1177/00220345660450060901 pone.0288747
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 56 ---
ESC Guidelines 4211
72.Zagozdzon P, Parszuto J, Wrotkowska M, Dydjow-Bendek D. Effect of unemployment 96.Krittanawong C, Maitra NS, Qadeer YK, Wang Z, Fogg S, Storch EA, et al. Association
on cardiovascular risk factors and mental health. Occup Med (Lond) 2014;64:436–41. of depression and cardiovascular disease. Am J Med 2023;136:881–95. https://doi.org/
https://doi.org/10.1093/occmed/kqu044 10.1016/j.amjmed.2023.04.036
73.Ahn J, Kim NS, Lee BK, Park J, Kim Y. Comparison of the physical and mental health 97.Rajan S, McKee M, Rangarajan S, Bangdiwala S, Rosengren A, Gupta R, et al. Association
problems of unemployed with employees in South Korea. Arch Environ Occup Health of symptoms of depression with cardiovascular disease and mortality in low-, middle-,
2021;76:163–72. https://doi.org/10.1080/19338244.2020.1783503 and high-income countries. JAMA Psychiatry 2020;77:1052–63. https://doi.org/10.1001/
74.Wang T, Li Y, Zheng X. Association of socioeconomic status with cardiovascular dis- jamapsychiatry.2020.1351
ease and cardiovascular risk factors: a systematic review and meta-analysis. Z Gesundh 98.Cao L, Sheng C, Luo G, Ou J. Depression as a risk factor for developing heart failure: a
Wiss 2023;32:385–99. https://doi.org/10.1007/s10389-023-01825-4 meta-analysis of prospective cohort studies. J Cardiovasc Nurs 2022;37:112–21. https://
75.Jackman MR, Jackman RW. An interpretation of the relation between objective and sub- doi.org/10.1097/JCN.0000000000000760
jective social status. Am Sociol Rev 1973;38:569–82. https://doi.org/10.2307/2094408 99.Shi S, Liu T, Liang J, Hu D, Yang B. Depression and risk of sudden cardiac death and
76.Tang KL, Rashid R, Godley J, Ghali WA. Association between subjective social status arrhythmias: a meta-analysis. Psychosom Med 2017;79:153–61. https://doi.org/10.
and cardiovascular disease and cardiovascular risk factors: a systematic review and 1097/PSY.0000000000000382
meta-analysis. BMJ Open 2016;6:e010137. https://doi.org/10.1136/bmjopen-2015- 100. Wu H, Li C, Li B, Zheng T, Feng K, Wu Y. Psychological factors and risk of atrial fib-
010137 rillation: a meta-analysis and systematic review. Int J Cardiol 2022;362:85–92. https://
77.Everson-Rose SA, Lutsey PL, Roetker NS, Lewis TT, Kershaw KN, Alonso A, et al. doi.org/10.1016/j.ijcard.2022.05.048
Perceived discrimination and incident cardiovascular events: the multi-ethnic study of 101. Gilman SE, Sucha E, Kingsbury M, Horton NJ, Murphy JM, Colman I. Depression and
atherosclerosis. Am J Epidemiol 2015;182:225–34. https://doi.org/10.1093/aje/kwv035 mortality in a longitudinal study: 1952–2011. CMAJ 2017;189:E1304–10. https://doi.
78.Lawrence WR, Jones GS, Johnson JA, Ferrell KP, Johnson JN, Shiels MS, et al. org/10.1503/cmaj.170125
Discrimination experiences and all-cause and cardiovascular mortality: multi-ethnic 102. DeMartini J, Patel G, Fancher TL. Generalized anxiety disorder. Ann Intern Med 2019;
study of atherosclerosis. Circ Cardiovasc Qual Outcomes 2023;16:e009697. https:// 170:ITC49–64. https://doi.org/10.7326/AITC201904020
doi.org/10.1161/CIRCOUTCOMES.122.009697 103. Nechita D, Nechita F, Motorga R. A review of the influence the anxiety exerts on hu-
79.Martos-Méndez MJ, García-Cid A, Gómez-Jacinto L, Hombrados-Mendieta I. Perceived man life. Rom J Morphol Embryol 2018;59:1045–51.
discrimination, psychological distress and cardiovascular risk in migrants in Spain. Int J 104. Steimer T. The biology of fear- and anxiety-related behaviors. Dialogues Clin Neurosci
Environ Res Public Health 2020;17:4601. https://doi.org/10.3390/ijerph17124601 2002;4:231–49. https://doi.org/10.31887/DCNS.2002.4.3/tsteimer
80.Harris LK, Berry DC, Cortés YI. Psychosocial factors related to cardiovascular disease 105. Batelaan NM, Seldenrijk A, Bot M, van Balkom AJ, Penninx BW. Anxiety and new onset
risk in young African American women: a systematic review. Ethn Health 2022;27:
of cardiovascular disease: critical review and meta-analysis. Br J Psychiatry 2016;208:
1806–24. https://doi.org/10.1080/13557858.2021.1990218
223–31. https://doi.org/10.1192/bjp.bp.114.156554
81.Kalmakis KA, Chandler GE. Adverse childhood experiences: towards a clear concep-
106. Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of incident coronary
tual meaning. J Adv Nurs 2014;70:1489–501. https://doi.org/10.1111/jan.12329
heart disease: a meta-analysis. J Am Coll Cardiol 2010;56:38–46. https://doi.org/10.
82.Jakubowski KP, Cundiff JM, Matthews KA. Cumulative childhood adversity and adult
1016/j.jacc.2010.03.034
cardiometabolic disease: a meta-analysis. Health Psychol 2018;37:701–15. https://doi.
107. Janszky I, Ahnve S, Lundberg I, Hemmingsson T. Early-onset depression, anxiety, and risk
org/10.1037/hea0000637
of subsequent coronary heart disease: 37-year follow-up of 49,321 young Swedish men. J
83.Batty GD, Kivimäki M, Frank P. State care in childhood and adult mortality: a systematic
Am Coll Cardiol 2010;56:31–7. https://doi.org/10.1016/j.jacc.2010.03.033
review and meta-analysis of prospective cohort studies. Lancet Public Health 2022;7:
108. Nabi H, Hall M, Koskenvuo M, Singh-Manoux A, Oksanen T, Suominen S, et al.
e504–14. https://doi.org/10.1016/S2468-2667(22)00081-0
Psychological and somatic symptoms of anxiety and risk of coronary heart disease:
84.Liang Y, Ai S, Weng F, Feng H, Yang L, He Z, et al. Associations of childhood maltreat-
the health and social support prospective cohort study. Biol Psychiatry 2010;67:
ment and genetic risks with incident heart failure in later life. J Am Heart Assoc 2022;11:
378–85. https://doi.org/10.1016/j.biopsych.2009.07.040
e026536. https://doi.org/10.1161/JAHA.122.026536
109. Emdin CA, Odutayo A, Wong CX, Tran J, Hsiao AJ, Hunn BH. Meta-analysis of anxiety
85.Jackson DB, Testa A, Woodward KP, Qureshi F, Ganson KT, Nagata JM. Adverse child-
as a risk factor for cardiovascular disease. Am J Cardiol 2016;118:511–9. https://doi.org/
hood experiences and cardiovascular risk among young adults: findings from the 2019
10.1016/j.amjcard.2016.05.041
behavioral risk factor surveillance system. Int J Environ Res Public Health 2022;19:11710.
110. Fu Y, He W, Ma J, Wei B. Relationship between psychological factors and atrial fibril-
https://doi.org/10.3390/ijerph191811710
lation: a meta-analysis and systematic review. Medicine (Baltimore) 2020;99:e19615.
86.Dong M, Giles WH, Felitti VJ, Dube SR, Williams JE, Chapman DP, et al. Insights into
https://doi.org/10.1097/MD.0000000000019615
causal pathways for ischemic heart disease: adverse childhood experiences study.
111. Gustad LT, Laugsand LE, Janszky I, Dalen H, Bjerkeset O. Symptoms of anxiety and de-
Circulation 2004;110:1761–6. https://doi.org/10.1161/01.CIR.0000143074.54995.7F
pression and risk of heart failure: the HUNT study. Eur J Heart Fail 2014;16:861–70.
87.Chandan JS, Thomas T, Bradbury-Jones C, Russell R, Bandyopadhyay S,
https://doi.org/10.1002/ejhf.133
Nirantharakumar K, et al. Female survivors of intimate partner violence and risk of de-
112. Smoller JW, Pollack MH, Wassertheil-Smoller S, Jackson RD, Oberman A, Wong ND,
pression, anxiety and serious mental illness. Br J Psychiatry 2020;217:562–7. https://doi.
et al. Panic attacks and risk of incident cardiovascular events among postmenopausal org/10.1192/bjp.2019.124
women in the Women’s Health Initiative Observational Study. Arch Gen Psychiatry
88.Chandan JS, Thomas T, Bradbury-Jones C, Taylor J, Bandyopadhyay S, Nirantharakumar
K. Risk of cardiometabolic disease and all-cause mortality in female survivors of domestic 2007;64:1153–60. https://doi.org/10.1001/archpsyc.64.10.1153
abuse. J Am Heart Assoc 2020;9:e014580. https://doi.org/10.1161/JAHA.119.014580 113. Thakur A, Choudhary D, Kumar B, Chaudhary A. A review on post-traumatic stress
89.Clark CJ, Alonso A, Everson-Rose SA, Spencer RA, Brady SS, Resnick MD, et al. disorder (PTSD): symptoms, therapies and recent case studies. Curr Mol Pharmacol
Intimate partner violence in late adolescence and young adulthood and subsequent 2022;15:502–16. https://doi.org/10.2174/1874467214666210525160944
cardiovascular risk in adulthood. Prev Med 2016;87:132–7. https://doi.org/10.1016/j. 114. Sladen RN, Shulman MA, Javaid A, Hodgson C, Myles PS, McGiffin D, et al.
ypmed.2016.02.031 Postdischarge functional capacity, health-related quality of life, depression, anxiety,
90.Prohaska T, Burholt V, Burns A, Golden J, Hawkley L, Lawlor B, et al. Consensus state- and post-traumatic stress disorder in patients receiving a long-term left ventricular as-
ment: loneliness in older adults, the 21st century social determinant of health? BMJ sist device. J Card Fail 2022;28:83–92. https://doi.org/10.1016/j.cardfail.2021.07.019
Open 2020;10:e034967. https://doi.org/10.1136/bmjopen-2019-034967 115. Beristianos MH, Yaffe K, Cohen B, Byers AL. PTSD and risk of incident cardiovascular
91.Newall NEG, Menec VH. A comparison of different definitions of social isolation using disease in aging veterans. Am J Geriatr Psychiatry 2016;24:192–200. https://doi.org/10.
Canadian Longitudinal Study on Aging (CLSA) data. Ageing Soc 2020;40:2671–94. 1016/j.jagp.2014.12.003
https://doi.org/10.1017/S0144686X19000801 116. Jacquet-Smailovic M, Brennsthul MJ, Denis I, Kirche A, Tarquinio C, Tarquinio C.
92.Valtorta NK, Kanaan M, Gilbody S, Ronzi S, Hanratty B. Loneliness and social isolation Relationship between post-traumatic stress disorder and subsequent myocardial in-
as risk factors for coronary heart disease and stroke: systematic review and farction: a systematic review and meta-analysis. J Affect Disord 2022;297:525–35.
meta-analysis of longitudinal observational studies. Heart 2016;102:1009–16. https:// https://doi.org/10.1016/j.jad.2021.10.056
doi.org/10.1136/heartjnl-2015-308790 117. Boscarino JA. A prospective study of PTSD and early-age heart disease mortality
93.Liang YY, Chen Y, Feng H, Liu X, Ai QH, Xue H, et al. Association of social isolation and among Vietnam veterans: implications for surveillance and prevention. Psychosom
loneliness with incident heart failure in a population-based cohort study. JACC Heart Med 2008;70:668–76. https://doi.org/10.1097/PSY.0b013e31817bccaf
Fail 2023;11:334–44. https://doi.org/10.1016/j.jchf.2022.11.028 118. Krantz DS, Shank LM, Goodie JL. Post-traumatic stress disorder (PTSD) as a systemic
94.World Health Organization. Depression and Other Common Mental Disorders: Global disorder: pathways to cardiovascular disease. Health Psychol 2022;41:651–62. https://
Health Estimates. Geneva: World Health Organization, 2017. doi.org/10.1037/hea0001127
95.Ladwig KH, Baumert J, Marten-Mittag B, Lukaschek K, Johar H, Fang X, et al. Room for 119. Fu Q. Autonomic dysfunction and cardiovascular risk in post-traumatic stress disorder.
depressed and exhausted mood as a risk predictor for all-cause and cardiovascular mor- Auton Neurosci 2022;237:102923. https://doi.org/10.1016/j.autneu.2021.102923
tality beyond the contribution of the classical somatic risk factors in men. Atherosclerosis 120. Peruzzolo TL, Pinto JV, Roza TH, Shintani AO, Anzolin AP, Gnielka V, et al.
2017;257:224–31. https://doi.org/10.1016/j.atherosclerosis.2016.12.003 Inflammatory and oxidative stress markers in post-traumatic stress disorder:
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 57 ---
4212 E S C G u id e l in e s
a systematic review and meta-analysis. Mol Psychiatry 2022;27:3150–63. https://doi.org/ 143. Heilmann C, Kaps J, Hartmann A, Zeh W, Anjarwalla AL, Beyersdorf F, et al. Mental
10.1038/s41380-022-01564-0 health status of patients with mechanical aortic valves, with ventricular assist devices
121. Edmondson D, Cohen BE. Posttraumatic stress disorder and cardiovascular disease. and after heart transplantation. Interact Cardiovasc Thorac Surg 2016;23:321–5.
Progress in Cardiovascular Diseases 2013;55:548–56. https://doi.org/10.1016/j.pcad.2013. https://doi.org/10.1093/icvts/ivw111
03.004 144. Thrall G, Lip GY, Carroll D, Lane D. Depression, anxiety, and quality of life in patients
122. Kelly MM, Jensen KP, Sofuoglu M. Co-occurring tobacco use and posttraumatic stress with atrial fibrillation. Chest 2007;132:1259–64. https://doi.org/10.1378/chest.07-0036
disorder: smoking cessation treatment implications. Am J Addict 2015;24:695–704. 145. Ghezzi ES, Sharman RLS, Selvanayagam JB, Psaltis PJ, Sanders P, Astley JM, et al. Burden
https://doi.org/10.1111/ajad.12304 of mood symptoms and disorders in implantable cardioverter defibrillator patients: a
123. van den Berk-Clark C, Secrest S, Walls J, Hallberg E, Lustman PJ, Schneider FD, et al. systematic review and meta-analysis of 39 954 patients. Europace 2023;25:euad130.
Association between posttraumatic stress disorder and lack of exercise, poor diet, https://doi.org/10.1093/europace/euad130
obesity, and co-occuring smoking: a systematic review and meta-analysis. Health 146. Pedersen SS, Nielsen JC, Wehberg S, Jørgensen OD, Riahi S, Haarbo J, et al. New onset
Psychol 2018;37:407–16. https://doi.org/10.1037/hea0000593 anxiety and depression in patients with an implantable cardioverter defibrillator during
124. Edmondson D. An enduring somatic threat model of posttraumatic stress disorder 24 months of follow-up (data from the national DEFIB-WOMEN study). Gen Hosp
due to acute life-threatening medical events. Soc Personal Psychol Compass 2014;8: Psychiatry 2021;72:59–65. https://doi.org/10.1016/j.genhosppsych.2021.07.003
118–34. https://doi.org/10.1111/spc3.12089 147. Ensslin C, Berg J, Hermes-Laufer J, Keller LS, Niederseer D, Pazhenkottil A, et al.
125. Tully PJ, Harrison NJ, Cheung P, Cosh S. Anxiety and cardiovascular disease risk: a re- Depressive symptoms in patients after primary and secondary prophylactic ICD im-
view. Curr Cardiol Rep 2016;18:120. https://doi.org/10.1007/s11886-016-0800-3 plantation. Clin Res Cardiol 2022;111:1210–8. https://doi.org/10.1007/s00392-021-
126. Shao M, Lin X, Jiang D, Tian H, Xu Y, Wang L, et al. Depression and cardiovascular dis- 01940-w
ease: shared molecular mechanisms and clinical implications. Psychiatry Res 2020;285: 148. Tagney J. A literature review comparing the experiences and emergent needs of adult
112802. https://doi.org/10.1016/j.psychres.2020.112802 patients with permanent pacemakers (PPMs) and implantable cardioverter defibrilla-
127. Pedersen SS, Andersen CM, Burg M, Theuns D. Anger and long-term mortality and tors (ICDs). J Clin Nurs 2010;19:2081–9. https://doi.org/10.1111/j.1365-2702.2009.
ventricular arrhythmias in patients with a first-time implantable cardioverter- 03031.x
defibrillator: data from the MIDAS study. Europace 2020;22:1054–61. https://doi. 149. Andonian C, Beckmann J, Biber S, Ewert P, Freilinger S, Kaemmerer H, et al. Current
org/10.1093/europace/euaa083 research status on the psychological situation of adults with congenital heart disease.
128. Rosenstrøm S, Risom SS, Hove JD, Brødsgaard A. Living with atrial fibrillation: a family
Cardiovasc Diagn Ther 2018;8:799–804. https://doi.org/10.21037/cdt.2018.12.06
perspective. Nurs Res Pract 2022;2022:7394445. https://doi.org/10.1155/2022/7394445
150. Udholm S, Nyboe C, Lundbye-Christensen S, Nordentoft M, Hjortdal VE. Congenital
129. Bermudez T, Bierbauer W, Scholz U, Hermann M. Depression and anxiety in cardiac re-
heart disease and risk of suicide and self-harm: a Danish nationwide cohort study. J Am
habilitation: differential associations with changes in exercise capacity and quality of life.
Heart Assoc 2020;9:e015735. https://doi.org/10.1161/JAHA.119.015735
Anxiety Stress Coping 2022;35:204–18. https://doi.org/10.1080/10615806.2021.1952191
151. Gu S, Hu H, Dong H. Systematic review of health-related quality of life in patients with
130. Szpakowski N, Qiu F, Masih S, Kurdyak P, Wijeysundera HC. Economic impact of sub-
pulmonary arterial hypertension. Pharmacoeconomics 2016;34:751–70. https://doi.org/
sequent depression in patients with a new diagnosis of stable angina: a population-based
10.1007/s40273-016-0395-y
study. J Am Heart Assoc 2017;6:e006911. https://doi.org/10.1161/JAHA.117.006911
152. Halimi L, Marin G, Molinari N, Gamez AS, Boissin C, Suehs CM, et al. Impact of psy-
131. Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a
chological factors on the health-related quality of life of patients treated for pulmonary
clinical review. Eur Heart J 2014;35:1365–72. https://doi.org/10.1093/eurheartj/eht462
arterial hypertension. J Psychosom Res 2018;105:45–51. https://doi.org/10.1016/j.
132. Lichtman JH, Bigger JT Jr, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F,
jpsychores.2017.12.003
et al. Depression and coronary heart disease: recommendations for screening, referral,
153. Pfeuffer-Jovic E, Joa F, Halank M, Krannich JH, Held M. Anxiety, depression and quality
and treatment: a science advisory from the American Heart Association Prevention
of life in pulmonary hypertension: a comparison of incident and prevalent cases.
Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology,
Respiration 2022;101:784–92. https://doi.org/10.1159/000524369
Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of
154. Zhang J, Yin Y, Wen Y, Shi F, Wang J. Anxiety and depression in patients with pulmon-
Care and Outcomes Research: endorsed by the American Psychiatric Association.
ary arterial hypertension in northwest China: a cross-sectional study. Front Psychiatry
Circulation 2008;118:1768–75. https://doi.org/10.1161/circulationaha.108.190769
2021;12:758120. https://doi.org/10.3389/fpsyt.2021.758120
133. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic dis-
155. Von Visger TT, Kuntz KK, Phillips GS, Yildiz VO, Sood N. Quality of life and psycho-
eases, and decrements in health: results from the World Health Surveys. Lancet 2007;
logical symptoms in patients with pulmonary hypertension. Heart Lung 2018;47:
370:851–8. https://doi.org/10.1016/S0140-6736(07)61415-9
115–21. https://doi.org/10.1016/j.hrtlng.2017.12.004
134. Mai AS, Lim OZH, Ho YJ, Kong G, Lim GEH, Ng CH, et al. Prevalence, risk factors and
156. Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Mortality and quality of life 12 months
intervention for depression and anxiety in pulmonary hypertension: a systematic re-
after myocardial infarction: effects of depression and anxiety. Psychosom Med 2001;63:
view and meta-analysis. Front Med (Lausanne) 2022;9:765461. https://doi.org/10.
221–30. https://doi.org/10.1097/00006842-200103000-00005
3389/fmed.2022.765461
157. Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J, et al. Adjusted
135. Alosaimi N, Sherar LB, Griffiths P, Pearson N. Clustering of diet, physical activity and
prognostic association of depression following myocardial infarction with mortality sedentary behaviour and related physical and mental health outcomes: a systematic re-
and cardiovascular events: individual patient data meta-analysis. Br J Psychiatry 2013;
view. BMC Public Health 2023;23:1572. https://doi.org/10.1186/s12889-023-16372-6
136. Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, et al. Prevalence of de- 203:90–102. https://doi.org/10.1192/bjp.bp.112.111195
pression in survivors of acute myocardial infarction. J Gen Intern Med 2006;21:30–8. 158. van Dijk MR, Utens EM, Dulfer K, Al-Qezweny MN, van Geuns RJ, Daemen J, et al.
https://doi.org/10.1111/j.1525-1497.2005.00269.x Depression and anxiety symptoms as predictors of mortality in PCI patients at 10
137. Mallik S, Spertus JA, Reid KJ, Krumholz HM, Rumsfeld JS, Weintraub WS, et al. years of follow-up. Eur J Prev Cardiol 2016;23:552–8. https://doi.org/10.1177/
Depressive symptoms after acute myocardial infarction: evidence for highest rates 2047487315571889
in younger women. Arch Intern Med 2006;166:876–83. https://doi.org/10.1001/ 159. Owen JE, Bonds CL, Wellisch DK. Psychiatric evaluations of heart transplant candi-
archinte.166.8.876 dates: predicting post-transplant hospitalizations, rejection episodes, and survival.
138. Pająk A, Jankowski P, Kotseva K, Heidrich J, de Smedt D, De Bacquer D. Depression, Psychosomatics 2006;47:213–22. https://doi.org/10.1176/appi.psy.47.3.213
anxiety, and risk factor control in patients after hospitalization for coronary heart dis- 160. Dew MA, Kormos RL, Roth LH, Murali S, DiMartini A, Griffith BP. Early post-transplant
ease: the EUROASPIRE III Study. Eur J Prev Cardiol 2013;20:331–40. https://doi.org/10. medical compliance and mental health predict physical morbidity and mortality one to
1177/2047487312441724 three years after heart transplantation. J Heart Lung Transplant 1999;18:549–62.
139. Brown T, Chen S, Ou Z, McDonald N, Bennett-Murphy L, Schneider L, et al. Feasibility https://doi.org/10.1016/S1053-2498(98)00044-8
of assessing adolescent and young adult heart transplant recipient mental health and 161. DeFilippis EM, Breathett K, Donald EM, Nakagawa S, Takeda K, Takayama H, et al.
resilience using patient-reported outcome measures. J Acad Consult Liaison Psychiatry Psychosocial risk and its association with outcomes in continuous-flow left ventricular
2022;63:153–62. https://doi.org/10.1016/j.jaclp.2021.08.002 assist device patients. Circ Heart Fail 2020;13:e006910. https://doi.org/10.1161/
140. de la Rosa A, Singer-Englar T, Hamilton MA, IsHak WW, Kobashigawa JA, Kittleson MM. CIRCHEARTFAILURE.120.006910
The impact of depression on heart transplant outcomes: a retrospective single-center 162. Mullan C, Caraballo C, Ravindra NG, Miller PE, McCullough M, Brown K, et al.
cohort study. Clin Transplant 2021;35:e14204. https://doi.org/10.1111/ctr.14204 Psychiatric comorbidity and outcomes after left ventricular assist device implantation
141. Dew MA, Kormos RL, DiMartini AF, Switzer GE, Schulberg HC, Roth LH, et al. for end-stage heart failure. JACC Heart Fail 2020;8:569–77. https://doi.org/10.1016/j.
Prevalence and risk of depression and anxiety-related disorders during the first three jchf.2020.03.011
years after heart transplantation. Psychosomatics 2001;42:300–13. https://doi.org/10. 163. Zhuo C, Ji F, Lin X, Jiang D, Wang L, Tian H, et al. Depression and recurrence of atrial
1176/appi.psy.42.4.300 fibrillation after catheter ablation: a meta-analysis of cohort studies. J Affect Disord
142. Rossi Ferrario S, Panzeri A, Pistono M. Psychological difficulties of LVAD patients and 2020;271:27–32. https://doi.org/10.1016/j.jad.2020.03.118
caregivers: a follow up over one year from discharge. Artif Organs 2022;46:479–90. 164. Sin NL, Kumar AD, Gehi AK, Whooley MA. Direction of association between depres-
https://doi.org/10.1111/aor.14071 sive symptoms and lifestyle behaviors in patients with coronary heart disease: the heart
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 58 ---
ESC Guidelines 4213
and soul study. Ann Behav Med 2016;50:523–32. https://doi.org/10.1007/s12160-016- 185. Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and anx-
9777-9 iety in heart failure: a review. Harv Rev Psychiatry 2018;26:175–84. https://doi.org/10.
165. Tang HY, Sayers SL, Weissinger G, Riegel B. The role of depression in medication ad- 1097/HRP.0000000000000162
herence among heart failure patients. Clin Nurs Res 2014;23:231–44. https://doi.org/10. 186. Alhurani AS, Dekker RL, Abed MA, Khalil A, Al Zaghal MH, Lee KS, et al. The associ-
1177/1054773813481801 ation of co-morbid symptoms of depression and anxiety with all-cause mortality and
166. Swardfager W, Herrmann N, Marzolini S, Saleem M, Farber SB, Kiss A, et al. Major de- cardiac rehospitalization in patients with heart failure. Psychosomatics 2015;56:371–80.
pressive disorder predicts completion, adherence, and outcomes in cardiac rehabilita- https://doi.org/10.1016/j.psym.2014.05.022
tion: a prospective cohort study of 195 patients with coronary artery disease. J Clin 187. Suzuki T, Shiga T, Kuwahara K, Kobayashi S, Suzuki S, Nishimura K, et al. Impact of clus-
Psychiatry 2011;72:1181–8. https://doi.org/10.4088/JCP.09m05810blu tered depression and anxiety on mortality and rehospitalization in patients with heart
167. Kronish IM, Rieckmann N, Halm EA, Shimbo D, Vorchheimer D, Haas DC, et al. failure. J Cardiol 2014;64:456–62. https://doi.org/10.1016/j.jjcc.2014.02.031
Persistent depression affects adherence to secondary prevention behaviors after acute 188. Kikkenborg Berg S, Caspar Thygesen L, Hastrup Svendsen J, Vinggaard Christensen A,
coronary syndromes. J Gen Intern Med 2006;21:1178–83. https://doi.org/10.1111/j. Zwisler AD. Anxiety predicts mortality in ICD patients: results from the cross-
1525-1497.2006.00586.x sectional national CopenHeartICD survey with register follow-up. Pacing Clin
168. Bermudez T, Maercker A, Bierbauer W, Bernardo A, Fleisch-Silvestri R, Hermann M, Electrophysiol 2014;37:1641–50. https://doi.org/10.1111/pace.12490
et al. The role of daily adjustment disorder, depression and anxiety symptoms for the 189. Cromhout PF, Christensen AV, Jørgensen MB, Ekholm O, Juel K, Svendsen JH, et al.
physical activity of cardiac patients. Psychol Med 2023;53:5992–6001. https://doi.org/ Exploring the use of psychotropic medication in cardiac patients with and without anx-
10.1017/S0033291722003154 iety and its association with 1-year mortality. Eur J Cardiovasc Nurs 2022;21:612–9.
169. Lapa ME, Swabe GM, Rollman BL, Muldoon MF, Thurston RC, Magnani JW. https://doi.org/10.1093/eurjcn/zvab111
Assessment of depression and adherence to guideline-directed medical therapies fol- 190. Grace SL, Abbey SE, Shnek ZM, Irvine J, Franche RL, Stewart DE. Cardiac rehabilitation
lowing percutaneous coronary intervention. JAMA Netw Open 2022;5:e2246317. II: referral and participation. Gen Hosp Psychiatry 2002;24:127–34. https://doi.org/10.
https://doi.org/10.1001/jamanetworkopen.2022.46317 1016/S0163-8343(02)00179-2
170. Poletti V, Pagnini F, Banfi P, Volpato E. The role of depression on treatment adherence 191. Eisenberg SA, Shen BJ, Schwarz ER, Mallon S. Avoidant coping moderates the associ-
in patients with heart failure–a systematic review of the literature. Curr Cardiol Rep ation between anxiety and patient-rated physical functioning in heart failure patients. J
2022;24:1995–2008. https://doi.org/10.1007/s11886-022-01815-0 Behav Med 2012;35:253–61. https://doi.org/10.1007/s10865-011-9358-0
171. Storer B, Kershaw KA, Braund TA, Chakouch C, Coleshill MJ, Haffar S, et al. Global 192. Edmondson D, Richardson S, Falzon L, Davidson KW, Mills MA, Neria Y.
prevalence of anxiety in adult cardiology outpatients: a systematic review and Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syn-
meta-analysis. Curr Probl Cardiol 2023;48:101877. https://doi.org/10.1016/j.cpcardiol. drome patients: a meta-analytic review. PLoS One 2012;7:e38915. https://doi.org/10.
2023.101877 1371/journal.pone.0038915
172. Hanssen TA, Nordrehaug JE, Eide GE, Bjelland I, Rokne B. Anxiety and depression after 193. Sumner JA, Kim ESH, Wood MJ, Chi G, Nolen J, Grodzinsky A, et al. Posttraumatic
acute myocardial infarction: an 18-month follow-up study with repeated measures and stress disorder after spontaneous coronary artery dissection: a report of the inter-
comparison with a reference population. Eur J Cardiovasc Prev Rehabil 2009;16:651–9. national spontaneous coronary artery dissection registry. J Am Heart Assoc 2024;13:
https://doi.org/10.1097/HJR.0b013e32832e4206 e032819. https://doi.org/10.1161/JAHA.123.032819
173. Johnson AK, Hayes SN, Sawchuk C, Johnson MP, Best PJ, Gulati R, et al. Analysis of 194. Kobayashi S, Nishimura K, Suzuki T, Shiga T, Ishigooka J. Post-traumatic stress disorder
posttraumatic stress disorder, depression, anxiety, and resiliency within the unique and its risk factors in Japanese patients living with implantable cardioverter defibrilla-
population of spontaneous coronary artery dissection survivors. J Am Heart Assoc tors: a preliminary examination. J Arrhythm 2014;30:105–10. https://doi.org/10.1016/
2020;9:e014372. https://doi.org/10.1161/JAHA.119.014372 j.joa.2013.07.004
174. Easton K, Coventry P, Lovell K, Carter LA, Deaton C. Prevalence and measurement of 195. Kapa S, Rotondi-Trevisan D, Mariano Z, Aves T, Irvine J, Dorian P, et al.
anxiety in samples of patients with heart failure: meta-analysis. J Cardiovasc Nurs 2016; Psychopathology in patients with ICDs over time: results of a prospective study.
31:367–79. https://doi.org/10.1097/JCN.0000000000000265 Pacing Clin Electrophysiol 2010;33:198–208. https://doi.org/10.1111/j.1540-8159.2009.
175. Dekker RL, Lennie TA, Doering LV, Chung ML, Wu JR, Moser DK. Coexisting anxiety 02599.x
and depressive symptoms in patients with heart failure. Eur J Cardiovasc Nurs 2014;13: 196. Simeone RM, Downing KF, Bobo WV, Grosse SD, Khanna AD, Farr SL. Post-traumatic
168–76. https://doi.org/10.1177/1474515113519520 stress disorder, anxiety, and depression among adults with congenital heart defects.
176. Loh AZH, Tan JSY, Tam JKC, Zhang MW, Ho CSH, Ho RC. Postoperative psychologic- Birth Defects Res 2022;114:124–35. https://doi.org/10.1002/bdr2.1971
al disorders among heart transplant recipients: a meta-analysis and meta-regression. 197. Harrison DJ, Kay J, Jacobsen RM, Londono-Obregon C, Yeung E, Kelly SL, et al. The
Psychosom Med 2020;82:689–98. https://doi.org/10.1097/PSY.0000000000000833 burden of psychological trauma and post-traumatic stress disorder among adults
177. Koleck TA, Mitha SA, Biviano A, Caceres BA, Corwin EJ, Goldenthal I, et al. Exploring with congenital heart disease: PTSD in ACHD. Am J Cardiol 2024;219:9–16. https://
depressive symptoms and anxiety among patients with atrial fibrillation and/or flutter doi.org/10.1016/j.amjcard.2024.03.007
at the time of cardioversion or ablation. J Cardiovasc Nurs 2021;36:470–81. https://doi. 198. Edmondson D, Rieckmann N, Shaffer JA, Schwartz JE, Burg MM, Davidson KW, et al.
org/10.1097/JCN.0000000000000723 Posttraumatic stress due to an acute coronary syndrome increases risk of 42-month
178. Grand J, Fuglsbjerg C, Borregaard B, Wagner MK, Kragh AR, Bekker-Jensen D, et al. major adverse cardiac events and all-cause mortality. J Psychiatr Res 2011;45:1621–6.
Sex differences in symptoms of anxiety, depression, post-traumatic stress disorder, https://doi.org/10.1016/j.jpsychires.2011.07.004
and cognitive function among survivors of out-of-hospital cardiac arrest. Eur Heart J 199. Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress.
Acute Cardiovasc Care 2023;12:765–73. https://doi.org/10.1093/ehjacc/zuad093 Psychosom Med 1979;41:209–18. https://doi.org/10.1097/00006842-197905000-00004
179. Peskine A, Cariou A, Hajage D, Deye N, Guérot E, Dres M, et al. Long-term disabilities 200. Ginzburg K, Kutz I, Koifman B, Roth A, Kriwisky M, David D, et al. Acute stress disorder
of survivors of out-of-hospital cardiac arrest: the Hanox study. Chest 2021;159: symptoms predict all-cause mortality among myocardial infarction patients: a 15-year
699–711. https://doi.org/10.1016/j.chest.2020.07.022 longitudinal study. Ann Behav Med 2016;50:177–86. https://doi.org/10.1007/s12160-
180. Joshi VL, Tang LH, Mikkelsen TB, Nielsen JF, Zinckernagel L, Borregaard B, et al. Does 015-9744-x
time heal fatigue, psychological, cognitive and disability problems in people who ex- 201. Shemesh E, Rudnick A, Kaluski E, Milovanov O, Salah A, Alon D, et al. A prospective
perience an out-of-hospital cardiac arrest? Results from the DANCAS survey study. study of posttraumatic stress symptoms and nonadherence in survivors of a myocar-
Resuscitation 2023;182:109639. https://doi.org/10.1016/j.resuscitation.2022.11.005 dial infarction (MI). Gen Hosp Psychiatry 2001;23:215–22. https://doi.org/10.1016/
181. Frydensberg VS, Johansen JB, Möller S, Riahi S, Wehberg S, Haarbo J, et al. Anxiety and S0163-8343(01)00150-5
depression symptoms in Danish patients with an implantable cardioverter- 202. Pedersen SS, van Domburg RT, Larsen ML. The effect of low social support on short-
defibrillator: prevalence and association with indication and sex up to 2 years of follow- term prognosis in patients following a first myocardial infarction. Scand J Psychol 2004;
up (data from the national DEFIB-WOMEN study). Europace 2020;22:1830–40. 45:313–8. https://doi.org/10.1111/j.1467-9450.2004.00410.x
https://doi.org/10.1093/europace/euaa176 203. von Känel R, Hari R, Schmid JP, Wiedemar L, Guler E, Barth J, et al. Non-fatal cardio-
182. Jackson JL, Leslie CE, Hondorp SN. Depressive and anxiety symptoms in adult congeni- vascular outcome in patients with posttraumatic stress symptoms caused by myocar-
tal heart disease: prevalence, health impact and treatment. Prog Cardiovasc Dis 2018;61: dial infarction. J Cardiol 2011;58:61–8. https://doi.org/10.1016/j.jjcc.2011.02.007
294–9. https://doi.org/10.1016/j.pcad.2018.07.015 204. Foa EB, Riggs DS, Dancu CV, Rothbaum BO. Reliability and validity of a brief instru-
183. Lebherz C, Frick M, Panse J, Wienstroer P, Brehmer K, Kerst G, et al. Anxiety and de- ment for assessing post-traumatic stress disorder. J Trauma Stress 1993;6:459–73.
pression in adults with congenital heart disease. Front Pediatr 2022;10:906385. https:// https://doi.org/10.1007/BF00974317
doi.org/10.3389/fped.2022.906385 205. Doerfler LA, Paraskos JA, Piniarski L. Relationship of quality of life and perceived control
184. Roest AM, Zuidersma M, de Jonge P. Myocardial infarction and generalised anxiety dis- with posttraumatic stress disorder symptoms 3 to 6 months after myocardial infarction.
order: 10-year follow-up. Br J Psychiatry 2012;200:324–9. https://doi.org/10.1192/bjp. J Cardiopulm Rehabil 2005;25:166–72. https://doi.org/10.1097/00008483-200505000-
bp.111.103549 00008
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 59 ---
4214 E S C G u id e l in e s
206. Shemesh E, Yehuda R, Milo O, Dinur I, Rudnick A, Vered Z, et al. Posttraumatic stress, 229. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depres-
nonadherence, and adverse outcome in survivors of a myocardial infarction. Psychosom sion. Two questions are as good as many. J Gen Intern Med 1997;12:439–45. https://doi.
Med 2004;66:521–6. https://doi.org/10.1097/01.psy.0000126199.05189.86 org/10.1046/j.1525-1497.1997.00076.x
207. Hari R, Begré S, Schmid JP, Saner H, Gander ML, von Känel R. Change over time in 230. Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV 3rd, Hahn SR, et al. Utility of a
posttraumatic stress caused by myocardial infarction and predicting variables. J new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000
Psychosom Res 2010;69:143–50. https://doi.org/10.1016/j.jpsychores.2010.04.011 study. JAMA 1994;272:1749–56. https://doi.org/10.1001/jama.1994.03520220043029
208. Zen AL, Whooley MA, Zhao S, Cohen BE. Post-traumatic stress disorder is associated 231. Whooley MA. Screening for depression–a tale of two questions. JAMA Intern Med
with poor health behaviors: findings from the heart and soul study. Health Psychol 2016;176:436–8. https://doi.org/10.1001/jamainternmed.2015.8493
2012;31:194–201. https://doi.org/10.1037/a0025989 232. Bosanquet K, Bailey D, Gilbody S, Harden M, Manea L, Nutbrown S, et al. Diagnostic ac-
209. Favaro A, Gerosa G, Caforio AL, Volpe B, Rupolo G, Zarneri D, et al. Posttraumatic curacy of the Whooley questions for the identification of depression: a diagnostic
stress disorder and depression in heart transplantation recipients: the relationship meta-analysis. BMJ Open 2015;5:e008913. https://doi.org/10.1136/bmjopen-2015-008913
with outcome and adherence to medical treatment. Gen Hosp Psychiatry 2011;33: 233. Smith RD, Shing JSY, Lin J, Bosanquet K, Fong DYT, Lok KYW. Meta-analysis of diag-
1–7. https://doi.org/10.1016/j.genhosppsych.2010.10.001 nostic properties of the Whooley questions to identify depression in perinatal women.
210. Sumner JA, Kronish IM, Pietrzak RH, Shimbo D, Shaffer JA, Parsons FE, et al. J Affect Disord 2022;315:148–55. https://doi.org/10.1016/j.jad.2022.07.026
Dimensional structure and correlates of posttraumatic stress symptoms following sus- 234. Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical set-
pected acute coronary syndrome. J Affect Disord 2015;186:178–85. https://doi.org/10. tings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen
1016/j.jad.2015.06.013 Intern Med 2007;22:1596–602. https://doi.org/10.1007/s11606-007-0333-y
211. Christensen AV, Juel K, Ekholm O, Thrysøe L, Thorup CB, Borregaard B, et al. 235. Kronish IM, Moise N, Cheung YK, Clarke GN, Dolor RJ, Duer-Hefele J, et al. Effect of
Significantly increased risk of all-cause mortality among cardiac patients feeling lonely. depression screening after acute coronary syndromes on quality of life: the
Heart 2020;106:140–6. https://doi.org/10.1136/heartjnl-2019-315460 CODIACS-QoL randomized clinical trial. JAMA Intern Med 2020;180:45–53. https://
212. Hagström E, Norlund F, Stebbins A, Armstrong PW, Chiswell K, Granger CB, et al. doi.org/10.1001/jamainternmed.2019.4518
Psychosocial stress and major cardiovascular events in patients with stable coronary 236. Bolgeo T, Di Matteo R, Simonelli N, Dal Molin A, Lusignani M, Bassola B, et al.
heart disease. J Intern Med 2018;283:83–92. https://doi.org/10.1111/joim.12692 Psychometric properties and measurement invariance of the 7-item general anxiety
213. Xu X, Bao H, Strait K, Spertus JA, Lichtman JH, D’Onofrio G, et al. Sex differences in per- disorder scale (GAD-7) in an Italian coronary heart disease population. J Affect
Disord 2023;334:213–9. https://doi.org/10.1016/j.jad.2023.04.140
ceived stress and early recovery in young and middle-aged patients with acute myocardial
237. van den Houdt S, Albus C, Herrmann-Lingen C, Widdershoven J, Kupper N. Validity of
infarction. Circulation 2015;131:614–23. https://doi.org/10.1161/CIRCULATIONAHA.
a multidimensional comprehensive psychosocial screening instrument based on the
114.012826
ESC Cardiovascular Prevention Guidelines—evidence from the general and cardiovas-
214. Le Grande MR, Murphy BM, Rogerson MC, Ski CF, Amerena J, Smith JA, et al.
cular patient population. J Psychosom Res 2022;157:110791. https://doi.org/10.1016/j.
Development of a short form of the cardiac distress inventory. BMC Cardiovasc
jpsychores.2022.110791
Disord 2023;23:408. https://doi.org/10.1186/s12872-023-03439-w
238. Staples LG, Dear BF, Gandy M, Fogliati V, Fogliati R, Karin E, et al. Psychometric prop-
215. Harris KM, Jacoby DL, Lampert R, Soucier RJ, Burg MM. Psychological stress in heart
erties and clinical utility of brief measures of depression, anxiety, and general distress:
failure: a potentially actionable disease modifier. Heart Fail Rev 2021;26:561–75. https://
the PHQ-2, GAD-2, and K-6. Gen Hosp Psychiatry 2019;56:13–8. https://doi.org/10.
doi.org/10.1007/s10741-020-10056-8
1016/j.genhosppsych.2018.11.003
216. Endrighi R, Waters AJ, Gottlieb SS, Harris KM, Wawrzyniak AJ, Bekkouche NS, et al.
239. Moons P, Norekvål TM, Arbelo E, Borregaard B, Casadei B, Cosyns B, et al. Placing
Psychological stress and short-term hospitalisations or death in patients with heart fail-
patient-reported outcomes at the centre of cardiovascular clinical practice: implica-
ure. Heart 2016;102:1820–5. https://doi.org/10.1136/heartjnl-2015-309154
tions for quality of care and management. Eur Heart J 2023;44:3405–22. https://doi.
217. Martire LM, Helgeson VS. Close relationships and the management of chronic illness:
org/10.1093/eurheartj/ehad514
associations and interventions. Am Psychol 2017;72:601–12. https://doi.org/10.1037/
240. Pedersen SS, Wehberg S, Nielsen JC, Riahi S, Larroudé C, Philbert BT, et al. Patients
amp0000066
with an implantable cardioverter defibrillator at risk of poorer psychological health
218. Knoll N, Scholz U, Ditzen B. Social support, family processes, and health. In: Revenson
during 24 months of follow-up (results from the Danish national DEFIB-WOMEN
TA, Gurung RAR (eds.), The Handbook of Health Psychology. New York: Routledge,
study). Gen Hosp Psychiatry 2023;80:54–61. https://doi.org/10.1016/j.genhosppsych.
2019, 279–89.
2022.12.006
219. Smith TW, Baucom BRW. Intimate relationships, individual adjustment, and coronary
241. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021
heart disease: implications of overlapping associations in psychosocial risk. Am Psychol
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
2017;72:578–89. https://doi.org/10.1037/amp0000123
Eur Heart J 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368
220. Randall G, Molloy GJ, Steptoe A. The impact of an acute cardiac event on the partners
242. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC
of patients: a systematic review. Health Psychol Rev 2009;3:1–84. https://doi.org/10.
Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;
1080/17437190902984919
45:3415–537. https://doi.org/10.1093/eurheartj/ehae177
221. Bouchard K, Dans M, Higdon G, Quinlan B, Tulloch H. Caregiver distress and coronary 243. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC
artery disease: prevalence, risk, outcomes, and management. Curr Cardiol Rep 2022;24:
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur
2081–96. https://doi.org/10.1007/s11886-022-01810-5
Heart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192
222. Kitko L, McIlvennan CK, Bidwell JT, Dionne-Odom JN, Dunlay SM, Lewis LM, et al.
244. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC
Family caregiving for individuals with heart failure: a scientific statement from the Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:
American Heart Association. Circulation 2020;141:e864–78. https://doi.org/10.1161/ 3720–826. https://doi.org/10.1093/eurheartj/ehad191
CIR.0000000000000768 245. Gorini A, Giuliani M, Raggio L, Barbieri S, Tremoli E. Depressive and anxiety symptoms
223. Kugler C, Malehsa D, Schrader E, Tegtbur U, Guetzlaff E, Haverich A, et al. A multi- screening in cardiac inpatients: a virtuous Italian approach to psychocardiology. Int J
modal intervention in management of left ventricular assist device outpatients: dietary Environ Res Public Health 2020;17:5007. https://doi.org/10.3390/ijerph17145007
counselling, controlled exercise and psychosocial support. Eur J Cardiothorac Surg 2012; 246. Barry LC, Kasl SV, Lichtman J, Vaccarino V, Krumholz HM. Social support and change in
42:1026–32. https://doi.org/10.1093/ejcts/ezs206 health-related quality of life 6 months after coronary artery bypass grafting. J Psychosom
224. Kugler C, Meng M, Rehn E, Morshuis M, Gummert JF, Tigges-Limmer K. Sexual activity Res 2006;60:185–93. https://doi.org/10.1016/j.jpsychores.2005.06.080
in patients with left ventricular assist devices and their partners: impact of the device 247. Dew MA, DiMartini AF, Dobbels F, Grady KL, Jowsey-Gregoire SG, Kaan A, et al. The
on quality of life, anxiety and depression. Eur J Cardiothorac Surg 2018;53:799–806. 2018 ISHLT/APM/AST/ICCAC/STSW recommendations for the psychosocial evalu-
https://doi.org/10.1093/ejcts/ezx426 ation of adult cardiothoracic transplant candidates and candidates for long-term mech-
225. UK Carers. State of Caring Survey 2023—The Impact of Caring on Health. https://www. anical circulatory support. J Heart Lung Transplant 2018;37:803–23. https://doi.org/10.
carersuk.org/reports/state-of-caring-survey-2023-the-impact-of-caring-on-health(23 1016/j.healun.2018.03.005
September 2024, date last accessed). 248. Vandenbogaart E, Doering L, Chen B, Saltzman A, Chaker T, Creaser JW, et al.
226. Buckner L, Yeandle S. Valuing Carers 2015 The Rising Value of Carers’ Support. 2015. Evaluation of the SIPAT instrument to assess psychosocial risk in heart transplant can-
https://www.carersuk.org/reports/valuing-carers-2015-research-report/ (23 didates: a retrospective single center study. Heart Lung 2017;46:273–9. https://doi.org/
September 2024, date last accessed). 10.1016/j.hrtlng.2017.04.005
227. Hopp FP, Camp JK, Perry TE. Addressing heart failure challenges through 249. Schneekloth TD, Hitschfeld MJ, Jowsey-Gregoire SG, Petterson TM, Dunlay SM, Niazi
illness-informed social work. Health Soc Work 2015;40:201–8. https://doi.org/10. SK, et al. Psychosocial risk predicts new episode depression after heart transplant.
1093/hsw/hlv036 Psychosomatics 2019;60:47–55. https://doi.org/10.1016/j.psym.2018.06.003
228. DeFrank JT, Barclay C, Sheridan S, Brewer NT, Gilliam M, Moon AM, et al. The psycho- 250. Olsson KM, Meltendorf T, Fuge J, Kamp JC, Park DH, Richter MJ, et al. Prevalence of
logical harms of screening: the evidence we have versus the evidence we need. J Gen mental disorders and impact on quality of life in patients with pulmonary arterial hyper-
Intern Med 2015;30:242–8. https://doi.org/10.1007/s11606-014-2996-5 tension. Front Psychiatry 2021;12:667602. https://doi.org/10.3389/fpsyt.2021.667602
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 60 ---
ESC Guidelines 4215
251. Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 well-being index: a 273. Wood C, Chalmin-Pui LS, Smyth N, Rajcani J. Editorial: nature-based social prescrip-
systematic review of the literature. Psychother Psychosom 2015;84:167–76. https:// tions for improving health and wellbeing. Front Psychol 2022;13:1095064. https://doi.
doi.org/10.1159/000376585 org/10.3389/fpsyg.2022.1095064
252. Europe WHOROf. Wellbeing Measures in Primary Health Care/The DepCare Project: 274. Cooper M, Avery L, Scott J, Ashley K, Jordan C, Errington L, et al. Effectiveness and active
Report on a WHO meeting: Stockholm, Sweden, 12–3 February 1998. World Health ingredients of social prescribing interventions targeting mental health: a systematic re-
Organization. Regional Office for Europe. 1998. https://iris.who.int/handle/10665/ view. BMJ Open 2022;12:e060214. https://doi.org/10.1136/bmjopen-2021-060214
349766(16 June 2025, date last accessed). 275. Nguyen PY, Astell-Burt T, Rahimi-Ardabili H, Feng X. Effect of nature prescriptions on
253. Baou CE, Desai R, Cooper C, Marchant NL, Pilling S, Richards M, et al. Psychological ther- cardiometabolic and mental health, and physical activity: a systematic review. Lancet
apies for depression and cardiovascular risk: evidence from national healthcare records in Planet Health 2023;7:e313–28. https://doi.org/10.1016/S2542-5196(23)00025-6
England. Eur Heart J 2023;44:1650–62. https://doi.org/10.1093/eurheartj/ehad188 276. Shukla A, Choudhari SG, Gaidhane AM, Quazi Syed Z. Role of art therapy in the pro-
254. Pedersen SS, Skov O, Ahm R. Are we getting closer to treating heart and mind to- motion of mental health: a critical review. Cureus 2022;14:e28026. https://doi.org/10.
gether and bridging the gap for individual patients attending cardiac rehabilitation? 7759/cureus.28026
Eur Heart J 2023;44:997–9. https://doi.org/10.1093/eurheartj/ehac820 277. Coventry PA, Brown JE, Pervin J, Brabyn S, Pateman R, Breedvelt J, et al. Nature-based
255. Ho FY, Yeung WF, Ng TH, Chan CS. The efficacy and cost-effectiveness of stepped outdoor activities for mental and physical health: systematic review and meta-analysis.
care prevention and treatment for depressive and/or anxiety disorders: a systematic SSM Popul Health 2021;16:100934. https://doi.org/10.1016/j.ssmph.2021.100934
review and meta-analysis. Sci Rep 2016;6:29281. https://doi.org/10.1038/srep29281 278. Haleem A, Javaid M, Singh RP, Suman R. Telemedicine for healthcare: capabilities, fea-
256. Davidson KW, Bigger JT, Burg MM, Carney RM, Chaplin WF, Czajkowski S, et al. tures, barriers, and applications. Sens Int 2021;2:100117. https://doi.org/10.1016/j.sintl.
Centralized, stepped, patient preference-based treatment for patients with post-acute 2021.100117
coronary syndrome depression: CODIACS vanguard randomized controlled trial. 279. Santo K, Redfern J. Digital health innovations to improve cardiovascular disease care.
JAMA Intern Med 2013;173:997–1004. https://doi.org/10.1001/jamainternmed.2013.915 Curr Atheroscler Rep 2020;22:71. https://doi.org/10.1007/s11883-020-00889-x
257. Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, et al. 280. Vidovic D, Reinhardt GY, Hammerton C. Can social prescribing foster individual and
Enhanced depression care for patients with acute coronary syndrome and persistent de- community well-being? A systematic review of the evidence. Int J Environ Res Public
pressive symptoms: coronary psychosocial evaluation studies randomized controlled Health 2021;18:5276. https://doi.org/10.3390/ijerph18105276
trial. Arch Intern Med 2010;170:600–8. https://doi.org/10.1001/archinternmed.2010.29 281. Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P, et al.
258. Tehranineshat B, Rakhshan M, Torabizadeh C, Fararouei M. Compassionate care in Psychological interventions for coronary heart disease: Cochrane systematic review
healthcare systems: a systematic review. J Natl Med Assoc 2019;111:546–54. https:// and meta-analysis. Eur J Prev Cardiol 2018;25:247–59. https://doi.org/10.1177/
doi.org/10.1016/j.jnma.2019.04.002 2047487317739978
259. Okunrintemi V, Spatz ES, Di Capua P, Salami JA, Valero-Elizondo J, Warraich H, et al. 282. Thoma N, Pilecki B, McKay D. Contemporary cognitive behavior therapy: a review of
Patient-provider communication and health outcomes among individuals with athero- theory, history, and evidence. Psychodyn Psychiatry 2015;43:423–61. https://doi.org/10.
sclerotic cardiovascular disease in the United States: medical expenditure panel survey 1521/pdps.2015.43.3.423
2010 to 2013. Circ Cardiovasc Qual Outcomes 2017;10:e003635. https://doi.org/10. 283. Magán I, Jurado-Barba R, Casado L, Barnum H, Jeon A, Hernandez AV, et al. Efficacy of
1161/CIRCOUTCOMES.117.003635 psychological interventions on clinical outcomes of coronary artery disease: systematic
260. Zwack CC, Smith C, Poulsen V, Raffoul N, Redfern J. Information needs and commu- review and meta-analysis. J Psychosom Res 2022;153:110710. https://doi.org/10.1016/j.
nication strategies for people with coronary heart disease: a scoping review. Int J jpsychores.2021.110710
Environ Res Public Health 2023;20:1723. https://doi.org/10.3390/ijerph20031723 284. Magán I, Casado L, Jurado-Barba R, Barnum H, Redondo MM, Hernandez AV, et al.
261. Mentrup S, Harris E, Gomersall T, Köpke S, Astin F. Patients’ experiences of cardiovas- Efficacy of psychological interventions on psychological outcomes in coronary artery
cular health education and risk communication: a qualitative synthesis. Qual Health Res disease: systematic review and meta-analysis. Psychol Med 2021;51:1846–60. https://
2020;30:88–104. https://doi.org/10.1177/1049732319887949 doi.org/10.1017/S0033291720000598
262. Mitropoulou P, Grüner-Hegge N, Reinhold J, Papadopoulou C. Shared decision making 285. Särnholm J, Skúladóttir H, Rück C, Axelsson E, Bonnert M, Bragesjö M, et al. Cognitive
in cardiology: a systematic review and meta-analysis. Heart 2022;109:34–9. https://doi. behavioral therapy improves quality of life in patients with symptomatic paroxysmal
org/10.1136/heartjnl-2022-321050 atrial fibrillation. J Am Coll Cardiol 2023;82:46–56. https://doi.org/10.1016/j.jacc.2023.
263. Ski CF, Taylor RS, McGuigan K, Long L, Lambert JD, Richards SH, et al. Psychological 04.044
interventions for depression and anxiety in patients with coronary heart disease, heart 286. Holdgaard A, Eckhardt-Hansen C, Lassen CF, Kjesbu IE, Dall CH, Michaelsen KL, et al.
failure or atrial fibrillation. Cochrane Database Syst Rev 2024;4:CD013508. https://doi. Cognitive-behavioural therapy reduces psychological distress in younger patients with
org/10.1002/14651858.CD013508.pub3 cardiac disease: a randomized trial. Eur Heart J 2023;44:986–96. https://doi.org/10.
264. Mou H, Lam SKK, Chien WT. The effects of a family-focused dyadic psychoeducational 1093/eurheartj/ehac792
intervention for stroke survivors and their family caregivers: a randomised controlled 287. Chen B, Wen J, You D, Zhang Y. Implication of cognitive-behavioral stress manage-
trial. Int J Nurs Stud 2023;143:104504. https://doi.org/10.1016/j.ijnurstu.2023.104504 ment on anxiety, depression, and quality of life in acute myocardial infarction patients
265. World Health Organization. Therapeutic Patient Education: An Introductory Guide. after percutaneous coronary intervention: a multicenter, randomized, controlled
Copenhagen: WHO Regional Office for Europe; 2023. Licence: CC BY-NC-SA 3.0 IGO. study. Ir J Med Sci 2024;193:101–9. https://doi.org/10.1007/s11845-023-03422-6
https://www.who.int/europe/publications/i/item/9789289060219 (17 December 288. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svärdsudd K. Randomized con-
2024, date last accessed). trolled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent
266. Shi W, Ghisi GLM, Zhang L, Hyun K, Pakosh M, Gallagher R. A systematic review, cardiovascular events in patients with coronary heart disease: Secondary Prevention in
meta-analysis, and meta-regression of patient education for secondary prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med 2011;171:134–40.
patients with coronary heart disease: impact on psychological outcomes. Eur J https://doi.org/10.1001/archinternmed.2010.510
Cardiovasc Nurs 2022;21:643–54. https://doi.org/10.1093/eurjcn/zvac001 289. Rawlings GH, Thompson AR, Armstrong I, Novakova B, Beail N. Coping styles asso-
267. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook ciated with depression, health anxiety and health-related quality of life in pulmonary
for Systematic Reviews of Interventions Version 6.4 (Updated August 2023). Cochrane, hypertension: cross-sectional analysis. BMJ Open 2022;12:e062564. https://doi.org/
2023. 2022. www.training.cochrane.org/handbook(24 May 2024, date last accessed). 10.1136/bmjopen-2022-062564
268. Kao CW, Chen MY, Chen TY, Lin PH. Effect of psycho-educational interventions on 290. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022
quality of life in patients with implantable cardioverter defibrillators: a meta-analysis of ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur
randomized controlled trials. Health Qual Life Outcomes 2016;14:138. https://doi.org/ Heart J 2022;43:3618–731. https://doi.org/10.1093/eurheartj/ehac237
10.1186/s12955-016-0543-2 291. Wittmann L, Blomert E, Linden M. Patients’ perception of side effects in cognitive-
269. Palm P, Qvist I, Rasmussen TB, Christensen SW, Håkonsen SJ, Risom SS. Educational behavior, psychodynamic, and psychoanalytic outpatient psychotherapy. Psychother
interventions to improve outcomes in patients with atrial fibrillation-a systematic re- Res 2023;35:112–24. https://doi.org/10.1080/10503307.2023.2290029
view. Int J Clin Pract 2020;74:e13629. https://doi.org/10.1111/ijcp.13629 292. Knowles KA, Tolin DF. Mechanisms of action in exposure therapy. Curr Psychiatry Rep
270. Whyne EZ, Woo J, Jeon-Slaughter H. The effects of subjective wellbeing and self-rated 2022;24:861–9. https://doi.org/10.1007/s11920-022-01391-8
health on lifetime risk of cardiovascular conditions in women. Int J Environ Res Public 293. IsHak WW, Hamilton MA, Korouri S, Diniz MA, Mirocha J, Hedrick R, et al.
Health 2023;20:6380. https://doi.org/10.3390/ijerph20146380 Comparative effectiveness of psychotherapy vs antidepressants for depression in
271. Araki K, Takahashi Y, Okada H, Nakayama T. Social prescribing from the patient’s per- heart failure: a randomized clinical trial. JAMA Netw Open 2024;7:e2352094. https://
spective: a literature review. J Gen Fam Med 2022;23:299–309. https://doi.org/10.1002/ doi.org/10.1001/jamanetworkopen.2023.52094
jgf2.551 294. Arabia E, Manca ML, Solomon RM. EMDR for survivors of life-threatening cardiac
272. Liebmann M, Pitman A, Hsueh YC, Bertotti M, Pearce E. Do people perceive benefits events: results of a pilot study. J EMDR Prac Res 2011;5:2–13. https://doi.org/10.
in the use of social prescribing to address loneliness and/or social isolation? A qualita- 1891/1933-3196.5.1.2
tive meta-synthesis of the literature. BMC Health Serv Res 2022;22:1264. https://doi. 295. Shemesh E, Annunziato RA, Weatherley BD, Cotter G, Feaganes JR, Santra M, et al. A
org/10.1186/s12913-022-08656-1 randomized controlled trial of the safety and promise of cognitive-behavioral therapy
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 61 ---
4216 E S C G u id e l in e s
using imaginal exposure in patients with posttraumatic stress disorder resulting from 319. Denison E, Underland V, Mosdøl A, Vist G. Cognitive Therapies for Smoking Cessation: a
cardiovascular illness. J Clin Psychiatry 2011;72:168–74. https://doi.org/10.4088/JCP. Systematic Review. 2017. https://www.ncbi.nlm.nih.gov/books/NBK482098/(13 January
09m05116blu 2024, date last accessed).
296. von Känel R, Barth J, Princip M, Meister-Langraf RE, Schmid JP, Znoj H, et al. Early psy- 320. Schuman-Olivier Z, Trombka M, Lovas DA, Brewer JA, Vago DR, Gawande R, et al.
chological counseling for the prevention of posttraumatic stress induced by acute cor- Mindfulness and behavior change. Harv Rev Psychiatry 2020;28:371–94. https://doi.
onary syndrome: the MI-SPRINT randomized controlled trial. Psychother Psychosom org/10.1097/HRP.0000000000000277
2018;87:75–84. https://doi.org/10.1159/000486099 321. Zaccaro A, Piarulli A, Laurino M, Garbella E, Menicucci D, Neri B, et al. How breath-
297. Walsh R. Lifestyle and mental health. Am Psychol 2011;66:579–92. https://doi.org/10. control can change your life: a systematic review on psycho-physiological correlates
1037/a0021769 of slow breathing. Front Hum Neurosci 2018;12:353. https://doi.org/10.3389/fnhum.
298. Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental 2018.00353
illness. Nat Rev Cardiol 2021;18:136–45. https://doi.org/10.1038/s41569-020-00463-7 322. Yaribeygi H, Panahi Y, Sahraei H, Johnston TP, Sahebkar A. The impact of stress on body
299. Ng R, Sutradhar R, Yao Z, Wodchis WP, Rosella LC. Smoking, drinking, diet and phys- function: a review. EXCLI J 2017;16:1057–72. https://doi.org/10.17179/excli2017-480
ical activity-modifiable lifestyle risk factors and their associations with age to first 323. Toussaint L, Nguyen QA, Roettger C, Dixon K, Offenbächer M, Kohls N, et al.
Effectiveness of progressive muscle relaxation, deep breathing, and guided imagery
chronic disease. Int J Epidemiol 2020;49:113–30. https://doi.org/10.1093/ije/dyz078
in promoting psychological and physiological states of relaxation. Evid Based
300. Tsima BM, Opondo P, Mosepele M, Mautle E, Bilker WB, Gross R. Prevalence of the
Complement Alternat Med 2021;2021:5924040. https://doi.org/10.1155/2021/5924040
metabolic syndrome and associated factors among inpatients with severe mental ill-
324. Masih T, Dimmock JA, Epel E, Guelfi KJ. An 8-week relaxation program consisting of
ness in Botswana: a cross-sectional study. BMC Cardiovasc Disord 2022;22:515.
progressive muscle relaxation and mindfulness meditation to reduce stress and attenu-
https://doi.org/10.1186/s12872-022-02939-5
ate stress-driven eating. Appl Psychol Health Well Being 2020;12:188–211. https://doi.
301. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary
org/10.1111/aphw.12179
care-led weight management for remission of type 2 diabetes (DiRECT): an open-
325. Xu J, Jo H, Noorbhai L, Patel A, Li A. Virtual mindfulness interventions to promote
label, cluster-randomised trial. Lancet 2018;391:541–51. https://doi.org/10.1016/
well-being in adults: a mixed-methods systematic review. J Affect Disord 2022;300:
S0140-6736(17)33102-1
571–85. https://doi.org/10.1016/j.jad.2022.01.027
302. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, et al. Intensive
326. Behan C. The benefits of meditation and mindfulness practices during times of crisis
lifestyle changes for reversal of coronary heart disease. JAMA 1998;280:2001–7.
such as COVID-19. Ir J Psychol Med 2020;37:256–8. https://doi.org/10.1017/ipm.
https://doi.org/10.1001/jama.280.23.2001 2020.38
303. Caparrós B, Masferrer L. Coping strategies and complicated grief in a substance use 327. Koerten HR, Watford TS, Dubow EF, O’Brien WH. Cardiovascular effects of brief
disorder sample. Front Psychol 2020;11:624065. https://doi.org/10.3389/fpsyg.2020. mindfulness meditation among perfectionists experiencing failure. Psychophysiology
624065 2020;57:e13517. https://doi.org/10.1111/psyp.13517
304. Ghodeshwar GK, Dube A, Khobragade D. Impact of lifestyle modifications on cardio- 328. Albus C, Herrmann-Lingen C, Jensen K, Hackbusch M, Munch N, Kuncewicz C, et al.
vascular health: a narrative review. Cureus 2023;15:e42616. https://doi.org/10.7759/ Additional effects of psychological interventions on subjective and objective outcomes
cureus.42616 compared with exercise-based cardiac rehabilitation alone in patients with cardiovas-
305. Basso JC, Suzuki WA. The effects of acute exercise on mood, cognition, neurophysi- cular disease: a systematic review and meta-analysis. Eur J Prev Cardiol 2019;26:
ology, and neurochemical pathways: a review. Brain Plast 2017;2:127–52. https://doi. 1035–49. https://doi.org/10.1177/2047487319832393
org/10.3233/BPL-160040 329. Shahrbabaki SS, Linz D, Hartmann S, Redline S, Baumert M. Sleep arousal burden is
306. Callaghan P. Exercise: a neglected intervention in mental health care? J Psychiatr Ment associated with long-term all-cause and cardiovascular mortality in 8001
Health Nurs 2004;11:476–83. https://doi.org/10.1111/j.1365-2850.2004.00751.x community-dwelling older men and women. Eur Heart J 2021;42:2088–99. https://
307. Doyle F, Freedland KE, Carney RM, de Jonge P, Dickens C, Pedersen SS, et al. Hybrid doi.org/10.1093/eurheartj/ehab151
systematic review and network meta-analysis of randomized controlled trials of inter- 330. Domínguez F, Fuster V, Fernández-Alvira JM, Fernández-Friera L, López-Melgar B,
ventions for depressive symptoms in patients with coronary artery disease. Psychosom Blanco-Rojo R, et al. Association of sleep duration and quality with subclinical athero-
Med 2021;83:423–31. https://doi.org/10.1097/PSY.0000000000000944 sclerosis. J Am Coll Cardiol 2019;73:134–44. https://doi.org/10.1016/j.jacc.2018.10.060
308. Blumenthal JA, Babyak MA, O’Connor C, Keteyian S, Landzberg J, Howlett J, et al. 331. Scott AJ, Webb TL, Martyn-St James M, Rowse G, Weich S. Improving sleep quality
Effects of exercise training on depressive symptoms in patients with chronic heart fail- leads to better mental health: a meta-analysis of randomised controlled trials. Sleep
ure: the HF-ACTION randomized trial. JAMA 2012;308:465–74. https://doi.org/10. Med Rev 2021;60:101556. https://doi.org/10.1016/j.smrv.2021.101556
1001/jama.2012.8720 332. Miller MA, Howarth NE. Sleep and cardiovascular disease. Emerg Top Life Sci 2023;7:
309. Ghosh RK, Ball S, Prasad V, Gupta A. Depression in heart failure: intricate relationship, 457–66. https://doi.org/10.1042/ETLS20230111
pathophysiology and most updated evidence of interventions from recent clinical stud- 333. Vandekerckhove M, Wang YL. Emotion, emotion regulation and sleep: an intimate re-
ies. Int J Cardiol 2016;224:170–7. https://doi.org/10.1016/j.ijcard.2016.09.063 lationship. AIMS Neurosci 2017;5:1–17. https://doi.org/10.3934/Neuroscience.2018.1.1
310. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC 334. Kulbayeva S, Tazhibayeva K, Seiduanova L, Smagulova I, Mussina A, Tanabayeva S, et al.
The recent advances of mobile healthcare in cardiology practice. Acta Inform Med 2022;
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;
30:236–50. https://doi.org/10.5455/aim.2022.30.236-250
42:3227–337. https://doi.org/10.1093/eurheartj/ehab484
335. Cruz-Cobo C, Bernal-Jiménez M, Vázquez-García R, Santi-Cano MJ. Effectiveness of 311. Rudzińska A, Perera I, Gryglewska B, Gąsowski J, Piotrowicz K. Can the Mediterranean
mHealth interventions in the control of lifestyle and cardiovascular risk factors in pa-
diet decrease the risk of depression in older persons—a systematic review. Psychiatr
tients after a coronary event: systematic review and meta-analysis. JMIR Mhealth
Pol 2023;57:339–54. https://doi.org/10.12740/PP/OnlineFirst/140465
Uhealth 2022;10:e39593. https://doi.org/10.2196/39593
312. Yin W, Löf M, Chen R, Hultman CM, Fang F, Sandin S. Mediterranean diet and depres-
336. Takahashi EA, Schwamm LH, Adeoye OM, Alabi O, Jahangir E, Misra S, et al. An over-
sion: a population-based cohort study. Int J Behav Nutr Phys Act 2021;18:153. https://
view of telehealth in the management of cardiovascular disease: a scientific statement
doi.org/10.1186/s12966-021-01227-3
from the American Heart Association. Circulation 2022;146:e558–68. https://doi.org/
313. Jacka FN, O’Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, et al. A randomised
10.1161/CIR.0000000000001107
controlled trial of dietary improvement for adults with major depression (the ‘SMILES’
337. Lee WW, Choi KC, Yum RW, Yu DS, Chair SY. Effectiveness of motivational inter-
trial). BMC Med 2017;15:23. https://doi.org/10.1186/s12916-017-0791-y
viewing on lifestyle modification and health outcomes of clients at risk or diagnosed
314. Granero R. Role of nutrition and diet on healthy mental state. Nutrients 2022;14:750.
with cardiovascular diseases: a systematic review. Int J Nurs Stud 2016;53:331–41.
https://doi.org/10.3390/nu14040750
https://doi.org/10.1016/j.ijnurstu.2015.09.010
315. O’Neil A, Quirk SE, Housden S, Brennan SL, Williams LJ, Pasco JA, et al. Relationship
338. Ambrosetti M, Abreu A, Corrà U, Davos CH, Hansen D, Frederix I, et al. Secondary
between diet and mental health in children and adolescents: a systematic review. Am J prevention through comprehensive cardiovascular rehabilitation: from knowledge to
Public Health 2014;104:e31–42. https://doi.org/10.2105/AJPH.2014.302110 implementation. 2020 update. A position paper from the Secondary Prevention and
316. Jiang W, Whellan DJ, Adams KF, Babyak MA, Boyle SH, Wilson JL, et al. Long-chain Rehabilitation Section of the European Association of Preventive Cardiology. Eur J
omega-3 fatty acid supplements in depressed heart failure patients: results of the Prev Cardiol 2021;28:460–95. https://doi.org/10.1177/2047487320913379
OCEAN trial. JACC Heart Fail 2018;6:833–43. https://doi.org/10.1016/j.jchf.2018.03.011 339. Salzwedel A, Jensen K, Rauch B, Doherty P, Metzendorf MI, Hackbusch M, et al.
317. Thorndike AN, Achtyes ED, Cather C, Pratt S, Pachas GN, Hoeppner SS, et al. Weight Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease pa-
gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with tients treated according to contemporary evidence based medicine: update of the
serious mental illness: a subgroup analysis of a randomized trial. J Clin Psychiatry 2016; Cardiac Rehabilitation Outcome Study (CROS-II). Eur J Prev Cardiol 2020;27:
77:e320–6. https://doi.org/10.4088/JCP.15m10074 1756–74. https://doi.org/10.1177/2047487320905719
318. Okorare O, Evbayekha EO, Adabale OK, Daniel E, Ubokudum D, Olusiji SA, et al. 340. Dibben G, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al.
Smoking cessation and benefits to cardiovascular health: a review of literature. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database
Cureus 2023;15:e35966. https://doi.org/10.7759/cureus.35966 Syst Rev 2021;11:CD001800. https://doi.org/10.1002/14651858.CD001800.pub4
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 62 ---
ESC Guidelines 4217
341. Morris NR, Kermeen FD, Jones AW, Lee JY, Holland AE. Exercise-based rehabilitation Psychopharmacology (Berl) 2017;234:3075–81. https://doi.org/10.1007/s00213-017-
programmes for pulmonary hypertension. Cochrane Database Syst Rev 2023;3: 4685-7
CD011285. https://doi.org/10.1002/14651858.CD011285.pub3 361. Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant
342. Molloy C, Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, et al. Exercise-based cardiac use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using
rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2024;3: primary care database. BMJ 2016;352:i1350. https://doi.org/10.1136/bmj.i1350
CD003331. https://doi.org/10.1002/14651858.CD003331.pub6 362. Prasitlumkum N, Cheungpasitporn W, Tokavanich N, Ding KR, Kewcharoen J,
343. Grünig E, MacKenzie A, Peacock AJ, Eichstaedt CA, Benjamin N, Nechwatal R, et al. Thongprayoon C, et al. Antidepressants and risk of sudden cardiac death: a network
Standardized exercise training is feasible, safe, and effective in pulmonary arterial meta-analysis and systematic review. Med Sci (Basel) 2021;9:26. https://doi.org/10.
and chronic thromboembolic pulmonary hypertension: results from a large 3390/medsci9020026
European multicentre randomized controlled trial. Eur Heart J 2021;42:2284–95. 363. Abbas R, Riley S, Nepal S, Bachinsky M, Lee KC, Chappell PB, et al. Lack of an effect of
https://doi.org/10.1093/eurheartj/ehaa696 supratherapeutic dose of venlafaxine on cardiac repolarization in healthy subjects. Clin
344. An QY, Wang L, Yuan P, Zhao QH, Gong SG, Zhang R, et al. Effectiveness and safety of Pharmacol Drug Dev 2022;11:100–11. https://doi.org/10.1002/cpdd.989
exercise training and rehabilitation in chronic thromboembolic pulmonary hyperten- 364. Tellone V, Rosignoli MT, Picollo R, Dragone P, Del Vecchio A, Comandini A, et al.
sion: a systematic review and meta-analysis. Ann Palliat Med 2021;10:8134–46. Effect of 3 single doses of trazodone on QTc interval in healthy subjects. J Clin
https://doi.org/10.21037/apm-21-1758 Pharmacol 2020;60:1483–95. https://doi.org/10.1002/jcph.1640
345. Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments 365. Gurkan S, Liu F, Chain A, Gutstein DE. A study to assess the proarrhythmic potential of
and cardiac rehabilitation for improving clinical outcomes and depression among pa- mirtazapine using concentration-QTc (C-QTc) analysis. Clin Pharmacol Drug Dev 2019;
tients with coronary heart disease. Psychosom Med 2013;75:335–49. https://doi.org/ 8:449–58. https://doi.org/10.1002/cpdd.605
10.1097/PSY.0b013e318291d798 366. Alvares GA, Quintana DS, Hickie IB, Guastella AJ. Autonomic nervous system dysfunc-
346. Zheng X, Zheng Y, Ma J, Zhang M, Zhang Y, Liu X, et al. Effect of exercise-based cardiac tion in psychiatric disorders and the impact of psychotropic medications: a systematic
rehabilitation on anxiety and depression in patients with myocardial infarction: a sys- review and meta-analysis. J Psychiatry Neurosci 2016;41:89–104. https://doi.org/10.
tematic review and meta-analysis. Heart Lung 2019;48:1–7. https://doi.org/10.1016/j. 1503/jpn.140217
hrtlng.2018.09.011 367. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, et al.
347. Mehra VM, Gaalema DE, Pakosh M, Grace SL. Systematic review of cardiac rehabilita- Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.
J Clin Psychiatry 2014;75:e441–9. https://doi.org/10.4088/JCP.13r08672
tion guidelines: quality and scope. Eur J Prev Cardiol 2020;27:912–28. https://doi.org/10.
368. Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine
1177/2047487319878958
use in depression: a systematic review. Lancet Psychiatry 2018;5:65–78. https://doi.
348. Abreu A, Frederix I, Dendale P, Janssen A, Doherty P, Piepoli MF, et al. Standardization
org/10.1016/S2215-0366(17)30272-9
and quality improvement of secondary prevention through cardiovascular rehabilita-
369. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al.
tion programmes in Europe: the avenue towards EAPC accreditation programme: a
Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology:
position statement of the Secondary Prevention and Rehabilitation Section of the
update 2017. Pharmacopsychiatry 2018;51:9–62. https://doi.org/10.1055/s-0043-116492
European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2021;28:
370. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of
496–509. https://doi.org/10.1177/2047487320924912
heavy smoking. Clin Pharmacol Ther 2004;76:178–84. https://doi.org/10.1016/j.clpt.
349. Helmark C, Harrison A, Pedersen SS, Doherty P. Systematic screening for anxiety and
2004.04.003
depression in cardiac rehabilitation—are we there yet? Int J Cardiol 2022;352:65–71.
371. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why,
https://doi.org/10.1016/j.ijcard.2022.02.004
how, and when? Basic Clin Pharmacol Toxicol 2005;97:125–34. https://doi.org/10.
350. Wells A, Reeves D, Capobianco L, Heal C, Davies L, Heagerty A, et al. Improving
1111/j.1742-7843.2005.pto_973160.x
the effectiveness of psychological interventions for depression and anxiety in cardiac
372. Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, et al. Bleeding risk
rehabilitation: PATHWAY-A single-blind, parallel, randomized, controlled trial of
under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of
group metacognitive therapy. Circulation 2021;144:23–33. https://doi.org/10.1161/
observational studies. Pharmacol Res 2017;118:19–32. https://doi.org/10.1016/j.phrs.
CIRCULATIONAHA.120.052428
2016.08.017
351. Egholm CL, Helmark C, Rossau HK, Munkehøj P, Brøndum S, Pedersen SS, et al.
373. Eckersley MJ, Sepehripour AH, Casula R, Punjabi P, Athanasiou T. Do selective sero-
Implementation of systematic screening for anxiety and depression in cardiac rehabili-
tonin reuptake inhibitors increase the risk of bleeding or mortality following coronary
tation: real world lessons from a longitudinal study. J Psychosom Res 2022;158:110909.
artery bypass graft surgery? A meta-analysis of observational studies. Perfusion 2018;
https://doi.org/10.1016/j.jpsychores.2022.110909
33:415–22. https://doi.org/10.1177/0267659118765933
352. Sweda R, Siontis GCM, Nikolakopoulou A, Windecker S, Pilgrim T. Antidepressant
374. Rahman AA, Platt RW, Beradid S, Boivin JF, Rej S, Renoux C. Concomitant use of se-
treatment in patients following acute coronary syndromes: a systematic review and
lective serotonin reuptake inhibitors with oral anticoagulants and risk of major bleed-
Bayesian meta-analysis. ESC Heart Fail 2020;7:3610–20. https://doi.org/10.1002/ehf2.
ing. JAMA Netw Open 2024;7:e243208. https://doi.org/10.1001/jamanetworkopen.
12861
2024.3208
353. Tully PJ, Ang SY, Lee EJ, Bendig E, Bauereiß N, Bengel J, et al. Psychological and pharma- 375. Rahman AA, He N, Rej S, Platt RW, Renoux C. Concomitant use of selective serotonin
cological interventions for depression in patients with coronary artery disease. reuptake inhibitors and oral anticoagulants and risk of major bleeding: a systematic re-
Cochrane Database Syst Rev 2021;12:CD008012. https://doi.org/10.1002/14651858. view and meta-analysis. Thromb Haemost 2023;123:54–63. https://doi.org/10.1055/a-
CD008012.pub4 1932-8976
354. He W, Zhou Y, Ma J, Wei B, Fu Y. Effect of antidepressants on death in patients with 376. Machado CM, Alves M, Caldeira D. Impact of selective serotonin-reuptake inhibitors in
heart failure: a systematic review and meta-analysis. Heart Fail Rev 2020;25:919–26. hemorrhagic risk in anticoagulated patients taking non-vitamin K antagonist anticoagu-
https://doi.org/10.1007/s10741-019-09850-w lants: a systematic review and meta-analysis. J Clin Psychopharmacol 2023;43:267–72.
355. Hedrick R, Korouri S, Tadros E, Darwish T, Cortez V, Triay D, et al. The impact of anti- https://doi.org/10.1097/JCP.0000000000001684
depressants on depressive symptom severity, quality of life, morbidity, and mortality in 377. Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazep-
heart failure: a systematic review. Drugs Context 2020;9:2020-5-4. https://doi.org/10. ine misuse: a systematic review. Drug Alcohol Depend 2019;200:95–114. https://doi.org/
7573/dic.2020-5-4 10.1016/j.drugalcdep.2019.02.033
356. Galling B, Calsina Ferrer A, Abi Zeid Daou M, Sangroula D, Hagi K, Correll CU. Safety 378. Kripke DF, Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: a
and tolerability of antidepressant co-treatment in acute major depressive disorder: re- matched cohort study. BMJ Open 2012;2:e000850. https://doi.org/10.1136/bmjopen-
sults from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf 2012-000850
2015;14:1587–608. https://doi.org/10.1517/14740338.2015.1085970 379. Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, et al. Effect of anxiolytic and
357. Behlke LM, Lenze EJ, Carney RM. The cardiovascular effects of newer antidepressants hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ
in older adults and those with or at high risk for cardiovascular diseases. CNS Drugs 2014;348:g1996. https://doi.org/10.1136/bmj.g1996
2020;34:1133–47. https://doi.org/10.1007/s40263-020-00763-z 380. Patorno E, Glynn RJ, Levin R, Lee MP, Huybrechts KF. Benzodiazepines and risk of all
358. Hughes JW, Kuhn TA, Ede D, Gathright EC, Josephson RA. Meta-analysis of anti- cause mortality in adults: cohort study. BMJ 2017;358:j2941. https://doi.org/10.1136/
depressant pharmacotherapy in patients eligible for cardiac rehabilitation: bmj.j2941
ANTIDEPRESSANT AMBIVALENCE. J Cardiopulm Rehabil Prev 2022;42:434–41. 381. Liu S, Soedamah-Muthu SS, van Meerten SC, Kromhout D, Geleijnse JM, Giltay EJ. Use
https://doi.org/10.1097/HCR.0000000000000699 of benzodiazepine and Z-drugs and mortality in older adults after myocardial infarc-
359. Park K, Kim S, Ko YJ, Park BJ. Duloxetine and cardiovascular adverse events: a system- tion. Int J Geriatr Psychiatry 2023;38:e5861. https://doi.org/10.1002/gps.5861
atic review and meta-analysis. J Psychiatr Res 2020;124:109–14. https://doi.org/10. 382. von Känel R, Schmid JP, Meister-Langraf RE, Barth J, Znoj H, Schnyder U, et al.
1016/j.jpsychires.2020.02.022 Pharmacotherapy in the management of anxiety and pain during acute coronary syn-
360. Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, dromes and the risk of developing symptoms of posttraumatic stress disorder. J Am
et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Heart Assoc 2021;10:e018762. https://doi.org/10.1161/JAHA.120.018762
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 63 ---
4218 E S C G u id e l in e s
383. Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, et al. Cardiovascular safety 404. Rollman BL, Anderson AM, Rothenberger SD, Abebe KZ, Ramani R, Muldoon MF,
of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. et al. Efficacy of blended collaborative care for patients with heart failure and comorbid
JAMA Intern Med 2018;178:622–31. https://doi.org/10.1001/jamainternmed.2018.0397 depression: a randomized clinical trial. JAMA Intern Med 2021;181:1369–80. https://doi.
384. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. org/10.1001/jamainternmed.2021.4978
Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in 405. Ferguson M, Kovacs AH. An integrated adult congenital heart disease psychology ser-
smokers with and without psychiatric disorders (EAGLES): a double-blind, rando- vice. Congenit Heart Dis 2016;11:444–51. https://doi.org/10.1111/chd.12331
mised, placebo-controlled clinical trial. Lancet 2016;387:2507–20. https://doi.org/10. 406. Kovacs AH, Brouillette J, Ibeziako P, Jackson JL, Kasparian NA, Kim YY, et al.
1016/S0140-6736(16)30272-0 Psychological outcomes and interventions for individuals with congenital heart disease:
385. Das A, Roy B, Schwarzer G, Silverman MG, Ziegler O, Bandyopadhyay D, et al. a scientific statement from the American Heart Association. Circ Cardiovasc Qual
Comparison of treatment options for depression in heart failure: a network Outcomes 2022;15:e000110. https://doi.org/10.1161/HCQ.0000000000000110
meta-analysis. J Psychiatr Res 2019;108:7–23. https://doi.org/10.1016/j.jpsychires. 407. Priegnitz J, Langheim E, Rademacher W, Schmitz C, Köllner V. Effectiveness of psycho-
2018.10.007 cardiological care in inpatient rehabilitation: a pilot study. Psychother Psychosom Med
386. Ladwig K-H, Baghai TC, Doyle F, Hamer M, Herrmann-Lingen C, Kunschitz E, et al. Psychol 2020;70:190–6. https://doi.org/10.1055/a-1023-4609
Mental health-related risk factors and interventions in patients with heart failure: a pos- 408. Langheim E, Schmitz C, Köllner V. Interdisciplinary psychocardiological rehabilita-
ition paper endorsed by the European Association of Preventive Cardiology (EAPC). tion: from model project to blueprint of the dual rehabilitation concept—from em-
Eur J Prev Cardiol 2022;29:1124–41. https://doi.org/10.1093/eurjpc/zwac006 pirical values to scientific data. Rehabilitation (Stuttg) 2022;61:230–9. https://doi.org/
387. Brouwers C, Christensen SB, Damen NL, Denollet J, Torp-Pedersen C, Gislason GH, 10.1055/a-1866-6781
et al. Antidepressant use and risk for mortality in 121,252 heart failure patients with or 409. Sadlonova M, Löser JK, Celano CM, Kleiber C, Broschmann D, Herrmann-Lingen C.
without a diagnosis of clinical depression. Int J Cardiol 2016;203:867–73. https://doi. Changes in treatment outcomes in patients undergoing an integrated psychosomatic
org/10.1016/j.ijcard.2015.11.032 inpatient treatment: results from a cohort study. Front Psychiatry 2022;13:964879.
388. Watson K, Summers KM. Depression in patients with heart failure: clinical implications and https://doi.org/10.3389/fpsyt.2022.964879
management. Pharmacotherapy 2009;29:49–63. https://doi.org/10.1592/phco.29.1.49 410. van der Voort TY, van Meijel B, Goossens PJ, Renes J, Beekman AT, Kupka RW.
389. de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: me- Collaborative care for patients with bipolar disorder: a randomised controlled trial.
chanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging BMC Psychiatry 2011;11:133. https://doi.org/10.1186/1471-244X-11-133
2011;28:345–67. https://doi.org/10.2165/11589340-000000000-00000 411. van der Voort TY, van Meijel B, Hoogendoorn AW, Goossens PJ, Beekman AT, Kupka
390. Braithwaite V, Gibson D, Holman J. Age stereotyping: are we oversimplifying the phe- RW. Collaborative care for patients with bipolar disorder: effects on functioning and
nomenon? Int J Aging Hum Dev 1985;22:315–25. https://doi.org/10.2190/Q2TM-B9V7- quality of life. J Affect Disord 2015;179:14–22. https://doi.org/10.1016/j.jad.2015.03.005
HDBD-6X6H 412. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life
391. Teply RM, Packard KA, White ND, Hilleman DE, DiNicolantonio JJ. Treatment of de- expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry
pression in patients with concomitant cardiac disease. Prog Cardiovasc Dis 2016;58: 2017;4:295–301. https://doi.org/10.1016/S2215-0366(17)30078-0
514–28. https://doi.org/10.1016/j.pcad.2015.11.003 413. Kessing LV, Vradi E, Andersen PK. Life expectancy in bipolar disorder. Bipolar Disord
392. Colucci VJ, Berry BD. Heart failure worsening and exacerbation after venlafaxine and 2015;17:543–8. https://doi.org/10.1111/bdi.12296
duloxetine therapy. Ann Pharmacother 2008;42:882–7. https://doi.org/10.1345/aph. 414. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease bur-
1L031 den implications: a systematic review and meta-analysis. JAMA Psychiatry 2015;72:
393. Zhang L, Bao Y, Tao S, Zhao Y, Liu M. The association between cardiovascular drugs 334–41. https://doi.org/10.1001/jamapsychiatry.2014.2502
and depression/anxiety in patients with cardiovascular disease: a meta-analysis. 415. Lomholt LH, Andersen DV, Sejrsgaard-Jacobsen C, Øzdemir CM, Graff C, Schjerning
Pharmacol Res 2022;175:106024. https://doi.org/10.1016/j.phrs.2021.106024 O, et al. Mortality rate trends in patients diagnosed with schizophrenia or bipolar dis-
394. Riemer TG, Villagomez Fuentes LE, Algharably EAE, Schäfer MS, Mangelsen E, Fürtig order: a nationwide study with 20 years of follow-up. Int J Bipolar Disord 2019;7:6.
MA, et al. Do β-blockers cause depression?: Systematic review and meta-analysis of https://doi.org/10.1186/s40345-018-0140-x
psychiatric adverse events during β-blocker therapy. Hypertension 2021;77:1539–48. 416. Paratz ED, van Heusden A, Zentner D, Morgan N, Smith K, Thompson T, et al. Sudden
https://doi.org/10.1161/HYPERTENSIONAHA.120.16590 cardiac death in people with schizophrenia: higher risk, poorer resuscitation profiles,
395. Ghaeli P, Solduzian M, Vejdani S, Talasaz AH. Comparison of the effects of melatonin and differing pathologies. JACC Clin Electrophysiol 2023;9:1310–8. https://doi.org/10.
and oxazepam on anxiety levels and sleep quality in patients with 1016/j.jacep.2023.01.026
ST-segment-elevation myocardial infarction following primary percutaneous coron- 417. Park CS, Choi EK, Han KD, Ahn HJ, Kwon S, Lee SR, et al. Increased cardiovascular
ary intervention: a randomized clinical trial. Ann Pharmacother 2018;52:949–55. events in young patients with mental disorders: a nationwide cohort study. Eur J
https://doi.org/10.1177/1060028018776608 Prev Cardiol 2023;30:1582–92. https://doi.org/10.1093/eurjpc/zwad102
396. Astarcioglu MA, Sen T, Kilit C, Durmus HI, Gozubuyuk G, Agus HZ, et al. Procedural 418. Rossom RC, Hooker SA, O’Connor PJ, Crain AL, Sperl-Hillen JM. Cardiovascular
sedation during transradial coronary angiography to prevent spasm. Herz 2016;41: risk for patients with and without schizophrenia, schizoaffective disorder, or bipo-
435–8. https://doi.org/10.1007/s00059-015-4373-5 lar disorder. J Am Heart Assoc 2022;11:e021444. https://doi.org/10.1161/JAHA.121.
397. Murphy KA, Dalcin A, McGinty EE, Goldsholl S, Heller A, Daumit GL. Applying care 021444
coordination principles to reduce cardiovascular disease risk factors in people with 419. Lambert AM, Parretti HM, Pearce E, Price MJ, Riley M, Ryan R, et al. Temporal trends in
serious mental illness: a case study approach. Front Psychiatry 2021;12:742169. associations between severe mental illness and risk of cardiovascular disease: a system-
https://doi.org/10.3389/fpsyt.2021.742169 atic review and meta-analysis. PLoS Med 2022;19:e1003960. https://doi.org/10.1371/
398. Huffman JC, Adams CN, Celano CM. Collaborative care and related interventions in journal.pmed.1003960
patients with heart disease: an update and new directions. Psychosomatics 2018;59: 420. Kugathasan P, Laursen TM, Grøntved S, Jensen SE, Aagaard J, Nielsen RE. Increased
1–18. https://doi.org/10.1016/j.psym.2017.09.003 long-term mortality after myocardial infarction in patients with schizophrenia.
399. Rollman BL, Belnap BH, LeMenager MS, Mazumdar S, Houck PR, Counihan PJ, et al. Schizophr Res 2018;199:103–8. https://doi.org/10.1016/j.schres.2018.03.015
Telephone-delivered collaborative care for treating post-CABG depression: a rando- 421. Polcwiartek C, Loewenstein D, Friedman DJ, Johansson KG, Graff C, Sørensen PL,
mized controlled trial. JAMA 2009;302:2095–103. https://doi.org/10.1001/jama.2009. et al. Clinical heart failure among patients with and without severe mental illness
1670 and the association with long-term outcomes. Circ Heart Fail 2021;14:e008364.
400. Katon WJ, Lin EH, Von Korff M, Ciechanowski P, Ludman EJ, Young B, et al. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008364
Collaborative care for patients with depression and chronic illnesses. N Engl J Med 422. Goldfarb M, De Hert M, Detraux J, Di Palo K, Munir H, Music S, et al. Severe mental
2010;363:2611–20. https://doi.org/10.1056/NEJMoa1003955 illness and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 2022;
401. Huffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC, et al. 80:918–33. https://doi.org/10.1016/j.jacc.2022.06.017
Collaborative care for depression and anxiety disorders in patients with recent cardiac 423. Polcwiartek C, O’Gallagher K, Friedman DJ, Correll CU, Solmi M, Jensen SE, et al.
events: the management of sadness and anxiety in cardiology (MOSAIC) randomized clin- Severe mental illness: cardiovascular risk assessment and management. Eur Heart J
ical trial. JAMA Intern Med 2014;174:927–35. https://doi.org/10.1001/jamainternmed.2014. 2024;45:987–97. https://doi.org/10.1093/eurheartj/ehae054
739 424. Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M, et al.
402. Morgan MA, Coates MJ, Dunbar JA, Reddy P, Schlicht K, Fuller J. The TrueBlue model Sedentary behavior and physical activity levels in people with schizophrenia, bipolar
of collaborative care using practice nurses as case managers for depression alongside disorder and major depressive disorder: a global systematic review and meta-analysis.
diabetes or heart disease: a randomised trial. BMJ Open 2013;3:e002171. https://doi. World Psychiatry 2017;16:308–15. https://doi.org/10.1002/wps.20458
org/10.1136/bmjopen-2012-002171 425. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. Cardiorespiratory fitness
403. Archer J, Bower P, Gilbody S, Lovell K, Richards D, Gask L, et al. Collaborative care for as a quantitative predictor of all-cause mortality and cardiovascular events in healthy
depression and anxiety problems. Cochrane Database Syst Rev 2012;10:CD006525. men and women: a meta-analysis. JAMA 2009;301:2024–35. https://doi.org/10.1001/
https://doi.org/10.1002/14651858.CD006525.pub2 jama.2009.681
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 64 ---
ESC Guidelines 4219
426. Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with 447. Quadackers D, Liemburg E, Bos F, Doornbos B, Risselada A, Berger M, et al.
schizophrenia. World J Diabetes 2017;8:390–6. https://doi.org/10.4239/wjd.v8.i8.390 Cardiovascular risk assessment methods yield unequal risk predictions: a large cross-
427. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of sectional study in psychiatric secondary care outpatients. BMC Psychiatry 2023;23:536.
metabolic syndrome and its components in people with schizophrenia and related https://doi.org/10.1186/s12888-023-05022-1
psychotic disorders, bipolar disorder and major depressive disorder: a systematic review 448. Perry BI, Upthegrove R, Crawford O, Jang S, Lau E, McGill I, et al. Cardiometabolic risk
and meta-analysis. World Psychiatry 2015;14:339–47. https://doi.org/10.1002/wps.20252 prediction algorithms for young people with psychosis: a systematic review and ex-
428. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin ploratory analysis. Acta Psychiatr Scand 2020;142:215–32. https://doi.org/10.1111/
Psychiatry 2001;62:15–26. discussion 40–11. https://www.psychiatrist.com/jcp/ acps.13212
hyperglycemia-antipsychotic-medications/ 449. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease
429. Vuk A, Kuzman MR, Baretic M, Osvatic MM. Diabetic ketoacidosis associated with anti- and diabetes in people with severe mental illness position statement from the
psychotic drugs: case reports and a review of literature. Psychiatr Danub 2017;29: European Psychiatric Association (EPA), supported by the European Association for
121–35. https://doi.org/10.24869/psyd.2017.121 the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur
430. Ayerbe L, Forgnone I, Addo J, Siguero A, Gelati S, Ayis S. Hypertension risk and clinical Psychiatry 2009;24:412–24. https://doi.org/10.1016/j.eurpsy.2009.01.005
care in patients with bipolar disorder or schizophrenia; a systematic review and 450. Chan JKN, Correll CU, Wong CSM, Chu RST, Fung VSC, Wong GHS, et al. Life ex-
meta-analysis. J Affect Disord 2018;225:665–70. https://doi.org/10.1016/j.jad.2017.09.002 pectancy and years of potential life lost in people with mental disorders: a systematic
431. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association review and meta-analysis. EClinicalMedicine 2023;65:102294. https://doi.org/10.1016/j.
between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005;76: eclinm.2023.102294
135–57. https://doi.org/10.1016/j.schres.2005.02.010 451. Solmi M, Fiedorowicz J, Poddighe L, Delogu M, Miola A, Høye A, et al. Disparities in
432. Fornaro M, Carvalho AF, De Prisco M, Mondin AM, Billeci M, Selby P, et al. The preva- screening and treatment of cardiovascular diseases in patients with mental disorders
lence, odds, predictors, and management of tobacco use disorder or nicotine depend- across the world: systematic review and meta-analysis of 47 observational studies.
ence among people with severe mental illness: systematic review and meta-analysis. Am J Psychiatry 2021;178:793–803. https://doi.org/10.1176/appi.ajp.2021.21010031
Neurosci Biobehav Rev 2022;132:289–303. https://doi.org/10.1016/j.neubiorev.2021. 452. Ayerbe L, Forgnone I, Foguet-Boreu Q, González E, Addo J, Ayis S. Disparities in the
11.039 management of cardiovascular risk factors in patients with psychiatric disorders: a sys-
433. Ohi K, Shimada T, Kuwata A, Kataoka Y, Okubo H, Kimura K, et al. Smoking rates and tematic review and meta-analysis. Psychol Med 2018;48:2693–701. https://doi.org/10.
number of cigarettes smoked per day in schizophrenia: a large cohort meta-analysis in 1017/S0033291718000302
a Japanese population. Int J Neuropsychopharmacol 2019;22:19–27. https://doi.org/10. 453. Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG. Comparing clinical trial
1093/ijnp/pyy061 population representativeness to real-world populations: an external validity analysis
434. Hjorthøj C, Østergaard ML, Benros ME, Toftdahl NG, Erlangsen A, Andersen JT, et al. encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and
Association between alcohol and substance use disorders and all-cause and cause- 286 conditions in England. Lancet Healthy Longev 2022;3:e674–89. https://doi.org/10.
specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nation- 1016/S2666-7568(22)00186-6
wide, prospective, register-based study. Lancet Psychiatry 2015;2:801–8. https://doi. 454. Chan JKN, Chu RST, Hung C, Law JWY, Wong CSM, Chang WC. Mortality, revascu-
org/10.1016/S2215-0366(15)00207-2 larization, and cardioprotective pharmacotherapy after acute coronary syndrome in
435. Meyer JM, Correll CU. Increased metabolic potential, efficacy, and safety of emerging patients with severe mental illness: a systematic review and meta-analysis. Schizophr
treatments in schizophrenia. CNS Drugs 2023;37:545–70. https://doi.org/10.1007/ Bull 2022;48:981–98. https://doi.org/10.1093/schbul/sbac070
s40263-023-01022-7 455. Hallyburton A. Diagnostic overshadowing: an evolutionary concept analysis on the
436. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes misattribution of physical symptoms to pre-existing psychological illnesses. Int J
mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: Ment Health Nurs 2022;31:1360–72. https://doi.org/10.1111/inm.13034
a systematic review and large scale meta-analysis. World Psychiatry 2016;15:166–74. 456. Szmukler G. “Capacity”, “best interests”, “will and preferences” and the UN conven-
https://doi.org/10.1002/wps.20309 tion on the rights of persons with disabilities. World Psychiatry 2019;18:34–41. https://
437. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. doi.org/10.1002/wps.20584
Comparative effects of 18 antipsychotics on metabolic function in patients with 457. Woesner ME, Marsh J, Kanofsky JD. The assertive community treatment team: an ap-
schizophrenia, predictors of metabolic dysregulation, and association with psycho- propriate treatment for medical disorders that present with prominent psychiatric
pathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020;7: symptoms. Prim Care Companion CNS Disord 2014;16:10.4088/PCC.14br01639.
64–77. https://doi.org/10.1016/S2215-0366(19)30416-X https://doi.org/10.4088/PCC.14br01639
438. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular 458. Spivak S, Mojtabai R, Green C, Firth T, Sater H, Cullen BA. Distribution and correlates of
adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8:114–26. assertive community treatment (ACT) and ACT-like programs: results from the 2015
https://doi.org/10.1038/nrendo.2011.156 N-MHSS. Psychiatr Serv 2019;70:271–8. https://doi.org/10.1176/appi.ps.201700561
439. Correll CU, Kane JM, Manu P. Obesity and coronary risk in patients treated with 459. Flodgren G, Rachas A, Farmer AJ, Inzitari M, Shepperd S. Interactive telemedicine: ef-
second-generation antipsychotics. Eur Arch Psychiatry Clin Neurosci 2011;261: fects on professional practice and health care outcomes. Cochrane Database Syst Rev
417–23. https://doi.org/10.1007/s00406-010-0177-z 2015;2015:CD002098. https://doi.org/10.1002/14651858.CD002098.pub2
440. Rotella F, Cassioli E, Calderani E, Lazzeretti L, Ragghianti B, Ricca V, et al. Long-term 460. Azad MC, Shoesmith WD, Al Mamun M, Abdullah AF, Naing DK, Phanindranath M,
metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of rando- et al. Cardiovascular diseases among patients with schizophrenia. Asian J Psychiatr
mized controlled trials. Eur Neuropsychopharmacol 2020;32:56–65. https://doi.org/10. 2016;19:28–36. https://doi.org/10.1016/j.ajp.2015.11.012
1016/j.euroneuro.2019.12.118 461. Masa-Font R, Fernández-San-Martín MI, Martín López LM, Alba Muñoz AM, Oller
441. Yu ZH, Jiang HY, Shao L, Zhou YY, Shi HY, Ruan B. Use of antipsychotics and risk of Canet S, Martín Royo J, et al. The effectiveness of a program of physical activity and
myocardial infarction: a systematic review and meta-analysis. Br J Clin Pharmacol 2016; diet to modify cardiovascular risk factors in patients with severe mental illness after
82:624–32. https://doi.org/10.1111/bcp.12985 3-month follow-up: CAPiCOR randomized clinical trial. Eur Psychiatry 2015;30:
442. Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year 1028–36. https://doi.org/10.1016/j.eurpsy.2015.09.006
follow-up study of physical morbidity and mortality in relationship to antipsychotic 462. Scheewe TW, Backx FJ, Takken T, Jörg F, van Strater AC, Kroes AG, et al. Exercise
treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). therapy improves mental and physical health in schizophrenia: a randomised con-
World Psychiatry 2020;19:61–8. https://doi.org/10.1002/wps.20699 trolled trial. Acta Psychiatr Scand 2013;127:464–73. https://doi.org/10.1111/acps.12029
443. Solmi M, Tiihonen J, Lähteenvuo M, Tanskanen A, Correll CU, Taipale H. 463. Stubbs B, Vancampfort D, Hallgren M, Firth J, Veronese N, Solmi M, et al. EPA guidance
Antipsychotics use is associated with greater adherence to cardiometabolic medica- on physical activity as a treatment for severe mental illness: a meta-review of the evi-
tions in patients with schizophrenia: results from a nationwide, within-subject design dence and position statement from the European Psychiatric Association (EPA), sup-
study. Schizophr Bull 2022;48:166–75. https://doi.org/10.1093/schbul/sbab087 ported by the International Organization of Physical Therapists in Mental Health
444. Vancampfort D, Van Damme T, Probst M, Firth J, Stubbs B, Basangwa D, et al. Physical (IOPTMH). Eur Psychiatry 2018;54:124–44. https://doi.org/10.1016/j.eurpsy.2018.07.004
activity is associated with the physical, psychological, social and environmental quality 464. Jakobsen AS, Speyer H, Nørgaard HCB, Karlsen M, Birk M, Hjorthøj C, et al. Effect of
of life in people with mental health problems in a low resource setting. Psychiatry Res lifestyle coaching versus care coordination versus treatment as usual in people with
2017;258:250–4. https://doi.org/10.1016/j.psychres.2017.08.041 severe mental illness and overweight: two-years follow-up of the randomized
445. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atyp- CHANGE trial. PLoS One 2017;12:e0185881. https://doi.org/10.1371/journal.pone.
ical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009;70: 0185881
1041–50. https://doi.org/10.4088/JCP.08r04392 465. Aschbrenner KA, Naslund JA, Gorin AA, Mueser KT, Browne J, Wolfe RS, et al. Group
446. Piras M, Chahma J, Ranjbar S, Laaboub N, Grosu C, Plessen KJ, et al. Is lifestyle intervention with mobile health for young adults with serious mental illness: a
clozapine-induced weight gain dose-dependent? Results from a prospective cohort randomized controlled trial. Psychiatr Serv 2022;73:141–8. https://doi.org/10.1176/
study. Schizophr Bull 2023;49:944–52. https://doi.org/10.1093/schbul/sbad009 appi.ps.202100047
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 65 ---
4220 E S C G u id e l in e s
466. Daumit GL, Dalcin AT, Dickerson FB, Miller ER, Evins AE, Cather C, et al. Effect of a 486. Woosley RL, Heise CW, Gallo T, Woosley RD, Lambson J, Romero KA. www.
comprehensive cardiovascular risk reduction intervention in persons with serious CredibleMeds.org, QTdrugs List, AZCERT, 1457 E. Desert Garden Dr., Tucson, AZ
mental illness: a randomized clinical trial. JAMA Netw Open 2020;3:e207247. https:// 85718. https://crediblemeds.org/(23 September 2024, date last accessed).
doi.org/10.1001/jamanetworkopen.2020.7247 487. Lambiase PD, de Bono JP, Schilling RJ, Lowe M, Turley A, Slade A, et al. British Heart
467. Druss BG, von Esenwein SA, Glick GE, Deubler E, Lally C, Ward MC, et al. Randomized Rhythm Society clinical practice guidelines on the management of patients developing
trial of an integrated behavioral health home: the health outcomes management and QT prolongation on antipsychotic medication. Arrhythm Electrophysiol Rev 2019;8:
evaluation (HOME) study. Am J Psychiatry 2017;174:246–55. https://doi.org/10.1176/ 161–5. https://doi.org/10.15420/aer.2019.8.3.G1
appi.ajp.2016.16050507 488. Nilsson BM, Edström O, Lindström L, Wernegren P, Bodén R. Tachycardia in patients
468. Prasad F, De R, Korann V, Chintoh AF, Remington G, Ebdrup BH, et al. Semaglutide for treated with clozapine versus antipsychotic long-acting injections. Int Clin
the treatment of antipsychotic-associated weight gain in patients not responding to Psychopharmacol 2017;32:219–24. https://doi.org/10.1097/YIC.0000000000000169
metformin—a case series. Ther Adv Psychopharmacol 2023;13:20451253231165169. 489. Siskind D, Sidhu A, Cross J, Chua YT, Myles N, Cohen D, et al. Systematic review and
meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. Aust N
https://doi.org/10.1177/20451253231165169
469. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Z J Psychiatry 2020;54:467–81. https://doi.org/10.1177/0004867419898760
490. Vickers M, Ramineni V, Malacova E, Eriksson L, McMahon K, Moudgil V, et al. Risk factors
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collab-
for clozapine-induced myocarditis and cardiomyopathy: a systematic review and
oration with the EASD. Eur Heart J 2020;41:255–323. https://doi.org/10.1093/
meta-analysis. Acta Psychiatr Scand 2022;145:442–55. https://doi.org/10.1111/acps.13398
eurheartj/ehz486
491. Authority MNZMaMDS. Clozapine and Cardiac Safety: Updated Advice for Prescribers.
470. Gierisch JM, Nieuwsma JA, Bradford DW, Wilder CM, Mann-Wrobel MC, McBroom
2003. https://www.medsafe.govt.nz/profs/PUarticles/clozcardiac.htm (8 July 2024,
AJ, et al. Pharmacologic and behavioral interventions to improve cardiovascular risk
date last accessed).
factors in adults with serious mental illness: a systematic review and meta-analysis. J
492. Andrade C. cardiometabolic risks in schizophrenia and directions for intervention, 3:
Clin Psychiatry 2014;75:e424–440. https://doi.org/10.4088/JCP.13r08558
psychopharmacological interventions. J Clin Psychiatry 2016;77:e1090–4. https://doi.
471. Cather C, Pachas GN, Cieslak KM, Evins AE. Achieving smoking cessation in individuals
org/10.4088/JCP.16f11128
with schizophrenia: special considerations. CNS Drugs 2017;31:471–81. https://doi.org/
493. World Economic Forum. Global Gender Gap Report 2022. 2022. https://www3.
10.1007/s40263-017-0438-8
weforum.org/docs/WEF_GGGR_2022.pdf(5 February 2024, date last accessed).
472. Windle SB, Filion KB, Mancini JG, Adye-White L, Joseph L, Gore GC, et al.
494. Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, et al.
Combination therapies for smoking cessation: a hierarchical Bayesian meta-analysis.
Acute myocardial infarction in women: a scientific statement from the American
Am J Prev Med 2016;51:1060–71. https://doi.org/10.1016/j.amepre.2016.07.011 Heart Association. Circulation 2016;133:916–47. https://doi.org/10.1161/CIR.
473. Cerimele JM, Durango A. Does varenicline worsen psychiatric symptoms in patients 0000000000000351
with schizophrenia or schizoaffective disorder? A review of published studies. J Clin 495. O’Neil A, Fisher AJ, Kibbey KJ, Jacka FN, Kotowicz MA, Williams LJ, et al. Depression is
Psychiatry 2012;73:e1039–47. https://doi.org/10.4088/JCP.11r07410 a risk factor for incident coronary heart disease in women: an 18-year longitudinal
474. Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, et al. Effects study. J Affect Disord 2016;196:117–24. https://doi.org/10.1016/j.jad.2016.02.029
of moderate-dose treatment with varenicline on neurobiological and cognitive bio- 496. O’Neil A, Scovelle AJ, Milner AJ, Kavanagh A. Gender/sex as a social determinant of cardio-
markers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. vascular risk. Circulation 2018;137:854–64. https://doi.org/10.1161/CIRCULATIONAHA.
Arch Gen Psychiatry 2011;68:1195–206. https://doi.org/10.1001/archgenpsychiatry. 117.028595
2011.83 497. Shah AJ, Veledar E, Hong Y, Bremner JD, Vaccarino V. Depression and history of at-
475. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, et al. Drug-induced tempted suicide as risk factors for heart disease mortality in young individuals. Arch
arrhythmias: a scientific statement from the American Heart Association. Circulation 2020; Gen Psychiatry 2011;68:1135–42. https://doi.org/10.1001/archgenpsychiatry.2011.125
142:e214–33. https://doi.org/10.1161/CIR.0000000000000905 498. Taylor JL, Makarem N, Shimbo D, Aggarwal B. Gender differences in associations be-
476. Stroup TS, Byerly MJ, Nasrallah HA, Ray N, Khan AY, Lamberti JS, et al. Effects of tween stress and cardiovascular risk factors and outcomes. Gend Genome 2018;2:
switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year cor- 111–22. https://doi.org/10.1177/2470289718820845
onary heart disease risk and metabolic syndrome status: results from a randomized 499. Seidler ZE, Dawes AJ, Rice SM, Oliffe JL, Dhillon HM. The role of masculinity in men’s
controlled trial. Schizophr Res 2013;146:190–5. https://doi.org/10.1016/j.schres.2013. help-seeking for depression: a systematic review. Clin Psychol Rev 2016;49:106–18.
01.013 https://doi.org/10.1016/j.cpr.2016.09.002
477. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. 500. Berke DS, Liautaud M, Tuten M. Men’s psychiatric distress in context: understanding
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment the impact of masculine discrepancy stress, race, and barriers to help-seeking. J
of adults with multi-episode schizophrenia: a systematic review and network Health Psychol 2022;27:946–60. https://doi.org/10.1177/1359105320977641
meta-analysis. Lancet 2019;394:939–51. https://doi.org/10.1016/S0140-6736(19)31135-3 501. Moons P, Kovacs AH, Luyckx K, Thomet C, Budts W, Enomoto J, et al.
478. Huhn M, Arndt T, Schneider-Thoma J, Leucht S. Effects of antipsychotics on heart Patient-reported outcomes in adults with congenital heart disease: inter-country vari-
rate in treatment of schizophrenia: a systematic review and meta-analysis. Ther Adv ation, standard of living and healthcare system factors. Int J Cardiol 2018;251:34–41.
https://doi.org/10.1016/j.ijcard.2017.10.064
Psychopharmacol 2022;12:20451253221097261. https://doi.org/10.1177/
502. Hillerer KM, Neumann ID, Couillard-Despres S, Aigner L, Slattery DA. Sex-dependent
20451253221097261
regulation of hippocampal neurogenesis under basal and chronic stress conditions in 479. Chou RH, Lo LW, Liou YJ, Shu JH, Hsu HC, Liang Y, et al. Antipsychotic treatment is
rats. Hippocampus 2013;23:476–87. https://doi.org/10.1002/hipo.22107 associated with risk of atrial fibrillation: a nationwide nested case-control study. Int J
503. Oyola MG, Handa RJ. Hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal
Cardiol 2017;227:134–40. https://doi.org/10.1016/j.ijcard.2016.11.185
axes: sex differences in regulation of stress responsivity. Stress 2017;20:476–94. https://doi.
480. Mehta N, Vannozzi R. Lithium-induced electrocardiographic changes: a complete re-
org/10.1080/10253890.2017.1369523
view. Clin Cardiol 2017;40:1363–7. https://doi.org/10.1002/clc.22822
504. Pelletier R, Khan NA, Cox J, Daskalopoulou SS, Eisenberg MJ, Bacon SL, et al. Sex ver-
481. Farran D, Feely O, Ashworth M, Gaughran F. Anticoagulation therapy and outcomes in
sus gender-related characteristics: which predicts outcome after acute coronary syn-
patients with atrial fibrillation and serious mental illness: a systematic review and
drome in the young? J Am Coll Cardiol 2016;67:127–35. https://doi.org/10.1016/j.jacc.
meta-analysis. J Psychiatr Res 2022;156:737–53. https://doi.org/10.1016/j.jpsychires.
2015.10.067
2022.11.002
505. Bangasser DA, Cuarenta A. Sex differences in anxiety and depression: circuits and me-
482. Ahn HJ, Lee SR, Choi EK, Bae NY, Ahn HJ, Kwon S, et al. Increased risk of incident atrial
chanisms. Nat Rev Neurosci 2021;22:674–84. https://doi.org/10.1038/s41583-021-
fibrillation in young adults with mental disorders: a nationwide population-based study.
00513-0
Heart Rhythm 2023;20:365–73. https://doi.org/10.1016/j.hrthm.2022.12.019 506. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovas-
483. Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, et al. Gender differ-
cular disease. Nat Rev Cardiol 2018;15:215–29. https://doi.org/10.1038/nrcardio.2017.189
ences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother 2017; 507. Rossi A, Mikail N, Bengs S, Haider A, Treyer V, Buechel RR, et al. Heart-brain interac-
3:163–82. https://doi.org/10.1093/ehjcvp/pvw042 tions in cardiac and brain diseases: why sex matters. Eur Heart J 2022;43:3971–80.
484. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 https://doi.org/10.1093/eurheartj/ehac061
ESC Guidelines for the management of patients with ventricular arrhythmias and 508. Sullivan S, Young A, Hammadah M, Lima BB, Levantsevych O, Ko YA, et al. Sex differ-
the prevention of sudden cardiac death. Eur Heart J 2022;43:3997–4126. https://doi. ences in the inflammatory response to stress and risk of adverse cardiovascular out-
org/10.1093/eurheartj/ehac262 comes among patients with coronary heart disease. Brain Behav Immun 2020;90:
485. Wilde AAM, Semsarian C, Márquez MF, Shamloo AS, Ackerman MJ, Ashley EA, et al. 294–302. https://doi.org/10.1016/j.bbi.2020.09.001
European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia 509. Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, et al.
Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society Guidelines for the evaluation and treatment of perimenopausal depression: summary
(LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac dis- and recommendations. Menopause 2018;25:1069–85. https://doi.org/10.1097/GME.
eases. Europace 2022;24:1307–67. https://doi.org/10.1093/europace/euac030 0000000000001174
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 66 ---
ESC Guidelines 4221
510. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of de- coronary artery disease. Eur J Prev Cardiol 2019;26:657–9. https://doi.org/10.1177/
pression during the menopausal transition: the Harvard study of moods and cycles. 2047487318814298
Arch Gen Psychiatry 2006;63:385–90. https://doi.org/10.1001/archpsyc.63.4.385 533. Rutledge T, Kenkre TS, Bittner V, Krantz DS, Thompson DV, Linke SE, et al. Anxiety
511. Rees M, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, et al. Global consensus associations with cardiac symptoms, angiographic disease severity, and healthcare util-
recommendations on menopause in the workplace: a European Menopause and ization: the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation. Int J Cardiol
Andropause Society (EMAS) position statement. Maturitas 2021;151:55–62. https:// 2013;168:2335–40. https://doi.org/10.1016/j.ijcard.2013.01.036
doi.org/10.1016/j.maturitas.2021.06.006 534. Vaccarino V, Almuwaqqat Z, Kim JH, Hammadah M, Shah AJ, Ko YA, et al. Association
512. Stute P, Spyropoulou A, Karageorgiou V, Cano A, Bitzer J, Ceausu I, et al. Management of mental stress-induced myocardial ischemia with cardiovascular events in patients
of depressive symptoms in peri- and postmenopausal women: EMAS position state- with coronary heart disease. JAMA 2021;326:1818–28. https://doi.org/10.1001/jama.
ment. Maturitas 2020;131:91–101. https://doi.org/10.1016/j.maturitas.2019.11.002 2021.17649
513. Corona G, Rastrelli G, Isidori AM, Pivonello R, Bettocchi C, Reisman Y, et al. Erectile 535. Vaccarino V, Sullivan S, Hammadah M, Wilmot K, Al Mheid I, Ramadan R, et al. Mental
dysfunction and cardiovascular risk: a review of current findings. Expert Rev Cardiovasc stress-induced-myocardial ischemia in young patients with recent myocardial infarc-
Ther 2020;18:155–64. https://doi.org/10.1080/14779072.2020.1745632 tion: sex differences and mechanisms. Circulation 2018;137:794–805. https://doi.org/
514. Dilixiati D, Cao R, Mao Y, Li Y, Dilimulati D, Azhati B, et al. Association between cardio- 10.1161/CIRCULATIONAHA.117.030849
vascular disease and risk of female sexual dysfunction: a systematic review and 536. O’Riordan A, Gallagher S, Howard S. Type D personality and cardiovascular reactivity
meta-analysis. Eur J Prev Cardiol 2024;31:782–800. https://doi.org/10.1093/eurjpc/zwae042 to acute psychological stress: a systematic review and meta-analysis. Health Psychol
515. Winter S, Diamond M, Green J, Karasic D, Reed T, Whittle S, et al. Transgender peo- 2023;42:628–41. https://doi.org/10.1037/hea0001328
ple: health at the margins of society. Lancet 2016;388:390–400. https://doi.org/10. 537. Mommersteeg PM, Pot I, Aarnoudse W, Denollet J, Widdershoven JW. Type D per-
1016/S0140-6736(16)00683-8 sonality and patient-perceived health in nonsignificant coronary artery disease: the
516. Ruppert R, Kattari SK, Sussman S. Review: prevalence of addictions among transgender TWeesteden mIld STenosis (TWIST) study. Qual Life Res 2013;22:2041–50. https://
and gender diverse subgroups. Int J Environ Res Public Health 2021;18:8843. https://doi. doi.org/10.1007/s11136-012-0340-2
org/10.3390/ijerph18168843 538. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas A, et al. An EAPCI expert
517. Streed CG Jr, Beach LB, Caceres BA, Dowshen NL, Moreau KL, Mukherjee M, et al. consensus document on ischaemia with non-obstructive coronary arteries in collabor-
Assessing and addressing cardiovascular health in people who are transgender and ation with European Society of Cardiology Working Group on Coronary
gender diverse: a scientific statement from the American Heart Association. Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders
International Study Group. EuroIntervention 2021;16:1049–69. https://doi.org/10.4244/
Circulation 2021;144:e136–48. https://doi.org/10.1161/CIR.0000000000001003
EIJY20M07_01
518. Onasanya O, Iyer G, Lucas E, Lin D, Singh S, Alexander GC. Association between exogen-
539. Adlam D, Alfonso F, Maas A, Vrints C. European Society of Cardiology, acute cardio-
ous testosterone and cardiovascular events: an overview of systematic reviews. Lancet
vascular care association, SCAD study group: a position paper on spontaneous coron-
Diabetes Endocrinol 2016;4:943–56. https://doi.org/10.1016/S2213-8587(16)30215-7
ary artery dissection. Eur Heart J 2018;39:3353–68. https://doi.org/10.1093/eurheartj/
519. Nota NM, Wiepjes CM, de Blok CJM, Gooren LJG, Kreukels BPC, den Heijer M.
ehy080
Occurrence of acute cardiovascular events in transgender individuals receiving hormone
540. Hayes SN, Tweet MS, Adlam D, Kim ESH, Gulati R, Price JE, et al. Spontaneous cor-
therapy. Circulation 2019;139:1461–2. https://doi.org/10.1161/CIRCULATIONAHA.
onary artery dissection: JACC state-of-the-art review. J Am Coll Cardiol 2020;76:
118.038584
961–84. https://doi.org/10.1016/j.jacc.2020.05.084
520. Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA, Cromwell L, et al.
541. Gurgoglione FL, Rizzello D, Giacalone R, Ferretti M, Vezzani A, Pfleiderer B, et al.
Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort
Precipitating factors in patients with spontaneous coronary artery dissection: clinical,
study. Ann Intern Med 2018;169:205–13. https://doi.org/10.7326/M17-2785
laboratoristic and prognostic implications. Int J Cardiol 2023;385:1–7. https://doi.org/
521. van Zijverden LM, Wiepjes CM, van Diemen JJK, Thijs A, den Heijer M. Cardiovascular
10.1016/j.ijcard.2023.05.027
disease in transgender people: a systematic review and meta-analysis. Eur J Endocrinol
542. Tofler GH, Kopel E, Klempfner R, Eldar M, Buckley T, Goldenberg I. Triggers and tim-
2024;190:S13–24. https://doi.org/10.1093/ejendo/lvad170
ing of acute coronary syndromes. Am J Cardiol 2017;119:1560–5. https://doi.org/10.
522. Suglia SF, Koenen KC, Boynton-Jarrett R, Chan PS, Clark CJ, Danese A, et al. Childhood
1016/j.amjcard.2017.02.022
and adolescent adversity and cardiometabolic outcomes: a scientific statement from
543. Smaardijk VR, Mommersteeg PMC, Kop WJ, Pellegrini D, van Geuns RJ, Maas A.
the American Heart Association. Circulation 2018;137:e15–28. https://doi.org/10.
Psychological and clinical characteristics of patients with spontaneous coronary artery
1161/CIR.0000000000000536
dissection: a case-control study. Int J Cardiol 2021;323:1–6. https://doi.org/10.1016/j.
523. Aspelund T, Gudnason V, Magnusdottir BT, Andersen K, Sigurdsson G, Thorsson B,
ijcard.2020.08.045
et al. Analysing the large decline in coronary heart disease mortality in the Icelandic
544. Lyon AR, Citro R, Schneider B, Morel O, Ghadri JR, Templin C, et al. Pathophysiology
population aged 25–74 between the years 1981 and 2006. PLoS One 2010;5:
of Takotsubo syndrome: JACC state-of-the-art review. J Am Coll Cardiol 2021;77:
e13957. https://doi.org/10.1371/journal.pone.0013957
902–21. https://doi.org/10.1016/j.jacc.2020.10.060
524. Shah AJ, Ghasemzadeh N, Zaragoza-Macias E, Patel R, Eapen DJ, Neeland IJ, et al. Sex
545. Dawson DK. Acute stress-induced (Takotsubo) cardiomyopathy. Heart 2018;104:
and age differences in the association of depression with obstructive coronary artery 96–102. https://doi.org/10.1136/heartjnl-2017-311579
disease and adverse cardiovascular events. J Am Heart Assoc 2014;3:e000741. https:// 546. Singh T, Khan H, Gamble DT, Scally C, Newby DE, Dawson D. Takotsubo syndrome:
doi.org/10.1161/JAHA.113.000741 pathophysiology, emerging concepts, and clinical implications. Circulation 2022;145:
525. Le Bras A. Risk factors: mental stress puts women’s hearts at risk. Nat Rev Cardiol 2018; 1002–19. https://doi.org/10.1161/CIRCULATIONAHA.121.055854
15:198. https://doi.org/10.1038/nrcardio.2018.23 547. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International ex-
526. Smaardijk VR, Lodder P, Kop WJ, van Gennep B, Maas A, Mommersteeg PMC. Sex- pert consensus document on Takotsubo syndrome (part I): clinical characteristics,
and gender-stratified risks of psychological factors for incident ischemic heart disease: diagnostic criteria, and pathophysiology. Eur Heart J 2018;39:2032–46. https://doi.
systematic review and meta-analysis. J Am Heart Assoc 2019;8:e010859. https://doi.org/ org/10.1093/eurheartj/ehy076
10.1161/JAHA.118.010859 548. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International ex-
527. Regitz-Zagrosek V, Gebhard C. Gender medicine: effects of sex and gender on cardio- pert consensus document on Takotsubo syndrome (part ii): diagnostic workup, out-
vascular disease manifestation and outcomes. Nat Rev Cardiol 2023;20:236–47. https:// come, and management. Eur Heart J 2018;39:2047–62. https://doi.org/10.1093/
doi.org/10.1038/s41569-022-00797-4 eurheartj/ehy077
528. Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M, et al. 549. Galiuto L, Crea F. Primary and secondary Takotsubo syndrome: pathophysiological de-
Depression and coronary heart disease: 2018 position paper of the ESC working terminant and prognosis. Eur Heart J Acute Cardiovasc Care 2020;9:690–3. https://doi.
group on coronary pathophysiology and microcirculation. Eur Heart J 2020;41: org/10.1177/2048872620963493
1687–96. https://doi.org/10.1093/eurheartj/ehy913 550. Templin C, Hänggi J, Klein C, Topka MS, Hiestand T, Levinson RA, et al. Altered limbic
529. Mehta PK, Thobani A, Vaccarino V. Coronary artery spasm, coronary reactivity, and and autonomic processing supports brain-heart axis in Takotsubo syndrome. Eur
their psychological context. Psychosom Med 2019;81:233–6. https://doi.org/10.1097/ Heart J 2019;40:1183–7. https://doi.org/10.1093/eurheartj/ehz068
PSY.0000000000000682 551. Pozzi G, D’Amario D, Princi G, Ciliberti G, Irano A, Simone MV, et al. Pre-existing psy-
530. Waheed N, Elias-Smale S, Malas W, Maas AH, Sedlak TL, Tremmel J, et al. Sex differ- chiatric morbidity is strongly associated to Takotsubo syndrome: a case-control study.
ences in non-obstructive coronary artery disease. Cardiovasc Res 2020;116:829–40. Front Cardiovasc Med 2022;9:925459. https://doi.org/10.3389/fcvm.2022.925459
https://doi.org/10.1093/cvr/cvaa001 552. Pandey A, Omar W, Ayers C, LaMonte M, Klein L, Allen NB, et al. Sex and race differ-
531. van der Meer RE, Maas AH. The role of mental stress in ischaemia with no obstructive ences in lifetime risk of heart failure with preserved ejection fraction and heart failure
coronary artery disease and coronary vasomotor disorders. Eur Cardiol 2021;16:e37. with reduced ejection fraction. Circulation 2018;137:1814–23. https://doi.org/10.1161/
https://doi.org/10.15420/ecr.2021.20 CIRCULATIONAHA.117.031622
532. Konst RE, Elias-Smale SE, Lier A, Bode C, Maas AH. Different cardiovascular risk fac- 553. Sowden E, Hossain M, Chew-Graham C, Blakeman T, Tierney S, Wellwood I, et al.
tors and psychosocial burden in symptomatic women with and without obstructive Understanding the management of heart failure with preserved ejection fraction:
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 67 ---
4222 E S C G u id e l in e s
a qualitative multiperspective study. Br J Gen Pract 2020;70:e880–9. https://doi.org/10. older adults: systematic review and meta-analysis. Br J Psychiatry 2019;215:449–55.
3399/bjgp20X713477 https://doi.org/10.1192/bjp.2019.74
554. Forsyth F, Blakeman T, Burt J, Chew-Graham CA, Hossain M, Mant J, et al. Cumulative 575. Moradi M, Doostkami M, Behnamfar N, Rafiemanesh H, Behzadmehr R. Global preva-
complexity: a qualitative analysis of patients’ experiences of living with heart failure lence of depression among heart failure patients: a systematic review and
with preserved ejection fraction. Eur J Cardiovasc Nurs 2023;22:529–36. https://doi. meta-analysis. Curr Probl Cardiol 2022;47:100848. https://doi.org/10.1016/j.cpcardiol.
org/10.1093/eurjcn/zvac081 2021.100848
555. Endrighi R, Dimond AJ, Waters AJ, Dimond CC, Harris KM, Gottlieb SS, et al. 576. Zhang S, Zhang N, Liu L, Zheng W, Ma ZL, Qiao SY, et al. Global epidemiology of mental
Associations of perceived stress and state anger with symptom burden and functional disorder in atrial fibrillation between 1998–2021: a systematic review and meta-analysis.
status in patients with heart failure. Psychol Health 2019;34:1250–66. https://doi.org/ World J Psychiatry 2024;14:179–93. https://doi.org/10.5498/wjp.v14.i1.179
10.1080/08870446.2019.1609676 577. Beishon L, Hickey B, Desai B, Chithiramohan T, Evley R, Subramaniam H, et al.
556. Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: Integrated physical-mental healthcare services in specialist settings to improve out-
JACC scientific statement. J Am Coll Cardiol 2023;81:1810–34. https://doi.org/10.1016/ comes for older people living with mental health diagnoses: a systematic review. Int
j.jacc.2023.01.049 J Geriatr Psychiatry 2024;39:e6146. https://doi.org/10.1002/gps.6146
557. Cirelli MA, Lacerda MS, Lopes CT, de Lima Lopes J, de Barros A. Correlations between 578. Purcell C, Dibben G, Hilton Boon M, Matthews L, Palmer VJ, Thomson M, et al. Social
stress, anxiety and depression and sociodemographic and clinical characteristics network interventions to support cardiac rehabilitation and secondary prevention in
among outpatients with heart failure. Arch Psychiatr Nurs 2018;32:235–41. https:// the management of people with heart disease. Cochrane Database Syst Rev 2023;6:
doi.org/10.1016/j.apnu.2017.11.008 CD013820. https://doi.org/10.1002/14651858.CD013820.pub2
558. Topel ML, Kim JH, Mujahid MS, Sullivan SM, Ko YA, Vaccarino V, et al. Neighborhood 579. Anrys P, Petit AE, Thevelin S, Sallevelt B, Drenth C, Soiza RL, et al. An international
socioeconomic status and adverse outcomes in patients with cardiovascular disease. consensus list of potentially clinically significant drug-drug interactions in older people.
Am J Cardiol 2019;123:284–90. https://doi.org/10.1016/j.amjcard.2018.10.011 J Am Med Dir Assoc 2021;22:2121–33.e24. https://doi.org/10.1016/j.jamda.2021.03.019
559. Polikandrioti M, Koutelekos I, Vasilopoulos G, Gerogianni G, Gourni M, Zyga S, et al. 580. Siwek M, Woroń J, Gorostowicz A, Wordliczek J. Adverse effects of interactions be-
Anxiety and depression in patients with permanent atrial fibrillation: prevalence and tween antipsychotics and medications used in the treatment of cardiovascular disor-
associated factors. Cardiol Res Pract 2018;2018:7408129. https://doi.org/10.1155/ ders. Pharmacol Rep 2020;72:350–9. https://doi.org/10.1007/s43440-020-00058-6
2018/7408129 581. Boyd C, Smith CD, Masoudi FA, Blaum CS, Dodson JA, Green AR, et al. Decision mak-
560. Gleason KT, Dennison Himmelfarb CR, Ford DE, Lehmann H, Samuel L, Jain S, et al. ing for older adults with multiple chronic conditions: executive summary for the
Association of sex and atrial fibrillation therapies with patient-reported outcomes.
American Geriatrics Society guiding principles on the care of older adults with multi-
Heart 2019;105:1642–8. https://doi.org/10.1136/heartjnl-2019-314881
morbidity. J Am Geriatr Soc 2019;67:665–73. https://doi.org/10.1111/jgs.15809
561. von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A, Kirchhof P, et al.
582. Piña IL, Di Palo KE, Ventura HO. Psychopharmacology and cardiovascular disease. J Am
Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial
Coll Cardiol 2018;71:2346–59. https://doi.org/10.1016/j.jacc.2018.03.458
fibrillation patients: a longitudinal analysis—data from the German Competence
583. Castaldelli-Maia JM, Hofmann C, Chagas ACP, Liprandi AS, Alcocer A, Andrade LH,
Network on Atrial Fibrillation. Europace 2015;17:1354–62. https://doi.org/10.1093/
et al. Major cardiac-psychiatric drug-drug interactions: a systematic review of the con-
europace/euv018
sistency of drug databases. Cardiovasc Drugs Ther 2021;35:441–54. https://doi.org/10.
562. Du H, Yang L, Hu Z, Zhang H. Anxiety is associated with higher recurrence of atrial
1007/s10557-020-06979-x
fibrillation after catheter ablation: a meta-analysis. Clin Cardiol 2022;45:243–50.
584. Sheikh-Taha M, Asmar M. Polypharmacy and severe potential drug-drug interactions
https://doi.org/10.1002/clc.23753
among older adults with cardiovascular disease in the United States. BMC Geriatr
563. Starrenburg A, Pedersen S, van den Broek K, Kraaier K, Scholten M, Van der Palen J.
2021;21:233. https://doi.org/10.1186/s12877-021-02183-0
Gender differences in psychological distress and quality of life in patients with an
585. Kim DH, Rockwood K. Frailty in older adults. N Engl J Med 2024;391:538–48. https://
ICD 1-year postimplant. Pacing Clin Electrophysiol 2014;37:843–52. https://doi.org/10.
doi.org/10.1056/NEJMra2301292
1111/pace.12357
586. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardi-
564. Paap E, Witjes M, van Landsveld-Verhoeven C, Pijnappel RM, Maas AH, Broeders MJ.
ology: definition, assessment and clinical implications for general cardiology. A consen-
Mammography in females with an implanted medical device: impact on image quality,
sus document of the Council for Cardiology Practice (CCP), Association for Acute
pain and anxiety. Br J Radiol 2016;89:20160142. https://doi.org/10.1259/bjr.20160142
Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied
565. Habibović M, Denollet J, Pedersen SS. Posttraumatic stress and anxiety in patients with
Professions (ACNAP), European Association of Preventive Cardiology (EAPC),
an implantable cardioverter defibrillator: trajectories and vulnerability factors. Pacing
European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases
Clin Electrophysiol 2017;40:817–23. https://doi.org/10.1111/pace.13090
(VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO),
566. Sliwa K, Rakisheva A, Viljoen C, Pfeffer T, Simpson M, Jackson AM, et al. Living with
Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology,
peripartum cardiomyopathy: a statement from the Heart Failure Association and
WG Thrombosis, of the European Society of Cardiology, European Primary Care
the Association of Cardiovascular Nursing and Allied Professions of the European
Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216–27. https://doi.org/10.
Society of Cardiology. Eur J Heart Fail 2024;26:2143–54. https://doi.org/10.1002/ejhf.
1093/eurjpc/zwaa167 3377
567. World Health Organization. Aging and Health: Key Facts. 2024. https://www.who.int/ 587. Talha KM, Pandey A, Fudim M, Butler J, Anker SD, Khan MS. Frailty and heart failure:
news-room/fact-sheets/detail/ageing-and-health#:∼:text=By%202050%2C%20the% state-of-the-art review. J Cachexia Sarcopenia Muscle 2023;14:1959–72. https://doi.org/
20world’s%20population,2050%20to%20reach%20426%20million (14 March 2025, 10.1002/jcsm.13306
date last accessed). 588. Liperoti R, Vetrano DL, Palmer K, Targowski T, Cipriani MC, Lo Monaco MR, et al.
568. Forman DE, Maurer MS, Boyd C, Brindis R, Salive ME, Horne FM, et al. Multimorbidity Association between frailty and ischemic heart disease: a systematic review and
in older adults with cardiovascular disease. J Am Coll Cardiol 2018;71:2149–61. https:// meta-analysis. BMC Geriatr 2021;21:357. https://doi.org/10.1186/s12877-021-02304-9
doi.org/10.1016/j.jacc.2018.03.022 589. Savelieva I, Fumagalli S, Kenny RA, Anker S, Benetos A, Boriani G, et al. EHRA expert
569. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular dis- consensus document on the management of arrhythmias in frailty syndrome, en-
ease, and frailty. Nat Rev Cardiol 2018;15:505–22. https://doi.org/10.1038/s41569-018- dorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society
0064-2 (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia
570. Wang MS, Deng JW, Geng WY, Zheng R, Xu HL, Dong Y, et al. Temporal trend and Society of Southern Africa (CASSA). Europace 2023;25:1249–76. https://doi.org/10.
attributable risk factors of cardiovascular disease burden for adults 55 years and older 1093/europace/euac123
in 204 countries/territories from 1990 to 2021: an analysis for the Global Burden of 590. Tan M, Bhanu C, Frost R. The association between frailty and anxiety: a systematic re-
Disease Study 2021. Eur J Prev Cardiol 2024;32:539–52. https://doi.org/10.1093/ view. Int J Geriatr Psychiatry 2023;38:e5918. https://doi.org/10.1002/gps.5918
eurjpc/zwae384 591. Zhu J, Zhou D, Nie Y, Wang J, Yang Y, Chen D, et al. Assessment of the bidirectional
571. Global, regional, and national burden of 12 mental disorders in 204 countries and terri- causal association between frailty and depression: a Mendelian randomization study.
tories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. J Cachexia Sarcopenia Muscle 2023;14:2327–34. https://doi.org/10.1002/jcsm.13319
Lancet Psychiatry 2022;9:137–50. https://doi.org/10.1016/S2215-0366(21)00395-3 592. Suo X, Zhang J, Guo J, Liu Y, You J, Lyu Q, et al. (6 March, 2025) Frailty mediated the
572. Jalali A, Ziapour A, Karimi Z, Rezaei M, Emami B, Kalhori RP, et al. Global prevalence of associations of fine particulate matter with depression and anxiety: findings from the
depression, anxiety, and stress in the elderly population: a systematic review and UK Biobank. J Gerontol A Biol Sci Med Sci, https://doi.org/10.1093/gerona/glaf047
meta-analysis. BMC Geriatr 2024;24:809. https://doi.org/10.1186/s12877-024-05311-8 593. World Health Organization. WHO Clinical Consortium on Healthy Ageing. Report of
573. Sivertsen H, Bjørkløf GH, Engedal K, Selbæk G, Helvik AS. Depression and quality of life Consortium Meeting 1–2 December 2016 in Geneva, Switzerland. 2016. https://www.
in older persons: a review. Dement Geriatr Cogn Disord 2015;40:311–39. https://doi.org/ who.int/publications/i/item/WHO-FWC-ALC-17.2 (5 February 2024, date last
10.1159/000437299 accessed).
574. Wei J, Hou R, Zhang X, Xu H, Xie L, Chandrasekar EK, et al. The association of late-life 594. Chowdhury SR, Chandra Das D, Sunna TC, Beyene J, Hossain A. Global and regional
depression with all-cause and cardiovascular mortality among community-dwelling prevalence of multimorbidity in the adult population in community settings:
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 68 ---
ESC Guidelines 4223
a systematic review and meta-analysis. EClinicalMedicine 2023;57:101860. https://doi. 616. Lionis C, Papadakaki M, Saridaki A, Dowrick C, O’Donnell CA, Mair FS, et al. Engaging
org/10.1016/j.eclinm.2023.101860 migrants and other stakeholders to improve communication in cross-cultural consult-
595. Zhu Y, Edwards D, Mant J, Payne RA, Kiddle S. Characteristics, service use and mor- ation in primary care: a theoretically informed participatory study. BMJ Open 2016;6:
tality of clusters of multimorbid patients in England: a population-based study. BMC e010822. https://doi.org/10.1136/bmjopen-2015-010822
Med 2020;18:78. https://doi.org/10.1186/s12916-020-01543-8 617. MacFarlane A, Dowrick C, Gravenhorst K, O’Reilly-de Brún M, de Brún T, van den
596. Soley-Bori M, Ashworth M, Bisquera A, Dodhia H, Lynch R, Wang Y, et al. Impact of Muijsenbergh M, et al. Involving migrants in the adaptation of primary care services
multimorbidity on healthcare costs and utilisation: a systematic review of the UK lit- in a ‘newly’ diverse urban area in Ireland: the tension between agency and structure.
erature. Br J Gen Pract 2021;71:e39–46. https://doi.org/10.3399/bjgp20X713897 Health Place 2021;70:102556. https://doi.org/10.1016/j.healthplace.2021.102556
597. Cottrell E, Yardley S. Lived experiences of multimorbidity: an interpretative meta- 618. Packness A, Halling A, Simonsen E, Waldorff FB, Hastrup LH. Are perceived barriers to
synthesis of patients’, general practitioners’ and trainees’ perceptions. Chronic Illn accessing mental healthcare associated with socioeconomic position among individuals
2015;11:279–303. https://doi.org/10.1177/1742395315574764 with symptoms of depression? Questionnaire-results from the Lolland-Falster Health
598. Coventry PA, Small N, Panagioti M, Adeyemi I, Bee P. Living with complexity; marshal- Study, a rural Danish population study. BMJ Open 2019;9:e023844. https://doi.org/10.
ling resources: a systematic review and qualitative meta-synthesis of lived experience 1136/bmjopen-2018-023844
of mental and physical multimorbidity. BMC Fam Pract 2015;16:171. https://doi.org/10. 619. Finegan M, Firth N, Delgadillo J. Adverse impact of neighbourhood socioeconomic de-
1186/s12875-015-0345-3 privation on psychological treatment outcomes: the role of area-level income and
599. Van Wilder L, Devleesschauwer B, Clays E, De Buyser S, Van der Heyden J, crime. Psychother Res 2020;30:546–54. https://doi.org/10.1080/10503307.2019.
Charafeddine R, et al. The impact of multimorbidity patterns on health-related quality 1649500
of life in the general population: results of the Belgian Health Interview Survey. Qual Life 620. Novak P, Anderson AC, Chen J. Changes in health insurance coverage and barriers to
Res 2022;31:551–65. https://doi.org/10.1007/s11136-021-02951-w health care access among individuals with serious psychological distress following the
600. Garin N, Koyanagi A, Chatterji S, Tyrovolas S, Olaya B, Leonardi M, et al. Global multi- affordable care act. Adm Policy Ment Health 2018;45:924–32. https://doi.org/10.1007/
morbidity patterns: a cross-sectional, population-based, multi-country study. J Gerontol s10488-018-0875-9
A Biol Sci Med Sci 2016;71:205–14. https://doi.org/10.1093/gerona/glv128 621. Mirza NA, Hulko W. The complex nature of transportation as a key determinant of
601. Sinnige J, Braspenning J, Schellevis F, Stirbu-Wagner I, Westert G, Korevaar J. The
health in primary and community care restructuring initiatives in rural Canada. J
prevalence of disease clusters in older adults with multiple chronic diseases—a system-
Aging Stud 2022;60:101002. https://doi.org/10.1016/j.jaging.2022.101002
atic literature review. PLoS One 2013;8:e79641. https://doi.org/10.1371/journal.pone.
622. Ahmedani BK. Mental health stigma: society, individuals, and the profession. J Soc Work
0079641
Values Ethics 2011;8:41–416.
602. Cuschieri S, Stranges S, Makovski TT. The different definitions of multimorbidity and
623. Collopy CM, Cosh SM, Tully PJ. Screening and referral is not enough: a qualitative ex-
their implications for research, surveillance, and policy. Eur J Public Health 2025;35:
ploration of barriers to access and uptake of mental health services in patients with
197–8. https://doi.org/10.1093/eurpub/ckae193
cardiovascular diseases. BMC Health Serv Res 2021;21:49. https://doi.org/10.1186/
603. Salisbury C, Man MS, Bower P, Guthrie B, Chaplin K, Gaunt DM, et al. Management of
s12913-020-06030-7
multimorbidity using a patient-centred care model: a pragmatic cluster-randomised
624. Montgomery RM, Boucher EM, Honomichl RD, Powell TA, Guyton SL, Bernecker SL,
trial of the 3D approach. Lancet 2018;392:41–50. https://doi.org/10.1016/S0140-
et al. The effects of a digital mental health intervention in adults with cardiovascular
6736(18)31308-4
disease risk factors: analysis of real-world user data. JMIR Cardio 2021;5:e32351.
604. Smith SM, Wallace E, O’Dowd T, Fortin M. Interventions for improving outcomes in pa-
https://doi.org/10.2196/32351
tients with multimorbidity in primary care and community settings. Cochrane Database
625. Cook JE, Purdie-Vaughns V, Meyer IH, Busch JTA. Intervening within and across levels:
Syst Rev 2016;3:CD006560. https://doi.org/10.1002/14651858.CD006560.pub3
a multilevel approach to stigma and public health. Soc Sci Med 2014;103:101–9. https://
605. Pampel FC, Krueger PM, Denney JT. Socioeconomic disparities in health behaviors.
doi.org/10.1016/j.socscimed.2013.09.023
Annu Rev Sociol 2010;36:349–70. https://doi.org/10.1146/annurev.soc.012809.102529
626. Henderson C, Noblett J, Parke H, Clement S, Caffrey A, Gale-Grant O, et al. Mental
606. Kimenai DM, Pirondini L, Gregson J, Prieto D, Pocock SJ, Perel P, et al. Socioeconomic
health-related stigma in health care and mental health-care settings. Lancet Psychiatry
deprivation: an important, largely unrecognized risk factor in primary prevention
2014;1:467–82. https://doi.org/10.1016/S2215-0366(14)00023-6
of cardiovascular disease. Circulation 2022;146:240–8. https://doi.org/10.1161/
627. Clement S, Schauman O, Graham T, Maggioni F, Evans-Lacko S, Bezborodovs N, et al.
CIRCULATIONAHA.122.060042
What is the impact of mental health-related stigma on help-seeking? A systematic re-
607. Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, et al. Socioeconomic
view of quantitative and qualitative studies. Psychol Med 2015;45:11–27. https://doi.org/
status and cardiovascular outcomes: challenges and interventions. Circulation 2018;
10.1017/S0033291714000129
137:2166–78. https://doi.org/10.1161/CIRCULATIONAHA.117.029652
628. Castillo EG, Ijadi-Maghsoodi R, Shadravan S, Moore E, Mensah MO 3rd, Docherty M,
608. Mariotti A. The effects of chronic stress on health: new insights into the molecular me-
et al. Community interventions to promote mental health and social equity. Curr
chanisms of brain-body communication. Future Sci OA 2015;1:FSO23. https://doi.org/
Psychiatry Rep 2019;21:35. https://doi.org/10.1007/s11920-019-1017-0
10.4155/fso.15.21
629. Mensah GA, Cooper RS, Siega-Riz AM, Cooper LA, Smith JD, Brown CH, et al.
609. Deferio JJ, Breitinger S, Khullar D, Sheth A, Pathak J. Social determinants of health in
mental health care and research: a case for greater inclusion. J Am Med Inform Assoc Reducing cardiovascular disparities through community-engaged implementation re-
2019;26:895–9. https://doi.org/10.1093/jamia/ocz049 search: a National Heart, Lung, and Blood Institute workshop report. Circ Res 2018;
610. Foroughi I, Gupta N, Crouse DL. Healthcare service use for mood and anxiety disor- 122:213–30. https://doi.org/10.1161/CIRCRESAHA.117.312243
ders following acute myocardial infarction: a cohort study of the role of neighbour- 630. Mezzina R, Gopikumar V, Jenkins J, Saraceno B, Sashidharan SP. Social vulnerability and
hood socioenvironmental characteristics in a largely rural population. Int J Environ mental health inequalities in the “syndemic”: call for action. Front Psychiatry 2022;13:
Res Public Health 2020;17:4939. https://doi.org/10.3390/ijerph17144939 894370. https://doi.org/10.3389/fpsyt.2022.894370
611. Aldridge RW, Story A, Hwang SW, Nordentoft M, Luchenski SA, Hartwell G, et al. 631. Ozbay F, Johnson DC, Dimoulas E, Morgan CA, Charney D, Southwick S. Social sup-
Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals port and resilience to stress: from neurobiology to clinical practice. Psychiatry
with substance use disorders in high-income countries: a systematic review and (Edgmont) 2007;4:35–40. https://doi.org/https://www.ncbi.nlm.nih.gov/pmc/articles/
meta-analysis. Lancet 2018;391:241–50. https://doi.org/10.1016/S0140-6736(17)31869-X PMC2921311/
612. Hill L, Baruah R, Beattie JM, Bistola V, Castiello T, Celutkienė J, et al. Culture, ethnicity, 632. Riegel B, Moser DK, Buck HG, Dickson VV, Dunbar SB, Lee CS, et al. Self-care for the
and socio-economic status as determinants of the management of patients with ad- prevention and management of cardiovascular disease and stroke: a scientific state-
vanced heart failure who need palliative care: a clinical consensus statement from ment for healthcare professionals from the American Heart Association. J Am Heart
the Heart Failure Association (HFA) of the ESC, the ESC Patient Forum, and the Assoc 2017;6:e006997. https://doi.org/10.1161/JAHA.117.006997
European Association of Palliative Care. Eur J Heart Fail 2023;25:1481–92. https:// 633. Swope CB, Hernández D. Housing as a determinant of health equity: a conceptual mod-
doi.org/10.1002/ejhf.2973 el. Soc Sci Med 2019;243:112571. https://doi.org/10.1016/j.socscimed.2019.112571
613. Thordardottir EB, Yin L, Hauksdottir A, Mittendorfer-Rutz E, Hollander AC, Hultman 634. Gustavson AM, Lewinski AA, Fitzsimmons-Craft EE, Coronado GD, Linke SE,
CM, et al. Mortality and major disease risk among migrants of the 1991–2001 Balkan O’Malley DM, et al. Strategies to bridge equitable implementation of telehealth.
wars to Sweden: a register-based cohort study. PLoS Med 2020;17:e1003392. https:// Interact J Med Res 2023;12:e40358. https://doi.org/10.2196/40358
doi.org/10.1371/journal.pmed.1003392 635. Curiale C, Lenzi M, Gaboardi M, Marino C, Ronconi L, Demita S, et al. Homeless peo-
614. Knappe F, Filippou K, Hatzigeorgiadis A, Morres ID, Tzormpatzakis E, Havas E, et al. ple’s recovery in housing first and traditional services: the role of working alliance in
Psychological well-being, mental distress, metabolic syndrome, and associated factors Italian housing services. J Community Psychol 2023;51:2758–73. https://doi.org/10.
among people living in a refugee camp in Greece: a cross-sectional study. Front Public 1002/jcop.23055
Health 2023;11:1179756. https://doi.org/10.3389/fpubh.2023.1179756 636. Belkin G, McCray C. ThriveNYC: delivering on mental health. Am J Public Health 2019;
615. Agyemang C, van den Born BJ. Cardiovascular health and disease in migrant popula- 109:S156–63. https://doi.org/10.2105/AJPH.2019.305040
tions: a call to action. Nat Rev Cardiol 2022;19:1–2. https://doi.org/10.1038/s41569- 637. Walton-Moss B, Samuel L, Nguyen TH, Commodore-Mensah Y, Hayat MJ, Szanton SL.
021-00644-y Community-based cardiovascular health interventions in vulnerable populations: a
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 69 ---
4224 E S C G u id e l in e s
systematic review. J Cardiovasc Nurs 2014;29:293–307. https://doi.org/10.1097/JCN. qualitative study. Eur J Cardiovasc Nurs 2022;21:235–42. https://doi.org/10.1093/
0b013e31828e2995 eurjcn/zvab057
638. Dai S, Mo Y, Wang Y, Xiang B, Liao Q, Zhou M, et al. Chronic stress promotes cancer 660. Harrison JM, Davis MA, Barton DL, Janz NK, Pressler SJ, Friese CR. Functional status
development. Front Oncol 2020;10:1492. https://doi.org/10.3389/fonc.2020.01492 and quality of life among breast cancer survivors with heart failure: results of the
639. Omari M, Amaadour L, El Asri A, Benbrahim Z, Mellas N, El Rhazi K, et al. Psychological Medicare Health Outcomes Survey. Support Care Cancer 2017;25:2463–73. https://
distress and coping strategies in breast cancer patients under neoadjuvant therapy: a doi.org/10.1007/s00520-017-3653-4
systematic review. Womens Health (Lond) 2024;20:17455057241276232. https://doi. 661. Ekels A, Oerlemans S, Schagen SB, Issa DE, Thielen N, Nijziel MR et al. The course of
org/10.1177/17455057241276232 self-perceived cognitive functioning among patients with lymphoma and the co-
640. Stabellini N, Cullen J, Bittencourt MS, Moore JX, Sutton A, Nain P, et al. Allostatic load/ occurrence with fatigue and psychological distress. J Cancer Surviv 2025;19:183–96.
chronic stress and cardiovascular outcomes in patients diagnosed with breast, lung, or https://doi.org/10.1007/s11764-023-01458-2
colorectal cancer. J Am Heart Assoc 2024;13:e033295. https://doi.org/10.1161/JAHA. 662. Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive im-
123.033295 pairment: an update on state of the art, detection, and management strategies in can-
641. Stabellini N, Cullen J, Bittencourt MS, Moore JX, Cao L, Weintraub NL, et al. Allostatic cer survivors. Ann Oncol 2019;30:1925–40. https://doi.org/10.1093/annonc/mdz410
load and cardiovascular outcomes in males with prostate cancer. JNCI Cancer Spectr 663. Deka R, Rose BS, Bryant AK, Sarkar RR, Nalawade V, McKay R, et al. Androgen depriv-
2023;7:pkad005. https://doi.org/10.1093/jncics/pkad005 ation therapy and depression in men with prostate cancer treated with definitive ra-
642. Fang F, Keating NL, Mucci LA, Adami HO, Stampfer MJ, Valdimarsdóttir U, et al. diation therapy. Cancer 2019;125:1070–80. https://doi.org/10.1002/cncr.31982
Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: 664. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy
cohort study in the United States. J Natl Cancer Inst 2010;102:307–14. https://doi. of hormone-responsive early breast cancer. Ann Oncol 2007;18:viii26–35. https://doi.
org/10.1093/jnci/djp537 org/10.1093/annonc/mdm263
643. Mędrek S, Szmit S. Are cardiovascular comorbidities always associated with a worse 665. Sung S, Min YH, Park SK, Lee SB. Hot flushes and sweating, sleep problems, joint and
prognosis in patients with lung cancer? Front Cardiovasc Med 2022;9:984951. https:// muscular discomfort, and physical and mental exhaustion in breast cancer survivors
doi.org/10.3389/fcvm.2022.984951 during the first 24 months of tamoxifen therapy: a prospective observational study.
644. Fang S, Wang Y, He PK, Han XN, Yang Y, Hong T, et al. Cardiogenic shock caused by Front Oncol 2022;12:844926. https://doi.org/10.3389/fonc.2022.844926
Takotsubo syndrome complicated with severe anxiety: a case report and literature review. 666. Lee Meeuw Kjoe PR, Kieffer JM, Small BJ, Boogerd W, Schilder CM, van der Wall E,
Medicine (Baltimore) 2021;100:e27812. https://doi.org/10.1097/MD.0000000000027812 et al. Effects of tamoxifen and exemestane on cognitive function in postmenopausal
645. Kinno R, Ono K. Takotsubo syndrome: optimizing care with a multidisciplinary ap- patients with breast cancer. JNCI Cancer Spectr 2023;7:pkad022. https://doi.org/10.
proach. J Multidiscip Healthc 2021;14:2487–99. https://doi.org/10.2147/JMDH.S283667 1093/jncics/pkad022
646. Desai A, Noor A, Joshi S, Kim AS. Takotsubo cardiomyopathy in cancer patients. 667. Park SK, Min YH. Fear of cancer recurrence in South Korean survivors of breast cancer
Cardiooncology 2019;5:7. https://doi.org/10.1186/s40959-019-0042-9 who have received adjuvant endocrine therapy: a cross-sectional study. Front Psychol
647. da Silva Costa IBS, Figueiredo CS, Fonseca SMR, Bittar CS, de Carvalho Silva CMD, Rizk 2023;14:1170077. https://doi.org/10.3389/fpsyg.2023.1170077
SI, et al. Takotsubo syndrome: an overview of pathophysiology, diagnosis and treat- 668. van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg DH, et al.
ment with emphasis on cancer patients. Heart Fail Rev 2019;24:833–46. https://doi. Associations between adjuvant endocrine therapy and onset of physical and emotional
org/10.1007/s10741-019-09813-1 concerns among breast cancer survivors. Support Care Cancer 2014;22:937–45. https://
648. Kim H, Senecal C, Lewis B, Prasad A, Rajiv G, Lerman LO, et al. Natural history and doi.org/10.1007/s00520-013-2041-y
predictors of mortality of patients with Takotsubo syndrome. Int J Cardiol 2018; 669. Koch L, Bertram H, Eberle A, Holleczek B, Schmid-Höpfner S, Waldmann A, et al. Fear
267:22–7. https://doi.org/10.1016/j.ijcard.2018.04.139 of recurrence in long-term breast cancer survivors-still an issue. Results on prevalence,
649. Desai R, Desai A, Abbas SA, Patel U, Bansod S, Damarlapally N, et al. National preva- determinants, and the association with quality of life and depression from the cancer
lence, trends and outcomes of Takotsubo syndrome in hospitalizations with prior his- survivorship–a multi-regional population-based study. Psychooncology 2014;23:
tory of mediastinal/intrathoracic cancer and radiation therapy. Int J Cardiol 2020;309: 547–54. https://doi.org/10.1002/pon.3452
14–8. https://doi.org/10.1016/j.ijcard.2020.02.036 670. Davies A, Lum C, Raju R, Ansell E, Webber K, Segelov E. Anti-cancer therapy made
650. Herrmann J, Loprinzi C, Ruddy K. Building a cardio-onco-hematology program. Curr easier: a 25-year update. Intern Med J 2021;51:473–80. https://doi.org/10.1111/imj.
Oncol Rep 2018;20:81. https://doi.org/10.1007/s11912-018-0725-7 14878
651. Podina IR, Todea D, Fodor LA. Fear of cancer recurrence and mental health: a com- 671. Mitchell JD, Cehic DA, Morgia M, Bergom C, Toohey J, Guerrero PA, et al.
prehensive meta-analysis. Psychooncology 2023;32:1503–13. https://doi.org/10.1002/ Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert
pon.6205 consensus statement from the International Cardio-Oncology Society. JACC
652. Yan G, Zhang Q, Yan Y, Zhang Y, Li Y, Liu M, et al. Trends in the prevalence and treat- CardioOncol 2021;3:360–80. https://doi.org/10.1016/j.jaccao.2021.06.003
ment of comorbid depression among US adults with and without cancer, 2005–2020. J 672. Corrigan KL, Reeve BB, Salsman JM, Siembida EJ, Smith GL, Swartz MC, et al.
Affect Disord 2023;340:743–50. https://doi.org/10.1016/j.jad.2023.08.091 Association of patient-reported health-related quality of life with physician-reported
653. Lubas MM, Wang M, Jefferies JL, Ness KK, Ehrhardt MJ, Krull KR, et al. The contribution toxicities in adolescents and young adults receiving radiation therapy for cancer. JCO
of stress and distress to cardiovascular health in adult survivors of childhood cancer. Oncol Pract 2023;19:610–9. https://doi.org/10.1200/OP.22.00852
Cancer Epidemiol Biomarkers Prev 2021;30:286–94. https://doi.org/10.1158/1055- 673. Kwon JY, Kopec J, Sutherland JM, Lambert LK, Anis AH, Sawatzky R. Patient-reported
9965.EPI-20-1183 mental health and well-being trajectories in oncology patients during radiation therapy:
654. Chan JSK, Satti DI, Dee EC, Sharma G, Virani SS, Liu T, et al. Association between psy- an exploratory retrospective cohort analysis using the Ontario Cancer Registry. Qual
chological distress and cardiovascular health amongst cancer survivors in the United Life Res 2023;32:2899–909. https://doi.org/10.1007/s11136-023-03430-0
States: findings from nationally representative data. Eur J Prev Cardiol 2023;30:e74–7. 674. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al.
https://doi.org/10.1093/eurjpc/zwad162 Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients
655. Gontijo Garcia GS, Meira KC, de Souza AH, Guimarães NS. Anxiety and depression and survivors: a scientific statement from the American Heart Association. Circulation
disorders in oncological patients under palliative care at a hospital service: a cross- 2019;139:e997–1012. https://doi.org/10.1161/CIR.0000000000000679
sectional study. BMC Palliat Care 2023;22:116. https://doi.org/10.1186/s12904-023- 675. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al.
01233-1 Evaluation and management of cancer patients presenting with acute cardiovascular
656. Caruso R, Nanni MG, Riba M, Sabato S, Mitchell AJ, Croce E, et al. Depressive spectrum disease: a Clinical Consensus Statement of the Acute CardioVascular Care
disorders in cancer: prevalence, risk factors and screening for depression: a critical re- Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart fail-
view. Acta Oncol 2017;56:146–55. https://doi.org/10.1080/0284186X.2016.1266090 ure, acute myocardial diseases, acute venous thromboembolic diseases, and acute ar-
657. Garrido MM, Prigerson HG, Neupane S, Penrod JD, Johnson CE, Boockvar KS. Mental rhythmias. Eur Heart J Acute Cardiovasc Care 2022;11:865–74. https://doi.org/10.1093/
illness and mental healthcare receipt among hospitalized veterans with serious physical ehjacc/zuac107
illnesses. J Palliat Med 2017;20:247–52. https://doi.org/10.1089/jpm.2016.0261 676. Williamson T, Moran C, Chirico D, Arena R, Ozemek C, Aggarwal S, et al. Cancer and
658. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. cardiovascular disease: the impact of cardiac rehabilitation and cardiorespiratory fit-
2022 ESC Guidelines on cardio-oncology developed in collaboration with the ness on survival. Int J Cardiol 2021;343:139–45. https://doi.org/10.1016/j.ijcard.2021.
European Hematology Association (EHA), the European Society for Therapeutic 09.004
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 677. Dolan LB, Barry D, Petrella T, Davey L, Minnes A, Yantzi A, et al. The cardiac rehabili-
(IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244 tation model improves fitness, quality of life, and depression in breast cancer survi-
659. Koop Y, van Zadelhof N, Maas A, Atsma F, El Messaoudi S, Vermeulen H. Quality of life vors. J Cardiopulm Rehabil Prev 2018;38:246–52. https://doi.org/10.1097/HCR.
in breast cancer patients with cancer treatment-related cardiac dysfunction: a 0000000000000256
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
--- Страница 70 ---
ESC Guidelines 4225
678. Wilk M, Kepski J, Kepska J, Casselli S, Szmit S. Exercise interventions in metastatic can- 683. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M,
cer disease: a literature review and a brief discussion on current and future perspec- et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity devel-
tives. BMJ Support Palliat Care 2020;10:404–10. https://doi.org/10.1136/bmjspcare- oped under the auspices of the ESC Committee for Practice Guidelines: The Task
2020-002487 Force for cancer treatments and cardiovascular toxicity of the European Society of
679. Heywood R, McCarthy AL, Skinner TL. Efficacy of exercise interventions in patients Cardiology (ESC). Eur Heart J 2016;37:2768–801. https://doi.org/10.1093/eurheartj/
with advanced cancer: a systematic review. Arch Phys Med Rehabil 2018;99:
ehw211
2595–620. https://doi.org/10.1016/j.apmr.2018.04.008
684. Shin J, Kober K, Yates P, Wong ML, Cooper BA, Paul SM, et al. Higher lifetime
680. Fradley MG, Alomar M, Kilpatrick MW, Shields B, Tran N, Best A, et al. Patient re-
stress and symptom burden contribute to the occurrence of shortness of
ported physical and mental health changes associated with a comprehensive cardio-
breath. Semin Oncol Nurs 2023;39:151471. https://doi.org/10.1016/j.soncn.2023.
vascular risk reduction program for women with breast cancer receiving potentially
151471
cardiotoxic chemotherapy. Cardiooncology 2021;7:22. https://doi.org/10.1186/
685. Teng AE, Noor B, Ajijola OA, Yang EH. Chemotherapy and radiation-associated car-
s40959-021-00107-w
681. Enriquez A, Biagi J, Redfearn D, Boles U, Kamel D, Ali FS, et al. Increased incidence of diac autonomic dysfunction. Curr Oncol Rep 2021;23:14. https://doi.org/10.1007/
ventricular arrhythmias in patients with advanced cancer and implantable cardioverter- s11912-020-01013-7
defibrillators. JACC Clin Electrophysiol 2017;3:50–6. https://doi.org/10.1016/j.jacep.2016. 686. Coumbe BGT, Groarke JD. Cardiovascular autonomic dysfunction in patients with
03.001 cancer. Curr Cardiol Rep 2018;20:69. https://doi.org/10.1007/s11886-018-1010-y
682. Anker MS, Sanz AP, Zamorano JL, Mehra MR, Butler J, Riess H, et al. Advanced cancer 687. Lakoski SG, Jones LW, Krone RJ, Stein PK, Scott JM. Autonomic dysfunction in early
is also a heart failure syndrome: a hypothesis. Eur J Heart Fail 2021;23:140–4. https:// breast cancer: incidence, clinical importance, and underlying mechanisms. Am Heart J
doi.org/10.1002/ejhf.2071 2015;170:231–41. https://doi.org/10.1016/j.ahj.2015.05.014
Downloaded
from
https://academic.oup.com/eurheartj/article/46/41/4156/8234498
by
guest
on
22
January
2026
